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Introduction - The link between low bone mineral density (BMD) leading to 
greater fracture risk is well established in the literature; what is not fully 
understood is the impact of total knee revisions (rTKR) and cone implantation 
on BMD. This is important due to the increasing fracture risk associated with 
reductions in BMD. This feasibility study investigated a new type of Stryker cone 
for rTKR patients, and its impact on BMD utilising different imaging technologies 
and providing recommendations to be implemented for a full follow-up trial.  
 
Method - A systematic review was conducted to investigate total knee 
replacement (TKR) and rTKR on BMD results to establish known reported BMD 
changes after surgery, and to highlight the knee regions investigated.  A bovine 
study was then conducted in order to test the different setup imaging 
technologies and possible analysis of the cones. Additionally, a novel piece of 
3D-SHAPER hip software was utilised to investigate bone changes in the hip 
across three groups (TKR, rTKR, and controls) which could then be compared 
to the main BMD changes or used as an alternative to the other imaging 
options. The main study involved recruiting 37 participants all undergoing rTKR 
to either a cone or non-cone group, with all participants undergoing a series of 
scans via: CT scans (only at six months), DXA and x-ray at intervals of pre-op, 
six weeks, three, six and 12 months. Additionally, all participants completed 
questionnaires on mental health, lower extremity functionality, and quality of life. 
In addition to BMD investigation, hip and knee alignment was also explored at 
pre and post-op intervals, as well as pixel density changes, both utilising long 
leg x-ray imaging.  
 
Results – Systematic review results reported 2,431 papers, of which 27 studies 
were included, across all the studies BMD losses appeared greatest at 12 
months. The bovine study helped develop the imaging and analysis required for 
the main study. The 3D-SHAPER ability to be applied to hip DXA imaging 
showed promise; which was reflected in the control, rTKR and TKR data. The 
development of different imaging technologies have potential in moving forward 
into a full trial. Recommendations would include: utilising DXA imaging as the 
main modality, given its gold standard for BMD changes and its consistency 
when using a standardised positioning protocol and ROI placement. Long leg x-
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ray imaging to be used to investigate alignment and pixel density changes, as 
this imaging is convenient as part of routine follow-up care, although the 
inclusion of a step wedge within all long leg images would be required to allow 
pixel density standardisation for investigating in-growth. Finally, the CT imaging 
could not determine ingrowth in this feasibility study, and therefore should not 
be utilised in the full study. For the main feasibility study results, 35 participants 
attended pre-op, 26 attended six weeks and three months, at six months 25 
attended, and 22 at 12 months. Results show rTKR is associated with lower 
BMD in the tibial and femoral stems, and in the medial tibial condyle, and 
associated with increases beyond the tibial and femoral stems, in both groups. 
The main difference is in lateral tibial condyle where there are associated 
increases in BMD in the cone group, and losses reported in the non-cone 
group. The questionnaire results show a favourable impact for rTKR, with 
reductions in depression, anxiety, and increases in functionality post-surgery, 
with the cone group reporting greater changes, although not statistically 
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OVERVIEW OF THESIS 
The primary goal was to conduct a feasibility study in order to investigate the 
impact of cone implantation in total knee revision patients has on bone mineral 
density (BMD), and compare them to their own baseline data, and against non-
cone (control) participants. A collection of methods and techniques were utilised 
and tested to answer this question in order to hopefully provide information 
towards moving to a full trial. 
 
Participants were recruited and randomly assigned into cone (those who 
received a cone implant as well as the knee revision), and non-cone groups 
(those who only received the knee revision) and monitored over a 12 month 
post operation recovery period. Bone mineral density changes were assessed 
from baseline against subsequent visits within the 12 month period, this was 
done utilising dual-energy x-ray absorptiometry (DXA) imaging of the; total 
body, lumbar spine, bilateral hips and bilateral knees. Furthermore, x-ray 
imaging was also used to investigate pixel density changes on long leg knee x-
rays throughout the visits, with alignment angulation also explored using x-ray 
imaging. Computed Tomography (CT) was also utilised to investigate bone in-
growth into the conal implants. Questionnaire data was also gathered on patient 
outcomes such as: depression and anxiety (Hospital Anxiety and Depression 
Scale (HADS)), functionality and pain (Lower Extremity Functional Scale 
(LEFS), Oxford Knee Score (OKS)), quality of life (EQ-5D-3L), and medical 
history (Bone health questionnaire), with these possibly contributing to bone 
changes and recovery. 
 
The original aim of this study was to recruit 51 participants in total, followed up 
over a 12 month period. Due to attrition, illness, recruitment, and COVID-19 
issues, only 37 participants consented, with 35 undergoing a DXA pre-op scan. 









Table 0.1. Participant completion numbers 
Completed Pre-op 6 weeks 3 months 6 months 12 months 
DXA 35 26 26 25 22 
X-ray  31 N/A 24 18 12 
CT N/A N/A N/A 13 N/A 
LEFS  35 28 28 28 25 
HADS 35 28 27 26 26 
OKS 35 29 27 26 27 
EQ-5D-3L 35 28 26 26 27 
Bone health questionnaire 35 26 26 25 22 
 
Over the coming chapters the background to the study, the development of the 
imaging methods and analysis involved, and the results gathered, will be 
























CHAPTER 1 INTRODUCTION AND BACKGROUND 
 
 
1.1 MOTIVATION FOR STUDY 
Low bone mineral density (BMD) is referred to as osteopenia; in its most severe 
form it is called osteoporosis (OP). In the United Kingdom (UK) over three 
million people suffer from OP [1], with an estimated 75 million people in Europe, 
USA and Japan [2]. 
 
Low BMD is most commonly seen in women more than men, in the elderly 
population (60+ years), including the post-menopausal age group. With OP 
causing more than 8.9 million fractures per year, resulting in an OP fracture 
every three seconds [3]. The majority of these fractures occur in the hip, wrist or 
vertebrae [1]. Studies have shown that fractures in the low BMD groups can 
lead to severe pain, low quality of life, and death [4, 5]. This is due to these 
fractures being a major source of morbidity and mortality especially in the low 
BMD group. 
 
1.1.1 BMD AND FRACTURE RISK 
The link between low BMD and fracture risk has been investigated utilising 
several different testing methods, in which several studies have shown a link 
between low BMD and fracture risk. Legrand et al [6] investigated BMD and 
vertebral fractures in 200 men, reporting a relationship between fracture 
numbers against femoral BMD, spinal BMD, and age; concluding that low 
trochanter BMD and age were the best for predictors for vertebral fracture. 
Additionally, Marshall et al [7] conducted a meta-analysis on 229 studies on 
BMD and fracture risk in women, and concluded that low BMD measurements 
can identify people who are at increased fracture risk. 
 
This link is supported by a study by De Laet et al involving 5814 men and 
women [8], concluding similar results, stating that fracture risk to the hip was 
determined by age and BMD. Cummings et al [9] research developed this idea 
further; stating that low hip BMD was a stronger predictor of fracture than BMD 
at other sites. They also reported that loss of BMD in the proximal femur was a 
major risk factor for hip fracture in the aged population [10]. 
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A study by Melton et al [11] concurred with the research of Cummings et al and 
Legrande et al in demonstrating that the more the BMD decreased the greater 
the risk of a femoral neck and trochanteric fracture; concluding that hip fractures 
were uncommon in women with a femoral bone density above or equal to 1.0 
grams per square centimetre (g/cm2), and as BMD declined fracture frequency 
increased. 
 
The link between low BMD with increased fracture risk is so strongly supported 
that several clinical trials have used patients’ low BMD to make sure they have 
a sufficient number of patients having fractures during follow-up [12].  
 
It is reported that older people with one or more long term condition such as OP 
account for 70 % of all National Health Service (NHS) spending [13], with £1.5 
billion spent every year on hip fractures alone [13] (excluding the cost to social 
care), and accounting for 69,000 unplanned hospital admissions [14]. 
Furthermore, as well as the increased risk of fracture, the physical and social 
ramification on patients with OP must be noted, with 42 % of patients with OP 
feeling socially isolated by their disease [15], and 50 % of people giving up sport 
or exercise due to the impact of having an OP fracture [15]. Of those who have 
experienced an OP fracture 42 % are in long term pain they do not think will 
ever go away [15]. 
 
Due to low BMD being so strongly associated with fracture risk, the impact of 
life changing repercussions and the cost to the NHS, any intervention to reduce 
BMD loss is extremely important. One area of research where there is a 
possible intervention, and where BMD loss has been evidenced is in total knee 
replacements (TKR), total knee revisions (rTKR) and total knee arthroplasties 
(TKA).  
 
1.1.2 TKR/A OR rTKR AND BMD  
Several studies have shown a loss of BMD post TKR (arthroplasty); Gazdzik et 
al [16] reported a decrease in BMD 12 months after TKR surgery with the most 
significant BMD decrease during the period of 5-12 weeks after the surgery at 
the periprosthetic region. Other research concurs with this, stating the greatest 
loss of periprosthetic BMD has been observed within the first three months (12 
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weeks) after surgery [17-19], with some research reporting a temporary BMD 
loss of 13 % at the proximal tibia [20].   
 
This BMD loss is further supported by a study by Kim et al [21] who investigated 
48 Korean patients (11 males, 37 females, mean age 63 years) post TKR, they 
reported a significant decrease in BMD at the trochanters and femoral neck in 
the first three months post-surgery, followed by a recovery of the BMD losses to 
-2.14 % at 12 months. A similar trend is seen across the research by Ishii et al 
[22], Hopkins et al [23] and Petersen et al [24] who all reported a decrease in 
total hip BMD during the first six months post-operative.  
 
Other research investigated the effects of TKR 12 months post-operative; 
Beaupre et al [25] conducted a cohort study across 12 months and 
demonstrated BMD decreased significantly by 1.80 % at the total hip over that 
time. Soininvaara et al [26] measured the BMD of bilateral hips in 69 patients 
undergoing TKA (20 male, 49 female, mean age 67 years). They found a 
decrease in BMD at 12 month post-operative of up to 2.7 % per year in the 
ipsilateral hip and up to 1.18 % per year in the contralateral hip. This bone loss 
affecting the operated side more than the non-operated has been seen in other 
studies [27]. Mintzer et al [28] reported that within the first 12 months post-
operative 68 % of patients had radiographic evidence of bone loss at the distal 
anterior femur. There are many more studies that have shown a correlation 
between TKR (arthroplasty) and BMD loss [24, 29, 30, 31, 32, 33, 34]. Although 
there are some studies that dispute this association and have shown no change 
in BMD post TKR/A [20, 35, 36], with some research actually showing a small 
increase [37]. 
  
One explanation for this decline in BMD is a reduction in mobility of the patient 
post-surgery leading to non-weight bearing and thus disuse related bone loss 
[28, 38], this potentially explains the trend of such significant BMD reductions in 
the first six months, and then levelling out at two years postoperative [22, 39, 
40], although this in itself has been contested [20, 41]. 
 
1.1.3 TKR/A OR rTKR AND FRACTURE RISK 
Due to the majority of research reporting a significant loss of BMD post TKR/A 
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or rTKR, the possible associated fracture risk must be investigated. A study by 
Meek et al [42] reported that women aged ≥70 years who had TKR were 1.6 
times more likely to have a fracture than younger patients, and 2.3 times more 
likely to suffer a fracture than men. This is further supported by Toogood et al 
[43] who stated that the greater majority of annual periprosthetic fractures were 
more often elderly and female. Preliminary results from the Sahlgrenska 
Academy in Mölndal [44], analysed medical records from 1987 to 2002; 
concluding that individuals who had TKR had an increased risk for hip fracture 
by 4 %, with the risk for vertebral fracture increasing by 19 % compared to the 
population without TKR. 
 
Prieto-Alhambra et al [45] research supports this increase in hip fracture post 
TKR, reporting that hip fracture rates were insignificantly reduced compared to 
controls before the operation, but within 12 months postoperative TKR patients 
had a higher rate of hip fracture than controls, with relative risk increasing 
significantly up to 1.58, and then declining to equal the controls by three years. 
Additional research [46] has also shown a relationship between TKA and 
fracture risk, reporting a 54 % increased risk of hip fracture, in particular among 
adult patients aged 71 years or older, with the increase risk of hip fracture 
greatest after the first few years. Research by Prieto-Alhambra et al has shown 
an even higher figure, reporting a 58 % increase in hip fracture in patients who 
had undergone TKR [45].  
 
This increase in fracture risk during the first few years is time-dependent, and 
as such could be associated with the evidence that supports early BMD decline 
as an important predisposing factor contributing to fracture risk [47, 48, 49, 50, 
51]. 
 
Although it must be acknowledged there are other reasons put forward for the 
increased fracture risk in patients undergoing TKR, with some reports stating 
there is a higher incidence of falls, thus a higher chance of fracture. Research 
by Matsumoto et al [52] reported that of 81 patients, who underwent TKA, the 
incidence of falls was 38 % in the first year post-operatively, compared to 24 % 
in non-TKA cohort. Additional research also shows a higher rate of falls 
indicating scores of between 23-43 % [53, 54, 55, 56]. Although some research 
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contradicts this and shows fall incidences were not significantly higher in the 
TKR group [23]. 
 
Due to an ageing population there is an increasing demand for TKR and rTKR, 
with a reported 79,000 primary TKR and 5,600 rTKR done in 2012 in the UK 
alone, this figure is estimated to increase to 117 % for primary TKR and 332 % 
for rTKR all by 2030 [57]. In addition to the increase in surgeries possibly 
resulting in more patients having low BMD following knee replacement or 
revision, there is the cost of the potential fractures associated. It is estimated in 
2010 that 536,000 new fragility fractures were experienced. With an estimated 
3.21 million people aged 50+ with OP; the economic burden of new and prior 
fractures stands at £3,496 million per year, and by 2025 this burden is 
estimated to increase by 24 % to £5,465 million [58]; therefore any intervention 
to reduce BMD loss should be considered. 
 
There is research that shows that for an 8 % increase in BMD this will result in a 
risk reduction in vertebral fractures by 54 %, and for a 5 % increase in BMD 
there can be a hip fracture relative risk reduced by 50 % [12]. With a 
combination of an ageing population, increase in surgeries, patient impact and 
budgetary influence, ways to increase BMD or at least reduce its loss through 
intervention needs to be investigated. These reasons are the motivation for this 
research, if there is a way to maintain, increase, or slow the loss of BMD in 
TKR, TKA or rTKR patients then this could not only reduce fracture rates and 
improve patient lives, but also reduce the financial burden on the NHS. 
 
This study addressed this by investigating how metaphyseal cone implants 
could potentially impact BMD changes. Currently there is no such type of cone 
study, but it is postulated this type of cone could help reduce BMD loss in 
patients having rTKR.  
 
 
1.2 STRUCTURE OF BONE: AN OVERVIEW 
The human adult skeletal consists of approximately 206 bones [59], of which 80 
make up the axial skeleton [60] and 126 make up the appendicular skeleton [61, 
60]. Bones  provide a combination of different functions such as permitting 
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movement and locomotion, structural framework support [59, 61], protecting 
vital internal organs, and maintaining mineral homeostasis; especially calcium 
and phosphorus, storing up to 99 % of the body’s calcium [59, 62]. Bones also 
provide the environment for haematopoiesis production; the creation of white 
blood cells, platelets and red blood cells [59, 63], as well as storing chemical 
energy in the form of yellow bone marrow [59].Each bone can be placed into 
one of five categories; long bones, short bones, flat bones, irregular and 
sesamoid bones [59]. 
 
LONG BONES 
A long bone (figure 1.1) is composed 
of three main subdivisions; the 
diaphysis which contains a long 
hollow shaft which promotes bone 
strength whilst minimising weight [59, 
61], and also contains yellow bone 
marrow and blood vessels. The 
epiphysis which forms the proximal 
and distal large rounded ends of the 
long bones, and finally the 
metaphysis which is located between 
the epiphysis and diaphysis and 
permits bone to grow in length [59, 
61]. Additional characteristics of a 
long bone include the articular 
cartilage; this is composed of elastic 
hyaline cartilage and covers the 
proximal and distal ends of the 
bones, providing shock absorption to 
the area of the joints [59, 65]. There is also the periosteum that covers the long 
bones and is made up of a tough connective tissue providing a blood supply 
[59, 65]. It can also serve as an attachment spot for ligaments and tendons, as 
well as helping nourish and repair bone during fracture recovery [59, 65].  
 
 
Figure 1.1 An illustration of the anatomy 
of a long bone [64] 
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Long bones are mainly composed of compact bone which is situated at the 
diaphysis, with spongy bone in the epiphysis [59]. Examples include the 
humerus, metacarpals, and femur. 
 
SHORT BONES 
Short bones are defined as being approximately equal in width as they are in 
length and have a primary function of providing stability and support whilst 
experiencing little movement [59]. They consist of only a thin layer of compact 
bone, with the majority being spongy bone on the inside along with relatively 




Flat bones are thin, strong, flat plates of bone with the main function of 
providing protection to the vital organs of the body whilst also providing a large 
area for muscle attachment [59]. They are made up of compact bone enclosing 
a layer of spongy bone [59]. Examples include the sternum, scapulae, and ribs. 
 
IRREGULAR BONES 
These are bones in the body which cannot be grouped into any other category 
due to their complex and irregular shape. They primarily consist of spongy 
bone, with a thin outer layer of compact bone, although this can vary depending 




Sesamoid bones are usually short and are embedded in a tendon where there 
is considerable friction [59]. Their main function is to protect the tendon from 
overuse improving the mechanical function of the joint [59]. Examples include 
the patella, and the pisiform.  
 
1.2.1 COMPACT AND SPONGY BONE 
As stated each of the five bone categories contains a combination of two 
different types of bone, these are: compact bone (also called cortical bone) and 
spongy bone (also referred to as cancellous or trabecular bone). Compact bone 
43 
 
Figure 1.2. An illustration of the anatomy of 
compact bone [67] 
makes up 80 % of the skeleton with 20 % being spongy bone [59].  
 
COMPACT BONE 
Compact bone is the strongest form of bone tissue, and is found underneath the 
periosteum of all bones, making up the majority of the diaphysis of the long 
bones [59]. Compact bone tissue provides support and protection whilst also 
withstanding the stresses produced by locomotion and weight bearing [59]. 
 
The basic structural units of compact bone are called osteons or Haversian 
systems (see figure 1.2). Each osteon has a central part called the central 
(Haversian) canal which contains blood vessels, lymphatic’s and nerves, the 
canal is also surrounded by concentric rings called lamellae which are circular 
plates of mineralised salts (primarily calcium and phosphate giving bone its 
compression strength), and collagen fibres (giving bone its tensile strength [59]) 
resulting in a matrix. Between the rings of this matrix, are small spaces called 
lacunae in which osteocytes are located [59]. Extending in all directions from 
the lacunae are tiny canaliculi, these contain extracellular fluid and connect 
lacunae with one another as well as the central canals, forming an intricate 
system of interconnected canals throughout the bone. This system provides 
many routes for oxygen and nutrients to reach the osteocytes and facilitates the 











In contrast to compact bone tissue, spongy bone tissue, also known as 
cancellous or trabecular bone does not contain osteons; it is also lighter and 
less dense than compact bone which reduces the overall weight to the bone. 
Spongy bone (figure 1.3) also makes up the majority of interior bone tissue, it is 
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Figure 1.3. An illustration of a crosssectional anatomy of 
spongy bone zoomed in [69] 
seen in the flat, short, sesamoid, and irregular bones, and it is also the core 
component of the epiphyses in long bones. Spongy bone is normally situated 
where the bone is not heavily stressed, or where stressors are applied from 
many directions, spongy bone is also always covered by a layer of compact 
bone to protect it. 
 
Due to spongy bone not containing osteons, it instead consists of lamellae 
arranged into thin columns of bone called trabeculae [59], these columns 
contain lacunae, canaliculi and osteocytes, between these trabeculae there are 
macroscopic spaces which are filled with red bone marrow [59] in bones that 
produce blood cells (such as the clavicle, sternum, vertebrae [68]), and yellow 
bone marrow in other bones (such as the shaft of the femur) and is used in the 
storage of fats [68]. Additionally, both types of bone marrow contain a large 


















1.2.2 CHARACTERISTICS OF BONE 
Both cortical and trabecular bone possess different properties, with the 
combination of these producing its mechanical qualities. Therefore, their 
geometric characteristics and architecture will be discussed, and the impact 
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these changes have in distribution of weight bearing loads and effect of fracture. 
 
Both cortical and trabecular bone prefer to be aligned in the optimal orientation 
to tolerate longitudinal loading forces, of which frequent weight bearing is 
applied. If these loading forces are applied across differing degrees rather than 
longitudinally, then there is an increase in stress upon the bone when the same 
load is applied across the transverse plan, reporting a higher stress to the bone, 
increasing its fracture risk [70]. 
 
As this stress is applied the energy is dissipated across the geometric and 
density properties of the bone dissipating the stress applied. With structural 
weak bone this stress might allow holes or cracks to appear creating porosity 
within the bone [71]. Porosity in both trabecular and cortical bone is well known, 
and its link to increased fracture risk has been demonstrated [72].  
 
Trabecular bone is designed for weight bearing and strength; it has a high 
surface to area and volume ratio allowing distribution of weight and helps in the 
remodelling process. The architectural factors that determine trabecular bone 
strength are interrelated with the greatest mechanical optimisation seen due to 
high trabecular number, higher trabecular thickness, and connectivity [73, 74]. 
This trabecular bone transfers weight bearing stressors to the cortical bone. Any 
bone loss in the trabeculae can lead to increased fracture risk which is 
associated with loss of trabecular number, reduced connectivity, and increase in 
porosity [75]. 
 
In cortical bone the surface to volume ratio in cortical bone is much lower than 
in trabecular bone [76], although cortical bone is denser than trabecula bone, 
with a reported porosity of 5-10 % (compared to approximately 50 % in 
trabeculae bone). Cortical bone also has a higher calcium and water content 
than trabecular bone [76]. Both trabecular and cortical bone are important to 
bone strength, and the relationships are complex [76]. 
 
1.2.3 BONE ANATOMY OF THE KNEE 
This research will be investigating rTKR and therefore the anatomy of the knee 
must be stated. The knee joint (see figure 1.4) also referred to as the 
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Figure 1.4. An x-ray of a knee labelled (A) [77] and an illustrated structural view 
of the knee (B) [78]. 
















This is a long bone, and is the strongest, heaviest, and longest bone in the 
human body [59]. The distal part of the femur makes up the superior portion of 
the knee joint and is composed of the medial and lateral epicondyles (which 
participate in the knee joint via ligament attachments), this distal femoral end 
articulates with the tibia and patella creating the knee joint [59]. 
 
TIBIA 
The tibia is the largest weight bearing medial bone of the lower leg and second 
longest bone in the body [78]. The proximal tibia makes up the inferior portion of 
the knee joint and is composed of the medial and lateral tibial condyles; these 
articulate with the medial and lateral condyles of the femur creating the knee 
joint. The tibia also contains the intercondylar eminence which is the attachment 
site for the cruciate knee ligaments [59], and inferior to that is the tibial 




The fibula is a thin bone which is parallel and lateral to the border of the tibia 
and connected via the interosseous membrane [59]. The head of the fibula 
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articulates with the tibia on its inferior surface on the lateral condyle. The fibula 
does not play a vital role in the knee joint as it does not articulate with the femur 
[59] and does not bear much the weight of the lower leg [59].  
 
PATELLA 
The patella is largest sesamoid bone, and it is positioned anteriorly at the knee 
and glides along the femoral condyles [78]. It gives mechanical advantage to 
the knee joint and relieves friction between the bone and muscles during 
movement [78]. 
 
In addition to the bones that create the knee joint there are also many 
articulations, tendons, and intracapsular components. The knee joint itself is the 
largest and most complex joint in the human body [59], and is classified as a 
modified hinge joint with three articulations [59]: 
 
1. Laterally between the meniscus, and the tibial and femoral lateral condyles 
[59] 
2. Medially between the meniscus, and the tibial and femoral medial condyles 
[59] 
3. An intermediate joint between the femur surface and the patella [59]. 
 
As stated there are a large amount of structures that support and stabilise the 
knee joint such as: the patellar ligament, oblique popliteal ligament, arcuate 
popliteal ligament, tibial collateral ligament, fibular collateral ligament, 
intracapsular ligament, anterior cruciate ligament, poster cruciate ligament, 
medial meniscus, lateral meniscus, prepatellar bursa, infrapatellar bursa and 
suprapatella bursa. These mentioned either strengthen the joint (e.g. patellar 
ligament), limit hyperextension (e.g. anterior cruciate ligament), provide and 
circulate synovial fluid cushioning the joint (e.g. medial meniscus) or reduce 
friction in the joint (e.g. suprapatellar bursa).  
 
1.2.4 BONE ANATOMY AND REGIONS OF THE HIP 
This research will also be investigating rTKR impact on the proximal femur 
recorded as hip BMD, and the subset regions and features within the hip. The 
proximal femur (hip) areas of interest within the bone are shown in figure 1.5.  
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Figure 1.5. A [79] shows a labelled left hip x-ray, and B shows a Dual-energy X-ray 
Absorptiometry (DXA) image of a left hip with the regions highlighted by the software 


















A feature of the proximal femur, which provides insertion points for muscles 
such as the gluteus and piriformis [80]. 
 
LESSER TROCHANTER 
The lesser trochanter lies inferiorly between the neck and the shaft, projecting 
medially, this feature provides an insertion point for the ilio-psoas muscle [80]. 
 
FEMORAL NECK  
Attaches the femoral shaft to the head of the femur, and lies at an average 
angle of 125° [80]. This the most common site for hip fracture [81] and is 
comprised of both cortical and trabecular bone [82]. 
 
FEMORAL SHAFT 
Makes up the main body of the femur and contains several features such as 
lines, muscle attachments, and insertion points. It also attaches the femoral 
neck to the more distal part of the femur [80].  
 
WARDS TRIANGLE 
Is an abundant area of trabeculae bone that sits within the region of the neck of 
the femur [83], reporting the lowest BMD in the femoral neck it has been 
reported as a sensitive indicator of OP [84], but should not be utilised 
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independently from the total hip BMD for a diagnosis of OP [85]. 
 
1.2.5 BONE HISTOLOGY 
As well as the structure and classification of bone, it must be recognised that all 
types of bone in the skeletal system must undergo continuous and dynamic 
bone remodelling. This is to help adapt to changing biomechanical forces and in 
removing old and damaged bone and replacing it with new, mechanically 
stronger bone, to build bone and preserve bone strength [61]. Therefore, the 
build-up of BMD, and the histology of bone creation, will now be described. 
 
Bone contains extracellular matrix which is made up of 30 % collagen fibres, 15 
% water, and 55 % crystallised mineral salts [59]. The most common mineral 
salt is calcium phosphate, in which it combines with calcium hydroxide to form 
crystals of hydroxyapatite [59].During the formation of these crystals they 
combine with several ions such as magnesium and potassium, and other salts 
like calcium carbonate and calcium hydroxide [59]. 
 
These mineral salts are then deposited into the spaces of the collagen fibres 
that form the skeletal framework, the minerals then crystallise, and the tissue 
hardens, this process is called calcification, this process is initiated by a type of 
cell called an osteoblast, which is one of three types of cell that contribute to 
bone homeostasis and building of BMD [59]. 
 
OSTEOBLASTS 
Osteoblasts are bone forming cells [86], they synthesise and secrete collagen 
fibres and other extracellular components, they also initiate calcification during 
which they become imprisoned by the extracellular matrix and are converted 
into osteocytes [59, 87]. 
 
OSTEOCYTES 
Osteocytes are formed from osteoblasts being trapped in the bone matrix [86], 
these are the most abundant bone cell composing 90-95 % of all bone cells [86, 






These are bone reabsorption cells [87], they secrete enzymes and acids such 
as lysosome, hydrochloric acid and proteases [90], these dissolve the bone 
matrix and minerals, so it can be reabsorbed as part of normal development, 
osteoclasts also facilitate the regulation blood calcium levels [59].  
 
1.2.6 BONE REMODELLING 
Osteoclasts, osteoblasts and osteocytes all work together to create, remodel, 
and repair bone [86]. The first phase involves the osteoclasts who become 
active and digest old bone creating a large cavity [91], second phase involves 
reversal, when mononuclear cells appear on the bone surface [91], with the 
third phase being when osteoblasts deposit collagen matrix that is then 
mineralised [86]. It must be noted that in trabecular bone resorption takes place 
along the bone surface, whereas in the cortical bone, resorption tunnels through 
the bone itself [76]. 
 
The regulation of bone remodelling is both local and systemic, with the major 
systemic regulators being hormones such as glucocorticoids, thyroid hormones, 
growth hormones, sex hormones and parathyroid hormone (PTH) [91]. Other 
components such as growth factors, cytokines and certain membrane proteins 
such as receptor activator of NF-kappa B ligand (RANKL) are involved as well 
[91]. 
 
Due to the impact of these factors in bone remodelling and the strong 
association between cycles of absorption and formation, equilibrium must be 




1.3 RISK FACTORS THAT LOWER BMD  
As stated in the previous section bone is in constant homeostasis equilibrium, 
during childhood and adolescence much more bone is formed than reabsorbed, 
so the skeleton grows in both density and size, as such this is a critical period 
for bone mass accumulation [62]. It must be noted that inability to establish an 
optimised BMD at the end of adolescence leaves the individual with much less 
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available in order to withstand the normal losses during later life [92]. Therefore, 
it is generally accepted that peak bone mass (PBM) is defined as the period at 
which BMD is stable and at its maximum [93]. PBM has been reported to be 
attained at any skeletal site in both sexes about the age of 35 years [94], with 
some reports stating the lumbar spine skeletal site takes the longest to reach, 
with PBM stability at ages 33 to 40 years in women, and 19 to 33 years in men 
[93]. After these years bone loss starts to gradually fall, with higher severity of 
loss seen in older patients [95]. A variety of genetic and environmental factors 
influence PBM and BMD. It has been suggested that genetic factors (gender 
and race) may account for between 50-90 % of PBM variance [96, 97], and 
environmental factors (exercise and diet) have been reported to account for 
around 25 % [98]. As previously stated, this loss of BMD can lead to higher 
fracture risk, with an estimated 10 % increase in BMD possibly reducing fracture 
risk by as much as 50 % [99]. The risk factors that influence BMD will now be 
discussed. 
 
GENDER AND AGE 
Before puberty, girls and boys acquire BMD at a comparable rate, after puberty; 
however, men tend to achieve greater BMD than women [98]. Gender also 
influences BMD due to age; women tend to experience minimal change in total 
BMD between age 30 and 40 years, with bone loss starting around age 40-44 
[95]. This loss is exacerbated when patients transitioned from premenopausal to 
postmenopausal (around age 50-54 years) were the bone loss becomes 
particularly rapid [95]. This rate of decline is particularly seen in the total hip, 
with the decline accelerating again when the women are 70 years or older. In 
men bone loss gradually began around 25–39 years of age (measured at three 
skeletal sites). This rate of decline of BMD in the total hip was nearly constant 
among men 35 years and older, with this decline accelerating again among men 
older than 65 [95]. 
 
RACE 
Ethnicity itself can affect BMD; African American females tend to achieve higher 
PBM than Caucasian females [98]. Reports have shown Black men had greater 
BMD than Hispanic or White men with femoral neck BMD being 13.3 % higher 
in Black men than in Hispanic and White men, respectively [100]. Other results 
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have shown a similar trend with United States (US) Caucasian men, being 
compared to Afro-Caribbean and African-American men, these results showed 
that Afro-Caribbean men had a higher BMD of between 8–20 %, and the 
African-American men had a 6–11 % increase in BMD (after age adjusted 
mean) compared to their US counterparts [101]. Furthermore, men of Asian 
origin had a BMD loss of 3-14 % when compared to US Caucasian men [101]. 




The hormone oestrogen has an effect on PBM. Girls going through puberty 
earlier had greater gains in bone mass especially during bouts of physical 
activity [102]. In addition, women, who had their first menstrual cycle at an early 
age and those who use oral oestrogen contraceptives, often have higher BMD 
(although this is influenced by the age of the woman) [98, 92]. Although it must 
be acknowledged that there are reports that show the short and long term 
impact on bone health remains unclear [103]. In contrast, young women who 
suffer from Amenorrhea (cessation of menstrual periods) because of extremely 
low body weight or excessive exercise, have been linked with a loss BMD [92], 
with research showing that it might not be recovered even after their periods 
return [98], resulting in a failure to attain PBM [92]. 
 
NUTRITIONAL IMPACT 
There are two crucial nutrients in bone health; calcium and vitamin D (although 
there are others, of less importance). Calcium is critically important to diet and 
has been widely reported to increase BMD [104, 105]; it is also important in 
determining PBM [105, 106, 107, 108]. Therefore, calcium deficiencies in young 
people can account for a significant difference in PBM increasing the risk for hip 
fracture later in life [98]. The importance of calcium is such that it has been 
singled out as a major public health concern, with a national survey suggesting 
that the average calcium intake of individuals is far below the levels 
recommended for optimal bone health [92]. 
 
Vitamin D in contrast aids in the absorption and utilisation of calcium [92]. The 
main source of vitamin D is sunlight, by the conversion of precursors in the skin 
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to active vitamin D. It has been reported that there is a high prevalence of 
vitamin D insufficiency in nursing home residents, hospitalised patients, and 
adults with hip fractures [92]. Many factors can impede the creation of vitamin D 
by the skin, such as the location in which residents/patients reside [109].  
 
PHYSICAL ACTIVITY 
Physical activity is important for bone health throughout life. Young adults who 
exercise regularly generally achieve greater PBM than those who do not [98]. 
Physical activity helps to preserve and increase BMD and reduces the risk of 
falling [92], reducing the chances of fracture. 
 
One study compared tennis players bone mineral content (BMC) with their 
dominant arm compared to their non-dominant, their results reported a BMD 
increase of 12-16 % due to exercise [110] (normal dominant to non-dominant 
arm comparisons range from 3-5 % BMC difference) [110]. All types of physical 
activity can contribute to bone health although the best activity is weight-bearing 
exercise [92]. This type of exercise forces you to work against gravity, such as 
hiking, jogging, climbing stairs, walking, dancing, and weight training [98].  
 
Muir et al reported that even in the over 75 age group it was reported that an 
increase in exercise using simple, daily performed tasks can help prevent 
decrease BMD in post-menopausal women [111]. 
 
LIFESTYLE BEHAVIOURS 
Lifestyle behaviours such as smoking have been reported to reduce BMD and 
increase fracture risk [92], with heavy cigarette smoking also showing a 
negative effect on the status of BMD [112]. This fact worsens the negative 
impact of smoking on PBM [98], with research supporting the argument that 
smoking may promote postmenopausal bone loss [113]. Women who smoke 
also have lower concentrations of oestrogen than women who do not smoke 
[114]. 
 
Another lifestyle factor affecting BMD is alcohol consumption. Research 
suggests that high consumption of alcohol has been linked to reduced BMD and 
increased fracture risk [115], with moderate consumption being associated with 
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increasing BMD [116, 117], although alcohol has been reported to inhibit bone 
remodelling, by possibly interfering with vitamin D, or by reducing bone 
formation and increasing calcium loss from the body [118].  
 
Caffeine also influences BMD, with reports revealing a link between the intake 
of caffeine and lowering BMD [112], with excess caffeine consumption 
contributing to a decrease in BMD in both the femoral neck and lumbar spine in 
healthy white women aged 19-26 years [119]. Additionally, caffeine may 
interfere with the calcium absorption in the intestines ultimately encouraging 
BMD loss and leading to an increased fracture risk [120]. 
 
MEDICATIONS 
Several prescription medications can also impact BMD through various 
mechanisms [92]. Anticonvulsants such as Phenytoin (Dilantin) and 
carbamazepine (Tegretol) have been associated with a reduction in BMD, 
possibly due to lowering vitamin D and interfering with intestinal absorption of 
calcium [121]. Additionally, high levels of glucocorticoid medications (both 
synthetic and natural) are associated with reduced activity of osteoblasts and 
increased activity of osteoclasts [121] leading to lower BMD. 
 
Breast and prostate cancer drugs have also been associated with lowering 
BMD, with breast cancer drugs preventing oestrogen formation, lowering BMD 
and increasing fracture risk [121]. Whilst androgen deprivation therapy 
treatment for prostate cancer involves the removal of the male sex hormone, 
which has been linked to reducing BMD and increasing fracture risk [121]. 
 
Diuretics, such as furosemide (Lasix), which are commonly used to treat fluid 
retention in order to increase urination, which in turn promotes calcium 
excretion from the kidneys. As a result, they have been associated with reduced 
BMD at the hip. They have also been associated with an increased risk of hip 
fracture [121]. Heparin is a blood thinning treatment which is also connected 






1.3.1 BONE DISEASES THAT AFFECT BMD 
 
OSTEOARTHRITIS AND OSTEOPOROSIS 
Two of the predominant and main pathological disorders that hugely affect BMD 
are osteoarthritis (OA) and OP; these conditions mainly affect the elderly 
population and are associated with high healthcare costs and morbidity [1].  
 
Osteoporosis is a condition that decreases BMD and reduces the structural 
integrity of bone [2]. This results in them becoming fragile and increasing 
fracture risk. The most commonly affected sites are the wrist, hip, and vertebrae 
[3], with an estimated 8.9 million new osteoporotic fracture cases per year [3]. 
 
As well as OP, fractures can be caused by many different mechanisms such as: 
stressors, extreme loads, and sudden impacts [122]. The annual fracture 
incidence rate in England is 3.6 %, with a lifetime fracture prevalence exceeding 
50 % for middle-aged men, and 40 % in women ≥75 years [122].  
 
Osteoarthritis is a condition in which the joints of the body become damaged 
and painful, resulting in a reduction in mobility in the appendicular skeleton and 
spine [123]. It is the most common form of arthritis in the UK, with 8.7 million 
people having sought treatment for the condition, of which 33 % are aged ≥ 45 
years; this percentage increases in the ≥75 years group to 49 % for women and 
42 % for men respectively [123, 124]. Due to the destructive nature of OA on 
the joints and the resulting loss of mobility and function, surgery is a primary 
option and therefore OA accounts for between 80-90 % of all total knee 
replacement (TKR/arthroplasty) procedures [125, 126, 127, 128]. 
 
The relationship between OA and OP is complex and has been reported to be 
an inverse one [129], with OA being reported to increase BMD it might be 
assumed to increase fracture protection. With such a high percentage of cases 
of TKR due to OA it could be concluded that this protective effect would reduce 
fracture risk in TKR patients due to having higher BMD, but increased fracture 





RELATIONSHIP BETWEEN OA AND BMD 
The relationship between OP and BMD is already firmly established within this 
paper (see section 1.1). Research on the relationship between OA, BMD, and 
the subsequent fracture risk has not been stated so far and has produced many 
controversial and conflicting results.  
 
In 1972 Foss et al were the first to observe the correlation between OA and 
fracture risk, concluding that patients with OA had a greater BMD for their age 
and thus had fewer hip fractures [129]. This suggested the possibility of a 
protective effect of OA due to higher BMD, with several studies supporting this 
theory; Dequeker et al in 2003 reviewed the relationship between increased 
severity of OA resulting in higher BMD, discovering 36 previous studies across 
16 countries (Europe, the US and Australia) covering a total of 37,774 subjects 
including 11,137 OA cases. Twenty eight of these studies showed an increase in 
BMD with the remainder eight studies showing there was no increase in BMD 
[130]. 
 
A study by Hart et al [131] of 95 women showed a higher hip and spine BMD 
versus controls (0.79 gm/cm2 versus 0.76 gm/cm2, or 3.9 %, and 1.01 gm/cm2 
versus 0.95 gm/cm2, or 6.3 % for hip and spine respectively), this itself is 
supported by other research [132] that concluded that OA resulted in higher 
BMD in the hip and spine, than women without hip OA. This trend was also 
seen in elderly men, who showed higher BMD in both the lumbar spine and hip 
compared to age similar matched controls without OA [133]. This is further 
validated by research that shows an increase in BMD of the spine of patients 
with OA compared to controls [134, 135, 136].  
 
There is research that states that although spine BMD might be high, hip BMD 
was not, as investigated by Lethbridge-Cejku et al [136] who recruited 402 men 
and 247 women with OA, reporting high levels of spine BMD but not hip BMD. 
This is supported by Arokoski et al [137] whose findings suggest that hip OA is 
not associated with an increase of BMD in the femoral neck or in the head of 
the femur. Although it must be stated that there is research to the contrary, a 




OA AND FRACTURE RISK 
Due to the majority of research showing an increase in BMD in OA patients 
[129, 131, 132, 134, 135, 136] it is generally thought that this should have a 
protective effect on the bone and reduce fracture risk. This idea has been 
supported by several studies. Vestergaard et al [139] conducted a case 
controlled study using over 24,655 fractures matched for age and gender, with 
the main exposure being OA; their research showed that OA seemed to be 
associated with a decreased risk of fractures in multiple skeletal sites. This is 
agreed by Cummings et al [140] who examined 189 participants (65-79 years 
old) with self-reported OA; the subjects with OA had fewer reported hip fractures 
than randomly assigned controls (4 % compared to 13 %). Additionally, 
Cummings et al showed an inverse association between the number of joints 
reported to be affected by OA and the risk of hip fracture, with this protective 
effect being reported in both women and men [140]. 
  
In contrast a number of studies have argued against the protective nature of 
OA, reporting an increase in fracture risk despite subjects having increased 
BMD. One study reported a BMD increase of 5.3 % compared to controls but no 
reduction in fracture risk [141], this is further supported by the Rotterdam study 
[142] which utilised 2,773 subjects and concluded that patients with knee OA 
had an increased risk of both vertebral (2.0-fold) and non-vertebral (1.5-fold) 
fractures. Individuals with self-reported OA also had higher BMD but were not 
protected against non-vertebral osteoporotic fracture [143]. 
 
A study in 2014 [144] also demonstrated an increase in fracture rate amongst 
OA patients, in which 3864 subjects aged >45 years were analysed. Results 
revealed that fracture risk was significantly higher in women with OA than those 
without OA. A prospective randomised control trial conducted by Arden et al 
supports this argument where over 6,500 men and women ≥75 years were 
recruited over three years, concluding that patients with knee pain and knee OA 
had an increased risk of non-vertebral and hip fracture [145].  
 
It must be acknowledged that a study by Arden et al, reported a lack of any 
relationship between OA and fracture risk despite increased BMD [146]. This is 
supported by additional research that used cohort studies and reported no 
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relationship between fracture risk and OA [140, 147]; contributing to the theory 
that OA does not have a protective effect on fracture risk. 
 
Due to the contradiction and failure of the observed increase in BMD to 
translate into a protective effect and reduce fracture risk, several rationales 
were investigated. One explanation for increased fracture risk may be 
explained, in part, due to an increased fall tendency in patients with OA [146]. 
Studies by Vennu et al and Doré et al have shown that people with knee or hip 
OA have a greater number of falls and fracture risk compared to the general 
population [148, 149], even showing an increase in odds of falling correlated to 
the number of affected joints with OA [149]. This theory is shared by other 
research [150], with some stating this is due to OA causing worsened postural 
stability increasing their tendency to fall [143]. This is contradicted however by 
two cohort studies, [145, 146] that reported that increased risk of fracture was 
independent of the number of falls. Although this in itself may be explained due 
to the severity of the falls and not the number of falls [145]. However, this 
rationale may be difficult to justify as fall data are often incomplete [151].  
 
Another rationale against the failed protective effective of high BMD from OA to 
translate into reduced fracture risk is demonstrated by Lee et al [152] whose 
cross-sectional study proposed that despite OA subjects having high systematic 
BMD, they were positively associated with vertebral fractures. Lee et al 
suggested that bone quality, and consequently bone strength, may be 
decreased at the systemic level in knee OA, resulting in a higher risk of fracture 
[152]. A similar idea is shared by Ding et al [153] whose research looked at OA 
in post mortem participants, using micro Computed Tomography (CT) scans of 
the microarchitecture of the proximal tibiae, this researched showed that medial 
OA trabecular bone was significantly denser, but had lower mechanical 
properties than normal bone. Ding et al suggested that bone remodelling in OA 
leads to deterioration in architecture; resulting in poor quality bone, so although 
BMD could be retained the bone quality was less, resulting in the possibility of 
greater fracture risk. This effect might be explained due to subjects with OA 
having a greater proportion of undermineralisation (immature matrix) in the 
bone [154]. This rationale is further supported by some research suggesting 
that bone trabecular microarchitecture was the key determinant of fractures in 
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addition to the BMD data [155]. 
 
Additional arguments [156] state that the BMD values themselves could be 
falsely elevated due to limitations in the DXA scans only measuring two-
dimensions, and not accounting for bone depth. Moreover, Chaganti et al has 
demonstrated that osteophytes (these are more common in OA patients due to 
joint damage, so bone wears against bone creating bony spurs [157]) contribute 
between 16.6 % and 22 % of the lumbar spine BMD variation in DXA scans in 
women and men respectively [158], possibly leading to an overestimation of 
higher BMD without the increase in bone strength. 
 
Due to the limitations and arguments put forward, other imaging techniques and 
methods have been investigated. Bousson et al created a tool called the 
trabecular bone score (TBS) [159], which is able to differentiate between two 
microarchitectures that exhibit, the same density [159]. This new method was 
investigated by Hopkins et al [23] who recruited 19 post-menopausal women 
pre and post TKR. The results exhibited that participants with TKR had higher 
mean lumbar BMD compared to controls but a lower TBS, suggesting that OA is 
potentially concealing poorer bone quality, even though it has a higher BMD. A 
further study by Hopkins et al investigated differences in bone quantity and 
quality assessed by spine BMD and TBS [160], these results demonstrated that 
the participants with TKR had higher BMD than the controls but poorer TBS 
scores [160]. 
 
TBS and BMD at the lumbar spine suggests that the generally higher BMD 
typically observed in OA patients may be disguising poor quality bone with less 
structural integrity [23], this is supported by the rationale and results of the 
previous studies mentioned [152, 153] and might be the main reason that OA 
with high BMD does not a have protective effect in reducing fracture risk.  
 
OA PHENOTYPE INFLUENCE ON BMD 
The majority of the research shows an increase in BMD in OA patients [129, 
131, 132, 134, 135, 136] but it must be acknowledged that there are other 
factors in OA; the phenotypes within OA such as osteophytic (which is 
osteophyte predominant [133]), and atrophic (which is joint space narrowing 
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(JSN) predominant) both influence BMD. Chaganti et al study showed 
significant differences in the hip and lumbar spine of areal BMD (aBMD) 
measurements for the two radiographic hip OA (RHOA) phenotypes compared 
to the control group. The osteophytic RHOA group had a higher aBMD at all 
sites compared to the control group: +3.9 % at the total hip (p = 0.002); +8.5 % 
at the femoral neck (p < 0.0001); + 4.6 % at the trochanter site (p = 0.002); and 
+7.2 % at the lumbar spine (p =0.0003). In contrast, the atrophic phenotype was 
not significantly associated with any difference in aBMD compared to controls 
[133]. This is further supported by research that showed that obese patients 
have a more osteophyte dominant OA pattern compared to non-obese patients; 
74.5 % compared to 34.8 % [161], this coupled with increasing obesity in the 
population and the association of obesity with the onset and progression of OA 
in the knee [162] resulting in more TKRs, might reflect the associated BMD 
change and OA diagnosis. 
 
OA AND JOINT ALIGNMENT  
Another factor that influences BMD in the hip and knee is the alignment and 
angulation of the joints, as OA deteriorates the joint spaces of the hips and 
knees these joints become more asymmetrical through changes in the load 
bearing mechanism, thus the knees become more varus (bow legged) or valgus 
(knock kneed). Czerwiñski et al reported that 90 % of patients with knee OA 
have a varus deformity [163], this varus deformity causes weight to be 
distributed along the medial tibial aspect, with severe cases of OA (with a varus 
deformity) reporting a statistically higher BMD in the tibial medial region than the 
lateral region, the opposite is seen in those with a valgus deformity, reporting a 
higher BMD through the lateral tibial aspect [164] (and lower in the medial). This 
deviation in malalignment and increased BMD has been reported in other 
studies [163, 165], although correct realignment through surgery has been 









1.3.2 OTHER DISEASES AFFECTING BMD  
 
DEPRESSION  
Bone mineral density and bone quality are affected by many other factors, not 
only the influence of OA. Depression has been shown to alter behaviour and 
neuroendocrine systems, with participants with depression having lower BMD 
[167, 168]. Studies have reported that women with past or current depression 
have 6.5 % lower BMD than compared to controls at the spine, and 13.6 % 
lower at the femoral neck [168], with Vyas et al reporting that depression 
increases cortisol and inflammation leading to lower BMD [167]. 
 
OBESITY/DIABETES AND CHRONIC KIDNEY DISEASE 
Obesity is associated with higher BMD [165] but has been reported to lead to a 
lower rate of bone formation [170], and has been linked to an increase in the 
risk of OA [37, 171]. Type two diabetes is also associated with higher BMD; 
whilst type one diabetes is associated with lower BMD, but both type one and 
type two have increased overall and hip fracture risk [172], with type one being 
greater than type two diabetes [86]. Research has shown that this might be due 
to changes in bone material properties rather than BMD, such as; bone 
strength, structure, and quality, encompassing the microstructural and tissue 
material properties [173]. This is further supported with research showing that 
type two diabetes patients have higher cortical porosity than normal controls 
[174]. Chronic kidney disease (CKD) has been reported to influence bone 
quality by altering bone turnover and mineralisation, resulting in micro damage 
and structural and material changes [175].  
 
1.3.3 ANDERSON DEFECTS AND CLASSIFICATION 
As stated there are many factors that affect BMD, the majority of the research 
stated affects BMD throughout the whole body, but as this study will review both 
systemic and local BMD loss it is important to understand BMD loss reported at 
the knee, especially due to the involvement of knee replacements, and more 
specifically total knee revisions. The reported BMD loss affects the implantation 
of the revision that the Anderson Orthopaedic Research Institute (AORI) have 
developed a classification system to describe the severity of the bone loss 
experienced by TKR/A patients prior to rTKR [176]. 
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A defect is only classified under the AORI system when a TKR/A component 
has been removed. Each component (femoral or tibial) is assigned an individual 
defect classifications upon removal either type one, two, or three. Defects are 
classified from preoperative radiographs for anticipated bone deficiency and 
then the classification is either confirmed or changed intraoperatively [177]. The 
arguments for this apparent bone loss are multifactorial and caused by: 
polyethylene particle disease, stress shielding, wear-debris-induced osteolysis, 
implant loosening, and bone necrosis from infection. Bone loss can also be 
experienced during the removal of the prosthesis [178, 179]. 
 
TYPES OF DEFECT 
Type one - Only minor bone defects and metaphyseal bone intact, stability of 
the component uncompromised [177, 180]. 
 
Type two - Metaphyseal bone damage and loss of cancellous bone that requires 
an area of cement fill, bone graft or metal augmentation is needed. Type two 
bone defects can occur singularly in a femoral condyle or tibial plateau, or in 
both condyles [177, 180]. 
 
Type three - Metaphyseal bone is deficient with bone loss that compromises a 
major portion of either condyle or plateau. These defects usually require a 
structural bone allograft or custom made implants [177, 180]. 
 
This AORI three part classification system is most frequently used [180]. It takes 
into consideration both the stability of the implants and the location of the 
defect. It also provides guidelines to managing treatment and enables 
preoperative planning on radiographs [177, 180]. 
 
Any associated BMD loss has real life implications in increasing fracture risk, 
thus any solutions of treatment or intervention that can lessen this loss of BMD 







1.4 TYPES OF BMD TREATMENT AND IMPLANTS 
As stated there is a need to address the loss of BMD especially in TKR/A and 
rTKR patients, and this section will discuss the treatments, options and 
interventions available. 
 
1.4.1 ANTIRESORPTIVE TREATMENTS 
Agents categorised as antiresorptive are those that work to inhibit osteoclasts 
and bone absorption, these include bisphosphonates, estrogen, Selective 
Estrogen Receptor Modulators (SERM) (although estrogen is a weaker 
antiresorptive drug than bisphosphonates and might also affect bone formation 
[181]), cathepsin K inhibitors, and most recently anti-RANKL antibodies [181]. 
 
The most commonly used intervention to increase BMD or to reduce the loss of 
BMD are bisphosphonates (examples include Fosamax, Actonel, Boniva and 
calcitonin) these inhibit osteoclasts, slowing down the progression of BMD loss 
[59]. Hahn et al [36] investigated these, concluding that bisphosphate treatment 
just after TKR surgery prevented early BMD reduction in the hip, and would be 
beneficial in the prevention of later hip fracture. This is supported by research 
by Carulli et al [182], who proposed the use of bisphosphonate treatment in 
patients to not only prevent bone loss but increase implant survival. Other 
studies [183] reviewed the effectiveness of bisphosphonate use on post TKR 
fracture risk, recruiting patients who had received a TKR between 1986 and 
2006 for knee OA. They concluded that bisphosphonate treatment after a TKR 
reduced the risk of fracture by 50-55 %. Additionally, a meta-analysis [184] in 
2015 reviewed the long-term effects in using bisphosphonates, reporting a 
significant decrease in implant revision after TKA or total hip arthroplasty (THA). 
Although caution should be utilised when administering bisphosphonates for 
long term use, as research from 2017 has reported an increase in the size and 
number of microcracks, leading to higher fracture risk in those patients on long-
term bisphosphate use [68]. Furthermore, there have been reports of long-term 
use leading to increased atypical femoral fractures [185].  
 
HORMONE REPLACEMENT THERAPY 
Some studies have looked at other possible antiresorptive treatments, such as 
hormone replacement therapy (HRT) which replaces oestrogen and 
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progesterone lost during and after menopause (example Prepro) to reduce 
BMD loss. This therapy influences osteoclast activity by reducing its impact in 
bone absorption [86]. Early and late postmenopausal women on HRT have 
shown an increase in BMD at all skeletal sites [186, 187], with some studies 
reporting a BMD increase of 5.3 % at the lumbar spine, and 7.6 % at the 
femoral neck compared to 0.2 % and 2.1 % in the control placebo group [188]. 
However, research by Legroux-Gerot et al reports no difference between groups 
[189], it must be stated that long term use of HRT has been strongly associated 
with breast cancer [190], and as such long term administration is no longer 
advisable [191]. Some research has investigated a similar therapy called 
Estrogen Replacement Therapy (ERT). This therapy replaces oestrogen lost 
during and after menopause (example Premarlin), ERT helps maintain and 
increase BMD, although it has also been associated with increasing the 
chances of stroke and blood clots [59]. Other possible antiresorptive treatments 
are SERM (examples include Raloxifene, Evista).These mimic the effects of 
estrogen [59] and have been reported to show an increase in BMD in the 
femoral neck by 2.1-2.4 % and in the spine by 2.6-2.7 % compared to placebo 
controls [192]. Unfortunately, there are side effects to SERM such as causing 
menopausal symptoms (breast pain, hot flushes) and resulting in an increase in 
thromboembolic events [193, 194]. 
 
Cathepskin K inhibitors (example odanacatib) are another antiresortive 
treatment option. These work by blocking a key osteoclast amino acid utilised in 
collagen degradation, reducing bone absorption [195], although this current 
treatment is unlicensed due to unresolved safety concerns [86]. As of 2016 the 
only candidate to continue in development was odanacatib [196], therefore a 
large multinational randomised, double-blind phase three clinical trial of 
odanacatib in postmenopausal women with osteoporosis was recently 
completed [196]. This study demonstrated clinically relevant reductions in 
fractures at multiple sites including the hip and spine, although odanacatib was 
found to be associated with an increased risk of cerebrovascular events [181] 
and ultimately withdrawn from the regulatory approval process. 
 
Anti-RANKL is an antibody agent (example Denosumab) given via 
subcutaneous injection [197], this drug inhibits osteoclast activity and bone 
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resorption; unfortunately, it also inhibits bone formation [86, 198]. Additionally, 
there are potential side effects such as; osteonecrosis of the jaw, low calcium 
levels, and atypical fractures due to long term treatment [197]. 
 
1.4.2 ANABOLIC TREATMENTS 
In contrast to the antiresorptive agents there are anabolic or pharmacologic 
agents. These promote osteoblast activity stimulating bone growth. This group 
is limited and made up of: parathyroid hormone (PTH), strontium ranelate, and 
anti-sclerostin antibodies.  
 
Currently the only approved anabolic for systemic use is PTH [86].This 
treatment stimulates osteoblasts promoting increased BMD (example 
teraparatide [Forsteo]), although studies are limited [59]. PTH has been 
associated with side effects such as headaches, dizziness, joint pain, and 
depression [199]. 
 
Another anabolic treatment investigated was strontium ranelate (example 
Protelos) [62] this treatment is capable of encouraging osteoblast activity, and to 
a certain extend inhibit osteoclast activity [200].  This drug was withdrawn in 
2017 [62] due to safety concerns [86], such as cardiovascular risks and an 
increased risk of death [201]. 
 
Additional anabolic research investigated sclerostin, which is a glycoprotein 
inhibitor of osteoblast cells [202]; as such anti-sclerostin antibodies (example 
blosozumab or romosozumab) reduce this inhibition of osteoblasts stimulating 
bone formation, but it also inhibiting bone resorption [86]. This type of treatment 
has shown an increase in BMD in the spine and hip [203], but is still 
undeveloped with a lack of published phase three clinical trial evidence [204] 
and thus efficacy and safety concerns have not been fully addressed yet [202].  
 
1.4.3 SURGICAL OPTIONS 
As the main body of this research will be investigating rTKR and given the 
current limited options in both bone anabolism treatments and antiresorptive 
therapies, coupled with an expanding elderly population that would likely benefit 
clinically from approaches to increase BMD, a clear need exists for additional 
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approaches that can reduce bone loss without inhibiting bone formation [181]. 
Therefore surgical implants addressing this problem are discussed in this 
section; these mainly come in the form of allografts and metal implants, and can 
be used in both tibial and femoral defects regardless of cementation, with the 
main design to reduce bone loss.  
 
ALLOGRAFTS  
Bone allografts are a biologic solution for the restoration of ‘bone stock’ in the 
knee almost to its original form [205]. Bone allografts have been used in rTKR; 
they can provide a stable and durable reconstruction of deficiencies [206]. The 
use of structural allografts is seen as a good option for younger patients [207] 
as it can restore bone stock for future revisions [207]. Unfortunately, this 
procedure is time consuming and technically challenging [208], and allografts 
are not always suitable for all defects in all patients, especially older patients, as 
well as the possible transmission of disease [209].  
 
SLEEVES 
Metaphyseal sleeves are normally made of titanium alloy with a porous surface 
that is sintered by titanium, with the porosity from 50 % to 80 %. Metaphyseal 
sleeves provide a stable scaffold for joint reconstruction [210, 211]. The 
metaphyseal sleeves come in variety of different shapes and are press fitted 
into bone allowing bony ingrowth. A paper by Watters et al reported excellent 
osseointegration and lasting fixation [212], showing ingrowth stability 3 month 
post-operation [213], with research by Agarwal et al reporting good 
osseointegration in 102 out of 104 knees at their final follow up scan [214]. 
Unfortunately, there appears a lack of data about metaphyseal sleeves in TKR/A 
affecting BMD; with the main priority being stabilisation and survivorship. 
 
CONES 
Cones are designed to act like a scaffold for osteoblast-mediated bone 
ingrowth, facilitating particulate graft incorporation as well as providing a porous 
surface with excellent properties to cement in the total knee revision implant in 
place [215]. These implants are primarily chosen due to being bioinert, able to 
support mechanical loads, and being highly porous, promoting osseointegration 
[216]. Furthermore, both metaphyseal sleeves and cones avoid issues of 
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disease transmission, graft resorption, and collapse associated with bone graft 
material [217]. A study by Lachiewicz et al reported that tantalum cone implants 
were fully integrated after two years [218], with other research reporting that all 
patients treated with a metaphyseal cone had radiographic evidence of 
osseointegration [219], with multiple studies demonstrating beneficial short term 
results [218, 219, 220, 221, 222, 223]. Furthermore, a paper by Harrison et al 
reported that cone implantation maintains tibial bone density [224]. Additionally, 
as well as the material tantalum, porous titanium cones have been investigated, 
this is due to porous titanium being considered the ideal graft material in 
orthopaedic surgery due to having similar structure and mechanical properties 
to normal trabecular bone [225]. This type of implant has been shown to 
increase BMD at particular regions by 8.1 % [226], with further research 
showing a similar favourable effect on BMD [227]. Although some research 
demonstrates that there is no significant difference in changes in BMD between 
the groups [228]. Titanium cone implants have also demonstrated better stability 
than their tantalum counterparts [229]. In addition to the cones some studies 
have investigated the effect of Hydroxyapatite bioceramic that resembles the 
mineral that constitutes human bones and teeth [76], coated onto the titanium 
implants to promote in-growth, this combination has demonstrated to increase 
shear strength [230], but has been reported to lead to decreased bone 
formation on porous coated titanium [231]. Further cone implantation research 
in rTKR produced a systematic review in 2014 [232] in which aseptic loosening 
rates of conal implantation against structural bone allografts were investigated. 
These results showed a significant decrease in loosening rates in the conal 
implantation group compared to allograft group, as well as substantially lower 
failure rates [232]. 
 
 
1.5 TYPES OF KNEE REPLACEMENT  
In order to understand the application and implementation of cone implantation 
the knee replacement and revision procedure will now be discussed. 
 
1.5.1 TOTAL KNEE REPLACEMENT                                                             
A TKR also called an arthroplasty (TKA) is a routine operation that replaces an 
arthritic, damaged diseased or worn knee with an artificial joint [233, 234]. The 
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Figure 1.6. Is an illustration of the structure of a knee once a TKR component 
has been implanted [236] 
 
procedure is carried out due to pain, reduction in mobility, and loss of function to 
the individual [233], with the typical patient age being 60 to 80 years old [234]. 
This option is normally only offered once other recommended treatments have 
been exhausted, such as physiotherapy and steroid injections [234]. 
 
During the operation the damaged cartilage is removed from the distal end of 
the femur, the femur is then resurfaced to fit a metal femoral component which 
is normally cemented to seal it into place [59]. The proximal end of the tibia is 
then operated on, with the damaged bone and cartilage excavated, the tibia is 
then resurfaced and fitted with a plastic and metal component, the metal 
component is fitted securely using bone cement to the tibial plateau whilst the 
plastic component made of polyethylene is placed on top of the tibial metal 
component (as shown in figure 1.6), this is in order to act as a buffer between 
the femoral and tibial components providing support to the knee joint [235]. In 
some cases, if the underside of the patella is also of poor quality then it might 






















During this type of surgery there are many potential complications including 
infection, increased risk of blood clots, stiffness and failure of the implant [59]. 
Although most studies demonstrate that between 85-90 % of TKR/A will last 
between 15 to 20 years [237], early failures may occur due to a variety of 
reasons. These include: infection, periprosthetic fracture, and loosening of the 
implant. When early failures occur, rTKR surgery is required [237]. 
 
1.5.2 TOTAL KNEE REVISION 
As stated the need for rTKR has several causes, the most common reason for 
rTKR to be performed is due to loosening (25-40 %), infection (24-44 %), wear 
of the polyethylene component/osteolysis (9 %), failure of the implant (2.8-6 %), 
and periprosthetic fracture (2.8-4 %) [238, 239]. During surgery the most 
complex issue is when the old implant is removed resulting in a large cavity, this 
combined with patients having less bone to implant the new revision into, 
makes a secure and stable implant even more important in promoting bone 
ingrowth and osseointegration. Therefore, this cavity has to be either filled in or 
the new replacement secured elsewhere to ensure the rTKR is fixed for long 
term survival. 
 
Various methods have been utilised to help achieve fixation and security within 
these cavities, including cemented or uncemented implants, using stems of 
differing lengths, and using additional methods to improve metaphyseal fixation 
(examples include: bone graft, augments, sleeves and cones).  
 
Stems are intramedullary extensions of either the tibial or femoral implant in 
order to achieve distal fixation [240] and stabilise the joint, the length of the 
revision stem is determined by multiple factors with fully cemented and press fit 
stems being available [240], with both short and long stems having advantages 
and disadvantages. 
 
Short metaphyseal stems suggested by Patel et al [240] are between 30-75 mm 
long, with the longer diaphyseal stems being greater than 75 mm in length, 
although it is suggested [240] that stem length is less important, and that the 




Figure 1.7. Anteroposterior x-ray knee view of a rTKR patient with an implanted 




















Both stem lengths (shown in figure 1.7) have positives and negatives. Short 
stems are generally cemented, have less end of stem pain, but tend to be more 
difficult to remove, which consequentially can lead to more bone loss [240]. 
Long stems are reported to be primarily uncemented in implantation and are 
easier to remove, although they are generally associated with an increase in 
end of stem pain, and a higher chance of periprosthetic fracture [240].  
 
Research suggests an optimum stem length for greatest clinical outcome is 
missing [240] and as such an ideal stem length is one in which the greatest 
bone is maintained whilst allowing the greatest stabilisation [240]. Data have 
also shown that cemented short stems provide as much stability as long 
uncemented stems which might add to the confusion between the two lengths 
comparisons [243]. 
 
One method to address stabilisation as already stated in the introduction is 
conal implantation, with cones reported to have shown excellent stabilisation 




Figure 1.8. This image shows three different variations of tibial cone implant 
shape, which can all be used in a rTKR. These are manufactured by Zimmer 
incorporated [244]. 
 
Figure 1.9. This image shows three different types of femoral cone implants, 
which can be used in rTKR. These are manufactured by Zimmer incorporated 
[244]. 
 
Figure 1.10. Shows the letters and associated sizes (with optimum sizes 
highlighted in green [245]).It also shows the tibial symmetric cone reamer with the 
recorded diameter and how this correspondes to the cone size.  
 
1.5.3 IMPLANTATION OF CONES 
Cones both tibial and femoral, come in different variations of shapes and sizes 














For the implantation of cones in both the tibial and femoral aspects certain 
protocols are followed, these ones stated below are from the Stryker TS 
triathlon cone implantation which will be utilised in this study.  
 
TIBIAL PREPARATION 
Tibial canal preparation involves creating a depth of a minimum of 175 mm to 
facilitate accurate cone reaming [245]. Cone reaming then takes place involving 
a tibial symmetric cone reamer producing a depth and diameter to match the 













Figure 1.11. Shows different preparations for different cone shapes, for instance A 
[229] shows symmetric cone preparation [229], this is for a symmetrical cone B [229] 
is for an asymmetric cone hence the difference in shape and additional cavity, with 
image C showing the reamer position (shown in yellow) being placed offset needed to 
create the asymmetric cavity shown in B [245]. 
 
The size of the cavity corresponds to the size of the conal implant, with size 
option of A-E spanning 21-25 mm in diameter.  
 
Asymmetric cone preparation if needed depending on the type of tibial cone 
used can then be performed; this is similar to the tibial symmetric cone 
preparation but produces an offset cavity (see figure 1.11), which again should 



















The femoral canal is prepared by creating a minimum depth of 175 mm [245] 
femoral sizing is then determined via a femoral sizing template (figure 1.12) or 
by measuring the previous implant. The femoral symmetrical cone reamer is 









Figure 1.12. A shows the femoral implantation sizes (optimum sizes highlighted in 
green [245]), with image B showing the femoral symmetrical cone reamer position 
(yellow) being placed into the femur in order to create the cavity [245]. 
 
 
Figure 1.13. Image A shows the femoral cone reamer (yellow) being placed to 
the left of the femoral symmetrical reamer [229]. Image B shows the three holes 
created in the femur [229], with the femoral cone reamer producing the holes 














The femoral cone reamer is then placed either side of the cavity created by the 
femoral symmetrical cone reamer creating a void made up of three insertions, 














The femoral cone component is then inserted into the designed cavity. This is a 
simplified version of the surgical procedure in order to underlie the insertion 
technique of conal augmentations. 
 
COMPLICATIONS 
During rTKR there are similar complications as seen in TKR, although there are 
some additional issues as well, such as dislocation of the new implant, with this 
risk of dislocation being twice as high for rTKR than in TKR [246], there is also 
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an increase loss of bone tissue [246] and an increase in bone fractures during 
the operation; this is due to the forces of pressure used in order to remove the 
old components [246, 247]. 
 
 
1.6 IMAGING TECHNOLOGIES 
Due to the associations between low BMD and fracture risk and its association 
in TKR/A an rTKRs, ways to image and report BMD will now be discussed in 
this section. 
 
1.6.1 DUAL ENERGY X-RAY ABSORPTIOMETRY IMAGING 
Dual energy x-ray absorptiometry (DXA) is the most commonly used imaging 
modality for OP diagnosis [248], it is utilised to assess BMD measurements and 
to calculate future fracture risk. It is simple, non-invasive, easy to set up, has 
short scan times [249] and it also uses low levels of radiation [249, 248] 
approximately one tenth a standard chest x-ray [250]. 
 
A DXA scanner works by utilising x-ray beams of two different energies 
(example 70 Kilovoltage peak (kVp) and 140 kVp [251]) resulting in two distinct 
peaks of x-ray radiation [248], these two different energies are attenuated 
differently based on the atomic number of the tissue being scanned. Low-
energy photons are attenuated slightly more than high energy photons in soft 
tissues. The attenuation differential between the two photon energies is greater 
in bone because it contains calcium which has a high attenuation coefficient, 
whilst soft tissue contains hydrogen which has a low attenuation coefficient 
[252]. 
 
This difference in attenuation characteristics allows an estimate to be calculated 
for soft tissue absorption subtracted from that of the bone absorption [253]. This 
produces a 2 dimensional picture where the radiation energy per pixel has been 
detected and converted into an areal density measurement in g/cm. The 
number of pixels in the area is summed then the amount of bone in each pixel is 





Dual energy x-ray absorptiometry is used at several skeletal sites, with the 
primary scans being total body, hip, and lumbar spine, it can also be used in 
lateral vertebral assessment and in the peripheral regions such as the forearm, 
heel, hand or knee [251, 254, 255]. It must be noted these scans are primarily 
done in the posterioanterior (PA) projection, due to the fixed orientation of the 
DXA scanner, although a small amount of scanners such as the GE lunar 
Expert perform them in the anteroposterior (AP) projection [251]. As stated 
there are many different skeletal sites and positioning techniques and these 
must be kept consistent due to their impact on precision of the BMD readings. 
 
T-SCORES AND Z-SCORES 
Bone mineral density results are reported in g/cm2 which is useful for 
intraoperator comparisons of the same position and patient across multiple 
periods of time. These BMD figures are also reported using T-scores and Z-
scores. A T-score is related to how much a patient’s BMD is higher or lower 
than the BMD of a healthy young adult of the same gender and race [254]. The 
World Health Organization (WHO) uses a classification system for patients 
score with the lowest T-score being used to determine its classification as 
follows: 
 
 A T-score of -1.0 or above is normal bone density.  
 A T-score between -1.0 and -2.5 means low BMD or osteopenia.  
 A T-score of -2.5 or below is a diagnosis of osteoporosis.  
 
The lower the T-score, the lower the BMD, additionally BMD results also include 
a Z-score that compares a patient’s BMD to what is normal in someone of the 
age and body size. Most experts recommend using Z-scores rather than T-
scores for children, teens, younger men and women under 50 years of age 
[256]. Although the national osteoporosis foundation does not recommend 
routine BMD testing in these age groups [256]. 
 
LIMITATIONS OF DXA 
Dual energy x-ray absorptiometry scans have high precision [254], but there are 




Firstly, the variation in repeated scans of the same patient, these can cause 
measurement errors It is therefore advantageous to use the same DXA 
radiographer to do all repeat scanning, to avoid interoperator variables of 
different positioning techniques and training. Participants may also change their 
posture throughout the scanning period either due to degenerative disease or 
after the rTKR affecting their flexibility for the negative or for the positive. This is 
important in scans of the hip where a stated addition of 10° internal rotation over 
the standard position significantly changed hip BMD in 12 % of participants 
[257]. 
 
All DXA equipment is calibrated prior to scanning using a daily phantom, 
although precision errors within scans are still inherent as such any biological 
BMD changes seen between repeat scans could be due to positioning error. 
Interpretation of consecutive BMD tests depends on knowledge of the least 
significant change (LSC) this is the percentage that must be achieved in order 
to have 95 % confidence that the difference in BMD has actually occurred and 
beyond the range of error [258, 259]. In clinical terms, this percentage is 
reported as a LSC of 2.77 % assuming a precision error of 1 % [258].  
Unfortunately, this precision error is calculated for standard DXA positioning; 
total body, lumbar spine, and bilateral hips, and not calculated for DXA knee 
scans.  
 
Although it must be acknowledged that there have been multiple studies 
investigating the impact of knee positioning in DXA scanning [24, 178, 226, 255, 
260, 261] and the associated precision errors inherent within those scans, these 
studies have investigated this positioning across multiple DXA machines 
including Norland, Lunar, and Hologic across a period of 1998 to 2016.  
 
Soininvaara et al in 2000 [260] investigated precision error via repeat scanning 
a total of 45 knees (24 TKA operated knees and 21 non-operated knees), 
reporting a coefficient of variation (COV) precision score of 3.1 % in the femur 
and 2.9 % in the tibia of the TKA knees, and 3.2 % and 2.5 % in the non-
operated knees. Jensen et al [178] also explored this, performing double scans 
of the proximal tibia in 11 participants (rTKR cone knees vs non cone knees) 
with a COV precision score of 3.6 % (cone knee) and 2.1 % (non-cone knee). 
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Trevisan et al [255] also investigated this and created a positioning protocol for 
DXA knee scans to improve precision and reduce errors (i.e. flexion of the 
lateral knee at 20 degrees, internal rotation of the PA knee at 15 degrees 
supported by the hip positioning device), in their study 10 TKA participants had 
repeated knee DXA scans reporting an overall precision score of 1.4 % on PA 
images and 2.5 % on lateral knee images. Petersen et al [24] also conducted a 
precision study on the proximal tibia, and distal tibia and fibula in TKA patients, 
reporting COV scores of 1.1 %, 0.9 %, and 1.1 % for the medial, lateral and 
distal ROI. Additionally, Winther et al [226] in 2016 investigated the precision of 
DXA TKA knee scans in utilising repeat scans on 10 patients of the proximal 
tibia reporting a COV of 2.3 %, 1.3 % and 1.8 % for three of the ROI. Therbo et 
al [261] investigated the precision in the distal femur in three different types of 
uncemented TKA; repeat scans of 28 participants resulted in DXA knee 
precision scores of 3.3 %, 3 % and 2.6 %.  
 
Therbo et al [261] also investigated the influence of rotation on precision in the 
lateral knee DXA images. The distal femur was rotated in different positions and 
a DXA scan performed, reporting a COV precision of 0.5-0.6 % for 0 degrees 
rotation, 7.3-10.1 % for 20 degrees rotation, and 12.3-14.9 % for 40 degrees 
rotation. 
 
All the studies reported low precision errors in both the PA and lateral knee DXA 
scans, therefore as there is a consensus of low precision errors, this study will 
be following the positioning protocol of Trevisan et al [255], therefore our study 
should produce similar precision errors as theirs. To test this a COV was 
calculated using a phantom knee (the knee from a the whole body phantom 
PBU-50 manufactured by Kyoto Kagaku corporation) following the positioning 
instructions of Trevisan et al [255], the phantom was placed in the PA position 
and a DXA scan performed, then the phantom was placed in the lateral position 
and another scan performed, this was repeated for 10 scans for the PA and nine 
for the lateral alternating between PA and lateral DXA scan positions between 
each scan, (one lateral image although scanned (resulting in 10 of each), was 
corrupted and therefore was excluded). The results reported a precision of 2.54 




Figure 1.14. A shows the DXA scan of the phantom knee on the thin setting. B 
is a DXA scan of a “normal” human knee (also done on a thin setting) (bone is 
defined as within the yellow border, blue is artefact which is defined as the 
fibula or fibula head, this excludes it from the data). 
 
Table 1.1. Showing the mean BMD score (g/cm2), SD and COV for the PA and 
lateral phantom knee  
 PA Lateral 
Mean BMD g/cm2 0.632 0.706 
Standard Deviation 0.016 0.021 
COV % 2.541 3.032 
 
Unfortunately, positioning of the knee was difficult due to being a disembodied 
phantom knee, and although it was strapped it provided a lack of resistance to 
internal rotation and could not be held in place easily. The phantom was 
designed for x-ray imaging and not directly with DXA, thus the knee BMD was 
very low making any variation in BMD more prominent, increasing the COV 
precision error, also the classification of the edges of bone, soft tissue and 
artefact, was more problematic due to the variation in the phantom knee (as 
discussed in more detail in chapter 6). Figures 1.14 and 1.15 show the 
difference between the DXA scan of the phantom and a DXA scan of a “normal” 





















Figure 1.15. Shows the same image as figure 1.14 but with brightness 
increased to show the difference in anatomy (bone is defined as within the 
yellow border, blue is artefact which is defined as the fibula, black is air, the 




















However, even with these reported issues the results are similar to those stated 
in the literature. Therefore, due to the drawbacks of the phantom study it was 
decided that the statistically significant changes required would be reported as 
the precision error provided by Trevisan et al’s study multiplied by the LSC (i.e. 
greater than: PA 1.4 x 2.77 = 3.88 %, Lateral 2.5 x 2.77 = 6.93 %). 
 
Additionally, DXA precision errors are affected by a higher body mass index 
(BMI), due to a decrease in signal to noise ratio in larger participants [262]. This 
signal may change over different time periods, especially if the patient 
increases or decreases in weight throughout the study, possibly changing the 
distribution of fat and soft tissue in the areas being scanned. It has been 
reported that patients of a higher BMI increase the precision errors in the DXA 
scans [263, 264], with the COV percentage in precision errors changing from 
0.99 % in normal BMI (less than 25) individuals to 1.68 % in participants with a 
BMI over 30 for the lumbar spine, and 1.32 % for normal BMI (under 25) and 
2.00 % for obese BMI (over 30) at the neck of femur. These type of precision 
errors must be acknowledged in the obese population as the LSC might be 
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higher that currently reported [189]. 
 
DXA also has other limitations it is highly influenced by bone size and does not 
distinguish between compact and spongy bone [265], therefore it cannot 
provide information on any treatments or medications that specifically target 
those particular bone types. Despite these limitations DXA is currently the gold 
standard for clinical diagnosis of OP and has many advantages in particular a 
consensus of BMD results by using the WHO T-score criteria, a proven ability to 
predict fracture risk, proven efficacy at targeting antifracture therapies, and the 
ability to monitor reactions to treatment interventions [254]. Furthermore, it is 
readily available and accessible for patients, has a low cost associated with it, 
has short scan times, high precision, and a low radiation dose [254]. 
 
1.6.2 X-RAY IMAGING 
X-ray imaging has been used as a screening tool for BMD [266] and has also 
been used to investigate osseointegration of implants [267], additionally they 
are part of routine care on patients with rTKR and as such their use in implant 
analysis and rTKR care is relevant. 
 
HOW AN X-RAY IMAGE IS PRODUCED  
X-ray imaging creates a two dimensional radiograph of a three dimensional 
image, x-ray radiographs produce a higher more detailed image than DXA 
scans, resulting in a higher radiation dose to the patient. These radiographs are 
produced via x-ray photons that are emitted via a rotating anode, these photons 
have a certain amount of energy defined as kVp and the amount of photons 
produced defined via its milliamps per second (mAs), as these x-ray photons 
are emitted they interact with the patients’ tissue [268] via two processes called 
Compton scatter and the photoelectric effect. During this phase the x-ray 
photons are attenuated based on the atomic number of the interacting tissue 
[268], similar to DXA, therefore x-ray photons moving through low attenuating 
soft tissue result in less interactions creating a greyer image, with air in the 
lungs being one of the most radiolucent (almost black) on the radiograph, 
likewise as the x-ray photons pass through a denser material such as bone the 
attenuation is higher resulting in more scattered photons, meaning fewer reach 
the cassette producing a more white region on the radiograph.  
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LIMITATIONS OF X-RAY  
Similar to DXA patient positioning repeatability and interoperator variability 
increases errors in the images produced. Although there are limitations in the x-
ray imaging, its ability to give high detail should allow a pixel density difference 
to be measured across multiple serial images, as well as the ability to 
distinguish the possible reduction in radiolucent lines between the conal implant 
and the surrounding bone, presenting evidence of bone in-growth around the 
implant. Furthermore, the issue of possible errors in repeatability will be 
addressed via the use of quality assurance (QA) systems and calibrated 
machines, also an item of known density (an aluminium step wedge) will be 
placed within every image in order to address and standardise the density being 
measured. This has been shown to produce accurate bone density 
measurements even in the advent of post processing changes [269].  
 
1.6.3 COMPUTED TOMOGRAPHY IMAGING 
Computed Tomography (CT) is used in BMD measurements via Quantitative CT 
(QCT) in which measurements of the spine can be taken [254] as well the axial 
skeleton [270], it has also been used to help in with preoperative rTKR planning 
in determining dimensions of a defect and whether it is contained or not [207]. 
Furthermore, micro-CT has also been utilised to look at bone ingrowth in porous 
implants [271, 272, 273, 274] with some directly testing bone ingrowth in TKR in 
CT images [275]. 
 
HOW A CT IMAGE IS PRODUCED 
Computed Tomography scanner uses an x-ray source that rotates around the 
patient instead of stationary tube, like in x-ray and DXA. During a CT scan, the 
patient lies either supine or prone on the bed, this bed then slowly moves 
through the gantry while the x-ray tube rotates around the patient, producing 
narrow beams of x-rays through the body. These x-rays attenuate in the same 
way as x-ray imaging with the x-ray photons finally hitting a special digital 
detector located directly opposite the x-ray source [276]. One full tube rotation 
produces one slice, with the thickness of these slices predetermined via the 
scanning setup, but usually between 1-10 mm [276], the bed then moves 
forward and the scan repeats creating another slice, these slices are then 
stacked on top of each other to create an entire 3D image [276]. 
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As CT scanning produces a 3D image it provides volumetric data [248] instead 
of 2D data; as such CT has a higher resolution of both x-ray and DXA and 
therefore has the highest radiation dose of the three imaging methods stated, 
although this increased dose allows the visualisation of more subtle bone 
structural and mechanical qualities [96]. 
 
LIMITATIONS OF CT 
Unfortunately, as stated with the x-ray and DXA data, the conal implants and 
other parts of the rTKR will create artefact on the image which is a larger issue 
on CT imaging due to increased dose leading to more attenuation, additionally 
being a volumetric image the streak artefact will be more prominent. 
Furthermore, the assessment of the actual region between the metal implant 
and bone tissue is less straightforward due to metal-induced artefacts such as 
beam hardening and scattering, as these effect the voxels closest to the implant 
surface [277]. As such Dual Energy CT (DECT) imaging will be utilised, as this 
type of scan can suppress beam hardening, scatter, and in some cases metal 
artefacts [278]. Furthermore, the conal implants being studied are composed of 
titanium so the degradation should be less pronounced especially compared to 
stainless steel implants [279]. Moreover, titanium has also been reported to 
minimise streak artefact [280].  
 
Additional actions to reduce errors in imaging will also be taken into account; 
this includes the standardised calibration of the machinery every day via a QA 
phantom. The biggest limitation in this imaging method utilised is the high 
radiation dose, although this is offset by the prospect of visualising in-growth 
behaviour of the conal implant, and the creation of higher resolution 3D 
volumetric images.  
 
1.7 AIMS OF THESIS  
In summary this thesis will develop and test different modality options. This will 
be done in order to assess what effect a newly implanted metaphyseal tritanium 
cone has on local and systemic BMD changes in rTKR patients. With these 





As per the protocol thirty-four total knee revision patients were to receive conal 
implants, 17 with long stems and 17 with short stems, additionally 17 
participants were to be used as controls and would not receive the conal 
implants. Furthermore, these 17 were to be allotted a stem length decided at 
the discretion of the attending orthopaedic surgeon. Those implanted with the 
cones would be compared to the non-cone group, with the primary question 
being: How do conal implants impact BMD changes both locally and 
systemically and when does this change happen. This aim is addressed in the 
forthcoming chapters below; 
 
Chapter 2. Presents a systematic review investigating the link between r/TKR/A 
and BMD at the knee, hip, spine, and total body, assessed via DXA scans. This 
was addressed to provide systematic evidence to establish any known 
association between BMD changes and r/TKR/A directly via DXA imaging. It 
also provided information on region placement analysis. 
 
Chapter 3. Details the development phase, this involved testing the conal 
implants after insertion into a bovine model substitute, and situated in a calcium 
phosphate bath solution, and then imaged via DXA, x-ray, and CT. This was 
addressed to review possible protocol issues and problems within imaging and 
analysis of the BMD, and allowed the development of the any modifications to 
the imaging to be implemented prior to starting the feasibility study. 
 
Chapter 4. Analyses a new piece of 3D modelling SHAPER Glago software was 
tested on TKR, rTKR, and control participants. Utilising DXA hip images at 
different post-surgery visit intervals. This included the separation of cortical and 
trabecular bone results in different sub regions of the hip. Participants’ data 
were then compared to their: baseline pre-op figures, contralateral hip, and 
between the three groups. This software was tested in parallel with the main 
study starting and provided an alternative method to DXA, x-ray and CT 
imaging and analysis.  
  
Chapter 5. Reported the participant numbers and attrition of the main study, and 
the subsequent BMD results from the DXA scans for the total body, lumbar 
spine, and bilateral hips, including cone and the non-cone group data. These 
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were recorded at pre-op, and six weeks, three months, six months and 12 
months post-op. The data was compared  between groups, visits and between 
ipsilateral and contralateral hips. 
 
Chapter 6. Reported the BMD knee results from main study for DXA, for both 
the cone and non-cone control groups. This included sub regions selected 
within the PA and lateral knee, as well as the different visits (pre-op, six weeks, 
three months, six months and 12 months post-op). The data were compared  
between groups and visits.  
 
Chapter 7. Reported the long leg x-ray imaging investigating pixel density 
differences, and hip and knee alignment angulation at six and 12 month visits. 
 
Chapter 8. Reported the CT imaging method, the analysis and 
recommendations.   
 
Chapter 9. Reported the questionnaire data including Lower Extremity 
Functionality Score (LEFS), Quality of Life (EQ-5D-3L), Oxford Knee Score 
(OKS) and Hospital Anxiety Depression Scale (HADS) compared between visits 
and between the cone and non-cone groups. These were recorded at pre-op, 
six weeks, three months, six months and 12 months. 
 
Chapter 10. Summary, conclusion, further work/recommendations for full trial. 
 
These methods will be discussed in more detail in later chapters but should 
provide adequate data in answering the aim of this study regarding the 
feasibility and effect a newly implanted metaphyseal tritanium cone has on BMD 









CHAPTER 2 A SYSTEMATIC REVIEW TO ASSESS THE IMPACT TOTAL 





The impact of low bone mineral density (BMD) increasing fracture risk is well 
established and several studies have shown this link- Legrand et al [6] 
investigated BMD and vertebral fractures in 200 men, reporting a relationship 
between fracture numbers and femoral neck BMD, vertebral BMD, and age; 
concluding that low trochanteric BMD and age were the best predictors for 
vertebral fracture. Additionally, Marshall et al [7] conducted a meta-analysis on 
229 studies evaluating BMD and fracture risk in women and concluded that low 
BMD can identify people who are at increased fracture risk. 
 
This link is further supported by a study by De Laet et al involving 5814 men 
and women [8], concluding similar results, stating that hip fracture risk was 
determined by age and BMD.  Cummings et al [9] developed this idea further, 
stating that low hip BMD was a stronger predictor of fracture than BMD at other 
sites. Furthermore, they also reported that loss of BMD in the proximal femur 
was a major risk factor for hip fracture in the aged population [10]. 
 
A study by Melton et al [11] concurred with the research of Cummings et al and 
Legrande et al in demonstrating that the more the BMD decreased the greater 
the risk of a femoral neck and inter-trochanteric fracture; concluding that hip 
fractures were uncommon in women with a femoral bone density above or 
equal to 1.0 g/cm2, and as BMD declined fracture frequency increased, this is 
due to a proportional correlation between the breaking strength and the square 
of the bone density. 
 
The association between low BMD with increased fracture risk is strongly 
supported by the evidence base. In patients undergoing total knee 
replacement/arthroplasty (TKR/A) or total knee revisions (rTKR) they 
themselves can experience reduced BMD (as shown in section 1.1.2). This is 
primarily due to the associated periods of inactivity and reduced weight bearing 
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experienced post-surgery resulting in disuse osteopenia [23]. Furthermore, low 
BMD contributes to periprosthetic fracture risk [281]. Periprosthetic fractures 
post TKR/A occurs in 0.3-2.5% [42, 282] of patients, although in rTKR it has 
been reported as high as 38% [283]. These fractures can lead to increased 
hospital readmissions, functional decline, and higher mortality rates [281, 284, 
285]. Currently no systematic review has been conducted to establish a 
consensus on when and where the greatest BMD changes occur post-surgery. 
Therefore, this systematic review was created and registered with PROSPERO 
under code CRD42017072714. 
 
2.1.1 AIM 
The aim of this systematic review was to investigate BMD changes locally and 
systemically in patients undergoing TKR, rTKR or TKA, and determine both the 
regions most affected and the time period. This aim was broken down into 
separate specific review questions. 
 
 
2.2 REVIEW QUESTIONS  
 
2.2.1 PRIMARY QUESTION 
What is the effect of total knee replacement (TKR), total knee arthroplasty 
(TKA) or total knee revision (rTKR) on bone mineral density (BMD) at the hip, 
knee, spine, or total body? 
 
2.2.2 SECONDARY QUESTION 
 Which anatomical sites (hip, knee, spine) experience the greatest 
changes (between time periods) in BMD or in bone mineral content 
(BMC)? 
 What is the post-operative timeframe for changes in BMD/BMC and what 




Pre-specified search terms and keywords were searched, as stated below: 
“bone mineral*” AND “total knee*”  
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“BMD” AND “total knee*” 
“bone mineral*” AND “TKR” 
“BMD” AND “TKR” 
“bone mineral*” AND “TKA” 
“BMD” AND “TKA” 
“bone mineral*” AND “rTKR” 
“BMD” AND “rTKR” 
“BMC” AND “total knee*” 
“BMC” AND “TKA” 
“BMC” AND “rTKR" 
“BMC” AND “TKR” 
 
This search strategy was combined when searching MEDLINE (Ovid) (including 
the EMBASE database and nine others) (see appendix 1), including the term: 
 
bone mineral* OR BMD OR BMC AND Total knee* OR TKR OR rTKR OR TKA 
  
All searches were recorded in a search log (See results table 2.2), alongside 
the database name, date, and the number of results retrieved. The reference list 
of any eligible backward citation chasing, were also retained if relevant to the 
topic of review. 
 
 
2.4 TYPES OF STUDY INCLUDED   
All papers meeting eligibility criteria were included. Predominantly this was 
cohort studies, as randomised control trials were unlikely in this type of 
research. Opinion pieces, ideas, case studies of single patients, and editorials 
were excluded. Additionally, only papers in English were retained. (see table 2.1 
for Patient Intervention Comparison Outcome (PICO) criteria). 
 
 
2.5 CONDITION/DOMAIN BEING STUDIED 
BMD/BMC difference at the hip, spine, knee, or whole body measured via DXA 




2.6 PARTICIPANTS/POPULATION  
Included participants: human studies only, all participants were adults (over 18 
years) having a TKR, rTKR or TKA and undergoing a DXA scan to determine 
BMD/BMC. DXA is the ‘gold standard’ for bone density imaging, furthermore, 
given its extremely low dose and ease of scanning, makes it the most viable 
and robust imaging option (the scans are short, and can be done in addition to a 
routine DXA scans). Excluded participants included: Children (under 18 years);- 
participants who had any other type of operation or joint replacement for 
example a total hip replacement (THR);- Participants with a BMD or BMC which 








Either baseline measurement via DXA scans of BMD/BMC, contralateral leg to 





2.9.1 PRIMARY OUTCOME 
Studies were included if they reported BMD/BMC at the hip, spine, knee or total 
body using DXA assessment at baseline and at any of the following time points: 
six weeks post operation, and at three, six, 12, 18, 24, 30, 36, 42, 48, 54 and 60 
months post operation, at the hip, spine, knee or total body. Change in BMD 
between baseline and these designated time points and anatomical locations 
will be the primary outcome. 
 
2.9.2 SECONDARY OUTCOME 
BMD/BMC changes between set time periods compared to matched controls or 
contralateral leg measurements, at baseline, and then six weeks post operation, 
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three, six, 12, 18, 24, 30, 36, 42, 48, 54 and 60 months post operation, at the 
hip, spine, knee or total body. 
 
Which anatomical site has the highest gain/loss in BMD/BMC compared to the 
other anatomical sites (e.g. spine, hip, knee) within the same time period. 
 
What time period results in the highest BMD difference compared to the 
baseline at the knee, spine, hip and total body. 
 
 
 Inclusion criteria  Exclusion criteria  
Population Human participants adults over 
18 having either a TKR, TKA or 
rTKR and a DXA scan 
THR or other type of 
replacement, children, 
animals 
Intervention TKR, TKA, or rTKR THR or other replacement 
Comparator Matched control group, BMD 
baseline or contralateral leg to 
surgery 
 
Outcome Bone mineral density/BMD at 
the hip, knee, spine or whole 
body  recorded via DXA 
Other type of 
measurement of BMD 
other than DXA 




Editorials, individual case 
studies 
Date Not set  
Language English only  
 
 
2.10 DATA SELECTION – EXTRACTION AND CODING 
Identified studies utilising the search terms stated were imported to EndNote 
(version 19.2.0.13018), and de-duplicated. Studies identified by the initial 
searches were reviewed by two researchers for title and abstract screening 
against the PICO criteria. Studies which passed this stage were retrieved in full 
for full text screening. All studies were then again screened against the PICO 




criteria to determine inclusion. Any disagreements between screeners were 
resolved by third party acting as arbitrator.  
 
The number of studies identified, screened, excluded and included was 
recorded and reported using the Preferred Reporting Items for Systematic 
reviews and Meta-Analysis (PRISMA) flow diagram (results figure 2.1). 
 
Data extraction of the final included studies was conducted by the researcher 
through a standardised data extraction form (appendix 2) based on: study first 
author, title, year of publication, study design, study setting and country, sample 
demographics and recruitment method, specific intervention, comparator, 
BMD/BMC scores and calculated differences (including when (e.g. six months 
post-surgery) and anatomically where (e.g. spinal BMD). 
 
 
2.11 RISK OF BIAS (QUALITY) ASSESSMENT 
Risk of bias/quality was assessed by the researcher using the Newcastle-
Ottawa Scale (NOS) (appendix 3). Furthermore, quality appraisal was not used 
to exclude studies, but was utilised to assess weight quality and any possible 
bias within the studies. 
 
 
2.12 STRATEGY FOR DATA SYNTHESIS 
A narrative synthesis was utilised to describe the features of the reviewed 
studies. If there were enough studies of similar design a meta-analysis would 
have been performed by producing pooled estimate of effect and a forest plot of 
the difference in BMD at set intervals via DXA scans. A meta-analysis was not 
appropriate, so the results were described narratively.  
 
 
2.13 RESULTS AND ANALYSIS 
Table 2.2 below shows the search log results of the searches performed based 






Database Date Hits 
PubMed  20th September 2017 705 
MEDLINE(Ovid) (10 resources 
selected including EMBASE)                            20th September 2017 911 
Scopus  20th September 2017 438 
Web of Science  20th September 2017 374 
Grey Literature (conference abstracts 
and unpublished works) including the 
database: 
OpenGrey  20th September 2017  3 
Total  2,431 
 
Of the 2,431 papers 1,474 were duplicates, after these were removed 957 
papers remained, (including a duplicate which was a PhD thesis), this was 
removed as a full paper based on the thesis work was recovered as part of the 
search), all papers were reviewed and either excluded or retained, with only 33 
in disagreement, resulting in an agreement of 96.55 % between the two 
researchers. These 33 papers were adjudicated on by a third party and resulted 
in 57 retained papers and 900 rejected based on title and abstract alone.  
 
These 57 papers were then reviewed for full text eligibility. Of the 57; four were 
excluded for being in a foreign language (the original abstract was in English, 
but the full article was not), 13 papers had incomplete BMD data, e.g. only 
having pre-op scans with no follow up or not reporting the BMD at all, in one 
case it only stated if patients were reported as osteoporotic or osteopenic. A 
further 6 papers did not use DXA but another type of scan, three papers were 
under the term other (e.g. not a knee replacement, reviewed precision 
measurements in BMD not BMD itself).  Finally, four papers added no new data 
to the review. Data from the abstract paper of one of the included papers Christ 
et al 2001 [286] was excluded due to reporting the same participants, analysis 
and results as Hagena et al 2001 [287] (they were also authors on each other’s 
papers and share a near identical title). Wang et al 2003 [288] had both an 
abstract and full article included with the same data on it, therefore the abstract 
was excluded, and the full paper included. Of the other two papers; one paper 




Lin et al 2012 [289] was a meta-analysis on joint replacement and 
bisphosphonates this contained 14 papers; 12 were regarding THR and two 
were TKA, these two were already included as part of the original search, thus 
this paper was not part of the results or analysis. Furthermore, Bhandari et al 
2005 [290] was also excluded from the analysis as it is a systematic review on 
bisphosphonate use, reporting on six papers involving joint arthroplasty and 
BMD, of these six, five involved THR and the sixth involved a TKR, although 
this paper had already been discovered during the original search. A PRISMA 





















Five of the 27 papers only included the abstract as these were conference 
presentations so were included as supplements in journals and contained no 
fully published articles. These were not excluded as “abstract only” was not part 
of the exclusion criteria. 
 
 Figure 2.1. PRISMA flow diagram reporting the inclusion/exclusion of studies 
prior to and after screening. 

































Additional records identified through 
other sources 
(n =0) (via forward citation) 
Records after duplicates removed (n =957) 
Records screened (n =957) Records excluded 
(n =900) 
Full-text articles assessed for eligibility 
(n =57)   
Full-text articles excluded, 
with reasons (n =30): 
13 incomplete BMD data 
6 not DXA scans 
4 not in English 






Studies included (n =27) (22 full 




The results from the 27 papers were highly heterogeneous, with different types 
of joint implant (e.g. cones, coated implants, fixed bearing, high press stems 
etc…) also these were under different types of replacement or revision. 
Furthermore, regional analysis varied between studies reviewing different 
aspects of the bone or area. Therefore, a meta-analysis was not appropriate, so 
results were described narratively and through a collection of modified forest 
plots.  
 
Only four papers reported BMD changes at the lumbar spine or hip, none 
reported the total body. The majority of papers investigated the BMD changes 
around the knee, therefore changes in the knee will be the primary focus 
(although this chapter will also discuss the results of the lumbar spine and hips), 
whilst still addressing the primary and secondary questions of the impact of 
TKR, rTKR and TKA on BMD changes, and when and where those changes are 
greatest. 
To further understand changes at the knee, the regions of interest (ROI) 
selected within each paper was investigated, these ROI were overlaid on a 
knee image in order to create a heat map of all ROI across all papers as shown 
in figure 2.2, the ROI in turquoise were only investigated by one paper (e.g. the 
patella) with the red areas showing 15 papers investigating that ROI (e.g. under 
the tibial component). It must be noted some ROI data were not clearly stated 
within the papers (e.g. ROI results were 0.834 g/cm2) or are ambiguous to their 
placement (e.g. just stating femur), as per some abstract or conference data. 
Therefore, these three have not been included in the heat map data due to 
being undefined. It must also be noted that ROI stating the same area might be 
of a different size as shown in figure 2.3 with the larger ROI having a higher 





































Due to this ROI heat map data (figure 2.2) showing the intensity of investigation, 
the knee was divided into the two main bones (femur and tibia), and into 
specified regions as determined by the paper. For AP/PA tibia, three regions 
were chosen; lateral tibia, medial tibia, and under the implant, total was also 
included. For PA/AP femur only above the implant and total was included; this 
was due to very few data investigating the AP/PA femur during TKR/rTKR or 
Figure 2.2. Heat diagram showing ROI overlap, turquoise = low overlap, orange= 
middle overlap, red = high overlap 
 
Figure 2.3. Example of ROI selected within different papers, both papers are 




TKA, with not one paper researching the femoral condyles (as shown on the 
heat map). For the lateral tibia, the regions were anterior tibia, posterior tibia, 
under implant and total. The lateral femur was divided into anterior of the distal 
femur, middle of distal femur, posterior of the distal femur, above the implant 
and total. All regions were categorised via either as stated within the paper (e.g. 
the lateral tibial condyle BMD was 0.875 g/cm2) or inferred from an image of the 
ROI selected within the paper. These ROI comparisons will answer the primary 
and secondary questions, especially regarding the anatomical site that is 
affected most by a TKR, rTKR or TKA.  
 
All the studies gathered reported a comparison to baseline data, due to this and 
a lack of contralateral data, and matched participants not undergoing a TKR. 
The data was only analysed and presented via comparisons to the baseline.  
 
Data from the papers were recorded in two ways; a reported score (normally a 
percentage difference) as determined by the author via their own calculation,  or 
a relative score this was determined by myself and involved calculating the 
BMD difference as a percentage in which the new figure (e.g. a six month scan 
result) for a given ROI was subtracted from the baseline result (for the same 
ROI) and then divided by the baseline score and that answer multiplied by 100 
to give a relative percentage change. Confidence intervals (CI) were also 
included in all results when reported, furthermore, if the paper reported the 
standard error (SE) or standard deviation (SD) then were possible a CI was 
calculated using confidence interval equals sample mean plus/minus 1.96 (95% 
CI) multiplied by SD/square root of the sample size. If only the SE was known, 
then the SE would be multiplied by the square root of the sample size (in order 
to get the SD). These figures were included in the results as well as a Cohen’s 
D effect calculation.  
 
Additionally, five of the 27 papers were investigating bisphosphonates were 
included in the study, although it must be stated that only their control 
participant data were included in this analysis, due to the impact of 
bisphosphonates increasing BMD (the results between the controls and the 
bisphosphonate groups are shown in appendix 4). It was also decided that a 
minimum of three papers would be needed for each time period per ROI, as it 
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was deemed there would not be enough data due to the variations in ROI size 







The data for the modified forest plots are of the three, six, 12, and 24 month 


























        
 
6 3 6 12 18 24 30 36 42 48 54 60 
AP/PA femur 0 2 5 5 0 2 0 1 0 0 0 0 
Lateral femur 0 5 5 7 0 6 0 0 0 2 0 1 
AP/PA tibia 0 6 9 13 1 12 0 1 0 2 0 2 
Lateral tibia 0 3 4 5 0 5 0 0 0 2 0 0 
Table 2.3. Number of papers for each time period 
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Percentage (%) BMD change
BMD changes between baseline and 3 months in the AP/PA tibia 











Percentage (%) BMD change
BMD changes between baseline and 3 months in the lateral tibia 
2.13.1 BASELINE COMPARED TO THREE MONTHS 
   
                                                                                                                                                      
                                                                                                                                                            
                                                                                                                                                           Jaroma et al,.(2015)  (N=14)   
                                                                                                                                                           TKA (calcium group) (effect  
                                                                                                                                                           size -0.045, 0.038)                                                                                                                                                                                 
                                                                                                                                                           Jaroma et al,. (2016) (N=91)  
                                                                                                                                                           TKA (varus knee N=73 vs  
                                                                                                                                                           valgus knee N=18) (effect size            
                                                                                                                                                           no data, -0.229, 0.00, no 
data, 0.192, 0.033) 
                                                                                                                                                     Jensen et al., (2012) (N=36)  
                                                                                                                                                           rTKR (TM cone N=17 vs no  
            TM cone N=19) (effect size   
                                                                                                                                                           -0.357, -0.536, -0.105, -0.190    
                                                                                                                                                           -0.071, -0.507)                                                                                                                           
              Soininvaara et al., (2004)                     
                                                                                                                                                           (tibia paper) (N=69) TKA   
                                                                                                                                                           (effect size no data, -0.174, 
no data, -0.034)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                           Windisch et al., (2012)    
                                                                                                                                                           (N=50) TKA (effect size no  
                                                                                                                                                           data, no data, no data, 
 -0.487, -0.447)                                                 
                                                                                                                                                          Winther et al., (2016) (N=57) 
                                                                                                                                                           TKA (Regenex N=30 vs PPS  
                                                   N=27 (effect size 0.745, 0.444   
                                                                                                                                                           0.347, 0.308, 0.392, 0.167,       
                                                                                                                                                           0.830, 0.500, 0.224, 0.067,    
                                                                                                                                                           0.241, 0.111) 
 
                                                                                                                
 










                                                                                                                                                          Jaroma et al,.(2015) (N=14)   
                                                                                                                                                          TKA  (calcium group) (effect  
                                                                                                                                                          size -0.223)                                                                                                 
                                                                                                                                                                                                                                                                                                               
                                                                                                                                                            
                                                                                                                                                          Jaroma et al,. (2016) (N=91)  
                                                                                                                                                          TKA (varus knee N=73 vs  
                                                                                                                                                          Valgus knee N=18) (effect size   
                                                                                                                                                          no data, -0.153, -0.121)     
                                                                                                                                                        
                                                                                                                                                                                                                                                                                                            
                                                                                                                                                          
                                                                                                                                                           Soininvaara et al., (2004)  
                                                                                                                                                           (tibia paper) (N=69) TKA   





Figure 2.4. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 3 months in the AP/PA tibia  
 
Figure 2.5. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 3 months in the lateral tibia  
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Percentage (%) BMD change
BMD changes between baseline and 3 months in the lateral femur  
                                                   
                                                                                                                                                          
             Jaroma et al,.(2015) (N=14)   
                                                                                                                                                           TKA  (calcium group) (effect  
                                                                                                                                                            size no data, -0.481, no data,   
                                                                                                                                                           -0.763, no data, -0.687, no   
                                                                                                                                                           data, -0.428, no data, -0.714)                                                                                                     
                                                                                                                                                                                                                                                                                                               
                                                                                                                                                            
 
 
Järvenpää et al., (2014) 
(N=69) TKA (effect size -0.667 
-0.656, -0.625, -0.280, -0.731) 
                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                            
Soininvaara et al., (2002)  
                                                                (N=11) TKA (calcium group)               
                                                                                                                                                          (effect size -0.833, -0.850,   
                                                                                                                                                           -0.900, -0.400, -0.938)                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                   
                                                                                                                                                           Soininvaara et al., (2004)  
                      (femur paper) (N=69) TKA  
                                                                                                                                                           (effect size -0.583, -0.618,  
                                                                                                                                                         -0.618, no data, -0.240, -0.679)  
                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                           Therbo et al., (2004) (N=11)  
                               TKA  (effect size -0.187, no            
                               data, -1.076, no data, 0.155,            
                               no data, -0.206, no data) 





The greatest reported loss in AP/PA tibia (figure 2.4) is Windisch et al 2012 
[291] with a reported loss of -9.59 % in the tibial medial region, although no CI 
are stated for the individual ROI, the total of all the regions are reported as -2.66 
% (CI -1.55 to -4.17), and the relative change was calculated as -2.44 % (CI -
0.93 to -3.95). It must be acknowledged that Winther et al 2016 [226] actually 
showed an increase in BMD with the highest reported being 8.2 % (CI 4.26 to 
12.1), a relative percentage change of 7.69 % (CI 1.92 to 13.46). Figure 19 
shows 35 data points, of which 19 are negative and 16 positive; although 12 of 
the 16 positive results are from one paper (Winther et al 2016 [226]).  
 
The lateral tibia (figure 2.5) only investigated under the tibial component, all of 
these five data points (three papers) show a BMD loss, with the highest 
calculated relative average of -4.5 % (CI -15.05 to 6.31) (Jaroma et al 2015 
Figure 2.6. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 3 months in the lateral femur  
99 
 
[292]) and reported average loss of -4.3 % (no CI) (Jaroma et al 2016 [29]). For 
the entire tibial data (lateral and AP/PA) eight of the nine papers show some 
form of average loss. 
 
The lateral femur three month data (figure 2.6) show a loss of BMD in a high 
majority of data points including the CI, the highest loss reported is in the 
Jaroma et al 2015 [301] paper reporting a loss of -26 %, this was calculated as 
a relative loss of -10.47 % (CI -18.6 to -2.33), this was at the posterior aspect of 
the femur. The highest relative loss was -15.33 % (CI -21.17 to -9.49) with the 
next highest relative change being -14.81 % (CI -25.19 to -4.44) these two 
figures are from different papers (Järvenpää et al 2014 [19] and Jaroma et al 
2015 [292]) but are both refer to losses in the middle of the distal femur. In total 
there are 34 data points, 31 show an average BMD loss, two show a positive 
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BMD change between baseline and 6 months in the AP/PA 
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Percentage (%) BMD change
BMD change between baseline and 6 months in the lateral femur




                                                                                                                                                         
                                                                                                                                            
                                                                                                                                           Jaroma et al,.(2015) (N=14)   
                                                                                                                                           TKA  (calcium group) (effect size 
 -0.910, -0.992, -0.763, -0.749, -0.938)   
 
                                                   Järvenpää et al., (2014) (N=69) TKA      
                                                   (effect size -0.750, -0.771, -0.767,  
                                                    -0.417, -0.885)                                                                                                                                                      
                                                                                                                                                        
                                                                                                                          Soininvaara et al., (2002) (N=11) TKA  
                                                                                                                                           (calcium group) (effect size -1.333,  
                                                                                                                                          -1.000, -0.741, -0.778, -1.235)                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                            Soininvaara et al., (2004) (femur  
               paper) (N=69) TKA (effect size -0.692,  
               -0.694, -0.710, -0.360, -0.759                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                           Soininvaara et al., (2008) (N=16) TKA    
                                                                                                                                           (effect size -0.654, -0.750, -0.464,  
                                                                                                                                           -0.250, -0.704)                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                           Therbo et al., (2004) (N=11) TKA 
(effect size 0.044, no data, -0.317, no  
                                                                                                                                           data, 0.192, no data, 0.078, no data)                      
   








                                                                                     
                                                                                                                                                        Hagena et al., (2000 Abstract)  
                                                                                                                                                        (N=73) TKA (effect size no data)                                                                                                                                                                                                                              
                                                                                                                                                        Jensen et al., (2010) (N=16)   
                                                                                                                                                        rTKR (effect size 0.754, 1.212   
                                                                                              
                                                                                                                                                        Wang et al., (2003) (N=48) TKA   
                                                                                                                                                        (effect size -0.793, -0.766)                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                        Wang et al., (2006) (N=25) TKA                                                                                                              
                                                                                                                                                        (effect size -0.807, -0.623)  
                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                        Windisch et al., (2012) (N=30)   







Figure 2.7. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 6 months in the lateral femur  
 
Figure 2.8. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 6 months in the AP/PA femur  
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BMD change between baseline and 6 months in the AP/PA tibia
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                                                                                                                                                           Jaroma et al,.(2015) (N=14)  
                                                                                                                                                           TKA  (calcium  group) (effect   
                                                                                                                                                           size -0.313)                                                                                                                           
                                                                                                                                                           Jaroma et al,. (2016) (N=87)   
                                                                                                                                                           TKA (varus knee N=67 vs  
                                                                                                                                                           valgus knee N=20) (effect size  
                                                                                                                                                          -0.200, -0.156)          
                                                                                                                                                           Soininvaara et al., (2004)  
                                                                                                                                                           (tibia paper) (N=69) TKA  
                                                                                                                                                           (effect size -0.208)                                                                                                                                     
                                                                                                                                                           Soininvaara et al., (2008)  











     Albanese et al,.(1997 Abstract)   
    (N=15) TKR (effect size no data)                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                  Hagena et al., (2000 Abstract)  
                                                                                                                                                  (N=73) TKA (effect size no data)                                                                                                                                                  
                                                                                                                                                  Jaroma et al,.(2015) (N=14) TKA   
                                                                                                                                                 (calcium group) (effect size 0.045,  
                                                                                                                                                  0.153)                                                                                                        
                                                                                                                                                                                                                                                                                                     
                                                                                                                                                  Jaroma et al,. (2016) (N=86) TKA  
                                                                                                                                                  (varus knee N=67 vs valgus knee  
                                                                                                                                                  N=19) (effect size -0.750, 0.042,  
                                                                                                                                                  0.313, 0.074)   
                                                                                                                                                  Lautridou et al., (2005) (Abstract)  
                                                                                                                                                  (N=38) TKR (effect size no data, no  
                                                                                                                                                  data, no data) 
                                                                                                                                                  Wang et al., (2003) (N=48) TKA  
                                                                                                                                                  Control group (effect size 0.055,  
                                                                                                                                                  -0.392, -0.357, -0.580, -0.333)                                                                                                                                                                                                                                                                               
                            
                       Wang et al., (2006) (N=25) TKA   
                      control group (effect size -1.140,  
                      -1.555, -1.308, -0.701, -0.392)                                                                                   
                                                                                                                                                      
                                                                                                                                                     
                                                                                                                                                  Windisch et al., (2012) (N=30) TKA     
                                                                                                                                                  (effect size no data, no data, no   
                                                                                                                                                  data, -1.031, -0.862)  
                                                                                                                                                        
                                                                                                                                                  Winther et al., (2016) (N=57) TKA   
                                                                                                                                                  (Regenex N=30  vs PPS N=27)                 
                                                                                                                                                  (effect size 0.508, 0.444, 0.775,   
                                                                                                                                                   0.526, 0.135, 0.214, 0.176, 0.235, 
                                                                                                                                                   -0.041, 0.000, -0.153, 0.056) 





Figure 2.9. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 6 months in the lateral tibia  
Figure 2.10. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 6 months in the AP/PA tibia  
102 
 
At six months the lateral femur (figure 2.7) shows only four of the 33 data points  
reporting an increase, with 28 stating a loss of BMD (one with no change), 23 of 
these data points have CI that do not overlap the 0 line, showing a loss of BMD 
of statistical significance. The highest loss is in the middle of the distal femur 
with a relative loss of -19.71 % (CI -29.41 to -8.89). Furthermore, all of the 
papers show the greatest loss in the middle distal femur reported as: relative 
loss -19.26 % (CI -29.41 to -8.89), -17.39 % (CI -28.77 to -5.8), -17.73 % (CI -
23.4 to -12.06), -18.05 % (CI -28.72 to -7.52), reported -3.7 % (CI 3.2 to -10.6), 
relative change -4.19 % (no CI).  
 
The AP/PA femur (figure 2.8) mainly reported the total of the regions with six of 
the eight data points showing a loss of BMD. With the greatest relative loss of -
14.45 % (CI -23.63 to -5.27) this was reported as -14.20 % (CI -21.1 to -7.3). 
 
The lateral tibia (figure 2.9) only reviewed the area under the implant with all 
five data point averages showing a BMD loss, with greatest loss reported as -
6.31 % (CI -16.85 to 4.5). The AP/PA tibia (figure 2.10) shows 38 data points 
with 22 showing a BMD loss, with the highest reported loss was -19.9 % (CI -
24.9 to -14.9) with this loss reported at the lateral aspect of the tibia. 
Furthermore, Winther et al [226] had a BMD increase of relative change of 9.71 
% (CI 2.91 to 16.5) this was reported at the medial aspect region. It must be 
noted the six papers reporting totals all show an average loss including the 
reported differences of  -7.5 % (CI -11.7 to -3.31), -6.5 % (CI -9.67 to -3.33), -6 


























Percentage (%) BMD change
BMD change between baseline and 12 months in the AP/PA tibia 
2.13.3 BASELINE COMPARED TO 12 MONTHS 
 
                                                                                                                                                                                   
                                                                                                                                                       
                                                                                                                                         Jaroma et al,.(2015) (N=14) TKA  
                                                                                                   (calcium group) (effect size 0.045, 0.191)       
                                                                                                                                                                                                                                                                                  
Jaroma et al,. (2016) (N=90) TKA (varus 
                                                                                                                                         knee N=72 vs valgus knee N=18 (effect 
                                                                                                                                         size -0.355, 0.000, 0.000, 0.034) 
                                                                                                                                         Jensen et al., (2012) (N=36) rTKR (TM                                                                                                                                             
                                                                                                                                         cone N=17 vs no TM cone N=19 (effect                                                                                                                          
                                                                                                                                         size -0.230, -0.120, -0.167, -0.273,                          
                                                                                                                                         0.063, -0.686) 
                                                                                                                                         Lautridou et al., (2005)   
                                                                                                                                         (Abstract) (N=38) TKR (lack of data no      
                                                                                                                                         effect size)                   
             Minoda et al., (2010) (N=56) TKA 
             (trabecular metal group N=28 vs                           
             cemented tibial group N=28) (effect size    
             -1.199, -1.026, -0.149, -0.225, -0.295,  
             -0.735, -2.540, -2.436,-1.251, -1.621,  
             -0.261, -0.346)    
 
             Saari et al., (2007) (N=46) TKR (PCL flat 
                                                                                                                                         N=13 vs PCL concaved N=11 vs PCL          
                                                                                                                                         resected concaved N=15 vs PCL           
                                                                                                                                         resected PS N=7) (lack of data no      
                                                                                                                                         effect size)     
                            
                                                                                                                                                       
                                                                                                                                         Soininvaara et al., (2004) (tibia paper)       
                                                                                                                                         (N=69) TKA (effect size no data, -0.360,      
                                                                                                                                         no data, 0.000) 
                                                                                                                                         Soininvaara et al., (2008) (N=16) TKA   
                                                                                                                                         (effect size -0.087, 0.054) 
                                                                                                                                          
                                                                                                                                         Tjornild et al., (2015) (N=46) TKA (fixed  
                                                                                                                                         bearing N=23 vs mobile bearing N=23   
                                                                                                                                         (lack of data no effect size)     
 
 
                                                                                                                                         Wang et al., (2003) (N=48) TKA control   
                                                                                                                                         Group (effect size 0.119, -0.397, -0.011,        
                                                                                                                                         -0.234, -0.091) 
  
                                                                                                                                         Wang et al., (2006) (N=25) TKA control               
                                                                                                                                         Group (effect size 0.027, -1.032, -0.465,   
                                                                                                                                         -0.469, -0.257)                                                                                                                             
                                                                                                                                         Windisch et al., (2012) (N=50) TKA    
                                                                                                                                         (effect size no data, no data, no data,   
                                                                                                                                         -0.308, -0.308)    
  
                                                                                                                                         Winther et al., (2016) (N=57) TKA   
                                                                                                                                        (Regenex N=30 vs PPS N=27)(effect size                
                                                                                                                                         0.734, 0.389, 0.221, 0.111, -0.053, 
                                                                                                                                        -0.063, 0.269, 0.711, 0.100, 0.155,  




                                                                                                                                                              
                                                                                                                                          
                                                                                                                                           Figure 2.11. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 12 months in the AP/PA tibia  
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Percentage (%) BMD change





                                                                                                                                                           Jaroma et al,.(2015) (N=14)  
                                       TKA  (calcium group) (effect              
                                                                                                                                                           size -0.909, -1.298, -1.107,      
                                                                                                                                                           -1.070, -1.205)                                                                                                         
                                                                                                                                                                                                                                                                                                
                                                                                                                                                            Järvenpää et al., (2014)  
            (N=69) TKA (non-obese N=39    
            obese N=30, and all  
             Participants (effect size  
                                                                                                                                                           -0.875, -0.952, -0.913, -0.968,     
                                                                                                                                                           -1.032, -0.968, -0.613, -0.793,   
                                                                                                                                                           -0.700, -0.400, -0.520, -0.440,   
                                                                                                                                                           -0.857, -1.087, -0.889)                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                     
 
                                                                                                                                                            
                                                                                                                                                           Saari et al., (2006) (N=47)   
TKR (PCL flat N=14 vs PCL  
                               concaved N=10 vs PCL   
                               resected concaved N=14 vs         
                               PCL resected PS N=9 (effect   
                               size -0.863, -0.204, -1.010,  
                               -0.751, -1.173, -0.145, -0.568,   
                               -0.254, -1.230, -0.354, -0.698,   
                               -0.670)                                                                                                                                                                                                                                                                                                             
 
                                                                                                                                                          Soininvaara et al., (2002)  
             (N=11) TKA (calcium group)              
             (effect size -1.615, no data,  
             -1.280, -1.261, -1.438, no  
             data, -1.750)                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                         
                                                                                                                                                           Soininvaara et al., (2004)   
             (femur paper) (N=69) TKA             
             (effect size –0.875, no data,  
             -0.934, no data, -0.710, 
             no data, -0.458, no data 
             -0.926)     
 
                                                                                     
              Soininvaara et al., (2008)  
            (N16) TKA (effect size -0.778,  
                                                                                                                                                          -0.967, -0.500, -0.240, -0.815)                                                                                                   
 
                                                                                                                                                                
                                                                                                                                                           Therbo et al., (2004) (N=11)  
              TKA  (effect size 0.111, no  
              data, -0.178, no data, 0.299,           
              no data, -0.107, no data) 
                










Figure 2.12. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 12 months in the lateral femur  
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                                                                                                                                                          Giorgini et al., (2014  
                                                          Abstract) (N=19) rTKR                                                                                                                                                         
                                                                                                                                                          low press fit stems (effect size  
                                                                                                                                                          no data) 
                                                                                                                                         Jensen et al., (2010) (N=16)      
rTKR (effect size 0.379, 0.817)                                                                                                            
                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                        
                                                                                                                                                          Wang et al., (2003) (N=48)   
                              TKA (effect size -0.373, -0.590)         
                                                                                                                                                                                                                                                                                                              
                                                                                                                                              
                                                                                                                                                           Wang et al., (2006) (N=25)  
              TKA (effect size -0.742, 
              -0.511)                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                           Windisch et al., (2012)  
              (N=50) TKA (effect size no  









                                                                                                                                                Jaroma et al,.(2015) (N=14) TKA 
                            (calcium group) (effect size -0.223)                                                                                                                                                                                                                                                   
                                                                                                                                                 Jaroma et al,. (2016) (N=90) TKA  
 (varus knee N=72 vs valgus knee  
                                                                                                                                                 N=18) (effect size -0.231, -0.168)            
                                                                                                                                                Soininvaara et al., (2004) (tibial 
 paper) (N=69) TKA (effect size no  
                                                                                                                                                data, -0.200)                                                                                                                                                                                                                        
                                                                                                                                                Soininvaara et al., (2008) (N=16   
                                                                                                                                                TKA)                                            
  Tjornold et al., (2015) (N=46) TKA  
 (fixed bearings N=23 vs mobile 
                                                                                                                                                bearings N=23) (effect size no data)  
                                                                                                                                                 
 
                                                                                                                                                            





At 12 months the AP/PA tibia (figure 2.11) has 83 data points, of which 63 
report a BMD loss (three are 0 change, and 17 show a positive increase; nearly 
half of these increases are from the Winther et al 2016 paper [226]). The 
highest loss is reported as -38.10 % (CI -32.5 to -43.7) and a calculated relative 
change of -39.71 % (CI -33.7 to -45.72) this is in the medial aspect of the tibia. 
Furthermore, the majority of the papers show a decrease in the BMD at the 
medial aspect, although Winther et al 2016 [226] shows an increase in BMD 
Figure 2.13. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 12 months in the AP/PA femur  
Figure 2.14. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 12 months in the lateral tibia 
106 
 
(reported as 8.1 % (CI 3.8 to 12.4), which was also calculated as a relative 
change of 6.73 % (CI 0.96 to 12.5). 
 
In the lateral tibia (figure 2.14) all 14 data points show a BMD loss, with the 
highest loss is reported as -17 % (no CI) at the posterior aspect of the tibia, 
closely followed by the anterior aspect reporting a BMD loss of -16.5 % (no CI). 
 
The 12 months lateral femur (figure 2.12) data show 58 out of 61 data points as 
a BMD loss (one data point reporting no change, and two showing an increase), 
the BMD greatest  loss is in Saari et al 2006 [293] with a reported loss of -28 % 
(CI -45 to -11). The greatest loss for each paper is the middle of the distal femur 
(with the exception of Saari et al 2006 [293] although the middle aspect region 
is not reported), with a relative change of -25.19 % (CI -35.33 to -14.81), -21.01 
% (CI -31.67 to -10.14), -22 %, -21.99 % (CI  -27.66 to -16.31), -23.6 %, -24.06 
% (CI -35.19 to –12.78), -3.4 % (CI -12.9 to 6.2) -4.19 %, -22.73 % (CI -30.08 to 
-15.15), -21.92 % (CI -29.45 to -14.38), -21.9 % (CI -27.23 to -16.79).  
 
With the AP/PA femur (figure 2.13) six of the eight data points show a BMD 
loss, the total regions show the greatest loss in the reported data, with the 
highest loss reported as -11.5 % (CI -17.6 to -5.42), a relative change of -9.38 




























Percentage (%) BMD change
BMD change between baseline and 24 months in the lateral femur
2.13.4 BASELINE COMPARED TO 24 MONTHS 
 
                                                                                                                                                    
 
 
                                                                                                                                                   Abu-Rajab et al,.(2006) (N=38)  
     TKA  (cemented knee vs                                                                                                              
                                                                                                                                                   cementless, baseline is  
    contralateral knee) (effect size  
                                                                                                                                                   -1.424, -0.924, -1.73, -1.406,  
                                                                                                                                                   -0.912, -0.975, -1.184, -1.160,  
                                                                                                                                                   -0.462, -0.462, -0.583, -0.620,  





                                                                                                                                                   Jaroma et al,.(2015) (N=13) TKA   
     (calcium group) (effect size no           
     data, -0.889, -1.270, -1.230, -
1.111,   
     -1.157)                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                         
    Järvenpää et al., (2014) (N=69)   
                       TKA (non-obese N=39 vs obese
    N=30, and all participants) (effect         
                       size -0.800, -0.680, -0.720, -1.161,   
                       -1.207, -1.167, -0.727, -0.700,  
                       -0.700, -0.536, -0.500, -0.680,  
                       -1.00, -1.00, -0.623)                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                         
 
                                                                                                                                                   Saari et al., (2006) (N=47) TKR  
     (PCL flat N=14 vs PCL  
                       concaved N=10 vs PCL resected  
                       concaved N=14 vs PCL resected        
                       PS N=9 (effect size -0.373, -0.775, 
                       -1.612, -0.704, -0.810, -0.568, 
                       -0.237, -0.073, -0.946, -1.280,  
                       -0.638, -0.523)                                                                                                                                                       
                                                                                                                                                                                                                                                  
                                                                                                                                                   Soininvaara et al., (2008) (N=16)  
    TKA (effect size -0.600, -0.940,  
                                                                                                                                                   -0.517, -0.385, -0.808)                                                                                                      
  
                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                   Therbo et al., (2004) (N=11) TKA  
                                                                                                                                                   (effect size 0.080, no data, -0.363,         
                                                                                                                                                   no data, 0.324, no data, 0.168, no  







Figure 2.15. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 24 months in the lateral femur  
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                                                                                                                    Abu-Rajab et al,.(2006) (N=38) TKA cemented knee 
                            vs cementless, baseline is contralateral knee) 
(effect size -0.278, -0.148, 0.080, 0.000, -0.231,  
                            -0.154,  0.080, 0.000, -0.607, -0.336, -0.760, -0.386) 
 
                                                                                                                    
                                                                                                                   Angers et al,.(2011 Abstract) N=65) TKA cemented   
                                                                                                                   knee vs  cementless (effect size no data) 
                                                                                                                    
Giorgini et al., (2014 Abstract) (N=19) rTKR high  
                                                                                                                   press fit stems (effect size no data)                                                                                                                   
 Jaroma et al,.(2015) (N=13) TKA (calcium group)     
                                                                                                                   (effect size 0.046, 0.238)                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                   Jaroma et al,. (2016) (N=89) TKA (varus knee N=70  
                                                                                                                   vs valgus knee N=19) (effect size -0.390, -0.039,      
                                                                                                                   0.000, -0.067)                                                                                                                                                                                                                          
                                                                                                                   Jensen et al., (2012) (N=36) rTKR (TM con N=17 vs 
no TM cone N=19) (effect size 0.382, 0.506, -0.119,       
                                                                                                                    0.171, 0.840, 0.500)            
                                                                                                                                                                                                                      
                                                                                                                   Minoda et al., (2010) (N=56) TKA (Trabecular metal                
                                                                                                                    group N=28 vs Cemented tibial group N=28) (effect    
                                                                                                                   size -2.118, -2.250, -1.657, -2.150, -0.293, -0.195,  
                                                                                                                   -1.521, -1.689, -0.307, -0.736, -0.529, -0.351)    
                                                                                                                                                                    
 
                                                                                                                    Petersen et al., (2005) (N=16) TKA (HA coated N=8     
                                                                                                                    vs Non-HA coated N=8) (effect size -0.202, -0.398,  
                                                                                                                   -0.527, 1.112, -0.025, 0.011, -0.374, 0.336)          
         
                                                                                                                   
 Saari et al., (2007) (N=46) TKR (PCL flat N=13 vs 
                                                                                                                   PCL concaved N=11 vs PCL resected concaved N=15   
                                                                                                                   vs PCL resected PS N=7 (effect size no data) 
 
                                                                                                                                                                                                                                                                                                      
                                                                                                               
 Soininvaara et al., (2008) (N=16) TKA (effect size  
                                                                                                                   0.000, -0.028) 
                                                                                                                   Tjornild et al., (2015) (N=46) TKA (fixed bearing 
N=23 vs mobile bearing N=23) (effect size no data)                                                                                                                                                         
  
                                                                                                                    
 
Winther et al., (2016) (N=60) TKA (Regenex N=31 vs  
                                                                                                                   PPS N=29) (effect size -0.130, 0.333, -0.221, 0.313,                           
                                                                                                                   0.173, 0.158, 0.075, 0.059, 0.702, -0429, 0.426,  
                                                                                                                   -0.313) 








Figure 2.16. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 24 months in the AP/PA tibia  
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                                                                                                                                             Abu-Rajab et al,.(2006) (N=38) TKA  
                 (cemented knee vs cementless,                                                                                                              
                                                                                                                                             baseline is contralateral knee) (effect   
                                                                                                                                             size 0.182, -0.185, -0.910, -0.351,  




                                                                                                                                         
     Jaroma et al,.(2015) (N=13) TKA   
                 (calcium group) (effect size -0.278)                                                                                                            
                                                                                                                                                                                                                                                                                                      
                                                                                                                                             Jaroma et al,. (2016) (N=19) TKA  
                                                                                                                                             (varus knee N=70 vs valgus knee  
                                                                                                                                             N=19) (effect size -0.234, -0.156)                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                             Soininvaara et al., (2008) (N=16) TKA  
                                                                                                                                             (effect size -0.235)                                                                                                                                             
                                                                                                                                             Tjornold et al., (2015) (N=46) TKA  
                                                                                                                                             (fixed bearing N=23 vs mobile 






At 24 months the lateral femur (figure 2.15) shows a similar pattern as the 
previous months with 58 of 64 data points showing a BMD loss (five positive 
and one 0 change), with the greatest loss reported of -40 % (CI -53 to -27) at 
the anterior aspect, but the majority of the research papers showing a loss of 
BMD in the middle region of the distal femur when compared to the other 
regions (four of the six papers have their highest loss reported as the middle of 
distal femur).  
 
At 24 months the PA/AP tibia (figure 2.16), the reported greatest loss is in the 
Minoda et al 2010 [294] paper of -46.37 % (CI -53.98 to -38.76). Of the 81 data 
points, several papers (22 data points) showed an average increase in BMD 
since the baseline. With 54 data points showing a decrease, and 5 data points 
showing 0 change. 
 
Figure 2.17. Forest plot showing the average BMD difference +/-95 % CI (were 
reported/calculated) between baseline and 24 months in the lateral tibia  
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The lateral tibia (figure 2.17) shows 19 of the 20 data points as a loss of BMD 
with the higher loss on the anterior aspect, with a reported loss of -10.9 % (-5.6 
to -16.1).  
 
2.13.5 HIP, TOTAL BODY, AND LUMBAR SPINE 
As stated many of the papers do not report the lumbar spine or bilateral hips, 
and not a single paper reported the total body data. Most papers mainly 
concentrated on the changes in and around the knee. Furthermore, some 
papers did include data about the hips and lumbar spine although these have 
had to be excluded as they have only reported T-scores and not the BMD or a 
percentage change (Abu-Rajab et al 2006 [395], Windisch et al 2012 [291]), or 
have only reported pre-op BMD, without follow up data (Minoda et al 2010 
[294]) so have been excluded from the analysis.  
 
Of the 27 papers only four have reported changes in BMD in either the lumbar 





Study name Lumbar spine BMD (g/cm2)  
Minoda Y, et al 
(2010) (N=56) 
2 weeks                                
pre op 
 24 months 
Trabecular metal 
group (N=28) 
0.937+/-0.199  0.881+/-0.113 
Cemented tibial 
group (N=28) 
0.874+/-0.120  0.946+/-0.210 










Study name Homolateral hip in BMD (g/cm2) 
 
Contralateral hip in BMD (g/cm2) 
 
Lautridou C, et al 
(2005) (reported as 
femoral neck) (N=38) 
Baseline 
0.768 
  60 m 
0.750 
    
Soininvaara TA, et al 








  12 m 
1.009 


















Table 2.4. Papers which investigated hip BMD, m = months, wks = weeks 
Table 2.5. Papers which investigated lumbar spine BMD 
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All 12 month scans show a BMD loss when compared to baseline, both for the 
hip and lumbar spine, yet at 24 months there is report of an increase in the 
lumbar spine cemented group (Minoda et al 2010 [294]). 
 
 
2.14 QUALITY OF STUDIES  
The quality of the studies was determined using the NOS, this was divided into 
three sections (selection, comparability, and outcome): 
 
Selection  
 Representative of the exposed cohort a) The participants/patients are a 
true representative of the average TKR/TKA/rTKR in the community b) 
Somewhat representative of the average TKR/TKA/rTKR in the 
community c) A selected group of users d) No description of the 
derivation of the cohort. 
 Selection of non-exposed cohort a) Are they drawn from the same 
community as the exposed cohort b) Drawn from a difference source c) 
No description of the derivation of the non-exposed cohort  
 Ascertainment of exposure a) Secure record (e.g. surgical records) b) 
Structured interview c) Written self-report d) No description 
 Demonstration that outcome of interest was not present at start of study 
a) Yes b) No 
 
Comparability 
 Comparability of cohorts on the basis of the design or analysis a) Study 
controls for (select most important factor) (e.g. age, BMI, gender etc.) b) 
Study controls for any additional factor (these criteria could be modified 
to indicate specific control for a second important factor). 
 
Outcome 
 Assessment of outcome a) Independent or blind assessment (e.g. by 
reference to secure records such as x-rays or medical record b) Record 
linkage (identified through ICD codes on database records) c) Self-
reported d) No description. 
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 Was follow-up long enough for outcome to occur a) Yes (three month 
minimum) b) No 
 Adequacy of follow-up of cohorts a) Complete follow-up - all subjects 
accounted for b) subjects lost to follow-up unlikely to introduce bias - 
small numbers lost >20 %  follow-up, or description provided of those 
lost) c) Follow up rate <20% and no description of those lost d) No 
statement 
 
The majority of the 27 papers all have very high quality (see table 2.6), this is 
mainly due to the criteria such as: all using DXA scans (reducing 
bias/interpretation), recording baseline measurements, recording data at 
appropriate time intervals, patients used as their own controls compared to their 
previous scans (or contralateral knee), thus variation and bias during 
comparison was reduced. The main reductions in quality were either the 
undefined loss of participants, in some cases this was not disclosed (especially 
in abstracts), the other issue was mainly the selection and recruitment criteria, 



























(max 2 stars) 
Outcome 
(max 3 stars) 
Total                          
(max 9 stars) 
Abu-Rajab RB, et al 2006 
[295] 
**** ** *** ********* 
Albanese C, et al 1997 [296] *** ** ** ******* 
Angers M, et al 2011 [297] *** ** ** ******* 
Giorgini, M, et al 2014 [298] ** * ** ***** 
Hagena FW, et al 2001 [287] ** - ** **** 
Hopkins S, et al 2016 [23] **** ** *** ********* 
Jaroma A, et al 2015 [292] **** * *** ******** 
Jaroma, A, et al 2016 [29] **** * *** ******** 
Järvenpää J, et al 2014 [19] **** * *** ******** 
Jensen CL, et al 2010 [179] **** * ** ******* 
Jensen CL, et al 2012 [178] **** ** *** ********* 
Lautridou C, et al 2005 [299] **** * ** ******* 
Minoda Y, et al 2010 [294] *** ** *** ******** 
Petersen MM, et al 2005 [37] **** * *** ******** 
Saari T, et al 2006 [293] *** ** *** ******** 
Saari T, et al 2007 [300] *** ** *** ******** 
Soininvaara TA, et al 2002 
[301] 
**** ** *** ********* 
Soininvaara TA, et al 2004 
(hip paper) [26] 
**** * ** ******* 
Soininvaara TA, et al 2004 
(tibia paper) [17] 
**** * *** ******** 
Soininvaara TA, et al 2004 
(femur paper) [302] 
**** * *** ******** 
Soininvaara TA, et al 2008 
[303] 
**** * ** ******* 
Therbo M, et al 2004 [304] **** ** *** ********* 
Tjornild M, et al 2015 [305] **** ** *** ********* 
Wang CJ, et al 2003 [288] **** ** *** ********* 
Wang CJ, et al 2006 [306] **** ** *** ********* 
Windisch C, et al 2012 [291] **** * ** ******* 





To answer the questions set out, and to review the impact of TKR, rTKR and 
TKA on BMD we must first review the BMD changes throughout the time period.  
Table 2.6 Quality check for all 27 papers 
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As reported in the literature in chapter one, one of the most important time 
periods is 5-12 weeks [17-19] due to the significant BMD decrease, with most 
research reporting data at three months and patients not fully ambulatory post-
operation. At three months the majority of papers show a loss of BMD within 
most ROI. Within the tibia the medial region seems the most affected reporting 
the highest BMD loss of -9.59 % (no CI) (although Winther et al 2016 [226] 
reports an increase in BMD in this region). For the femur this loss is more 
severe than the tibia, a loss of -26 % (no CI) was reported at the posterior 
aspect of the distal femur. Furthermore, the distal middle ROI within the femur 
shows a consistent loss across all papers (the highest relative loss in all papers, 
and the highest reported loss in four out of five of the papers). Looking at the 
data points; 54.29 % of them in the PA/AP tibia show BMD loss, with the lateral 
femur reporting 91.18% of the data points as a BMD loss.  
 
At six months this overall loss increases, although some regions in the tibia 
show an increase, the reported totals of all the ROI show a decrease (with six 
papers reporting as such). The highest reported AP/PA tibia loss was -19.9 % 
(CI -24.9 to -14.9) reported at the lateral aspect of the tibia. This overall loss 
increase is seen in the data points as well, with 57.89 % of the data points now 
showing a loss. 
 
This BMD loss is more prominent in the lateral femur, were 23 of the 33 data 
points that have CI do not overlap the 0 line, showing a loss of BMD of 
statistical significance with all reporting large effect sizes. The highest relative 
loss is in the middle of the distal femur with a result of -19.71 % (CI -29.41 to -
8.89). Furthermore, all of the papers in the lateral femur each show the greatest 
loss in the middle distal femur. The PA/AP femur adds to the overall reported 
loss showing a similar result of -14.45 % (CI -23.63 to -5.27). Interestingly 
although the BMD loss is greater in percentage across most points, only 84.85 
% of data points show a loss in the lateral femur (compared to 91.18 % at 3 
months).  
 
At 12 months the AP/PA tibia loss seems to increase, with the tibial medial 
aspect reporting large losses with the highest reported as -38.10 % (CI -32.5 to 
-43.7).  This is reflected in the data points as 75.90 % (63 of 83) of the data 
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points show a BMD loss, this is also supported by the lateral femur data points 
reporting 95.08 % (58 of 61) of data reported as a BMD loss. The highest 
reported loss in the lateral femur was reported by Saari et al 2007 [300] with a 
reported loss of -28 % (CI -45 to -11) in the anterior region. The greatest relative 
loss was for the middle of the distal femur (it must be noted that Saari et al 2007 
[300] did not investigate the middle aspect region) with a relative change of -
25.19 % (CI -35.33 to -14.81). The greatest regional loss in every single lateral 
femur paper at 12 months was in the middle femoral region (but only if the 
paper investigated this region). 
 
At 24 months the PA/AP tibia data points reporting a BMD loss drops to 66.67 
% (54 out of 81), this change is reflected in the lateral femur as well, although 
not as dramatically reporting a bone loss of 90.63 % (58 out of 64) and in the 
lateral tibia from 100% loss (14 out of 14) to 95% loss 19 out of 20). The 
greatest loss reported in the femur was at the anterior aspect reported as -40 % 
(CI -53 to -27), although the majority of the research papers reporting a BMD 
loss report it at the middle region of the distal femur, when compared to the 
other regions (four of the six papers have their highest loss reported as the 
middle of the distal femur). The AP/PA tibia (figure 28), reported the greatest 
loss of -46.37 % (CI -53.98 to -38.76) (Minoda et al 2010 paper) [294], although 
several papers report an average increase. 
 
To answer the primary question regarding the effect of TKR, rTKR or TKA on 
BMD over a period of time, the research would suggest that at three months 
post-op there is BMD loss, this is reflected in the reported highest loss of -4.5 % 
(CI -15.05 to 6.31) on the lateral tibial image, and the -9.59 % in the AP/PA 
image on the medial side, with the femoral aspect more affected by this 
implantation.  At six month this loss seems to have increased with the lateral 
femur suffering greater losses especially in the middle of the distal femur. At 12 
months this seems to reach its height in terms of BMD regions suffering loss, 
with high amounts of data points showing BMD loss in both the tibia (75.90 % of 
PA/AP data points, and 100% lateral tibia points), and the femur (95.08 % of the 
lateral, 75 % for the AP/PA). At 24 months there seems more of a turnaround, 
22 data points show a positive increase (27.16 % of data points, increasing to 
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33.33 % if you include the results that are now the same as baseline i.e. 0 % 
change) in BMD at 24 months. 
 
The secondary question regarding period of greatest difference is unclear, 
although it is this author’s opinion that 12 months shows the greatest difference 
in both terms of being compared to six months and compared to 24 months. 
The data points show the highest average loss of BMD across the tibia and 
femur compared to all time periods, and an increase in BMD loss compared to 6 
months, although this might be due to there being more data points at 12 
months (compared to six or three months), so this change in loss might be due 
to more data availability rather than an actual change, especially as 12 months 
also has the highest amount of papers (13). 
 
The difference between 24 months and 12 months is easier to argue and shows 
a similar comparison; 24 months has 12 papers, 81 data points for the AP/PA 
tibia, 20 data points for the lateral tibia and 64 data points for the lateral femur, 
and 12 months has 13 papers, 83, 14 and 61 data points respectively. The 
difference seems to be that 24 months is moving towards a more positive BMD 
(33.33 % in the PA/AP tibia, 5 % lateral tibia, lateral femur 9.38 %, compared to 
24.10 %, 0 % and 4.92 %). This is backed up by the data from the Soininvaara 
et al papers (2002 [301] and 2008 [303]) which both show the highest BMD loss 
(in the lateral femur) at 12 months, furthermore Jaroma et al 2015 [292], 
Järvenpää, et al 2014 [19], and Soininvaara et al 2008 [303] which reported a 
BMD increase in the total regional data of the lateral femur for between 12 
months and 24 months (an increase reported of +1.43 %, +0.7 % and +0.7 % 
respectively), although this was still a loss compared to the baseline, but it does 
show a change towards regaining BMD. Although, it must be acknowledged the 
other two papers (Therbo et al 2004 [304] and Saari et al 2006 [293]) that 
investigated the lateral femur between 12 months and 24 months showed both 
losses and increases in BMD at 24 months depending on the region and 
implant investigated, unfortunately no total region was reported in either of 
these two papers. In the lateral tibia when comparing 12 months to 24 months 
Soininvaara et al 2008 [303] showed a loss under the implant (-0.92 %), with 
Jaroma et al 2015 [292] also showing a similar loss under the implant (-0.91 %), 
but Jaroma et al 2016 [29] reported no change (0.00 %) in either the valgus or 
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varus group. Furthermore, Tjornild et al 2015 [305] actually showed an increase 
at 24 months compared to 12 months in all regions; anterior, posterior, under 
the implant, and the total region, across both testing groups (mobile bearing vs 
fixed bearings) with a difference of; +8.6 %, +6.1 % (anterior), +8.8 %, +6.0 % 
(posterior), +4.4 %, +9.3 % (under) and +7.4 %, +5.6 % (total), it must be noted 
all regions still reported a BMD loss when compared to the baseline, but the 
difference between 12 months and 24 months was an increase. 
 
In the AP/PA tibia comparison between 12 and 24 months this increase in BMD 
is supported by several papers such as: Jaroma et al 2015 [292] (+0.86 %), 
Jensen et al 2012 [178] (+5.8 %, +6.5 %, +9.1 %, +7.8 %), Saari et al 2007 
[300] (+13.75 %, +7.92 %, +11.47 %, +4.55 %, +7.3 +4.86 %), Tjornild et al 
2015 [305]  (+8.9 %, +9.9 %, +6.4 %, +8.0 %) all showing increases in BMD 
when compared to 12 months. Although certain papers still report a loss; 
Winther et al 2016 [226] reported a BMD difference as high as -11.5 % in the 
medial aspect, but also reports changes such as +6.8 % under the implant, or 
+1.1 % in the lateral aspect. Furthermore, Minoda et al 2010 [294] reports a 
continued loss compared to 12 months with changes of -11.2 %, -11.9 % and -
8.0 %. 
 
This change in BMD difference increasing at 24 months when compared to 12 
months might be due to the plateau effect, in which due to movement, load 
bearing and additional adaptions and stressors the BMD is starting to return to 
the baseline figure, this theory is supported in the literature.  It must also be 
noted that bone loss continues naturally at approximately 1.4 % [307] loss per 
year (depending on age and gender), thus the difference between 12 months 
and 24 months is probably far greater than reported and this natural decline 
might explain some results between the 12 and 24 month BMD (examples such 
as the lateral tibial data of Soininvaara et al 2008 [303] and Jaroma et al 2015 
[292] both reporting losses under 1 %).  
 
These data would suggest that 12 months is the most useful time period in 
assessing BMD loss, due to the increases reported at 24 months. This would 
mean that at 12 months patients have their lowest BMD making it their most 
vulnerable time period, increasing their chance of fracture should they fall. 
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Although it must be noted that a meta-analysis has not been performed due to 
high heterogeneity within the studies, and these variations could be the reason 
behind some of the results, therefore it is difficult to conclude with confidence 
that this is the case. 
 
Furthermore, when reviewing the four papers investigating the lumbar spine and 
hip, all figures reported at 12 months show a BMD loss when compared to 
baseline both for the hip and lumbar spine, yet at 24 months there is reported 
increase in the lumbar spine cemented group. Although these data are 
extremely limited and there is a lack of overlap within the time periods the result 
would agree with the theory of BMD plateau effect at 24 months. 
 
Although, it must be acknowledged that at 24 months Minoda et al 2010 [294] 
was still reporting increasing BMD losses (when comparing 24 months to 12 
months), including reporting the highest loss reported by any paper. This 
division between the slight increases and increasing losses might be a reason 
for contradictions in the literature about the plateau effect of two years. 
Furthermore, it must be understood that the differences between this one paper 
and the other 11 (in the AP/PA tibia) might be due to the type of implant or 
participants used. 
 
In reference to the additional secondary question regarding which anatomical 
area is affected by the most change, there is one region that throughout 
different papers shows a consistent change. This is reported throughout as the 
middle of the distal femur (on the femoral lateral image), as this is shown 
strongly across all time periods, were in nearly every report the greatest loss is 
in this region.  
 
Although the greatest loss from any individual paper is that of 24 months in 
PA/AP tibia, reported by Minoda et al 2010 [294] reporting a loss of -46.37 % 
(CI -53.98 to -38.76) on the medial aspect. This is not considered consistent 
enough, furthermore Winther et al 2016 [226] has shown in that same area 
(medial tibial aspect) an increase in BMD throughout starting from three 
months, even though both papers had a high-quality score ( eight and nine 
respectively), the score is inconsistent with the other results but may well be 
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due to the implant type being investigated (i.e. the Regenex and PPS inserts). 
Therefore, the middle of the distal femur is the most anatomically affected area. 
This ROI information is useful as it could be useful clinically in helping to 
develop TKR implants that specifically target this area, or due to its consistent 
loss across multiple papers over multiple types of implant, this ROI could be 
used clinically to investigate BMD changes between various participants implant 
and interventions, with all studies reporting the same standardised ROI. So as 
previously stated no meta-analysis was performed, so it is unclear how accurate 




As stated several papers were excluded due to incomplete data, and some 
forest plot graphs were not created for the time periods due to lacking data as 
shown in table 2.3 (two papers or fewer per area were excluded). As reported 
one of the most consistent losses within the papers was on the lateral femur in 
the distal middle region, unfortunately no study reviewed the impact of TKR, 
rTKR or TKA on the femoral condyles on the PA/AP images, therefore the exact 
region is only defined by the lateral image so there is a limit in defining that 
anatomical region. 
 
It must be noted that the 27 papers showed good generalisability as they 
covered seven different countries such as Denmark, Japan and England. 
Unfortunately, the sample groups for all studies were small, with an average of 
41 participants a range of 11-86.  
  
Other limitations within the studies were the inaccuracies of the region 
selection, with variation due to lack of consensus in ROI selection, as shown in 
figure 2.3. 
Although it must be acknowledged that these regions were grouped together 
depending on stated region (or via visual confirmation), this inconsistency might 
still impact the results. Moreover, the possibility that incorrect positioning, 
especially medially and laterally might impact the precision errors of the study 
(although it must be noted several studies investigated their positioning 
precision). Furthermore, as stated some regions were not included (Jensen et al 
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2012 [178]) within the analysis due to being regions around the stem as well as 
the primary implant, the stem ROI could not be compared to the other papers 
due to lack of regional data (no other papers reported these ROI), so were 
excluded. 
  
Data set comparisons were also limited in this study due to heterogeneity 
because of different types of implant, which might explain some of the extreme 
BMD figures in both the positive and negative BMD differences. 
 
Further limitations are due to the calculations used, in some studies it is only 
reported as a percentage difference, without any definition of the calculation. As 
for the relative calculations the author performed, these are consistent for 
comparisons between studies but neglect natural BMD changes such as the 
reported loss of approximately 1.4 % [307] of BMD per year. This would impact 
the possible plateau effect. Additionally, the reported figures might take this 
difference into account and might represent a more accurate figure, although 
different DXA systems might use different algorithms to reach such calculations 
and conclusions. 
 
Finally, papers lacking SD, SE or CI (or were CI could not be calculated) 
influenced results and conclusion especially given the low number of 
participants, and those with reported CI tended to have a wide range, 




Based on this systematic review and the literature available, the primary and 
secondary questions have not been fully answered. Although the data does 
suggest the ROI of the lateral image of the middle of the distal femur is the most 
consistent in its loss across multiple papers. The data discussed also supports 
the possible idea of a two-year plateau effect, with losses shown throughout but 
appear greatest at 12 months with BMD increasing at around 24 months. The 
limitations regarding the sample size and lack of data especially for the total 
body, lumbar spine, and bilateral hips means these specific questions remain 
unanswered and further study including scans of the lumbar spine and bilateral 
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hips are needed. Furthermore, the BMD loss seen throughout post-surgery 
adds to the supporting idea of using either pharmaceuticals such as 
bisphosphonates (which as shown in appendix 4 show an increase in BMD), or 
the utilisation of next generation implant designs to helpfully reduce the impact 
of TKR, rTKR, and TKA has on BMD. It must be noted that due to the variations 
and limitations and heterogenicity of the studies stated, a meta-analysis was not 
performed, this impacts the importance of the data presented and the 
confidence associated with it, for both the primary and secondary questions, 
therefore the results should be treated with caution. 
 
 
2.18 FUTURE WORK 
This systematic review data provide DXA/BMD knee regional information and 
























CHAPTER 3: DEVELOPMENT PHASE – INVESTIGATING THE METHODS 
AND ANALYSIS OF THE DATA IN A BOVINE MODEL IN PREPARATION 
FOR THE FEASIBILITY RANDOMISED CONTROL TRIAL  
 
 
3.1 INTRODUCTION  
This chapter will help develop, confirm or modify the procedures, methods and 
analysis required prior to the main feasibility randomised control trial. In order to 
achieve this a femoral and tibial Stryker cone (the same ones which will be used 
in the main study) were acquired and investigated for BMD changes through 
integration of calcium phosphate in a bovine femur and tibia model. Discussed 
within this will be the selection and justification of the apparatus employed, the 
different imaging modalities applied (DXA, x-ray and CT), and any modifications 
needed to the methods or analysis utilising these approaches. The results of the 
pixel density and BMD differences across multiple exposures at different time 
periods within this bovine model will be tested on using the same proposed 
analysis as the main study.  
 
3.1.1 AIM  
The aim of this study was to highlight osteointegration of the cones and 
investigate BMD analysis, whilst determining if the three imaging methodologies 
proposed (DXA, x-ray and CT) were feasible in how this osteointegration could 




This study utilised two Stryker Triathlon TS cone implants (size C); consisting of 
a femoral cone (figure 3.1) and a tibial cone (figure 3.2). The femoral cone 
measured 2.3 cm medially to laterally (ML) at the top, 5.5 cm ML at the base 
aspect, 4.3 cm caudally to cranially (CC), with a maximum anterior to posterior 
(AP) or depth measurement of 3.6 cm. The tibial cone implant was 3 cm CC, 
2.3 cm ML at the base, and 5.2 cm ML at the top, with a maximum AP or depth 


















The cones had been 3D printed into predetermined shapes specifically 
designed to press fit into AORI grade two defects, they were created via a 
highly porous metal alloy called tritanium which was derived from pure titanium 
powder [308]. Titanium was used due to being bioinert [309, 310], and has a 
proven history having been employed across orthopaedic and dentistry fields 
from metaphyseal sleeves [311] to dental implants [312]. Furthermore, titanium 
components have been reported to increase BMD in or around the implant 
[313], this effect of titanium is then coupled with the cones trabecular bone 
porous design pattern, promoting bone adhesion and osseointegration [312]. 
Research has shown that the relationship between titanium and 
osseointegration is based on composition and surface roughness, allowing 
bone anchoring and biomechanical stability [310, 312], allowing a stronger bone 
response [314]. 
 
It must be noted that current research into cone implants tend to utilise tantalum 
instead of titanium, showing similar results to the titanium implants [315], 
although research from June 2017 which utilised the same titanium 
metaphyseal Stryker cones used in this study, reported results showing that the 
stability of the titanium cones was equal to, or superior to that of tantalum cones 
[229]. 
 
Figure 3.1. Photographs of the femoral cone 
 






Prior to any imaging, the cones where first placed into a plastic box (Lock and 
Lock 3.9 litre), this type of container was preferential for three specific reasons: 
 
1. It was water tight  
2. It was constructed from plastic  
3. Its dimensions; measured 23.2 cm (L) by 16.2 cm (H) by 16.5 cm (W)  
 
The container being water tight was essential due to the cones being 
submerged in water; which was used as a viable substitute for human muscle 
tissue, due to having similar attenuating and absorbing properties: water reports 
an atomic number of 7.42, a density of 1.0 g/cm3, and an electron density of 
3.34 x1023 per gram [316]. Muscle reports similar figures of 7.42, 1.0g/cm3, and 
3.36 x1023 per gram [316]. Because of these values coupled with waters low 
cost and almost universal availability it is regarded as an acceptable substance 
for this BMD study, in addition it has been utilised in numerous papers and 
research, were water baths have been employed as tissue equivalent materials  
[317, 318, 319, 320]. Furthermore the container being water tight was significant 
for both transport and movement, especially during CT scanning where the bed 
conveys through the scanner. 
 
The container being constructed of plastic (also known as Lucite or Perspex) 
was relevant due to having a similar atomic number, density, and electron 
density to water [316], so is deemed as an acceptable tissue equivalent 
substitute for density measurements. 
 
Thirdly the dimensions of the container had to be comparable to a human knee, 
prior to TKR the average human knee circumference (as defined at the position 
of the mid-patellar around the knee, whilst in the supine position)  is 43.7 cm 
(+/- 4.2 cm) [321], and after one month post-operative is 45.3 cm (+/- 4.4 cm), 
and after two months is 43.1 cm (+/- 4 cm) [321], the upper limit figure of 49.7 
cm was utilised in order to represents the highest possible knee circumference. 
Due to the human knee not being spherical, the ratio of width to depth was 
calculated in order to purchase a plastic container that closely represented the 
knee dimensions, thus a ratio against the circumference from the available 
research data were calculated. 
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For this calculation the human knee was divided into the two main bones: the 
femur, and the tibia (with the fibula and patella not being included in the cone 
implantation testing). Based on information from two studies the average 
femoral ML distance was between 6.78 cm (+/-0.40 cm) [322] and 8.12 cm (+/- 
0.62 cm) [323] (depending on sex and ethnicity). The femoral AP distance was 
calculated as between 6.15 cm (+/- 0.49 cm) [322] and 7.03cm (+/- 0.47 cm) 
[322]. The tibial ML measurements were between 6.96cm (+/- 0.43 cm) [322] 
and 7.98 cm (+/-0.58 cm) [322] and the tibial AP distance calculated to be 
4.60cm (+/- 0.40 cm) [322] to 5.39 cm (+/-0.61 cm) [322]. 
 
The ratio was then calculated from the upper and lower limits of each bone 
giving a range and variability in the measurements and ratios; as such: 
 
1. Highest Femur ML 8.74 cm AP 7.5 cm  = ratio of 1:1.165 
2. Lowest Femur ML 6.38 cm AP 5.64 cm = ratio of 1:1.131 
3. Highest Tibia ML 8.56 cm AP 6.0 cm = ratio of 1:1.427 
4. Lowest Tibia ML 6.53 cm AP 4.2 cm = ratio of 1:1.555 
 
Each ratio results in the upper measurement of both the femur and tibia for the 
AP and ML figures, thus representing the highest amount of tissue equivalent 
mass to be penetrated making the test more representative. By utilising the 
circumference of 49.7 cm the external width and depth measurements were 
calculated within 0.05 cm: 
 
1. Highest Femur  Ratio 1.165 = 13.37 cm (ML) by 11.48 cm (AP) = 49.71 
cm 
2. Lowest Femur  Ratio 1.131 = 13.20 cm (ML) by 11.67 cm (AP) = 49.74 
cm 
3. Highest Tibia Ratio 1.427 = 14.61 cm (ML) by 10.24 cm (AP) = 49.70 cm 
4. Lowest Tibia Ratio 1.555 = 15.13 cm (ML) by 9.73 cm (AP) = 49.72 cm 
 
The largest AP result (11.67 cm) and the largest ML result (15.13 cm result in 
the maximum figures for depth (AP) and width (ML), meaning these are the 
minimum figures for the plastic container. The length of the plastic container 
was computed using an additional test utilising a whole body phantom (PBU-
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50), this involved collimating to the phantoms knee (in the supine position) using 
the standard protocol for an AP knee radiograph: a height of 100 cm, centering 
point of 2.5 cm below the apex of the patella [324], and collimating to include all 
the required knee anatomy. This collimation (13.9 cm by 20.8 cm) was recorded 
and imaged (figure 3.3), the figure 20.8 cm was then used for the Perpex 
container minimum length, as such this knee positional set up and collimation 




















A plastic container with similar dimensions of 11.67 cm by 15.13 cm by 20.8 cm 
was sought, and it was decided that the depth (AP) of the container was the 
least important issue due to that being controlled by the water level, the length 
as well, as long as it was over 21 cm did not impact the imaging as dramatically 
due to collimation restrictions, the most important issue was the width (ML) of at 
least 15.13 cm being required. A water tight plastic container was found and 
ultimately purchased which had a width (ML) of 16.2 cm, a length of 23.4 cm, 
and a maximum height (depth/AP) of 16.5 cm. 
 
Figure 3.3. X-ray of whole body phantom (PBU-50) to 




Due to the dimensions now available, and other studies research reviewing 
knee imaging [325, 326], it was concluded to scan the cone implants at a 
submerged depth of 15 cm. The cones were then imaged through the three 
different modalities: DXA, CT and X-ray.  
 
 
3.3 IMAGING THE CONES  
The cones were positioned in the centre of the plastic container and orientated 
in a similar manner as if they were in vivo, they were then separated from each 
other by a 1 cm gap to simulate the joint space, tap water was then poured into 
the plastic container up to the 15 cm depth line, with conal orientation checked 
prior to any imaging. All three types of imaging were photographed prior to 
starting any scans and were used as positional reference; additionally any 
previous scan results were also used as positional aids in making sure 
consistency on positioning was seen throughout all imaging modalities. 
 
3.3.1 DXA IMAGING 
Dual energy X-ray absorptiometry imaging was conducted on a GE lunar 
prodigy (Bedford, MA) utilising enCore  GE Healthcare software (version 
14.10.22), which was calibrated prior to each session with a quality assurance 
(QA) block phantom, and once a week with a spine phantom. 
 
The cones were imaged three times per setting to investigate variation: 
1) AP spine, thin mode, collimation was set at 20.2 cm by 19.8 cm, 
exposure factors were 76 Kv 0.75 ma, time: 56 seconds, dose 9.0 uGy 
2) AP spine, standard mode, collimation was set at 20.2 cm by 19.8 cm, 
exposure factors were 76 Kv, 3 ma, time: 56 seconds, dose 37.0 uGy 
3) AP spine, thick mode, collimation was set at 20.2 cm by 19.8 cm, 
exposure factors were 76 Kv, 3 ma, time: 1 minute 59 seconds, dose 
83.0 uGy 
These setting had been predetermined and used in previous and current DXA 
knee studies, and as such were not changed. With the thin setting being used 
for most DXA knee scans [179, 228], this is due to a lack of a knee DXA setting 
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on DXA machines, with the “spine” on thin setting giving the most optimum 
image for dose (the thin setting relates to the obesity of the patient which is 
important in spine imaging (a thick setting for an obese patient, a standard for 
standard, and thin for a thin patient), with knees an obese patient is still 
scanned on a thin setting as the knee thickness does not vary enough to 
exceed the thin range). Although a wide range of setting was investigated in this 
section due to this setup involving the highest possible knee thickness features. 
This was also why rice bags were not used in these scans due to the large 
amount of water placed within the plastic container which is providing the same 
soft tissue substitute as the rice bags do. 
 
Positioning was kept constant throughout, with the DXA positioning laser line 
through the inferior aspect of the plastic box intersecting at the midsagittal 
plane, and through the cones. 
 
3.3.2 CT IMAGING 
Computed Tomography imaging was conducted on a Siemens somatom 
definition edge scanner, used clinically at the RD&E hospital and was calibrated 
everyday using a standard QA phantom (Siemens Healthcare, Germany). 
 
The dual energy CT settings used in the scan were: extremity feet first, supine, 
80 kVp and 47 mAs and 140 kVp 15 mAs, 1 mm slices, field of view (FOV) of 
134 mm. Due to a positional issue of the plastic container originally being 
outside the FOV, and thus the centering laser, the plastic container was 
elevated by 7.6 cm (via a glove box), this was deemed acceptable as the glove 
box was outside the FOV and would not affect the image, the laser line was 
then placed through the central axis of both cones. This positional setup was 
repeated for all CT imaging.  
 
3.3.3 X-RAY PROJECTION IMAGING 
X-ray imaging was conducted on a Siemens multi fusion XPB2-
100.620.04.03.02 (Siemens Healthcare, Germany) which was calibrated weekly 
for dose, and yearly as part of maintenance. The positioning and imaging of the 
cones was done in the same manner as the positioning already stated 
regarding the AP phantom knee, with the modification to the central beam so 
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that the centre point was the axis between the two cones. Five scans were 
produced at the kVp and mAs of 60 and 2.5, 60 and 8, 70 and 2.8, 70 and 5, 
and 81 and 3.2 respectively. These were chosen in order to create a range of 
the most common exposures in x-ray imaging [327, 328]. 
 
 
3.4 CONE IMPLANTATION INTO A BOVINE SUBSTITUTE 
In addition to the cones being imaged on their own (submerged in water), they 
were also inserted into a bovine tibia and femur in order to investigate the 
development and confirmation needed to establish conal bonding and in-growth 
within a substitute model and solution.  
 
Ovine (sheep) bones were originally considered as the best possible 
representation available for a human knee, as research has already 
demonstrated their use in investigating osseointegration in porous coated 
implant knee arthroplasty’s [329], in-growth assessment in implants [330] and in 
other orthopaedic research [331]. They have also been utilised in representing 
the human knee in many other studies such as osteoporosis [332], cruciate 
ligament reconstruction [333], OA [334], bone repair [335] and tibial osteotomy 
[336].  There are many reasons for their use, with two of the strongest 
arguments being the femoral cortical index being nearly the same as a humans; 
0.33 (+/- 0.08) compared to sheep 0.32 (+/- 0.04) [323], and their intercondylar 
ratio of the femur and the tibial aspect appearing almost identical [323]. 
 
Unfortunately, the tibial ML width measurement of a human was recorded as 
7.64 cm (+/- 0.54 cm) compared to a sheep’s tibial ML width of 5.17 cm (+/- 
0.20 cm) these data were based on 24 measurements of skeletally mature 
merino sheep, and 24 alcohol fixated human cadaver knees [323]. Furthermore 
the femoral ML width measurement of a human was recorded at 8.12 cm (+/- 
0.62 cm) compared to the sheep femoral ML width of 4.72 cm (+/- 0.18 cm) 
[323].  
 
This size disparity meant the ovine bones would only be viable for scaled down 
prosthetic replacements; this issue was also evident in similar animals such as 
goats, pigs, and rabbits [337]. Therefore larger animals were investigated with a 
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bovine model the forerunner; having themselves been used in diverse knee 
studies from: cruciate ligament investigations, tibial osteotomy, mechanisms of 
cartilage repair, osteoarthritis, drug treatments and current reconstructive 
surgery [338, 339, 340, 341, 342, 343]. Furthermore, bovine bones had several 
advantages over other possible candidates due to being easily accessible, 
technically feasible, affordable, and with transferable results due to bovine 
structure. 
 
Two bovine knees (approximately two years old) were collected by a third party 
from the Ashburton Abattoir (after being hung up for 48 hours first), these were 
then stored in the University of Exeter’s physics department at the Streatham 
campus in a refrigerator for 24 hours, and transferred to another freezer for the 











The muscles, tendon, ligaments and superfluous bones (patella and fibula) 
were removed via a hacksaw, with both the femoral and tibial bones reduced in 
length to fit the plastic box whilst maintaining the knee proportions reported. 
 
Finer cuts using a scalpel were utilised In order to remove excess flesh and to 
cut through the tougher ligamentous structures. The bones were then exposed 
to the water maceration technique [344], in which the bones were placed into a 
plastic box containing nine litres of warm tap water and four table spoons of 
biological washing powder, thoroughly stirred twice daily (a ratio of one gallon to 
two tablespoons [344]), this process was repeated for six weeks with the water 
and powder being replaced weekly, this maceration procedure was 
Figure 3.4. Photographs of the left bovine femur, tibia and patella, showing the 
amount of tendons, ligaments and muscles still on the bone that needed to be 





implemented in order to denature the proteins in the tissue, and weaken and 
remove loose ligaments and any remaining tendons.  
 
Due to time restraints imposed by scanning arrangements, and the slowness of 
the maceration process the bones were not fully defleshed at the end of the six 
weeks, although some of the tissue remained on the bones these were mainly 
the ligaments at root insertion points and some muscle attachments, several 
additional attempts were made to remove the excess tissue but were 
unsuccessful. 
 
In order to create the cavities for the cone implantation, the instructions from the 
Stryker triathlon revision knee system were followed [245]. Although 
unfortunately due to time constraints, cost, and the availability of the correct 
tools (reamers), the method had to be modified, therefore a Bosch SDS-plus 
drill was utilised in conjunction with several drill attachments, and a Soriace 
titanium coated step drill bit (10-45 mm). This was employed to match the 
maximum cavity size required for each cone, with the tibial cone being reported 
as the widest at 40 mm in diameter.  
The excavations of the drilling applied an ever increasing bit size until the 
Soriace step drill bit was administered creating a cavity approximately the width 












Figure 3.5. Photographs of the bovine tibia (right) and femur (left) with the 














The bovine bones, prior to cone implantation were then submerged in 15 cm of 
water in the pre-specified plastic box, and x-rayed (figure 3.7) and DXA (figure 














Figure 3.6. Photographs of the bovine tibia (right) and femur (left) placed in 
their in vivo position, which will be their orientation for all positioning images. 
 
Figure 3.7. Photographs of the bovine bones positional x-ray setup on an imaging 
















The cones were then implanted into the bovine bones and another set of 
images taken via x-ray and DXA, again using the same positional set up and 
settings as mentioned.  These first conal images created a baseline score both 
in DXA and x-ray which would then be utilised as a comparator to future 
imaging post solution immersion. 
 
 
3.5 SELECTION, IMMERSION AND DIFFUSION 
In order to investigate the tritanium cones ability to osseointegrate it was 
decided to submerge the bovine bones with the implanted cones in a substitute 
solution.  
 
A simple substitute solution to encourage bone integration was researched. 
Unfortunately most of these substitute solutions were complex solutions 
mimicking entire tissue responses and required advanced chemical controls 
which could not be established with limited time and resources. An aqueous 
solution combining calcium carbonate and water was considered, but upon 
reviewing the research it became apparent that calcium carbonate was not 
utilised as much as calcium phosphate (CaP) also called hydroxyapatite. CaP 
Figure 3.8. Photograph of the DXA scanner bed and positional setup used in 
DXA scanning the bovine bones. The starting position is shown via the red 




makes up 70% of human bone [345] and has similar bioactive and 
osteoconductive properties [346], it also improves osseointegration [347]. 
 
Calcium phosphate has been utilised as a bone substitute [348] with the first 
CaP bone graft substitutes launched over 40 years ago [345]. Since then CaP 
has been utilised in orthopaedic surgeries [349], and used in coating medical 
devices [350], such as porous metal implants [351], femoral stems [352] and 
dental implants [353]. 
 
A study by Tas et al [354] investigated calcium phosphate bonding at room 
temperature on a titanium alloy using a concentration of 10 times the amount of 
calcium and phosphate ions in human plasma, with them investigating bonding 
over a two to six hour period. Although no additional buffering solutions were 
used a surface treatment and reagents were applied to raise the pH level [354]. 
Due to scarce means, agents and treatments were not available, due to this 
limitation pH was not controlled or recorded during the session. For this study, 
the main aim was to investigate osteointegration into the cones and how this 
osteointegration might be visualised on the image and change over time, with 
this imaging setup and analysis feeding into the main study.  
 
The reported literature of bonding after two to six hours, implies that an even 
longer time period might yield a greater result. Therefore, two hundred and forty 
calcium hydroxyapatite capsules (NOW – sports bone and health) were 
purchased, each capsule contained 250 mg of calcium (25 % the recommended 
daily dose for an adult) and 100 mg phosphorus (10 % the daily recommended 
dose for an adult). It was decided to start with a small concentration over a five-
day period, and then increase it later on. Twenty-five  capsules (6250 mg of 
calcium and 2500 mg of phosphorus) (6.25 times the recommended dose for 
calcium and 2.5 times for phosphorus) were opened and emptied into nine litres 
of water and were stirred to diffuse in the aqueous solution over a five-day 
period prior to imaging, after imaging this process was repeated until the fourth 
and final scan, were a total of 139 capsules placed into nine litres of water 
(34,750 mg calcium and 13,900 mg phosphorous equating to 34.75 times the 
recommended dose for calcium and 13.9 times for phosphorus). This was in 
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order to create an exaggerate saturation point to determine osteointegration 
areas more visually within the imaging modalities utilised. 
 
For each solution soaking session, the bovine bones where then placed in a 
non-vivo orientation into the calcium phosphate solution in order to maximise 
diffusion through the bones and cones themselves. In order to maintain this 
diffusion throughout the day a waterproof fan (MasterPal Telego cooling fan - 
waterproof with 10,000 rotations per minute) was situated into the water and 
placed at an angle to maximise diffusion towards the bovine bones, (shown in 
figures 3.9 and 3.10). Additionally, the solution was also stirred twice daily to 
help diffusion, and the temperature recorded Due to a lack of time and 
resources, a large limitation was that a true reflection of internal temperature in 
vivo could not be maintained or replicated, although the temperature was 
recorded, and varied between 21 and 23 degrees Celsius throughout the study 


















Figure 3.9. Photograph (from the top) of the positional setup of the waterproof 


















Although the fan was tested in the solution prior to beginning the experiment, 
after 11 hours the fan began to only work intermittently, this fan was then 
cleaned and dried, but failed completely after approximately 14 hours. An exact 
replacement was purchased as well as an additional two different types (a 
sourcing map 80 x 80 x 25 mm DC Brushless Cooling Blower Fan USB Charger 
5V 0.4A and an ARCTIC Breeze Mobile - 92 mm USB Fan), these were all 
placed in the same position as shown above. These also failed after 10-15 
hours, as these had worked competently in the beginning the most likely cause 
was the bonding of the calcium phosphate resulting in intermitted rotation and 
eventual failure.  Due to the diffusion issue an aquatic environment specialist 
was contacted regarding the use of a fan or pump that was robust enough but 
would not filter out the calcium phosphate. It was recommended to use the 
Eheim compact 300 pump (pumps through 300 litres per hour) which was 
utilised replacing the fan in the same position for the rest of the study period, 
without any future incident.  
 
The bovine bones were left in the calcium phosphate solution for five 
consecutive days, after which they were removed from the solution, rinsed, and 
placed into the plastic box; tap water was then decanted into the box up to the 
15 cm depth mark. This was then x-rayed and DXA imaged in the positional 
process already stated. Upon completion the bones were then returned to the 
Figure 3.10. Photograph (from the side) of the positional setup of the waterproof 




larger plastic box (in the position shown in figures 3.6 and 3.7) and refilled with 
nine litres of fresh tap water and another 25 capsules (6250 mg of calcium and 
2500 mg of phosphorus), these bones were then left in calcium phosphate 
solution for another five days, and the same preparation and imaging was 
repeated. This entire method was repeated three times, creating post calcium 
one, post calcium two and post calcium three, upon the fourth time, the set up 
was repeated but rather than 25 capsules, a total of 139 capsules were placed 
into nine litres of tap water (34,750 mg calcium and 13,900 mg phosphorous) 
this was in the hope to create a saturation point (post calcium four), this fourth 
and final scan followed the same preparation and positional set up as the 
previous ones and only varied in the solution concentration as stated. 
 
After the baseline and post calcium one were imaged it was concluded there 
was a drawback to this method in providing adequate data for the analysis 
section of the x-ray imaging. Therefore it was decided to include a metal marker 
in order to have a known size comparator regardless of magnification impact, 
and to have a consistent measure of known density. This meant it could be 
used as a calibration device to allow standardisation to the pixel density score, 
instead of using the water density as a comparator which was the current 
situation.  
 
This marker was measured using a Mitutoyo absolute digimatic calliper (code 
no 500-191U model no CD-6”CP serial number 007750); recording the marker 


























This marker was placed into the plastic box 4.6 cm inferior to the central line 
and 5.6 cm away from the central line and adhered in place; additionally its 
position was outlined in permanent marker. Post calcium one was then 
reimaged with the marker in place and used in all subsequent imaging. 
 
 
3.6 IMAGES PRODUCED  
 
3.6.1 CONES DXA AND X-RAY IMAGES 
As stated the cones were placed in 15 cm of water and were imaged via DXA 






Figure 3.11. Photograph of calliper 
measuring the mediolateral dimensions 
of the marker 
 
Figure 3.12. Photograph of the calliper 
measuring the inferior and superior 















They were also imaged through x-ray, as shown in the example in figure 3.14. 
 
3.6.2 CONE CT IMAGES 
Using the CT positional setup described previously (section 3.3.2) it produced a 
three dimensional image of the cones submerged in 15 cm of water. 
Unfortunately these tritanium implants caused a minor starburst streaking 
artefact on the image as shown in figures 3.15 and 3.16, although the dual 














Figure 3.13. DXA scan of just the cones 
submerged in water (thin setting) 
 
Figure 3.14. X-ray scan of just the 
cones submerged in water 81kv 




















Regrettably due to artefact on the image from the tritanium conal implants, it 
was decided to now only CT the implants after the final full saturation of post 
calcium four, as this would allow the maximum deposition of the calcium 
phosphate into the implanted cones to occur increasing, the chances of visual 
change. Furthermore, with the surrounding bovine bone and concentration of 
calcium phosphate this might subdue, or at least supress the artefact affect, 
compared against the current cones in water. 
 
3.6.3 COW BONE DXA AND X-RAY IMAGES 
The cow bones (bovine femur and tibia) were DXA scanned (figure 3.17) prior 
to conal implantation across the three DXA scan modes (thin, standard and 
thick) all utilising the same positional setup as stated. Furthermore, the bovine 




Figure 3.15. CT scan showing the 
anterior portion of the tibial cone, this 
image shows streaking artefact 
 
Figure 3.16. CT scan showing the 
lateral view of both cones, this image 
















3.6.4 CONES AND BONES DXA IMAGES 
After conal implantation the cow bones were DXA scanned across the three 












Figure 3.17. DXA scan (thin mode) of 
cow bones in 15 cm of water in plastic 
container 
 
Figure 3.18. X-ray (81kv 3.2 mAs) of 
cow bones in 15 cm of water in plastic 
container 
 
Figure 3.20. DXA scan (standard setting), 
of cones and bones in 15 cm water 
 
 
Figure 3.19. DXA scan (thin setting), of 















3.6.5 CONES AND BONES X-RAY IMAGES 
Furthermore, the bone implanted with the cones were x-rayed an example of 












Figure 3.21 DXA scan (thick setting), of 
cones and bones in 15 cm water 
 
 
Figure 3.22. Baseline x-ray done at 60 
kv 8 mAs 
 
 
Figure 3.23. Baseline x-ray done at 70 





Additionally an example of the DXA 
and x-ray images that were taken after 
the inclusion of the marker are shown 






















Figure 3.24. Baseline x-ray done at 81 
kv 3.2 mAs 
 
 
Figure 3.25. Post calcium 1 with 
marker DXA scan on thin setting 
 
 
Figure 3.26. Post calcium 1 with 





3.6.6 CONES AND BONES CT IMAGES  
Computed tomography images were also produced after the final fourth 























Figure 3.27. CT images produced of post calcium 4, A shows a sagittal plane through 
th bovine model, B shows a transverse slice of the tibial cone in the bovine model, C 





3.7 ANALYSIS  
 
3.7.1 ANALYSIS OF X-RAYS AND INTRAOPERATOR DATA 
Prior to any density analysis of the x-ray images, radiographs in their DICOM 
format were all rotated left 90 degree and their canvas size normalised to 1052 
by 1552 pixels (the range for all images was 1012 to 1052 pixels by 1536 to 
1552). The window level (WL) and window width (WW) was then standardised 
across all images and across all doses, this was standardised as WL 1800 and 
WW 2100, then all images were converted to eight bit from 16 bit and saved as 
TIFF images in order to allow standardisation and comparison across all 
images. 
 
The mean pixel density of water was originally utilised as the standardised 
measure as the comparator of known density in which future images would be 
compared, as this was standardised to depth (15 cm) and was repeatable. After 
the baseline images were taken it was decided to supersede this by introducing 
the metallic marker which had a known and consistent density, as this would be 
a more dependable measure, as such all subsequent images were taken with 
the marker included within the image. It was decided to normalise all the images 
to the marker pixel density average, therefore marker reading were taken 
across all images and averaged, and a normalised coefficient applied to each 
image. Unfortunately this meant that the baseline image already taken could not 
be included in the calculation due to being utilised with the water density 
measure, therefore additional images were taken without the marker in order to 
quantify and compare the pixel density to that of water in the same area and 
allow a comparator to the baseline, albeit it a less comparable one. 
 
This resulted in 28 images being analysed (via using ImageJ), 16 of these were 
made up of four post calcium time intervals (first, second, third, fourth (full 
saturation)) with a marker across four different exposure factors (60 kVp 8 mAs, 
70 kVp 2.8 mAs, 70kVp 5 mAs, 81 kVp 3.2 mAs), and 12 images (the baseline, 
the first post calcium and the full saturation or fourth post calcium) across the 
same four exposure factors. It must be noted that although a 60 kVp 2.5 mAs 
dose was imaged and recorded, the images were rejected from the analysis as 
the imaging resulted in a stretched canvas prior to any normalisation resulting in 
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the majority of the images being unable to be compared, this stretching is 











The x-ray images themselves were then divided into regions in order to 
calculate pixel density differences within parts of the cones themselves. These 
regions were based on similar region analysis used in DXA research [178, 305]. 
The regions selected are shown in figure 3.29. 
 
Each region was numbered one to seven 
and measured via their pixel density 
mean; this was then recorded in an Excel 
spreadsheet. Multiple regions were 
sampled in order to create a fair reflection 
on the pixel density changes, but 
additionally to provide information where 
these possible changes might occur within 
the porous cones. Additionally, these 
images were converted via a look up table 
(LUT) to show express the pixel density 
visually. 
 
These regions were created and saved in 
a ROI manager, (within imageJ) and were 
loaded onto each image and adjusted, this 
adjustment was due to the research 
mimicking repeated knee x-rays thus there 
Figure 3.28. X-ray of baseline image of cow cones on exposure setting 
60 kVp 2.5 mAs, showing stretched canvas issue 
 
 
Figure 3,29. X-ray showing the 





was no perfect alignment between imaging weeks, as such, the regions were 
adjustable as long as they contoured to the conal implants and were positioned 
correctly over the marker. An example of the regions not lining up is shown in 
figure 3.30. 
 
Due to possibility of bias within the 
region adjustment placement it 
was decided to conduct an 
intraoperator variability study of the 
region placement within the x-ray 
images. Due to imaging across 
exposures not being affected by 
the positional adjustment these 
were not included in the 
intraoperator study i.e. the 
positional set up was not modified 
or touched between exposures 
only between post calcium weeks, 
and thus to include them would 
lower the variability and provide 




Therefore the exposure setting of 70 kVp 5 mAs was chosen, as this was close 
to the average of the analysed exposures. Five images were chosen: baseline, 
first post calcium (marker), second post calcium (marker), third post calcium 
(marker) and fourth post calcium/full saturation (marker). The first post calcium 
(no marker) and fourth post calcium (no maker) were not included due to 
similarly having been minimally moved (i.e. the marker was removed and 
reimaged without moving the bones). The standardised regions were loaded 
from the ROI manager from the second post calcium file (as they were during 
the original analysis) and modified to fit each image. Furthermore in order to 
reduce bias the second post calcium image was done last out of the five, in 
order that enough adjustments had been made throughout the first four that it 
Figure 3.30. X-ray showing the regions 





itself would need to be adjusted and would not reflect the original regions. 
Besides that there was no order to the region analysis, each image was loaded, 
the regions placed on top and adjusted measurements taken and the process 
repeated until all five images had been analysed, these measurements were 
then placed in an Excel spreadsheet and recorded under their date, on average 
8.2 days (range six – 12 days) would pass until the analysis was repeated, this 
time period separation was in order reduce learning or remembering bias. 
 
3.7.2 ANALYSIS OF THE DXA IMAGES 
In order to analyse the DXA images first the classification of the anatomy within 
the image had to be corrected, thus manual classification of the bones, tissues 
and artefacts had to be annotated via post processing as shown below in figure 
3.31, hence it was decided to only analyse the thin setting knee scans, this was 
due to the thin setting being used on human DXA knee scans and would 













 Figure 3.31. DXA image showing the selected classifications 





Four regions were chosen within the DXA image to be analysed as shown in 
figure 3.32 in order to calculate BMD differences across the different post 
calcium weeks. 
In total seven images were 
analysed for their BMD across 
the DXA images; post calcium 
one, post calcium two, post 
calcium three and post calcium 
four (full saturation) all with their 
marker, and baseline, post 
calcium one and post calcium 







3.7.3 ANALYSIS OF CT IMAGES 
Due to the limitations stated in the CT imaging it was decided to only analyse 
the CT images visually, as although the CT images provide positional data in 
the form of transverse sectional data and in-growth data they do not contain 
comparison data. Additionally the results will support or argue possible 
positional density difference data revealed via the x-ray or DXA images, and 
thus might help finer pinpoint the difference in positional. As such LUT were 
applied to the image (via ImageJ) in order to show any density difference in and 












3.8 RESULTS  
 
3.8.1 X-RAY RESULTS 
Tables 3.1 to 3.4 show the pixel density results (post coefficient marker 
normalisation) for all four post calcium scores for each region across the 
different exposures (region four is the marker and therefore has not been 
included), Due to only small value differences figures 3.33-3.36 show data only 
comparing the pixel density differences and not the total pixel score, thus have 
been expressed as each regions final digit plus three significant figures, e.g. 
















Post calcium 1 177.710 186.415 134.039 179.354 162.147 145.002 
Post calcium 2 174.790 184.911 130.419 175.032 160.530 140.677 
Post calcium 3 176.367 185.978 132.911 176.930 163.608 145.072 
Post calcium 4 
(full sat) 
179.210 187.538 135.616 180.063 166.991 148.837 
Difference 
between 1 and 4 
1.500 1.123 1.577 0.709 4.844 3.836 
 
Table 3.1. Pixel density difference of 60 kv 8 mAs for each region across four 






















Post calcium 1 169.658 176.123 135.300 175.970 162.369 145.896 
Post calcium 2 168.036 175.473 132.559 170.969 160.964 142.602 
Post calcium 3 169.170 176.605 134.306 174.815 162.670 146.283 
Post calcium 4 
(full sat) 
172.073 180.955 128.270 177.232 163.707 144.508 
Difference 
between 1 and 4 





























Post Calcium 1         Post Calcium 2           Post Calcium 3        Post Calcium 4 
(full saturation) 








Figure 3.33. Pixel density differences for 60 kv 8 mAs across four visits and 
seven regions, errors bars are standard error  
 
 










































Post Calcium 1     Post Calcium 2   Post Calcium 3        Post Calcium 4 
(full saturation) 





















Post calcium 1 169.278 177.224 127.806 177.033 160.905 141.035 
Post calcium 2 167.225 176.365 124.901 170.967 159.236 137.281 
Post calcium 3 168.685 177.796 126.951 175.804 161.386 141.701 
Post calcium 4 
(full sat) 
171.455 179.849 129.610 176.376 163.601 145.104 
Difference 
between 1 and 4 
2.177 2.626 1.804 -0.658 2.696 4.069 




Figure 3.34. Pixel density differences for 70 kv 2.8 mAs across four visits and 











































Post Calcium 1    Post Calcium   Post Calcium 3        Post Calcium 4 
(full saturation) 





















Post calcium 1 164.540 171.387 129.046 175.705 161.315 142.709 
Post calcium 2 161.981 170.295 125.867 173.048 161.610 138.944 
Post calcium 3 163.795 172.035 127.699 175.687 162.948 143.465 
Post calcium 4 
(full sat) 
166.358 173.728 130.638 175.865 164.310 146.620 
Difference 
between 1 and 4 
1.818 2.341 1.593 0.160 2.995 3.912 
Figure 3.35. Pixel density differences for 70 kv 5 mAs across four visits and 










Figure 3.36. Pixel density differences for 60 kv 8 mAs across four visits 






Across all four exposures 21 out of 24 results show an increase in pixel density 
between post calcium one and full saturation, with the largest increase 4.832 
seen in region two of 70 kVp 2.8 mAs, incidentally the largest negative 
difference is also seen in 70 kVp 2.8 mAs with a pixel density average loss of 
7.030 seen in region three. The trends across exposures shows a similar 
pattern of low pixel density in post calcium two (compared to post calcium one) 
which gradually increases in post calcium three and exceeding post calcium 
one at the point of imaging post calcium four. 
 
Additionally, data were analysed by using the water density average for 
coefficient normalisation across the three time periods which were scanned 
without a marker (baseline, post calcium one and full saturation), as shown in 



































Post Calcium 1   Post Calcium 2    Post Calcium 3        Post Calcium 4 
(full saturation) 
Pixel density difference for 81 Kv 3.2 










60 kv 8 mAs 














Baseline 351.668 367.753 273.569 347.394 328.217 293.236 
Post calcium 1 464.011 501.504 338.111 449.738 430.347 370.966 
Post calcium 4 
(full sat) 
401.668 423.519 307.159 402.662 373.389 335.246 
Difference 
between 
baseline and 4 




      70 kv 2.8 mAs 














Baseline 327.274 342.677 254.152 335.277 313.662 277.494 
Post calcium 1 334.164 355.220 259.002 335.618 323.517 283.539 
Post calcium 4 
(full sat) 
385.353 406.637 289.952 398.576 369.520 325.824 
Difference 
between 
baseline and 4 









Table 3.5. Pixel density difference of 60 kv 8 mAs for each region across three post 
calcium visits normalised to the coefficient of water 
 
 
Table 3.6. Pixel density difference of 70 kv 2.8 mAs for each region across three post 




















Baseline 315.607 329.949 247.951 323.504 303.460 269.859 
Post calcium 1 321.138 340.524 251.677 321.318 311.546 274.749 
Post calcium 4 
(full sat) 
365.197 384.879 278.014 376.793 351.115 310.562 
Difference 
between 
baseline and 4 




      81 kv 3.2 mAs 














Baseline 277.173 288.713 225.252 291.120 275.556 245.566 
Post calcium 1 279.475 293.890 225.464 288.099 278.875 247.462 
Post calcium 4 
(full sat) 
309.314 324.075 244.368 327.830 307.305 273.689 
Difference 
between 
baseline and 4 
32.142 35.362 19.116 36.710 31.750 28.123 
 
These tables show a similar trend to the marker data albeit with a much larger 
density difference average increase between the baseline and full saturation, 
with the highest average pixel difference being 63.960 in region two on image 
70 kVp and 2.8 mAs which is shown in the marker data analysis, although there 
is no negative pixel data, the lowest pixel average density increase is 19.116 as 
seen in region three (again this trend is seen in the marker data) albeit in image 
81 kVp 3.2 mAs. The data also show an increase in average pixel density 
between the baseline and post calcium one.  
Table 3.7. Pixel density difference of 70 kv 5 mAs for each region across three post 
calcium visits normalised to the coefficient of water 
 
 
Table 3.8. Pixel density difference of 81 kv 3.2 mAs for each region across three post 





The main two results of the data are to demonstrate the increase of pixel 
density for the full saturation compared to the baseline or post calcium one, as 
well as mathematically through calculation of average pixel density difference it 
is also shown visually (figures 3.37 and 3.38), which shows where the density 
changes (via an applied LUT representation). With figure 3.38 showing full 
saturation (with marker) compared to figure 3.34 showing post calcium one 
(with marker). It must be stated these figures are pre normalisation to the 
marker so are an exaggeration of the difference but highlight where the 















This representation was repeated with the baseline and full saturation images 
that did not contain the marker; these are shown in figures 3.39 and 3.40 and 




Figure 3.37. X-ray post calcium 1 
after a LUT has been applied, low 
pixel density is in red and high pixel 




Figure 3.38. Shows an X-ray image of the 
cones at full saturation after a LUT has 
been applied, low pixel density is in red 




















These four figures 3.37-3.40 are shown for illustrative purposes only, in order to 
indicate where average pixel density difference of deposited calcium phosphate 
has most likely occurred, but again these images have been produced prior to 
any pre normalisation so are a hyperbolic reflection of the true result. 
 
3.8.2 INTRAOPERATOR RESULTS 
Following the analysis discussed in section 3.7.1 five tables were produced 
covering the baseline (table 3.9), post calcium one (table 3.10), post calcium 
two (table 3.11), post calcium three (table 3.12), and post calcium four (full 
saturation) (table 3.13), calculating the COV. It must be stated that region four is 
not included as this was the marker region and to include the data from this 
region would reduce the variation and create an erroneous result. 
 
 
Figure 3.39. X-ray baseline after a 
LUT has been applied, low pixel 
density is in red, and high pixel 
density is in yellow. 
 
 
Figure 3.40. X-ray full saturation after a 
LUT has been applied, low pixel 
density is in red, and high pixel density 





















FIRST (7/7/17) 181.170 189.403 142.333 185.703 174.197 154.909 
SECOND 
(19/7/17) 
181.135 189.311 142.551 185.365 174.668 155.097 
THIRD (31/7/17) 181.293 188.534 142.694 186.086 175.695 154.968 
FOURTH 
(7/08/17) 
181.233 188.951 142.456 186.086 176.234 155.492 
FIFTH 
(14/08/17) 
181.052 188.820 142.598 186.565 175.694 155.191 
SIXTH 
(21/08/17) 
181.088 189.235 142.806 186.269 174.776 154.756 
SEVENTH 
(29/8/17) 
181.134 189.164 142.685 186.750 176.444 155.526 
EIGHTH 
(04/09/17) 
181.290 189.105 142.649 185.858 176.330 155.192 
NINTH 
(11/09/17) 
181.287 188.899 142.582 185.858 175.890 155.314 
TENTH 
(19/09/17) 
180.982 188.883 142.929 185.276 175.890 154.885 
       
Variation 0.01173 0.068758 0.028432 0.224603 0.593994 0.067252 







Table 3.9. Average pixel density for baseline for each region for 70 kVp and 5 mAs 






















FIRST (7/7/17) 155.780 163.092 117.615 162.917 148.075 129.789 
SECOND 
(19/7/17) 
155.219 163.513 117.435 162.258 148.011 129.781 
THIRD 
(31/7/17) 
155.446 163.361 117.544 162.042 149.420 130.099 
FOURTH 
(7/08/17) 
155.914 163.861 117.824 161.302 148.423 129.665 
FIFTH 
(14/08/17) 
155.533 164.336 117.833 161.832 148.170 129.862 
SIXTH 
(21/08/17) 
155.722 163.681 117.548 161.736 146.424 129.369 
SEVENTH 
(29/8/17) 
155.670 163.344 117.548 162.042 147.432 129.832 
EIGHTH 
(04/09/17) 
155.746 163.385 117.783 161.736 148.316 129.696 
NINTH 
(11/09/17) 
155.697 163.204 117.574 162.042 149.420 130.036 
TENTH 
(19/09/17) 
155.677 164.066 117.700 162.222 149.047 129.621 
       
Variation 0.038275 0.158044 0.0187 0.179465 0.833242 0.043449 
       COV % 0.314931      
Table 3.10. Average pixel density for post calcium 1 for each region for 70 kVp and 5 




















FIRST (7/7/17) 152.746 161.095 114.087 156.164 145.449 125.395 
SECOND 
(19/7/17) 
152.637 161.183 114.006 158.501 146.995 125.683 
THIRD (31/7/17) 152.745 161.512 114.001 157.551 146.239 125.421 
FOURTH 
(7/08/17) 
152.319 160.983 114.102 157.245 146.644 125.693 
FIFTH 
(14/08/17) 
152.469 161.229 114.260 158.278 146.746 125.290 
SIXTH 
(21/08/17) 
152.548 161.469 113.986 158.278 146.125 124.916 
SEVENTH 
(29/8/17) 
152.562 161.618 114.050 158.077 146.614 125.591 
EIGHTH 
(04/09/17) 
152.741 161.608 114.012 157.551 147.416 124.833 
NINTH 
(11/09/17) 
152.597 161.539 114.260 158.814 146.614 125.361 
TENTH 
(19/09/17) 
152.187 161.881 113.988 157.791 145.607 125.654 
       
Variation 0.03492 0.07785 0.011072 0.57285 0.363529 0.092679 
COV % 0.306647 







Table 3.11. Average pixel density for post calcium 2 for each region for 70 kVp and 5 


























FIRST (7/7/17) 157.602 166.114 118.610 164.253 150.783 132.391 
SECOND 
(19/7/17) 
157.296 165.660 118.754 162.996 151.593 132.491 
THIRD (31/7/17) 157.663 166.070 118.626 164.056 150.124 132.777 
FOURTH 
(7/08/17) 
157.781 166.350 118.648 163.684 150.553 132.745 
FIFTH 
(14/08/17) 
157.546 166.876 118.589 163.750 151.688 132.728 
SIXTH 
(21/08/17) 
157.639 165.942 118.686 162.079 151.101 132.127 
SEVENTH 
(29/8/17) 
157.444 165.930 118.581 163.750 151.490 132.490 
EIGHTH 
(04/09/17) 
157.545 165.813 118.727 163.560 151.423 132.352 
NINTH 
(11/09/17) 
157.226 166.070 118.656 164.056 151.871 132.493 
TENTH 
(19/09/17) 
157.518 165.767 118.790 164.253 150.926 132.546 
       Variation  0.028088 0.121194 0.005061 0.44239 0.310194 0.040226 
COV % 0.267983      
Table 3.12. Average pixel density for post calcium 3 for each region for 70 kVp and 5 




















FIRST (7/7/17) 160.805 168.678 121.559 165.420 153.439 136.091 
SECOND 
(19/7/17) 
160.925 168.505 121.379 166.975 153.497 136.536 
THIRD (31/7/17) 160.705 168.323 121.256 167.282 153.086 136.282 
FOURTH 
(7/08/17) 
160.760 168.602 121.244 166.272 153.497 136.288 
FIFTH 
(14/08/17) 
160.787 168.133 121.265 166.975 153.279 136.131 
SIXTH 
(21/08/17) 
160.776 168.320 121.265 166.920 153.350 136.380 
SEVENTH 
(29/8/17) 
160.658 168.011 121.244 166.272 153.497 135.891 
EIGHTH 
(04/09/17) 
160.733 168.391 121.275 167.282 155.417 136.118 
NINTH 
(11/09/17) 
160.753 167.644 121.409 166.690 154.558 136.482 
TENTH 
(19/09/17) 
160.776 166.980 121.388 167.380 154.539 136.577 
 
      
Variation  0.004899 0.263312 0.010685 0.369163 0.569148 0.048894 
COV % 0.303848      
 
Across all five images the coefficient of variation was reported as 0.237 %, 
0.315 %, 0.307 %, 0.268 % 0.304 % (to three significant figures), all showing a 
similar result. Additionally the highest variation within the individual regions was 
seen in region six with a reported variation of 0.833, with the lowest reported 
seen in region one recording 0.005. The average for each region (across all five 
images) shows the highest variation is seen in region six an average of 0.534, 
closely followed by region five with an average of 0.358, with the lowest score 
reported in region three of 0.015, and region one with an average of 0.024.  
Table 3.13. Average pixel density for post calcium 4 (full saturation) for each region for 70 






3.8.3 DXA RESULTS 
Table 3.14 and figure 3.41 show BMD across the four regions measured using 
g/cm2 compared between the intervals of post calcium one, post calcium two, 
post calcium three and full saturation 
 
  Region (g/cm2)     
Time period 1 2 3 4 
Post calcium 1 2.939 1.894 2.879 2.517 
Post calcium 2 2.984 1.952 2.866 2.553 
Post calcium 3 2.960 1.915 2.959 2.543 
Post calcium 4 (full sat) 2.964 1.953 2.851 2.464 




DXA results show minimal difference between figures, although there is a loss 
of BMD in regions three and four which is where the cones are situated. 
Although it must be noted the cones themselves are not included in the 
calculation as they are excluded due to being artefacts in the DXA image. Both 
region one and region two show a very slight increase in BMD across the visits. 
 
Table 3.15 and figure 3.42 show the BMD differences across three visits; 

















Post Calcium 1   Post Calcium 2    Post Calcium 3        Post Calcium 4 
(full saturation)
BMD changes in g/cm2 in DXA thin scan 





Table 3.14. BMD result (g/cm2) between four selected regions across four visits 
 
 







  Region (g/cm2)     
Time period 1 2 3 4 
Baseline 2.950 2.136 2.952 2.620 
Post calcium 1 2.913 1.832 3.089 2.500 
Post calcium 4 (full sat) 2.913 1.933 2.838 2.546 






Table 3.15 and figure 3.42 show a BMD loss between the baseline and the full 
saturation across all four regions. 
 
3.8.4 CT RESULTS 
Figure 3.43 shows a LUT applied to an axial slice of a CT eight bit image (via 
imageJ), in order to visualise possible ingrowth. Unfortunately, the white and 
yellow pixels which would represent high pixel density and in-growth around the 
conal implants, are minimal, and as such might be obscured by artefact caused 
by the implant instead of calcium phosphate deposits, as discussed in 3.6.2 and 




















Baseline              Post Calcium 1            Post Calcium 4 
(full saturation)
BMD changes in g/cm2 in DXA thin scan 





Table 3.15. BMD difference (g/cm2) between four selected regions across three visits 
 
 
Figure 3.42. DXA BMD results across three visits and four regions, 























3.9.1 X-RAY IMAGES 
The x-ray images show an increase of average pixel density between post 
calcium one and full saturation across 21 of the 24 images, and in all of the no 
marker images when comparing baseline to full saturation, with the largest 
increase seen in region two across both sets of data. Incidentally, the largest 
negative difference is an average pixel density loss of 7.030 and is seen in 
region three which does not cover the cones but is actually the area under the 
tibial cone. This negative result might be due to deterioration of the tissue and 
bone itself, this is further supported by region seven which also encompasses 
some of the surrounding tissue and also shows a negative result (-1.388) in the 
same exposure factor, even though region seven includes region five and six 
(both regions of the femoral cone and showing positive results +1.262 and 
+1.338).  Although it must be noted both regions four and seven show positive 
results for the other exposures. The overall average pixel density increase 
across multiple regions when comparing post calcium one and full saturation 
might be due to the calcium phosphate depositing itself within the conal pores, 
whilst the negative result might be due to deterioration of the surrounding 
structures. 
Figure 3.43. Shows a CT image of the tibial cone in the axial plane, with 
the application of a LUT via ImageJ having been applied to in order to 
determine the possibility of in-growth. Red shows low density, and white 






3.9.2 INTRAOPERATOR  
The intraoperator variability results show a small deviation of the figures across 
all repeats (0.237-0.315 %) and address the issues of error margins and bias 
within the region selection and division. If this largest percentage 0.315 is 
applied to the results of the x-ray images only one result is affected (region 5 81 
kVp 3.2 mAs), furthermore one x-ray result has a recorded loss of -0.658 
between post calcium one and full saturation which is also in region five and this 
loss might be explained due to high average variation within region five (0.358). 
Furthermore, region six produces some of the largest average pixel density 
differences and this again might be explained by the average variation reported 
(0.534), with region six having the largest variation out of all the regions. 
 
The intraoperator figures were only produced reviewing one set of exposures 
(70 kVp 5 mAs), although as the other exposures were done at the same time 
and thus the cones and bones in the plastic box was not moved neither was the 
x-ray tube or digital detector, the results should be generalisable to the other 
exposures used in the same post calcium visit. 
 
3.9.3 DXA IMAGES 
Dual energy X-ray absorptiometry results show a small amount of change of 
BMD density across all regions, with six out of eight of the results (either post 
calcium one compared to full saturation, or baseline compared to full saturation) 
showing a loss of BMD. This loss of BMD may well be due to the deterioration 
of tissue and bone which would correspond to the results mentioned in the x-ray 
imaging as a possible reason for the pixel density differences. It must also be 
noted that the DXA images do not include the information of the bone 
integration within the cones (as these are classed as artefacts). Incidentally 
there might be region selection or artefact inclusion bias within the study; with 
this artefact inclusion bias possibly being the reason two of the results are very 
slightly positive (0.025, 0.059).  
 
3.9.4 CT IMAGES 
The CT images show the possibility of in-growth, although it must be noted this 
could easily be artefact from the imaging system, and therefore cannot be 
concluded on, although if it is in-growth it shows a similar slight pixel density 
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change around the implants which would coincide with the pixel density 




The results themselves lack generalisabilty to any real world reported changes, 
this is due to several issues including temperature, saturation, and 
osteointegration. As this study was conducted in a non-biologically active ex 
vivo bovine stifle, this means the main premise of osteointegration involving 
osteoblast activity, bone remodelling and mechanical loading; resulting in 
bonding between the implant and the bone as a living tissue could not occur 
due to the limitations of the study. Resulting in only the deposited changes 
being registered, this is coupled with the research being done at room 
temperature (21-23 oC) with some reports stating that hydroxyapatite bonding to 
tritanium is problematic at room temperature [356], which would further 
exacerbate the integration issue. The saturation of calcium phosphate may 
have also been too low at the beginning, and only the full saturation produced a 
large enough positive effect (comparing post calcium three to full saturation). 
This solution also lacked the biochemistry present, or a representative pH level 
in tissue and bone matrix present to promote and compliment bone integration, 
which again may have impacted the result. 
 
Additionally, the one odd result was that of a loss of pixel density during the 
post calcium two visit across multiple regions (see tables 3.1-3.4 and figures 
3.33 to 3.36), this loss of density may have been due to the fault of the fans 
losing diffusion reducing deposition time and bonding, which was then rectified 
by the pump prior to the third post calcium visit. This loss of deposition may well 
have also been exacerbated by heavy vibrational transportation. For example if 
during the diffusion five day session 10 pieces of CaP were deposited on to the 
conal implants, then during transport (which was a train journey of 60-80 
minutes and additional walking of 30-40 minutes) eight pieces became 
dislodged or unintegrated, the scan will still produce a positive difference of two, 
if the deposition is insufficient during the five day diffusion session then the 
build-up might only be six, but with the same loss of eight during transport 
resulting in negative of two. 
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Furthermore, the depositing of calcium phosphate might have been affected by 
the cavities that were originally created during the implantation phase. The 
press fit design nature of cones, and how they bond via close proximity to the 
bone could have been comprised due to the modified implantation technique 
utilised, due to the limitations already mentioned regarding lacking correct 
surgical tools. This idiosyncratic preparation may have influenced the implants 
ability to bond to the bone due to a gap being present between the cavity and 
the cone. 
 
Allowances must also be made for the use of cow bones over human bones 
which are not a fair reflection on human integration and density. Furthermore, 
the removal of the patella and the fibula made the results less generalisable and 
applicable reducing surfaces for the CaP to adhere to.  
 
The limitations stated although important address more about the bovine model 
than the development of the imaging methods and analysis. Limitations such as 
not having a standardised marker from the beginning (to allow calibration and 
standardisation across the pixel densities for x-ray imaging), and being aware of 




The cone results are very limited but do show promise, with 21 out of 24 results 
showing an increase in average pixel density in multiple regions (when 
comparing first post calcium to full saturation). The loss in BMD across multiple 
visits and regions as reported by the DXA results is in contradiction to the x-ray 
analysis, although both investigated differing regions of interest (ROI) and the 
inert non vivo system makes a standardised conclusion problematic, thus It 
must be acknowledged that there are many variables and limitations which 
need to be addressed before a true significant conclusion can be reached, as 
such caution should be taken with these results until they can be verified in a 
more robust in vivo clinical trial. 
 
Due to these factors and limitations stated the results cannot be generalised or 
provide representations of true osteintegration or BMD change, that being said, 
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the imaging methods presented here, and the ability to investigate, record and 




3.12 FUTURE WORK 
Bringing these procedures and methods into the main feasibility study, there 
were several learned lessons that were brought forward. For example, in 
addition to DXA PA images, lateral DXA images were also to be produced, in 
order to investigate BMD changes in both planes. This addressed some of the 
issues of BMD ROI changes caused due to superimposition of bone. 
 
Moreover, for the feasibility study a metal of known density was included (an 
aluminium step wedge) so standardisation was available for all images from the 
start. Incidentally due to not being able to control the saturation of calcium and 
other chemicals clinically within our participants, medical history was recorded 
for any medications, calcium or multi vitamins the participants were prescribed, 
addressing the issue of differences between the two groups (if any) of certain 



















CHAPTER 4 AN ANALYSIS USING 3D SHAPER MODELLING SOFTWARE 
ANALYSIS OF THE HIP – A COMPARISON BETWEEN DIFFERENT 
BASELINE AND FURTHER VISITS, AND BETWEEN IPSILATERAL AND 




From the systematic review, it has been shown that there are limited data 
regarding ipsilateral and contralateral hip BMD reported via Dual-energy X-ray 
absorptiometry (DXA) scans in the pre- and early post- surgery periods for total 
knee replacements (TKR). Furthermore, there are no reported DXA data 
available regarding BMD changes at the hip post total knee revision (rTKR).   
 
4.1.1 AIM  
In addition to the methods and analysis stated in the previous chapter which will 
be utilised in the full trial. I also investigated an alternative method, with the aim 
of this chapter to investigate 3D-SHAPER modelling software in determining 
bone quality in hip DXA images. This chapter will therefore provide an additional 
method for analysing bone quality, and will provide a set of descriptive data for 
the various populations to help provide sample data for future comparisons. 
 
The impact of bone changes in the bilateral hips will be investigated across 
three groups; rTKR, TKR, and a control group (whom have not had any 
previous joint replacements), applying 3D-SHAPER software to analyse DXA 
scans. This software enables measurements of: 
 
 Cortical surface BMD (cortical sBMD) in mg/cm2; calculated as the 
multiplication of the cortical thickness (in cm) by the cortical volumetric 
density (in mg/cm3). Cortical sBMD is associated with the strength of the 
cortex, the higher the cortical thickness and/or the cortical volumetric 
density, the higher the cortical sBMD [357]. 
 
 Trabecular volumetric BMD (trabecular vBMD) in mg/cm3, measures 
the mean density in the trabecular compartment. Trabecular vBMD is 
associated with the strength of trabecular bone [357]. 
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 Integral volumetric BMD (integral vBMD) in mg/cm3, measures the 
mean density in the integral (union of the cortical and trabecular) 
compartment. Integral vBMD is associated with the global strength of the 
proximal femur. All measurements are calculated in the total femur ROI 
[357]. 
 
 Cross sectional moment of inertia (CSMI) in cm4 describes geometric 
structure and density in the femoral neck and is a measure of the index 
of structural rigidity around the axis of the neck [358, 359]. It is calculated 
via the Hip structural analysis (HSA) definition of the sum of pixel mass 
at each point and multiplied by the square of its distance from the centre 
of mass [360]. 
 
 Cross sectional area (CSA) – reported in cm2 measures the minimum 
of the CSMI section within the femoral neck. An index of axial 














Figure 4.1. Diagram illustrating geometric location of CSMI and CSA in the hip 
[361] 
 
Both the CSMI and CSA (figure 4.1) impact the femoral strength index score 
and subsequent fracture risk [358]. Calculated via the HSA definition in which 
the area of each pixel is weighted by the amount of bone in the pixel [362]. 
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Bone mineral density and the characteristics and architecture of bone have 
already been discussed in Chapter 1 section 1.2.2. Further to this, there is a 
direct link between the influences of both cortical and trabecular bone and hip 
strength; cortical bone supports the flexibility of the hip in the distal regions of 
the femoral neck, with trabecular bone supporting the proximal loads the hip 
has to undergo [363]. Both of these bone types combine in a complex 




The ability to separate cortical from trabecular bone might allow greater 
understanding of bone loss increasing fracture risk. This is due to BMD 
predominantly accounting for only 60% of variation in bone fragility [364], and 
with DXA scans being unable to differentiate differences in BMD composition 
and structural design [365], other options must be investigated. Furthermore, 
the importance in defining exact areas of weaknesses or bone loss is important, 
especially with the advent of atypical femoral fractures, and the issue that BMD 
measurements only calculate an average of mineral content over a given area 
and thus exclude structural detail [359]. In contrast, cross-sectional geometric 
measurements of CSMI and CSA can provide detailed data about mechanical 
properties, based on the distribution of the bone [359]. 
 
4.1.2 PREVIOUS RESEARCH 
The 3-D Shaper modelling software was developed in 2011 and tested against 
a collection of Quantitative Computed Tomography (QCT) images. This 
involved a reconstruction experiment, where a model was constructed from a 
database of QCT scans of 85 subjects. The accuracy was evaluated by 
comparing the reconstructions with 30 DXA images with same subject QCT 
scans [366]. This model has since been evaluated further using a database of 
157 study subjects, by comparing 3D-DXA analysis (using DXA scanners from 
three manufacturers) with measurements performed by QCT [367]. Since 2017 
there have been published papers using the 3D-SHAPER software, for 
example: “Structural Parameters of the Proximal Femur by 3-Dimensional Dual-
Energy X-ray Absorptiometry Software: Comparison With Quantitative 
Computed Tomography [368]”. The software has also been involved in 
investigating osteoporosis drug treatments on cortical and trabecular bone 
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impact [369]. In patients with Down syndrome [370], investigating cortical and 
trabecular bone changes in professional dancers [371], and analysing the 
evolution of cortical and trabecular bone compartments in the proximal femur 
after spinal cord injury by 3D-DXA [372]. These research papers are all very 
specific and limited, and none have covered either TKR or revisions, so 
unfortunately there is a lack of comparison data for this study.  
 
 
4.2 THE 3D MODELLING SOFTWARE 
Three-Dimensional Shaper is processing software (version v2.7.3) developed 
by Galgo Medical SL which incorporates model based algorithms via statistical 
shape and density modelling of 3D patient specific mapping onto DXA hip scans 
[373, 374]. This software utilises mathematical modelling across the femoral 
surface [374, 375], and has been evaluated for accuracy and validity using 
comparisons with quantitative computed tomography (QCT) imaging (an 
imaging modality which has been shown to be equal to DXA [376]) as shown in 
table 4.1 [375]. The software has been tested clinically via other fields, including 
treatment monitoring, fracture discrimination, and secondary osteoporosis [357, 
377, 378, 379].  
 








The 3D-SHAPER software was created from a population database of QCT 
images, overlaid onto the DXA scans of the patients [357], resulting in patient 
specific shape and density 3D models, with cortical and trabecular bone 
segmentation [374].  
 
The software reports the BMD, but can also calculate both cortical and 
trabecular BMD from standard DXA hip images, with the addition of generating 
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a report and a 3D visual model, as well as providing percentage change for 
tracking changes throughout subsequent participant visits. Furthermore, the 
software is compatible with a multitude of different DXA scanners [357]. As 
stated the software calculates three main outcomes of the hip DXA scans; the 
cortical sBMD, the trabecular vBMD and the integral vBMD, as well as reporting 




The testing involved recruiting participants from three groups: 
 
rTKR group – This group was from the main feasibility study undergoing a rTKR 
and cone implantation. At the point of utilising the software 27 participants had 
undergone pre-op scans. The group included both male and female (seven 
female, 20 male, mean age 71.6 (SD 7.403), mean weight 89.78 kg (SD 
17.141), mean height 171.36 cm (SD 9.490)) resulting in a mean body mass 
index (BMI) of 30.57 (see table 4.2), 12 of these were due their revision on their 
left side, and 15 on their right. Data were recorded at pre-op (N=27), six week 
post rTKR (17 completed), three months post rTKR (17 completed), six months 
post rTKR (14 completed), 12 months post rTKR (seven completed). As part of 
the analysis there was no separation between the participants receiving a cone 
and those without, as all participants underwent a rTKR. 
 
TKR group – This group was from an existing study (Hopkins et al [23]) and the 
data had already been collected, so only required software input and analysis. 
The participants were scanned following the same protocol and on the same 
make and model of DXA scanner as the rTKR and control groups. The group 
started with 23 postmenopausal women (mean age 65.3, (SD 6.708), mean 
weight 89.74 kg (SD 18.177), mean height 161.33 cm (SD 5.859)) resulting in a 
mean BMI of 34.48 (see table 4.2), with seven participants having their left side 
replaced, and 16 having their right. Data were recorded at pre-op (N=23), six 
week post TKR (15 completed), six months post TKR (17 completed), 12 





Controls – This group was from the Hopkins et al study [23]. This group started 
with 45 postmenopausal women (mean age 64.4, (SD 7.828), mean weight 
68.12 kg (SD 9.991), mean height 163.56 cm (SD 5.926)) resulting in a BMI of 
25.46 (see table 4.2), with the left hip being compared to right, as neither side 
had a TKR. Data were recorded at their 1st visit (mimicking the pre-op in the 
other groups) (N=45), six months (43 completed), and 12 months (36 
completed). 
 
All participants had to pass exclusion criteria prior to their inclusion in the study, 
the exclusion criteria for the rTKR study (which is discussed in chapter five). For 
the disuse osteopenia study this excluded: participants who had used 
Corticosteroids >2.5 mg for more than three months within last five years, 
participants who had suffered a lower limb fracture or TKR post age 21 years, 
immobilisation of a lower limb for greater than four weeks within last 10 years or 
in the postmenopausal period, and participants who were unable to give 
consent.  
 
After initial recruitment and data collection the only excluded participants across 
all three groups were those who had been placed on bisphosphonates during 
the study, and those who had had a previous total hip replacement (THR) on 
either side. This was due to impact of bisphosphonates increasing BMD, and 
due to the DXA scanner and computer software unable to read THR scans, and 
thus those participants would lack a contralateral hip for comparison, analysis, 
and interpretation.  
 
388 files from the disuse osteopenia study (controls and TKR) and 164 rTKR 
files were loaded into Galgo software.  After importation the hip scans had a 
mask applied over the DXA image and registered via the 3D-SHAPER 
software’s own acquisition tool, after this was applied an analysis result and 3D 
model of the hip, as well as a DXA style report was produced (including 




















Figure 4.2. Galgo 3D-SHAPER software creating a 3D heat map model via the 
analysis of the hip data 
 
 
4.4 ANALYSIS OF IMAGES 
After all the files were analysed the data were exported to a Microsoft Excel 
spreadsheet and separated based on group, side (replacement or revision 
side), and time period (pre-op, six weeks, three months, six months, and 12 
months). 
 
Data were analysed via comparison to the pre-op/first appointment baseline 
result, these data provided changes between visits compared to a known 
baseline measurement. Therefore, for each visit the participants were only 
compared to the group mean baseline i.e. at 12 months for the rTKR group only 
had seven participants completed this visit, thus this mean figure was compared 
to the baseline mean score of only those seven.  
 
This analysis involved each appointment date being compared to the first 
appointment e.g. the rTKR six week appointment on the ipsilateral side was 
compared to the pre-op scan on that same side, this was repeated for the three 
month, six month, and 12 month appointments for both the ipsilateral and 
contralateral hips with standard deviation (SD), standard error (SE), paired 
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samples t-test, percentage change (calculated as new BMD figure minus 
baseline figure divided by baseline figure multiplied by 100), and 95 % 
Confidence intervals (CI) calculated. This method was repeated across all three 
groups with each being compared to their pre-op/first appointment DXA scan.  
 
Further analysis was performed with a comparison between ipsilateral and 
contralateral hips for reporting differences between the two sides. First the pre-
op data for the rTKR group was analysed; the data were compared between the 
ipsilateral (the hip side the revision was located) and contralateral (the opposite 
side) hips for the pre-op time period, with the ipsilateral mean minus the 
contralateral mean calculated. The difference between the means were 
calculated across all rTKR participants as well as the SD, SE, a paired samples 
t-test was also performed. The difference between the means was also 
calculated as a percentage difference between the two sides and a 95 % CI e.g. 
an ipsilateral mean of 170 and a contralateral mean of 175 would result in a 
percentage difference of -2.86 %. This process was repeated for the TKR, and 
the control group (instead of pre-op this was referred to as first appointment). 
This analysis was again repeated for the six week, three month, six month, and 




4.5 3D-SHAPER RESULTS 
 
4.5.1 BASELINE FIGURES  











Controls 45 64.4 (+/-7.83) 163.56 (+/-7.83) 68.12 (+/-9.99) 25.46 
rTKR 27 71.6 (+/-7.40) 171.36 (+/-9.49) 89.78 (+/-17.14) 30.57 









Table 4.3. Shows the mean BMD baseline/pre-op scores of each of the three 




IPSILATERAL SD SE CONTRALATERAL SD SE 
Cortical sBMD (mg/cm2) 170.996 26.951 5.187 176.175 24.173 4.652 
Trabecular vBMD 
(mg/cm3) 
168.482 49.015 9.433 175.602 49.894 9.602 
Integral vBMD (mg/cm3) 316.949 58.600 11.278 326.937 57.744 11.113 
Neck CSA (cm2) 1.194 0.263 0.051 1.246 0.256 0.049 
Neck CSMI (cm4) 1.975 0.713 0.137 2.070 0.705 0.136 
InterTroch CSA (cm2) 2.078 0.648 0.125 2.158 0.589 0.113 





IPSILATERAL SD SE CONTRALATERAL SD SE 
Cortical sBMD (mg/cm2) 163.858 24.832 3.702 163.748 25.631 3.821 
Trabecular vBMD 
(mg/cm3) 
164.511 42.384 6.318 164.739 44.100 6.574 
Integral vBMD (mg/cm3) 322.585 58.292 8.690 321.208 58.570 8.731 
Neck CSA (cm2) 1.032 0.200 0.030 1.031 0.181 0.027 
Neck CSMI (cm4) 1.386 0.354 0.053 1.371 0.301 0.045 
InterTroch CSA (cm2) 1.703 0.382 0.057 1.706 0.394 0.059 





IPSILATERAL SD SE CONTRALATERAL SD SE 
Cortical sBMD (mg/cm2) 167.055 20.143 4.200 170.213 24.189 5.044 
Trabecular vBMD 
(mg/cm3) 
172.895 39.761 8.291 173.880 43.604 9.092 
Integral vBMD (mg/cm3) 331.391 47.481 9.900 334.314 55.373 11.546 
Neck CSA (cm2) 1.077 0.206 0.043 1.052 0.219 0.046 
Neck CSMI (cm4) 1.375 0.364 0.076 1.354 0.347 0.072 
InterTroch CSA (cm2) 1.715 0.359 0.075 1.751 0.407 0.085 












4.5.2 CORTICAL sBMD BONE RESULTS 
Figure 4.3. Shows the changes in cortical sBMD in the ipsilateral hip across the 
three groups (error bars are SE) over 12 months 
 
Figure 4.4. Shows the changes in cortical sBMD in the contralateral hip across 
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Table 4.4. Shows the data compared to baseline for the cortical sBMD, including 
percentage change, CI (95 %), and the t-test and p-value (there was no data 
collected for 6 week and 3 month control data, and none for 3 month TKR data) 
 









% Change 95 % CI 
 
rTKR (mg/cm2) -2.208 6.979 1.693 1.304 (0.21) -1.249 -10.525 8.026 
TKR (mg/cm2) -3.151 6.632 1.712 1.840 (0.09) -1.911 -8.435 4.612 
Control (mg/cm2) - - - - - - - 
rTKR Contralateral (mg/cm2) 0.020 7.172 1.739 -0.012 (0.99) 0.011 -7.826 7.848 
TKR Contralateral (mg/cm2) -1.077 5.196 1.342 0.803 (0.44) -0.645 -7.230 5.940 
Control Contralateral (mg/cm2) - - - - - - - 
 








% Change 95 % CI 
 
rTKR (mg/cm2) -1.990 8.800 2.134 0.932 (0.36) -1.126 -9.901 7.649 
TKR (mg/cm2) - - - - - - - 
Control (mg/cm2) - - - - - - - 
rTKR Contralateral (mg/cm2) -2.068 8.311 2.016 1.026 (0.32) -1.144 -9.334 7.046 
TKR Contralateral (mg/cm2) - - - - - - - 
Control Contralateral (mg/cm2) - - - - - - - 








% Change 95 % CI 
 
rTKR (mg/cm2) -2.415 7.688 2.055 1.175 (0.26) -1.429 -11.037 8.179 
TKR (mg/cm2) -3.957 5.071 1.230 3.217 (0.01) -2.360 -8.625 3.904 
Control (mg/cm2) -0.632 4.430 0.676 0.936 (0.35) -0.386 -4.913 4.141 
rTKR Contralateral (mg/cm2) -2.595 9.044 2.417 1.074 (0.30) -1.491 -10.024 7.043 
TKR Contralateral (mg/cm2) -1.284 4.524 1.097 1.170 (0.26) -0.753 -7.804 6.299 
Control Contralateral (mg/cm2) 0.387 4.308 0.657 -0.589 (0.56) 0.236 -4.410 4.882 








% Change 95 % CI 
 
rTKR (mg/cm2) -3.016 10.882 4.113 0.733 (0.49) -1.735 -11.767 8.298 
TKR (mg/cm2) -3.609 6.884 1.777 2.031 (0.06) -2.139 -8.919 4.640 
Control (mg/cm2) -0.512 5.433 0.906 0.566 (0.58) -0.307 -5.029 4.415 
rTKR Contralateral (mg/cm2) -0.691 2.700 1.102 0.627 (0.55) -0.391 -8.833 8.051 
TKR Contralateral (mg/cm2) -0.862 4.639 1.198 0.719 (0.48) -0.502 -8.725 7.721 
Control Contralateral (mg/cm2) -0.727 5.270 0.878 0.827 (0.41) -0.434 -4.944 4.075 
 
Figure 4.3, 4.4 and table 4.4 show the cortical sBMD data compared to baseline 
(pre-op/first appointment from table 4.2) for both the contralateral and ipsilateral 
hip. The control group as expected shows a low range of changes (-0.386 %, 
0.236 %, -0.307 %, -0.434 %). The rTKR ipsilateral has a six week change of -
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1.249 %, at six months this loss reaches -1.429 % and -1.735 at 12 months. 
The rTKR contralateral side has a six week change of 0.011 % but this 
decreases at three months (-1.144 %) at six months this loss has increased to -
1.491 %, at 12 months this loss has been reduced to -0.391 %. The TKR shows 
a statistical significant and steady loss throughout the visits on the ipsilateral 
side, at six months there is a reported loss of -2.360 % (p-value 0.01), at 12 
months this loss is reported as -2.139 % (p-value 0.06). The TKR contralateral 
side shows a decline at six weeks, six months, and at 12 months. All three 
groups show a similar change at 12 months on the contralateral side when 
compared to baseline figures. 
Figure 4.5. Shows the difference in cortical sBMD between the ipsilateral vs 
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Table 4.5. Shows the difference in cortical sBMD between ipsilateral and 
contralateral data, including percentage difference, CI (95 %), t-test, and p-
value (there was no data collected for 6 week and 3 month control data, and 
none for 3 month TKR data) 
 









95 % CI   
rTKR (mg/cm2) -5.179 9.725 1.871 2.767 (0.01) -2.940 -8.729 2.850 
TKR (mg/cm2) -3.158 8.679 1.245 1.745 (0.09) -1.855 -6.691 2.980 
Control (mg/cm2) 0.110 8.354 1.635 -0.088 (0.93) 0.067 -4.367 4.501 
 









95 % CI   
rTKR (mg/cm2) -6.337 10.673 2.589 2.448 (0.03) -3.504 -12.568 5.559 
TKR (mg/cm2) -4.245 7.689 1.985 2.139 (0.05) -2.558 -9.039 3.923 
Control (mg/cm2) - - - - - - - 
 









95 % CI   
rTKR (mg/cm2) -4.031 8.138 1.974 2.042 (0.06) -2.255 -10.929 6.420 
TKR (mg/cm2) - - - - - - - 
Control (mg/cm2) - - - - - - - 
 









95 % CI   
rTKR (mg/cm2) -4.951 8.938 2.389 2.072 (0.06) -2.887 -12.353 6.579 
TKR (mg/cm2) -5.602 7.240 1.756 3.190 (0.00) -3.309 -9.513 2.895 
Control (mg/cm2) -1.016 9.102 1.388  0.732 (0.47) -0.619 -5.135 3.898 
 









95 % CI   
rTKR (mg/cm2) -5.109 13.499 5.511 0.927 (0.39) -2.903 -12.816 7.010 
TKR (mg/cm2) -5.849 8.565 2.212 2.645 (0.02) -3.421 -10.112 3.269 
Control (mg/cm2) -0.317 8.003 1.334 0.237 (0.81) -0.190 -4.918 4.538 
 
Figure 4.5 and table 4.5 show the cortical sBMD bone across the three groups 
with the ipsilateral compared to the contralateral. In the control group there is a 
lack of difference or fluctuation a pre-op/first appointment 0.067 % difference 
and a reported difference of -0.190 % at 12 months. In the TKR group it was 
reported as a difference in the ipsilateral of -1.855 % pre-op, and in the rTKR 
side it was reported as a difference of -2.940 % (p-value 0.01). This trend 
continues in the rTKR group with a reported difference at six weeks of -3.504 % 
(p-value 0.03) (-2.558 % (p-value 0.05) in the TKR group), this difference 
continues in the six and 12 month TKR data (-3.309 % (p-value 0.00) and -
3.421 % (p-value 0.02) respectively), this is similar in the rTKR group (-2.887 % 
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and -2.903 % for six and 12 months. 
 
4.5.3 TRABECULAR vBMD BONE RESULTS 
 
Figure 4.6. Shows the trabecular vBMD changes in the ipsilateral hip across the 




Figure 4.7. Shows the trabecular vBMD changes in the contralateral hip across 
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Table 4.6. Shows the data compared to baseline for the trabecular vBMD, 
including percentage change, CI (95 %), and the t-test and p-value (there was 
no data collected for 6 week and 3 month control data, and none for 3 month 
TKR data) 









95 % CI   
rTKR (mg/cm3) 0.640 10.656 2.584 -0.248 (0.81) 0.365 -14.542 15.273 
TKR (mg/cm3) -3.305 8.977 2.318 1.426 (0.18) -1.968 -11.943 8.007 
Control (mg/cm3) - - - - - - - 
rTKR Contralateral (mg/cm3) -0.721 7.325 1.777 0.406 (0.69) -0.398 -15.513 14.717 
TKR Contralateral (mg/cm3) 0.470 8.025 2.072 -0.227 (0.82) 0.274 -10.257 10.805 
Control Contralateral (mg/cm3) - - - - - - - 
 









95 % CI   
rTKR (mg/cm3) 1.800 10.671 2.588 -0.696 (0.50) 1.028 -14.093 16.149 
TKR (mg/cm3) - - - - - - - 
Control (mg/cm3) - - - - - - - 
rTKR Contralateral (mg/cm3) 0.471 8.131 1.972 -0.239 (0.81) 0.260 -13.992 14.512 
TKR Contralateral (mg/cm3) - - - - - - - 
Control Contralateral (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -0.535 7.055 1.885 0.284 (0.78) -0.331 -17.851 17.190 
TKR (mg/cm3) -4.617 9.016 2.187 2.111 (0.05) -2.640 -12.322 7.043 
Control (mg/cm3) 0.223 13.846 2.112  -0.106 (0.91) 0.136 -7.666 7.937 
rTKR Contralateral (mg/cm3) -3.502 12.206 3.262 1.074 (0.30) -2.095 -18.981 14.791 
TKR Contralateral (mg/cm3) 4.554 7.448 1.806  -2.521 (0.02) 2.575 -8.606 13.757 
Control Contralateral (mg/cm3) -1.850 5.922 0.903  2.049 (0.05) -1.124 -9.079 6.831 
 









95 % CI   
rTKR (mg/cm3) 4.387 11.032 4.170 -1.052 (0.33) 2.477 -13.740 18.695 
TKR (mg/cm3) -4.605 10.240 2.644 1.742 (0.10) -2.579 -13.403 8.245 
Control (mg/cm3) -1.750 8.126 1.354 1.292 (0.20) -1.029 -8.748 6.690 
rTKR Contralateral (mg/cm3) -4.359 4.074 1.663 2.621 (0.04) -2.347 -19.249 14.555 
TKR Contralateral (mg/cm3) 2.496 6.784 1.752 -1.425 (0.18) 1.394 -10.716 13.504 
Control Contralateral (mg/cm3) -1.762 6.477 1.080  1.632 (0.11) -1.032 -8.418 6.353 
 
In figure 4.6, 4.7 and table 4.6 the trabecular vBMD data was compared to the 
baseline of ipsilateral and contralateral hips (table 4.3). One of the largest 
increases is reported in the rTKR ipsilateral group at 12 months; with an 
increase of 2.477 %, although prior to this there was a loss reported at six 
months (-0.331 %) but an increase at six weeks (0.365 %) and three months 
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(1.028 %). The contralateral side of rTKR follows a similar trend with a loss at 
six weeks and a small increase at three months, although at six and 12 months  
both report large losses (-2.095 % and -2.347 % (p-value 0.04)) in contradiction 
with the rTKR ipsilateral increase at 12 months. The TKR ipsilateral shows a 
similar trend to the rTKR contralateral side with large losses at six months (-
2.640 % p-value 0.05) and at 12 months (-2.579 %), as oppose to increases in 
the contralateral TKR side reported as 2.575 % (p-value 0.02) and 1.394 % at 
both the six and 12 month visits respectively. The control group reported six 
month differences of -1.124 % (contralateral) and 0.136 % (ipsilateral) although 
these figures are of nearly equal difference at 12 months, reported as -1.032 % 
and -1.029 %. 
 
Figure 4.8. Shows the trabecular vBMD difference between ipsilateral and 
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Table 4.7. Shows the difference in trabecular vBMD between ipsilateral and 
contralateral data, including percentage difference, CI (95 %), t-test, and p-
value (there was no data collected for 6 week and 3 month control data, and 
none for 3 month TKR data) 
 









95 % CI   
rTKR (mg/cm3) -7.120 12.782 2.460 2.894 (0.01) -4.055 -14.590 6.481 
TKR (mg/cm3) -0.985 14.907 3.108 0.317 (0.75) -0.567 -9.883 8.750 
Control (mg/cm3) -0.228 11.596 1.729 0.132 (0.90) -0.138 -7.665 7.389 









95 % CI   
rTKR (mg/cm3) -4.687 20.546 4.983 0.941 (0.36) -2.597 -17.065 11.871 
TKR (mg/cm3) -7.394 16.126 4.164 1.776 (0.10) -4.299 -14.037 5.439 
Control (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -4.719 16.900 4.099 1.151 (0.27) -2.598 -17.176 11.981 
TKR (mg/cm3) - - - - - - - 
Control (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -2.302 12.008 3.209 0.717 (0.49) -1.406 -18.737 15.925 
TKR (mg/cm3) -11.115 16.592 4.024 2.762 (0.01) -6.127 -15.463 3.208 
Control (mg/cm3) 1.948 20.653 3.149 -0.618 (0.54) 1.197 -6.688 9.081 









95 % CI   
rTKR (mg/cm3) 0.074 24.264 9.906 -0.007 (0.99) 0.041 -15.791 15.872 
TKR (mg/cm3) -7.636 14.471 3.736 2.044 (0.06) -4.206 -14.849 6.4371 
Control (mg/cm3) -0.547 12.557 2.093 0.261 (0.80) -0.324 -8.0977 7.4503 
  
Figure 4.8 and table 4.7 show the differences in trabecular vBMD with ipsilateral 
compared to contralateral hips. The control group maintains a difference for all 
visits (-0.138 %, 1.197 %, -0.324 %), all within the SE of a recorded zero 
difference for trabecular vBMD. For the other two group at pre-op the data 
states: -4.055 % difference for the rTKR group and -0.567 % for the TKR group. 
The rTKR ipsilateral group shows a reported mean difference of -4.055 % (p-
value 0.01) pre-op, -2.597 % at six weeks, -2.598 % at three months, -1.406 % 
at six months, and a difference of 0.041 % at 12 months. For the TKR group the 
difference is reported as -4.299 % (p-value 0.10) at three months and then -
6.127 % at six months (p-value 0.01), at 12 months this difference is reported 
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as -4.206 % (p-value 0.06). 
 
4.5.4 INTEGRAL vBMD RESULTS 
Figure 4.9. Shows the integral vBMD changes in ipsilateral hip across the three 
groups (error bars are SE) over 12 months 
 
 
 Figure 4.10. Shows the integral vBMD changes in the contralateral hip across 
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Table 4.8. Shows the data compared to baseline for the integral vBMD, 
including percentage change, CI (95 %), and the t-test and p-value (there was 
no data collected for 6 week and 3 month control data, and none for 3 month 
TKR data) 









95 % CI   
rTKR (mg/cm3) -1.624 6.686 1.622 1.001 (0.33) -0.500 -10.322 9.323 
TKR (mg/cm3) -5.583 9.709 2.507 2.227 (0.04) -1.706 -8.251 4.840 
Control (mg/cm3) - - - - - - - 
rTKR Contralateral (mg/cm3) -0.836 9.827 2.383 0.351 (0.73) -0.250 -9.564 9.063 
TKR Contralateral (mg/cm3) -0.994 11.299 2.918 0.341 (0.74) -0.301 -7.108 6.507 
Control Contralateral (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) 0.443 13.671 3.316 -0.134 (0.90) 0.136 -9.338 9.611 
TKR (mg/cm3) - - - - - - - 
Control (mg/cm3) - - - - - - - 
rTKR Contralateral (mg/cm3) -2.192 9.302 2.256 0.972 (0.35) -0.656 -9.992 8.680 
TKR Contralateral (mg/cm3) - - - - - - - 
Control Contralateral (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -2.997 7.486 2.001 1.498 (0.16) -0.965 -11.750 9.820 
TKR (mg/cm3) -7.726 8.644 2.097  3.685 (0.00) -2.300 -8.733 4.132 
Control (mg/cm3) 1.012 25.135 3.833  -0.264 (0.79) 0.314 -5.189 5.816 
rTKR Contralateral (mg/cm3) -6.829 15.177 4.056 1.684 (0.12) -2.135 -12.916 8.647 
TKR Contralateral (mg/cm3) 1.951 10.941 2.653  -0.735 (0.47) 0.575 -7.339 8.488 
Control Contralateral (mg/cm3) -1.020 6.171 0.941  1.084 (0.28) -0.317 -5.734 5.099 









95 % CI   
rTKR (mg/cm3) 1.159 7.771 2.937 -0.394 (0.71) 0.358 -10.641 11.357 
TKR (mg/cm3) -7.977 8.940 2.308 3.456 (0.00) -2.344 -9.556 4.867 
Control (mg/cm3) -1.368 10.830 1.805 0.758 (0.45) -0.416 -5.888 5.056 
rTKR Contralateral (mg/cm3) -4.669 3.650 1.490 3.133 (0.02) -1.393 -11.939 9.153 
TKR Contralateral (mg/cm3) -0.382 10.038 2.592 0.147 (0.88) -0.111 -8.780 8.558 
Control Contralateral (mg/cm3) -1.773 8.243 1.374  1.290 (0.20) -0.539 -5.763 4.685 
 
Figure 4.9, 4.10 and table 4.8 show integral vBMD compared to the baseline 
visit for the ipsilateral and contralateral hips. TKR ipsilateral at six weeks report 
a loss, this loss steadily continues at six and 12 months, accumulating in the 
highest loss reported across all group (-2.344 % p-value 0.00). The contralateral 
TKR hip shows a small loss at six weeks (-0.301 %) first, with an increase then 
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reported at six months (0.575 %) and a minimal loss again at 12 months (-0.111 
%). The control group is around the zero figure including SE with the 12 month 
data reporting both the ipsilateral and contralateral hips having a loss of -0.416 
% and -0.539 % respectively. The rTKR ipsilateral side shows both non-
statistically significant increases and decreases throughout the visits with it 
reaching a reported 0.358 % at 12 months. The contralateral rTKR shows a loss 
across all four visits, with the largest loss reported at 6 months as -2.135 % (p-
value 0.10). 
 
Figure 4.11. Shows integral vBMD difference between ipsilateral vs contralateral 
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Table 4.9. Shows the difference in integral vBMD between ipsilateral and 
contralateral data, including percentage difference, CI (95 %), t-test, and p-
value (there was no data collected for 6 week and 3 month control data, and 
none for 3 month TKR data) 
 









95 % CI   
rTKR (mg/cm3) -9.988 12.559 2.417 4.132 (0.00) -3.055 -9.815 3.705 
TKR (mg/cm3) -2.923 18.887 3.938 0.742 (0.47) -0.874 -6.677 4.929 
Control (mg/cm3) 1.377 14.676 2.188 -0.629 (0.53) 0.429 -4.864 5.721 









95 % CI   
rTKR (mg/cm3) -10.073 12.917 3.133 3.215 (0.01) -3.022 -12.595 6.552 
TKR (mg/cm3) -8.120 20.756 5.359 1.515 (0.15) -2.461 -8.956 4.034 
Control (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -6.650 16.314 3.957 1.681 (0.11) -2.003 -11.275 7.269 
TKR (mg/cm3) - - - - - - - 
Control (mg/cm3) - - - - - - - 









95 % CI   
rTKR (mg/cm3) -5.597 13.111 3.504 1.597 (0.13) -1.788 -12.483 8.908 
TKR (mg/cm3) -13.178 23.582 5.720 2.304 (0.03) -3.861 -10.191 2.469 
Control (mg/cm3) 3.280 29.565 4.509  -0.728 (0.47) 1.024 -4.518 6.566 
 









95 % CI   
rTKR (mg/cm3) -5.670 11.586 4.730 1.199 (0.28) -1.716 -12.487 9.056 
TKR (mg/cm3) -10.667 20.776 5.364  1.988 (0.07) -3.110 -10.265 4.0451 
Control (mg/cm3) 0.294 15.455 2.576 -0.114 (0.91) 0.090 -5.4101 5.5898 
 
Figure 4.11 and table 4.9 show Integral vBMD results of ipsilateral compared to 
contralateral hips. At pre-op rTKR reported difference of -3.055 % (p-value 0.00) 
after pre-op the integral vBMD difference is–3.022 % (p-value 0.01) at six 
weeks, -2.003 % (p-value 0.11) at three months, -1.788 % at six months and -
1.716 % at 12 months. The TKR group had a reported difference of -2.461 % (p-
value 0.15) at six weeks, -3.861 % (p-value 0.03) at six months and then -3.110 
% (p-value 0.07) at 12 months. The control data are still all within the overlap of 
0 via the SE for all appointment dates, with the highest difference reported at six 




4.5.5 CSMI RESULTS 
Figure 4.12. Shows CSMI changes in the ipsilateral neck region across the 
three groups (error bars are SE) over 12 months 
 
Figure 4.13. Shows CSMI changes in the ipsilateral hip in the intertrochanteric 








































Baseline         6 weeks       3 months           6 months           12 months
Ipsilateral vs baseline measuring CSMI in the neck 
region across 3 groups



































Baseline             6 weeks           3 months         6 months            12 months
Ipsilateral vs baseline measuring CSMI in the 
intertrochanteric region across 3 groups
intertroch rTKR intertroch TKR intertroch control
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Table 4.10. Shows the data compared to baseline for the CSMI, including 
percentage change, CI (95 %), and the t-test and p-value (there was no data 
collected for 6 week and 3 month control data, and none for 3 month TKR data) 
 









95 % CI 
  
neck rTKR (cm4) 0.083 0.205 0.050 -1.661 (0.12) 3.905 -16.472 24.283 
neck TKR (cm4) -0.024 0.104 0.027  0.908 (0.38) -1.858 -15.813 12.097 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) -0.144 0.505 0.123 1.173 (0.26) -1.388 -20.996 18.220 
intertroch TKR (cm4) -0.143 0.237 0.061  2.330 (0.04) -2.597 -17.637 12.444 
intertroch control (cm4) - - - - - - - 









95 % CI 
  
neck rTKR (cm4) -0.035 0.379 0.092 0.385 (0.71) -1.674 -22.336 18.988 
neck TKR (cm4) - - - - - - - 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) -0.229 1.094 0.265 0.863 (0.40) -2.211 -23.652 19.229 
intertroch TKR (cm4) - - - - - - - 
intertroch control (cm4) - - - - - - - 









95 % CI 
  
neck rTKR (cm4) -0.003 0.204 0.054 0.046 (0.96) -0.128 -24.122 23.866 
neck TKR (cm4) -0.028 0.097 0.024 1.200 (0.25) -2.179 -13.392 9.033 
neck control (cm4) -0.039 0.327 0.050 0.781 (0.44) -2.815 -10.703 5.073 
intertroch rTKR (cm4) -0.115 0.258 0.069 1.672 (0.12) -1.238 -26.769 24.293 
intertroch TKR (cm4) -0.103 0.221 0.054  1.921 (0.07) -1.882 -13.485 9.721 
intertroch control (cm4) -0.149 1.134 0.173  0.862 (0.39) -2.542 -10.991 5.907 









95 % CI 
  
neck rTKR (cm4) -0.088 0.217 0.082 1.069 (0.33) -4.325 -18.091 9.442 
neck TKR (cm4) -0.001 0.077 0.020 0.035 (0.97) -0.053 -11.878 11.772 
neck control (cm4) -0.069 0.254 0.042 1.630 (0.11) -4.734 -11.694 2.226 
intertroch rTKR (cm4) -0.329 0.488 0.185 1.784 (0.12) -3.226 -21.382 14.931 
intertroch TKR (cm4) -0.006 0.289 0.075 0.083 (0.94) -0.113 -12.987 12.762 
intertroch control (cm4) -0.085 0.858 0.143 0.593 (0.56) -1.377 -9.198 6.444 
 
Figures 4.12, 4.13 and table 4.10 show the CSMI ipsilateral hip compared to the 
baseline, the greatest loss reported in the rTKR group is reported in the neck 
region, reported as -4.325 % at 12 months. The highest positive figure across 
all groups was reported in the rTKR in the neck at six weeks reported as 3.905 
% (p-value 0.12). The control data cross the SE for the 0 value in three of the 
four data reported, although this is small (-0.069 cm4), there is a reported loss of 
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-4.734 % (p-value 0.11) in the femoral neck at 12 months which is the highest 
change in the neck reported. At 12 months the TKR intertrochanteric group 
show a positive gain as the rTKR intertrochanteric group shows a large decline.  
Figure 4.14. Shows CSMI changes in the contralateral neck region across the 
three groups (error bars are SE) over 12 months 
 
Figure 4.15. Shows CSMI changes in the contralateral hip in the 
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Contralateral hip vs baseline measuring CSMI in the 
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Baseline                6 weeks           3 months            6 months         12 months
Contralateral hip vs baseline measuring CSMI in the 
intertrochanteric region across 3 groups
intertroch rTKR intertroch TKR intertroch control
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Table 4.11. Shows the data compared to baseline for the CSMI, including 
percentage change, CI (95 %), and the t-test and p-value (there was no data 
collected for 6 week and 3 month control data, and none for 3 month TKR data) 









95 % CI   
neck rTKR (cm4) -0.011 0.151 0.037 0.294 (0.77) -0.488 -17.862 16.886 
neck TKR (cm4) 0.017 0.080 0.021  -0.805 (0.43) 1.288 -12.886 15.462 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) -0.009 0.775 0.188 0.046 (0.96) -0.085 -17.227 17.056 
intertroch TKR (cm4) 0.019 0.191 0.049  -0.375 (0.71) 0.322 -13.999 14.642 
intertroch control (cm4) - - - - - - - 









95 % CI   
neck rTKR (cm4) 0.039 0.178 0.043 -0.903 (0.38) 1.770 -15.453 18.992 
neck TKR (cm4) - - - - - - - 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) 0.116 0.607 0.147 -0.785 (0.44) 1.144 -16.933 19.222 
intertroch TKR (cm4) - - - - - - - 
intertroch control (cm4) - - - - - - - 









95 % CI   
neck rTKR (cm4) 0.124 0.483 0.129 -0.961 (0.35) 6.007 -18.416 30.430 
neck TKR (cm4) -0.010 0.068 0.016  0.614 (0.55) -0.780 -10.013 8.453 
neck control (cm4) 0.015 0.064 0.010  -1.506 (0.14) 1.076 -5.897 8.048 
intertroch rTKR (cm4) -0.313 0.894 0.239 1.312 (0.21) -3.423 -27.345 20.498 
intertroch TKR (cm4) 0.104 0.245 0.059 -1.745 (0.10) 1.783 -10.289 13.855 
intertroch control (cm4) -0.022 0.220 0.033  0.659 (0.51) -0.372 -8.530 7.786 









95 % CI   
neck rTKR (cm4) 0.050 0.066 0.027 -1.840 (0.12) 2.403 -8.886 13.692 
neck TKR (cm4) -0.016 0.049 0.013 1.277 (0.22) -1.257 -12.053 9.539 
neck control (cm4) -0.007 0.072 0.012 0.591 (0.56) -0.501 -7.669 6.668 
intertroch rTKR (cm4) 0.056 0.309 0.126 -0.444 (0.67) 0.567 -12.960 14.094 
intertroch TKR (cm4) 0.047 0.191 0.049  -0.948 (0.36) 0.805 -12.058 13.667 
intertroch control (cm4) -0.021 0.242 0.040 0.520 (0.61) -0.339 -8.516 7.837 
 
Figure 4.14, 4.15 and table 4.11 shows the CSMI contralateral hip in every 
group compared to the baseline. The majority of the results show a positive 
increase compared to the baseline hip score. The highest being a change of 
6.007 % (p-value 0.35) in the neck region at six months in the rTKR group, 
which is also the time period and group in which the greatest loss is reported; 
reported as -3.423 % (p-value 0.21) in the intertrochanteric region, although this 
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loss is regained at 12 months with an increase to 0.567 %. The control group 
shows no statistically difference across all visits and regions. 
Figure 4.16. Shows the CSMI differences between ipsilateral and contralateral 




Figure 4.17. Shows the CSMI differences between ipsilateral and contralateral 
hips in the intertrochanteric region across the three groups (error bars are SE) 
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intertrochanteric region across 3 groups
intertroch rTKR intertroch TKR intertroch control
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Table 4.12. Shows the difference in CSMI between ipsilateral and contralateral 
data, including percentage difference, CI (95 %), t-test, and p-value (there was 
no data collected for 6 week and 3 month control data, and none for 3 month 
TKR data)  
 









95 % CI   
neck rTKR (cm4) -0.095 0.276 0.053 1.783 (0.09) -4.579 -17.574 8.417 
neck TKR (cm4) 0.021 0.134 0.028 -0.753 (0.46) 1.552 -9.452 12.556 
neck control (cm4) 0.015 0.264 0.039 -0.383 (0.70) 1.100 -6.412 7.512 
intertroch rTKR (cm4) -0.167 1.623 0.31 0.533 (0.60) -1.745 -18.616 15.125 
intertroch TKR (cm4) -0.260 0.521 0.11 2.393 (0.03) -4.319 -14.316 5.669 
intertroch control (cm4) -0.078 1.103 0.16 0.474 (0.64) -1.314 -10.942 8.314 









95 % CI   
neck rTKR (cm4) 0.003 0.29 0.070 -0.048 (0.96) 0.155 -19.487 19.797 
neck TKR (cm4) -0.023 0.145 0.037  0.612 (0.55) -1.738 -15.709 12.234 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) 0.120 1.107 0.269 -0.447 (0.66) 1.189 -18.932 21.310 
intertroch TKR (cm4) -0.418 0.398 0.103  4.068 (0.00) -7.242 -21.565 7.082 
intertroch control (cm4) - - - - - - - 









95 % CI   
neck rTKR (cm4) -0.165 0.460 0.112 1.475 (0.16) -7.326 -26.800 12.148 
neck TKR (cm4) - - - - - - - 
neck control (cm4) - - - - - - - 
intertroch rTKR (cm4) -0.089 1.293 0.313 0.285 (0.78) -0.876 -22.609 20.858 
intertroch TKR (cm4) - - - - - - - 
intertroch control (cm4) - - - - - - - 









95 % CI   
neck rTKR (cm4) -0.227 0.658 0.176 1.289 (0.22) -10.343 -31.883 11.197 
neck TKR (cm4) -0.017 0.157 0.038  0.437 (0.67) -1.300 -12.613 10.014 
neck control (cm4) -0.040 0.224 0.034 1.162 (0.25) -2.874 -10.757 5.009 
intertroch rTKR (cm4) 0.352 0.945 0.253 -1.395 (0.19) 3.984 -22.897 30.865 
intertroch TKR (cm4) -0.554 0.516 0.125 4.422 (0.00) -9.348 -20.068 1.372 
intertroch control (cm4) -0.196 0.598 0.091 2.149 (0.04) -3.317 -11.699 5.065 









95 % CI   
neck rTKR (cm4) -0.172 0.226 0.092 1.861 (0.11) -8.113 -21.334 5.109 
neck TKR (cm4) 0.021 0.155 0.040 -0.526 (0.61) 1.647 -10.379 13.673 
neck control (cm4) -0.024 0.161 0.027  0.897 (0.38) -1.704 -8.885 5.478 
intertroch rTKR (cm4) -0.043 1.166 0.476 0.090 (0.93) -0.434 -19.114 18.246 
intertroch TKR (cm4) -0.358 0.526 0.136 2.639 (0.02) -6.116 -18.217 5.984 
intertroch control (cm4) -0.095 0.544 0.091 1.049 (0.30) -1.541 -9.350 6.267 
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The data in figures 4.16, 4.17 and table 4.12. The control group show the least 
amount of difference between the ipsilateral and contralateral, although a figure 
at six months reports a difference of  -2.874 % (p-value 0.25) in the femoral 
neck and -3.317 (p-value 0.04) in the intertrochanteric region, both of these are 
at six months. Interestingly at six months we also see some of the biggest 
differences of CSMI; reported as -10.343 % (p-value 0.22) (neck) and 3.984 % 
(p-value 0.19) (intertrochanteric) in the rTKR group, and -9.348 % (p-value 0.00) 
(intertrochanteric) in the TKR group.  
 
4.5.6 CSA RESULTS 
Figure 4.18. Shows CSA changes in the ipsilateral neck region across the three 








































Baseline                   6 weeks                  3 months            6 months                  12 months
Ipsilateral vs baseline hip measuring CSA in the neck 
across 3 groups




Figure 4.19. Shows CSA changes in the ipsilateral intertrochanteric region in all 























































Baseline             6 weeks                3 months            6 months                  12 months
Ipsilateral vs baseline hip measuring CSA in the 
intertrochanteric region across 3 groups
intertroch rTKR intertroch TKR intertroch control
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Table 4.13. Shows the data compared to baseline for the CSA, including 
percentage change, CI (95 %), and the t-test and p-value (there was no data 
collected for 6 week and 3 month control data, and none for 3 month TKR data) 









95 % CI   
neck rTKR (cm2) 0.026 0.065 0.016 -1.668 (0.11) 2.132 -11.609 15.873 
neck TKR (cm2) -0.017 0.056 0.014 1.204 (0.25) -1.649 -11.383 8.084 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.018 0.066 0.016 1.137 (0.27) -0.815 -16.077 14.446 
intertroch TKR (cm2) -0.032 0.060 0.015  2.060 (0.06) -1.922 -13.197 9.353 
intertroch control (cm2) - - - - - - - 
 









95 % CI   
neck rTKR (cm2) 0.000 0.083 0.020 0.020 (0.98) 0.032 -13.813 13.877 
neck TKR (cm2) - - - - - - - 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.015 0.099 0.024 0.611 (0.55) -0.652 -16.895 15.590 
intertroch TKR (cm2) - - - - - - - 
intertroch control (cm2) - - - - - - - 
 









95 % CI   
neck rTKR (cm2) -0.017 0.083 0.022 0.766 (0.46) -1.446 -16.799 13.907 
neck TKR (cm2) -0.027 0.042 0.010 2.583 (0.02) -2.510 -10.381 5.361 
neck control (cm2) -0.014 0.118 0.018 0.761 (0.45) -1.325 -7.401 4.752 
intertroch rTKR (cm2) -0.017 0.050 0.013 1.238 (0.24) -0.810 -19.298 17.678 
intertroch TKR (cm2) -0.043 0.055 0.013 3.218 (0.01) -2.528 -12.003 6.946 
intertroch control (cm2) -0.031 0.150 0.023  1.375 (0.18) -1.838 -8.852 5.177 
 









95 % CI   
neck rTKR (cm2) -0.027 0.046 0.017 1.593 (0.16) -2.260 -14.678 10.158 
neck TKR (cm2) -0.013 0.040 0.010  1.286 (0.22) -1.254 -10.136 7.627 
neck control (cm2) -0.024 0.084 0.014 1.705 (0.10) -2.229 -7.946 3.489 
intertroch rTKR (cm2) -0.023 0.055 0.021 1.136 (0.30) -1.045 -16.096 14.006 
intertroch TKR (cm2) -0.026 0.072 0.019 1.400 (0.83) -1.520 -12.066 9.026 
intertroch control (cm2) -0.028 0.115 0.019  1.456 (0.15) -1.560 -8.122 5.003 
 
Figure 4.18, 4.19 and table 4.13 show the CSA change in the ipsilateral hip 
compared to baseline across all three groups. The largest increase was seen in 
the six week data of the rTKR in the femoral neck an increase of 2.132 % (p-
value 0.11) at three months there is a beginning of a decline; reported as 0.032 
%, at six months this loss is -1.446 % with the greatest loss reported at -2.260 
% (p-value 0.16) at the 12 month visit. In the rTKR group the intertrochanteric 
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region shows a similar but smaller decline; three months reported as -0.652 %, 
six months -0.810 % and 12 months -1.045 %. The TKR group reports its 
greatest loss at six months reported as -2.510 % (p-value 0.02) (neck) and -
2.528 % (p-value 0.01) (intertrochanteric), at 12 months there is a recovery but 
still a loss (-1.254 % neck, and -1.520 % intertrochanteric). Again, the highest 
loss in the control group are reported as -1.325 % (neck) and -1.838 % 
(intertrochanteric) at six months, and -2.229 % (p-value 0.10) (neck) and -1.560 
% (intertrochanteric).  
 
Figure 4.20. Shows CSA changes in the contralateral neck region across the 
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Figure 4.21. Shows CSA changes in the contralateral intertrochanteric region 























Table 4.14. Shows the data compared to baseline for the CSA, including 
percentage change, CI (95 %), and the t-test and p-value (there was no data 
collected for 6 week and 3 month control data, and none for 3 month TKR data) 









95 % CI   
neck rTKR (cm2) -0.003 0.054 0.013 0.263 (0.80) -0.266 -12.268 11.736 
neck TKR (cm2) 0.012 0.051 0.013 -0.944 (0.36) 1.204 -9.057 11.465 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.005 0.110 0.027 0.175 (0.86) -0.205 -14.228 13.818 
intertroch TKR (cm2) 0.001 0.064 0.017 -0.072 (0.94) 0.070 -10.928 11.067 
intertroch control (cm2) - - - - - - - 
 









95 % CI   
neck rTKR (cm2) 0.007 0.061 0.015 -0.499 (0.62) 0.565 -10.994 12.124 
neck TKR (cm2) - - - - - - - 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.009 0.775 0.188 -0.454 (0.66) 0.463 -14.019 14.945 
intertroch TKR (cm2) - - - - - - - 
intertroch control (cm2) - - - - - - - 
 









95 % CI   
neck rTKR (cm2) -0.010 0.057 0.015 0.632 (0.54) -0.777 -13.767 12.212 
neck TKR (cm2) 0.006 0.042 0.010 -0.627 (0.54) 0.616 -7.396 8.628 
neck control (cm2) 0.003 0.030 0.005 -0.731 (0.47) 0.330 -4.871 5.530 
intertroch rTKR (cm2) -0.026 0.080 0.021 1.222 (0.24) -1.248 -17.992 15.496 
intertroch TKR (cm2) 0.023 0.056 0.014 -1.676 (0.11) 1.306 -8.878 11.490 
intertroch control (cm2) -0.007 0.042 0.006  1.052 (0.30) -0.395 -7.197 6.408 
 









95 % CI   
neck rTKR (cm2) 0.001 0.028 0.012 -0.088 (0.93) 0.080 -10.150 10.309 
neck TKR (cm2) -0.009 0.034 0.009 1.013 (0.33) -0.848 -9.773 8.076 
neck control (cm2) -0.006 0.039 0.007 0.882 (0.38) -0.543 -5.628 4.541 
intertroch rTKR (cm2) -0.014 0.029 0.012 1.189 (0.28) -0.629 -14.344 13.086 
intertroch TKR (cm2) 0.007 0.056 0.014 -0.466 (0.65) 0.383 -10.780 11.546 
intertroch control (cm2) -0.013 0.049 0.008  1.606 (0.12) -0.733 -7.097 5.632 
 
Figure 4.20, 4.21 and table 4.14 show the CSA change in the contralateral hip 
compared to the baseline measurement for each group. The greatest loss is 
reported by rTKR group in the intertrochanteric region of -1.248 % at six 
months, with the greatest reported as 1.306 % in the intertrochanteric region of 
the TKR group. At 12 months across all groups (in both the neck and 









































Pre-op                   6 weeks                 3 months                6 months                12 months
Ipsilateral vs contralateral hip measuring CSA in the 
intertrochanteric region across 3 groups
intertroch rTKR intertroch TKR intertroch control
-0.848 %, -0.543 %, -0.629 %, 0.383 %, and -0.733 %.  
Figure 4.22. Shows CSA differences between ipsilateral and contralateral in the 
















Figure 4.23. Shows CSA differences between ipsilateral and contralateral in the 








































Pre-op                   6 weeks                     3 months            6 months               12 months
Ipsilateral vs contralateral hip measuring CSA in the 
neck across 3 groups
neck rTKR neck TKR neck control
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Table 4.15. Shows the difference in CSA between ipsilateral and contralateral 
data, including percentage difference, CI (95 %), t-test, and p-value (there was 
no data collected for 6 week and 3 month control data, and none for 3 month 
TKR data) 
 









95 % CI   
neck rTKR (cm2) -0.052 0.092 0.018  2.938 (0.01) -4.190 -12.150 3.770 
neck TKR (cm2) 0.024 0.070 0.015 -1.689 (0.11) 2.328 -5.676 10.331 
neck control (cm2) 0.001 0.099 0.015 -0.087 (0.93) 0.124 -5.540 5.789 
intertroch rTKR (cm2) -0.080 0.201 0.04  2.065 (0.05) -3.701 -15.006 7.604 
intertroch TKR (cm2) -0.036 0.121 0.03 1.412 (0.17) -2.040 -10.437 6.357 
intertroch control (cm2) -0.003 0.168 0.03 0.104 (0.92) -0.153 -10.942 8.314 
 









95 % CI   
neck rTKR (cm2) -0.025 0.101 0.025 1.019 (0.32) -1.933 -15.127 11.261 
neck TKR (cm2) -0.013 0.080 0.021 0.624 (0.54) -1.224 -11.000 8.551 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.047 0.146 0.035 1.312 (0.21) -2.052 -17.123 13.020 
intertroch TKR (cm2) -0.080 0.111 0.029  2.786 (0.01) -4.676 -15.635 6.283 
intertroch control (cm2) - - - - - - - 









95 % CI   
neck rTKR (cm2) -0.062 0.129 0.031 1.973 (0.07) -4.744 -17.927 8.440 
neck TKR (cm2) - - - - - - - 
neck control (cm2) - - - - - - - 
intertroch rTKR (cm2) -0.058 0.165 0.040 1.451 (0.17) -2.543 -18.476 13.391 
intertroch TKR (cm2) - - - - - - - 
intertroch control (cm2) - - - - - - - 
 









95 % CI   
neck rTKR (cm2) -0.062 0.096 0.026 2.436 (0.03) -5.122 -19.902 9.659 
neck TKR (cm2) -0.016 0.068 0.017 0.968 (0.35) -1.528 -9.479 6.422 
neck control (cm2) -0.015 0.102 0.015 0.945 (0.35) -1.419 -7.490 4.651 
intertroch rTKR (cm2) -0.033 0.114 0.030 1.092 (0.29) -1.606 -19.945 16.734 
intertroch TKR (cm2) -0.115 0.109 0.026 4.379 (0.00) -6.542 -15.627 2.542 
intertroch control (cm2) -0.024 0.117 0.018 1.377 (0.18) -1.440 -8.483 5.603 
 









95 % CI   
neck rTKR (cm2) -0.090 0.077 0.031  2.877 (0.03) -7.079 -18.885 4.728 
neck TKR (cm2) 0.011 0.070 0.018 -0.621 (0.54) 1.075 -8.016 10.166 
neck control (cm2) -0.011 0.077 0.013  0.858 (0.40) -1.044 -6.830 4.743 
intertroch rTKR (cm2) -0.031 0.084 0.034  0.913 (0.40) -1.400 -16.398 13.597 
intertroch TKR (cm2) -0.074 0.125 0.032  2.298 (0.04) -4.222 -14.479 6.034 
intertroch control (cm2) -0.014 0.112 0.019 0.738 (0.47) -0.778 -7.393 5.836 
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Figures 4.22, 4.23 and table 4.15 show the difference in CSA  between 
ipsilateral and contralateral hips, with the biggest difference of CSA reported in 
the rTKR group in the neck region reported as -7.079 % (p-value 0.03) at 12 
months. In the pre-op in the neck of femur in the TKR group the difference is 
reported as 2.328 % (p-value 0.11) with further differences reported at six 
weeks (-1.224 %) and six months (-1.528 %) until reaching a final difference of 
1.075 % at 12 months. Similar to the CSMI result when investigating the 
difference between the ipsilateral and contralateral hips the control group shows 
no statically difference (all overlap 0 with their SE), except the two reported 
scores at six months -1.440 % (p-value 0.18) at the neck and -1.419 % (p-value 





4.6.1 CORTICAL SURFACE BMD 
The cortical surface BMD (sBMD) results when compared to baseline hip data 
show minimal changes across all control participants; this is the same in the hip 
comparison data. One study involving the 3D-SHAPER software [380] used 
control participants, although these were a much younger cohort of controls 
(mean age 33+/-10 years) their cortical sBMD (164+/-22 g/cm2) was similar to 
the control baseline scores reported in this study (163.86 g/cm2), although no 
longitudinal changes were investigated. Further to this, a study investigating 3D-
SHAPER and hip fracture association [381], reported controls of post-
menopausal women aged 68.8+/-8.9 years, weight 62.6+/-7.9, height 153.2+/-
6.4, BMI 26.7+/-3.3 (similar characteristics shared by our group, although our 
control group is taller). They reported a cortical sBMD of 138.1+/-19.9 mg/cm2 
which overlaps with the SD of our group 163.86+/-24.83 mg/cm2, although 
these differences might be related to regional, ethnicity or other co-founding 
factors. Unfortunately, there is limited data on 3D-SHAPER software, and no 
studies investigating longitudinal changes.      
 
Therefore, due to the limited 3D-SHAPER data, data investigating the BMD in 
the hip will be utilised (not directly cortical bone in this region). Changes 
reported in on study [23] described that the control group (who were matched to 
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participants undergoing TKR) reported a BMD loss of -0.89 % in the ipsilateral 
neck and -0.32 % in the total hip BMD over 12 months [23]. Additionally, 
research by Rao et al reports that there is no dominant hip, and that the left and 
right hip are highly correlated [382], this again supports the control comparison 
data showing minimal change.  
 
These control results are supportive in what we would expect to see a control 
group, supporting the idea that the software is accurate. Furthermore, this is 
contributed by a 3D-SHAPER precision study, which showed similarities 
between the software and areal BMD reported in DXA scans [383]. 
 
The rTKR ipsilateral group data reported a large loss of cortical bone at six 
weeks (-1.249 %) with losses continuing at three, six and 12 months (-1.735 %). 
The contralateral hip comparator data show a similar trend with cortical sBMD 
loss reported in all visits. The TKR group baseline data show a comparable 
declination to the rTKR data, reporting an ipsilateral hip loss of -1.911 % at six 
weeks, with this gradually decreasing until reaching -2.139 % at 12 months. The 
hip comparator TKR data again show a similar trend.  
 
Unfortunately there are no data reporting cortical BMD in the hips and rTKR, but 
there is research investigating TKA and BMD in the hip [26]. This research 
reported BMD losses of -2.7 % at 12 months post-surgery in the ipsilateral hip, 
and losses of -1.18 % in the contralateral hip [26].  Other research supports this 
loss, reporting a figure of -1.80 % [25] in the ipsilateral hip post TKR.  
 
Both the rTKR and TKR group show analogous changes in the cortical sBMD. 
This change is especially important given that a lack of cortical bone can 
increase fracture risk in both groups [384, 385], as it has been reported that 
thicker cortices contribute to greater mechanical strength, and with both groups 
reporting a loss of cortical bone there is an increase in associated hip fracture 
risk [384]. It has also been reported that identifying cortical thinning which this 






Furthermore, this loss might be due to the reported changes in cortical bone 
compared to trabecular bone, where trabecular bone turnover is higher than in 
cortical bone [76]. This change might be due to cortical bone not being under 
the same direct stressors as trabecular bone due to its more brittle structure 
[387]; cortical bone can only withstand strains (the deformity the bone can 
undergo) of around 2 %, with trabecular bone withstanding strains of 30 % 
[388], and is highly metabolically active with a higher surface area to volume 
ratio than cortical bone [389, 390]. Thus the majority of bone remodelling and 
turnover is conducted by the trabeculae even though it only makes up 20 % of 
the skeletal bone mass [365]. Additionally, there is also the impact of the 
inflammatory response slowing BMD recovery [391]. Therefore, this loss at 12 
months in both groups might be due to slower turnover of bone in the cortical 
area, with these participants possibly not recovering BMD until 24 months post-
surgery, as shown in the systematic review and Soininvaara et al data [26].  
 
4.6.2 TRABECULAR VOLUMETRIC BMD 
The trabecular volumetric BMD (vBMD) for the controls again shows minimal to 
no change between baseline and subsequent visits and for the comparison 
data, although there is a loss reported at 12 months in both the ipsilateral and 
contralateral sides compared to baseline (-1.029 % and -1.032 %), these losses 
might be due to precision or positional errors, but are more likely due to natural 
changes in BMD in post-menopausal women, in which hip BMD is reported to 
decline 1–1.4 % per year [307]. This loss is reported in the trabecular vBMD 
which supports the idea of the impact of bone turnover. Furthermore, a study 
utilising the 3D-SHAPER software [379] reported controls of a similar age, 
height, weight, and BMI as our control group, reporting a trabecular vBMD of 
136.1+/-38.5 mg/cm3 with our control group reporting a score of 164.51+/-42.38, 
again as previously stated this differences may be regional, due to the impact of 
surgery, or other variations within the two control groups. Unfortunately, there is 
no follow up for this control group so it is unknown if these change are mimicked 
directly in other groups.  
 
In the rTKR group recovery was seen immediately post-surgery in the ipsilateral 
hip, which continued throughout reporting a positive score by 12 months. The 
TKR group shows a post-surgery decline but reports some recovery between 
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six and 12 months. Investigating the comparison data, the BMD differences in 
the rTKR group are still shown, with a large positive difference at 12 months, 
showing an increase in trabeculae vBMD, the TKR group shows a steady loss 
throughout with a slight difference between six and 12 months, mimicking the 
baseline changes. 
 
This slow recovery in the TKR group agrees with the systematic review knee 
data regarding a lack of a plateau effect until at 24 months [26], as oppose to 12 
months. Although it is unclear if this was due to changes in cortical opposed to 
trabecular bone, especially as the TKR group showed a loss at 12 months in 
both the cortical and trabecular bone. Furthermore, the data gathered from the 
TKR group would agree with the data from the systematic review and the 
current available research [26] regarding the changes in BMD, which parallel 
the DXA data adding to the software’s potential accuracy. Additionally, the 
changes in the rTKR group might be due to the influence of the new 
metaphyseal cone being tested as part of this study, promoting remodelling due 
to participant early weight bearing, leading to the ipsilateral hip undergoing 
mechanical loads promoting bone turnover. This is supported by research that 
shows trabecular bone has a higher turnover than cortical bone [76], thus 
increased weight bearing could be the reason for the increased trabecular 
vBMD. Furthermore, cone implantation has shown to increase BMD in rTKR 
[226, 392].  
 
The trabecular volumetric data for the TKR group also aligns with current 
research regarding BMD loss, as reported in a small amount of hip data in TKR 
and DXA scans [26], as well as the BMD knee data in the systematic review, in 
which participants who underwent a TKR lost BMD consistently throughout the 
first 12 months around the knee implant, with data then suggesting that at 24 
months there was a recovery and possible plateau effect.  
 
Additionally, the physiotherapy regime which the rTKR participants underwent 
as part of their routine recovery pathway cannot be underestimated, and this 
might be the reason for the difference between the TKR and rTKR groups and 
the increased trabecular vBMD, as a study by Benedetti et al has shown that 
physiotherapy and exercise can increase BMD [393]. 
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4.6.3 INTEGRAL VOLUMETRIC BMD 
Integral vBMD again shows minimal change in the control data for the baseline 
or comparison figures. Furthermore, a study involving 3D-SHAPER software 
[380] had controls reporting an integral vBMD of 345+/-51, this is within the 
reported figures in this study (322.59+/-58.29 mg/cm3), although this cohort is 
not matched to TKR participants and has an average age of 33+/-10 years. 
Another 3D-SHAPER study [379] with control reported scores of 279.3+/-54.3 
mg/cm3. As stated there is overlap between the SD, but the variations between 
our controls and these controls might be due to regional differences, 
medications, exercise (the control group did report high pedometer readings 
[23]), and other variables. 
 
The rTKR ipsilateral baseline data show small losses and gains throughout the 
visits with a reported loss of -0.965 % (-2.997 mg/cm3) at six months, and a gain 
of 0.358 % (1.159 mg/cm3) at 12 months. This integral volumetric data are in the 
area where there is a unison of cortical and trabecular bone [357], this result is 
reflected in the results so far, with the increases and decreases most likely due 
to the combination of the trabecular vBMD gains, and cortical sBMD losses. The 
rTKR comparison data show a large difference at pre-op of -3.055 % (-9.988 
mg/cm3) this difference gradually reduces throughout the months with a 
reported difference of -1.716 % (-5.670 mg/cm3) at 12 months similar to the 
trabecular vBMD. 
 
The TKR group reports an ipsilateral gradual loss throughout, with a loss of -
2.344 % at 12 months. These results again are reflective of the combined 
trabecular vBMD loss and the loss in the cortical sBMD. The comparison data 
reported shows a similar trend in change with a difference of -2.461 % at six 
weeks, -3.861 % at six months, and then a difference of -3.110 % at 12 months. 
 
Bringing all these data together, you can see that the cortical sBMD data for 
both the TKR and rTKR show that the cortical thickness is being reduced across 
the hip region without any implication of recovery compared to either baseline or 
contralateral hip, the cortical sBMD gradually decreases even at 12 months, as 




The trabecular vBMD and integral vBMD show similar patterns in both the 
baseline and comparison data. The rTKR group data show a gradual increase 
throughout for both comparison and baseline data when reviewed against the 
previous months, even in one instance reporting a positive 12 month change 
having recovered from a large pre-op deficit. The TKR data show the opposite 
trend, with a starting equal or negative score and decreasing it further across 
each visit, resulting in a large negative at 12 months. 
 
All control results across all three tests (cortical sBMD, trabecular vBMD and 
integral vBMD) show minimal change both the baseline changes and between 
the ipsilateral and contralateral hip data. As for the TKR and rTKR there is no 
comparison data for this software’s use. These changes are important, as 
reductions in volumetric, cortical, and trabecular bone is associated with 
increased fracture risk [394] as well as being correlated with ageing. 
Furthermore, differences in volumetric BMD (total hip) were measured by 3D-
SHAPER software in an article in press (November 2018 [379]), in which they 
reported that in Caucasian post-menopausal participants who had suffered a 
fractured hip within a six year period, had a cortical sBMD mg/cm2 difference of 
-13.9 % (p-value <0.001), trabecular vBMD mg/cm3 difference of -31.8 %, and 
an integral vBMD mg/cm3 difference of -44.2 % all compared to the control 
group who did not have a fracture [379]. This shows a strong statistical 
association between fracture risk and cortical sBMD, trabecular BMD, and 
integral vBMD. Although it must be noted this was a retrospective case 
controlled study.  
  
4.6.4 CROSS SECTIONAL MOMENT OF INERTIA  
The CSMI control data show some change, there is a loss reported at  12 
months in the intertrochanteric region, a baseline change of -4.734 % (-0.069 
cm4). Furthermore, the baseline data recorded for the CSMI control group 
reports losses at other time periods and regions; at six months there is a loss 
reported of -2.815 % (neck), and -2.542 % (intertrochanteric), at 12 months it is 
reported as -1.377 % (neck). As stated previously these losses might be due to 
natural BMD loss in the post-menopausal group [307], which is reflected in the 
ipsilateral vs contralateral control data which shows minimal difference between 
the two hips. Additionally, the CSA data show a similar trend of loss in the 
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control group, with this idea is further supported by the trabecular vBMD that 
shows a loss for the controls at 12 months compared to baseline, in both the 
ipsilateral and contralateral hips but minimal change between the two hips, 
which is supported by the he left and right hip being highly correlated [382]. 
 
Across both the neck and intertrochanteric there are losses reported in both 
groups at every visit (with only the neck in rTKR group at six weeks reporting an 
increase), this might be due to cortical thinning as supported by the cortical 
sBMD data, leading to reduced flexibility and bending stress, increasing the 
chances of buckling and fracture, this is supported by the literature that has 
shown that participants who have lower CSMI and lower cortical thickness have 
an increased association of hip fracture in both men and women [363, 395, 
396]. It must also be noted that the TKR group baseline data show an increase 
in CSMI which is not reflected in the cortical sBMD, but this could be due to the 
cortical sBMD reporting the mean cortical surface of the entire hip and not 
individual regions which show these variations.  
 
4.6.5 CROSS SECTIONAL AREA  
The CSA shows minimal changes in the control group in both the baseline and 
comparison data changes, although at six months there is a loss at the femoral 
neck and the intertrochanteric region, with the reasoning behind these changes 
already discussed as part of the trabecular vBMD changes and CSMI data.  
 
The CSA data show the loss at the femoral neck which is reported by the 
cortical bone loss in the cortical sBMD in the rTKR, this is shown in both the 
baseline and comparison data and shows the same trend of gradual loss 
throughout each visit. The pattern in the CSA is similar to the pattern in the 
CSMI for each group, the TKR group in the neck region has a loss at six weeks, 
and an increase at 12 months when compared to the 6 months score. For the 
same data the rTKR has a similar trend across the CSA and CSMI, with an 
increase at six weeks (in comparison to the pre-op) and then a continuing loss 
at 12 months, this trend is seen in both the baseline and comparison data.  
 
In the intertrochanteric ipsilateral baseline data, the TKR group shows a loss 
throughout, but by 12 months there is an increase when compared to the six 
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month data, again this is shown in the baseline and comparison data. The rTKR 
group for the intertrochanteric data again shows a similar trend to the TKR 
group, reporting a loss throughout, although there is no increase at 12 months 
compared to six months. 
 
Unfortunately, even after extensive searching there seems a limited amount of 
data reporting CSA or CSMI hip data and its relation to rTKR or TKR. A study 
from Özen et al [397] investigated hip CSA and CSMI in control participants, but 
their findings were recorded in a different format and provided no longitudinal 
data, so cannot be compared to this study. Although, Beck et al [398] found a 
decline of 5 % per decade in CSMI in both pre- and postmenopausal women. 
Furthermore, it must be note there are some software that has been developed 
for enhancing diagnostic precision in hip fracture risk by using CSMI and CSA 
[399]. 
 
Finally, as stated the CSMI and CSA show very similar trend lines and the 
losses reported might be due to cortical thinning, with this supported by the 
cortical sBMD data but also due to the CSA only investigating the cortical 
equivalent area of the cross section of the femoral neck, with all trabecular and 




Across all three groups there are many variations, the rTKR group had an older 
mean age, as these participants have already undergone a TKR previously. 
Furthermore, only women were included in the TKR and control groups, This 
might impact the BMD changes reported, as women have reported to lose BMD 
of between 3.4-4.8 % over four years, with men losing 0.2-3.6 % over the same 
time period [400]. As noted this might have impacted the control group results 
within the study. 
 
Furthermore, all participants were white, and it has been reported that black 
people have higher BMD, CSMI, and CSA when compared to white people, so 
these results cannot be generalised to other ethnicities or demographics [359]. 
Additionally, cortical, trabecular, and volumetric BMD loss appears to follow 
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different patterns amongst African participants [394], again reducing the 
generalisability of this data. 
 
Further to this, the sample size was small, especially at 12 months were there 
was attrition of participants, this sample size impacted the results creating larger 
SD and SE margins in the 12 month data (seven, 15, and 36 participants across 
all three groups). This was due to the revision group being preliminary data due  
to time limitations on the software’s licence.  
 
The impact on the results of some participants having already undergone TKR 
prior to their rTKR, might have been exacerbated due to the participants having 
already had a TKR on their contralateral knee. Although this figure is not 
recorded several patients did have bilateral TKR, meaning possible 
deterioration in the contralateral knee might have hastened the BMD turnover 




For all control data there are minimal reported changes throughout for both the 
baseline and contralateral data, with some minimal changes reported as 
plausible natural bone changes.  
 
The knowledge about these differences between trabecular and cortical bone, 
and the changes of their relation due to ageing has multiple potential 
implications for clinical practice in understanding and treatment of a TKR or 
rTKR. It might be advantageous to apply anti-resorptive medications or 
regimens that aim for modification of trabecular bone remodelling in TKR 
patients due to their slower recovery, or rTKR patients due to the quicker 
recovery might benefit more directly from modification of cortical bone 
remodelling. This has already been investigated with this software [394] which 
investigated different drug treatments in osteoporotic women and reported on 
their cortical and trabecular bone changes. This might also impact future ideas 
of surgical procedures in addressing either trabecular or cortical characteristics, 
for example bone cement, is strong in compression and weak in shear and 
tension forces, and is a useful tool the treatment of osteoporosis, in which it 
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imitates trabecular bone as shown in its treatment in osteoporotic vertebral 
fractures [401, 402]. With cortical modifications the focus could be on the use of 
cortical bone grafts [403, 404]. 
 
Overall the 3D-SHAPER software’s ability to be applied to hip DXA imaging 
shows promise; this is reflected in the control participant’s results showing 
minimal changes throughout. This is also supported by the trabecular vBMD 
data from the TKR group data agreeing with current DXA literature [26], and the 
CSA and CSMI data showing similar trends, due to their correlation in the 
femoral strength index.  
 
Furthermore, it must be acknowledged that the separation of cortical from 
trabecular bone does give a deeper underpinning of the mechanical structures 
and effects bone undergoes as part of the recovery process pre and post total 
knee revisions and replacements, as well as showing the losses in CSA and 
CSMI suggesting that the spatial distribution of bone in the femoral neck is less 
able to resist greater loading, increasing fracture risk. This is supported by data 
from the Humbert et al study [379], which shows how this type of software could 
be integrated into predicting or identifying those at future fracture risk.  
 
Finally, as stated this software is in its infancy and these results should be 
treated with caution, although 3D measurements could potentially provide 
additional indicators to improve patient monitoring in clinical practice. It is still 
unclear as to why these changes might be between the groups, and thus further 
investigated is required. 
 
 
4.9 FUTURE WORK 
Further development of the 3D-SHAPER software should be undertaken, with 
additional validation and testing. Additionally, investigation into the 24 month 
appointment scans and into the full clinical trial could provide additional 
evidence regarding the changes in both cortical and trabecular bone, in 
conjunction this dataset, if it could be expanded, would allow a stronger 
comparison between the groups. Especially if more data could be collected 
regarding other TKR and rTKR groups/studies. This would address issues that 
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both the data and the systematic review have raised regarding plateau effects 
of BMD. Additionally, there should be investigations into the changes perceived 
between the rTKR and TKR groups, and the root cause for this possible 
difference and investigations into post-care influences. Unfortunately, although 
the 3D-analysis software offers preliminary greater information into the 
characteristics of the BMD results, it is unlikely to be used in the full study due 
to the time and cost limitations of licencing the software. Although given as the 
main pilot study will cover a five year period and this software can be used 
retrospectively, it could still be utilised even after the research is nearing its end. 
This would still allow this data to be directly compared to the BMD results 


























CHAPTER 5: MAIN STUDY – BMD CHANGES IN TOTAL BODY, LUMBAR 
SPINE AND BILATERAL HIPS – A COMPARISON BETWEEN BASELINE, 
IPSILATERAL AND CONTRALATERAL FOR RTKR PARTICIPANTS  
 
 
5.1 INTRODUCTION  
This chapter will report the BMD results of the main study covering the total 
body, lumbar spine, and bilateral hips. It will outline the participant recruitment, 
DXA method and the analysis used in the main study (The knee DXA data is 
addressed separately in the subsequent chapters, as are the additional scans). 
 
From the systematic review data, it has been shown that there are little data 
regarding ipsilateral and contralateral hip BMD and the subsequent changes 
throughout the revision and replacement process, with no reported data 
regarding BMD hip impact from total knee revisions (rTKR).   
 
This chapter will report on the results of exploring the impact of rTKR on BMD 
on the bilateral hip regions (neck, wards, trochanter, shaft, and total) of cone 
and non-cone participants, as reported via DXA scans. Additionally, changes in 
the lumbar spine (L1, L2, L3, L4 and L1-L4) and total body BMD will be 
investigated between cone and non-cone participants as well as comparisons 
between visits at pre-op (baseline) and six weeks, three months, six months 
and 12 months. 
 
It must be noted that due to the COVID-19 pandemic, I was unable to conduct 
the 12 month DXA scans on four participants due to lockdown, closure of the 
University campuses and a complete halt on all non-COVID-19 research both 
within the University and the hospital.  Since many of the participants on this 
study are in the over 70 group and often have multiple co-morbidities, I was 
advised to write up without completing data collection in June 2020 because it 
was deemed unlikely that both the RD&E department, the University or the risk 
assessments on the individual participants would allow for scanning of these 





Bone mineral density and the characteristics and architecture of bone have 
already been discussed in chapter 1 section 1.2.2. Although it must be stated 
that there is a direct link between hip strength and the influence of both cortical 
and trabecular bone as mentioned in the previous chapter; with cortical bone 
supporting flexibility in the distal regions of the femoral neck, and trabecular 
bone supporting the proximal loads the hip has to undergo [405]. With both 
bone types creating a complex relationship in supporting the hip function and 
load bearing. 
 
Furthermore, the importance in defining exact areas of weaknesses or bone 
loss is important especially with the advent of atypical femoral fractures. 
 
5.1.1 AIM  
This study was a prospective randomised feasibility study to investigate BMD 
changes in patients with and without cone implants in rTKR at pre-determined 
time intervals over a one year period. In order to identify when these BMD 
changes occur, and in what regions and the differences between the groups. 
Therefore, the total body, lumbar spine and bilateral hips were investigated 
through DXA imaging. .  
 
 
5.2 PARTICIPANT RECRUITMENT 
This study focused on recruiting rTKR patients with an AORI type two defect, 
and included both men and women in the study. This group was selected for 
two reasons. The participants required a revision, and be viable to undergo 
cone implantation, this meant the participants had to have an AORI type two 
defect, thus having enough bone to support the additional implantation, but not 
too much as to deem the implant superfluous. Since the participants are having 
a knee revision rather than a primary knee replacement, the group on average 
would be older, and thus more likely to have poorer baseline BMD due to 
natural progression with age. Matched controls undergoing rTKR but who did 
not received a cone were also recruited (non-cone group), with all participants 





5.2.1 PARTICIPANT GROUPING AND RECRUITMENT 
Participants were recruited for the cone testing through the knee research team 
at the RD&E hospital via one of two ways outlined below. These were matched 
against to the inclusion and exclusion criteria (see table 5.1 and 5.2). Firstly, 
patients that were listed for rTKR surgery whilst attending orthopaedic out-
patient clinics at the RD&E Hospital were consulted and given the opportunity to 
participate in the study. They were given a copy of the participant information 
sheet (PIS) (appendix 5), and the consent form (appendix 6). Secondly, patients 
were identified from existing surgical waiting lists, contacted by telephone or in 
writing asking for their permission for one of the study team to approach them 
about the study. Patients interested in the study were then sent a copy of the 
PIS and a consent form. PGH or one of the research team at the RD&E then 
contacted the patient and obtained written consent for study participation. 
Consent in most cases was obtained at the pre-operative assessment clinic 




·       Patients undergoing first time revision knee replacement for aseptic  
        loosening or wear of the components 
·       Patient has signed an ethics committee approved consent form 
·       rTKR to be performed at The Royal Devon and Exeter Hospital 
·       AORI class 2 defects of femur and/or tibia  
·       Skeletally mature male or female 
·       Patient is willing and able to comply with postoperative scheduled  
        clinical and radiological evaluations and rehabilitation                                                                                                        
·       Patient must be suitable for a rTKR with the Triathlon TS system i.e.  













·      Refusal to consent to participate in the study 
·      Patients known to have an infected joint replacement prior to revision  
       surgery 
·      Patients identified with an unexpected infected joint replacement   
       identified per-operatively 
·      AORI class 1 defects of tibia or femur where metaphyseal cone  
       fixation is not indicated 
·      AORI class 3 defects of tibia and femur where distal femoral  
       replacement or proximal tibial replacement is required 
·      Cases of ligamentous instability where condylar knee revision is not  
       indicated 
·      Patient is diagnosed with a systemic disease or metabolic disorder  
       leading to progressive bone deterioration 
·      Patient has a neuromuscular or neurosensory deficiency 
·      Patients undergoing patella revision in isolation 
·      Pregnancy 
 
5.2.2 REASONS FOR EXCLUSION  
The exclusions were made due to the possible impact of confounding variables 
affecting the BMD results (e.g. long-term corticosteroid use) and thus were 
justified. This study had few exclusions, as it was felt that it was important to 
keep the patients in the study as close to those in real life clinical practice, in 
order to ensure that the results were more generalisable to the clinical 
population. Furthermore, extensive exclusions in the study would have resulted 
in a smaller pool of participants over the two years recruiting period making the 
results less statistically relevant. 
 
5.2.3 GROUP ALLOCATION 
Originally the aim of the study was to recruit 51 participants. The number 51 
was calculated due to several factors (from the protocol). Firstly, there were no 
prospective studies to use as a basis for calculating sample size. The choice of 
51 participants initially with the potential for further recruitment after preliminary 





analysis, was determined by statistical advice who were confident that 51 will be 
sufficient to test the progression rules and to offer reasonable estimates of 
standard deviations of the intended outcome measures.  
 
Pragmatically, (based on the 2015 figures) the RD&E undertook approximately 
62 rTKR procedure per year and in 2015, 27 of these did not meet the inclusion 
criteria. Of the remaining 35 cases, with an assumed 20% unwilling to 
participate left 28 cases per annum. With a likely 56 potential participants in just 
under a two-year period. With the initial plan to recruit 51 subjects (17 to the no 
cone arm and 17 each to the cone with short or long stem arms respectively). 
With a preliminary analysis after 51 participants have been recruited. Due to 
time constraints, winter bed pressures, delays in surgery, and COVID-19, the 
results were a total of 37 participants who were recruited and consented for this 
study. Participants were then randomly allocated, with 24 assigned to undergo 
an implant with a Triathlon Cone and a new rTKR (cone group), and 13 to 
undergo just a new rTKR (non-cone group), with varying stem lengths used in 
both groups. The 13 participants who were assigned to the non-cone group (the 




5.3 PARTICIPANT RECRUITMENT RESULTS  
During the recruitment period of those who were eligible post screening 21 
declined to enter the study, although this is actually a lower figure than the 50 % 
expected (37 (consented) + 21 (declined) = 58 (total) so 36.21 % declined). 
  
The commonest reasons for declining study entry were:  
 Too far to travel for extra appointments needed for study (six 
participants) 
 Too many extra appointments (10 participants) 
 Patient recently required oxygen therapy at home so felt it was too much 
(1 participant, although this participant could have been excluded rather 
than declined) 
 Unhappy with concept of randomisation (two participants) 
 No reason given (four participants) 
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From this list above there are 23 reasons, this was because two participants 
declined for multiple reasons.  
  
A number of the participants initially stated yes, when they were sent the 
participant information sheet. Upon being phoned up by the research team at 
the RD&E regarding the study, and being given a date for the hospital 
admission (many months later), they then declined to go into the study. 
 
Conclusively, this resulted in 37 participants being consented into the study 
between the dates of 03/07/2017 and 17/06/2019, they were randomly allocated 
into either the cone (24) or the non-cone (13) group, with 13 male and 11 
female participants in the cone group, and eight male and five female 
participants in the non-cone group. Of the original 37, 35 participants completed 
the pre-op DXA scan (22 cone, 13 non-cone), a mean of 8.71 days prior to their 
surgery (range 1-62 days). Of the two who did not attend: one participant was 
consented then withdrew, due to revaluating the number of scans and 
questionnaires they would have to undertake, the second participant (although 
wanting to be part of the study) was withdrawn due to being prescribed 
alendronic acid (a bisphosphonate medication that increases BMD), and part of 
the study exclusion criteria.  
 
At six weeks post-surgery 26 participants completed the DXA scan (18 cone, 
eight non-cone) at a six week mean of +4.58 (range -1 to +15) days. Of those 
who did not attend: one participant died prior to surgery, one participants 
husband had died, two participants cancelled their six week appointment on 
pre-existing health grounds unrelated to their rTKR, and five were for surgical 
reasons, so were withdrawn from the study. These surgical reasons meant the 
participants could not have the rTKR type originally proposed, this was due to 
two main reasons; three participants required a special type of hinge joint, and 
two participants did not have enough bone in their distal femur for this type of 
revision, both of these reasons were discovered whilst the participants were 
undergoing surgery.  
 
At the three month visit, 26 participants completed the DXA scan (18 cone, eight 
non-cone) at a three month mean of +7.04 (range -1 to +32) days. One 
223 
 
participant could not attend the appointment, and the same two who failed to 
attend their six week due to health reasons, also could not attend their three 
month appointment due to ill health. At the six month visit, 25 participants 
completed the DXA scan (17 cone, eight non-cone) at a six month mean of 
+8.04 (range -13 to +29) days, four participants did not attend their 
appointment, one could not attend (no explanation was given), the same two 
who had previously missed their previous appointments due to ill health could 
unfortunately not attend their six month appointment either, and one participant 
had a myocardial infarction so missed their appointment. 
 
At the 12 month visit, 22 participants completed the DXA scan (15 cone, seven 
non-cone) at a 12 month mean of +13.50 (range -7 to +81) days. One 
participant cancelled due to health reasons, one participant was withdrawn due 
to an infection in their knee revision, and four DXA scans could not be 
performed due to the emergence of the COVID-19 pandemic, and the university 
closedown procedures and health concerns. An entire synopsis of the 





















Table 5.3. CONSORT table showing participant attrition per visit. 
 
Consented and randomised by 
research team at RD&E (N=37) 
  
cone group (N=24)   non-cone group (N=13) 
24   13 
   
 
Pre-op DXA (N= 35)   
cone group (N=22) 2 withdrew prior to scanning non-cone group (N=13) 
22 (1 due to time 
commitment, and 1 due 
to medication exclusion) 
  13 
   
 
6 week DXA (N=26)    
cone group (N=18) 
35 participants still available, 9 did 
not undergo a 6 week scan: 6 
withdrawn (5 plus one died), 3 
unable to attend 
non-cone group (N=8) 
18 (1 died, 1 due to poor 
health, 2 had surgical 
issues) 
  
8 (1 due to poor health,  3 
due to surgical issues, 1 
cancelled the appointment 
due to an bereavement) 
   
 
3 month DXA (N=26)   
cone group (N=18) 
29 participants still available, 3 did 
not undergo a 3 month scan 2 due 
to poor health, 1 could not attend 
non-cone group (N=8) 
18 (1 due to poor health) 
 
8 (1 due to poor health, 1 
could not attend appointment) 
   
 
6 month DXA (N=25)   
cone group (N=17) 
29 participants still available, 4 did 
not undergo a 6 month scan 2 due 
to poor health, 1 could not attend, 
1 had a myocardial infarction 
non-cone group (N=8) 
17 (1 due to poor health, 
1 could not attend)  
8 (1 due to poor health, 1 due 
to myocardial infarction) 
   
 
12 month DXA (N=22)   
cone group (N=15) 
28 participants still available; 6 did 
not undergo a 12 month scan; 1 
due to poor health, 1 withdrew due 
to knee infection, and 4 were 
cancelled due to the issues of 
COVID-19 
non-cone group (N=7) 
15 (3 due to COVID-19) 
 
7 (1 due to poor health, 1 
withdrew due to knee 
infection, 1 due to COVID-19) 
 
5.3.1 PRE-OP BMD FOR SURGICALLY WITHDRAWN PARTICIPANTS 
In total 35 participants completed a pre-op scan, of those, five participants had 
to be withdrawn post-surgery due to the standard rTKR not being a suitable 
option, and a different surgical procedure required (three required a hinge joint, 
and two lacked bone in the distal femur for this type of operation). Therefore, in 
order to investigate differences, the pre-op BMD results were separated into two 
groups (the five who withdrew post-op due to surgical reasons, and the 30 other 
participants who continued in the study).  
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Tables 5.4 and 5.5 report the pre-op BMD of each group, with an independent 
unpaired samples t-test and p-value performed. 
 
Table 5.4. Total body and lumbar spine mean BMD (g/cm2) of the five 




L1 L2 L3 L4 L1-L4 
Average BMD g/cm2 (N=30) 1.230 1.104 1.237 1.339 1.367 1.270 
SD 0.147 0.234 0.260 0.283 0.306 0.262 
SE 0.027 0.043 0.047 0.052 0.056 0.048 
Average BMD g/cm2 (N=5) 
(withdrawn group) 
1.212 1.114 1.225 1.283 1.308 1.237 
SD 0.081 0.065 0.056 0.142 0.205 0.098 
SE 0.036 0.029 0.025 0.063 0.092 0.044 
BMD difference between 
groups 
0.017 -0.010 0.012 0.056 0.059 0.033 
T-Critical 0.388 -0.193 0.227 0.685 0.548 0.512 
P-Value 0.707 0.849 0.822 0.509 0.601 0.616 
 
Table 5.5. Ipsilateral hip and contralateral hip average BMD (g/cm2) of the five 
withdrawn, and 30 included participants including t-test and p-value  
IPSILATERAL HIP 
 NECK WARDS TROCH SHAFT TOTAL 
Average BMD g/cm2 (N=30) 0.957 0.718 0.872 1.175 1.013 
SD 0.142 0.181 0.212 0.206 0.183 
SE 0.027 0.035 0.041 0.040 0.035 
Average BMD g/cm2 (N=5) 
(withdrawn group) 
0.907 0.680 0.786 1.106 0.941 
SD 0.101 0.096 0.220 0.142 0.136 
SE 0.045 0.043 0.098 0.064 0.061 
BMD difference 0.050 0.038 0.085 0.069 0.072 
T-Critical 0.950 0.690 0.801 0.914 1.018 
P-Value 0.317 0.506 0.460 0.387 0.342 
CONTRALATERAL HIP 
 NECK WARDS TROCH SHAFT TOTAL 
Average BMD g/cm2 (N=30) 0.967 0.725 0.871 1.174 1.017 
SD 0.170 0.168 0.201 0.203 0.181 
SE 0.032 0.031 0.037 0.038 0.034 
Average BMD g/cm2 (N=5) 
(withdrawn group) 
0.962 0.733 0.856 1.184 1.006 
SD 0.108 0.097 0.209 0.113 0.127 
SE 0.048 0.044 0.093 0.051 0.057 
BMD difference 0.005 -0.008 0.015 -0.009 0.011 
T-Critical 0.082 -0.158 0.148 -0.150 0.168 





Tables 5.4 and 5.5 show that the BMD difference show a larger average BMD in 
lumbar spine in the standard rTKR group, reporting a L1-L4 figure of 1.270 
g/cm2 compared to 1.237 g/cm2. Otherwise there is minimal difference between 
the BMD reported scores in the total body and lumbar spine. 
 
The contralateral hip differences between the groups is minimal, although the 
ipsilateral BMD average across all regions of the hip is smaller in the withdrawn 
group, with the total hip reported as 1.013 g/cm2 from the 30 participants, and 
0.941 g/cm2 from the five participants in the withdrawn group, although there is 
no reported statistical significance reported. 
 
 
5.4 METHOD, IMAGING 
Those who were eligible and who had consented were sent a pre-op letter with 
the date and time for a physiotherapy appointment and DXA scan (appendix 7). 
 
5.4.1 DXA IMAGING METHOD 
Prior to their rTKR all 37 participants were invited to undergo a pre-operative 
BMD evaluation via a DXA scan (GE Lunar prodigy, Bedford, MA). This 
involved scanning the total body, bilateral hips, and lumbar spine. 
 
TOTAL BODY POSITIONING 
The patient should be situated in the supine position and placed within the 
boundaries of the white lined marks on top of the DXA bed; they should be 
straight and in the midline of the scanner table. The pelvis should not be 
rotated, and the anterior superior iliac spines (ASIS) should be equidistant. The 
legs should be separated via the midline and slightly internally rotated to make 
them straight, the arms are placed by the patient’s side with palms of the hands 
resting against the side of the patient in the lateral position, with the thumbs 
closest to the scanner arm, positioning should be checked to make sure the 
hands are not obstructed or placed under the patient’s buttocks [406].  
 
If the patient was too tall to fit within the boundaries of the box then the patient 
would be placed outside the box at the superior aspect, as to include the feet 
and disregard the head. Furthermore, if the patient was obese it was difficult to 
227 
 
fit the patient within the boundaries, so support bands were placed to allow the 
elbows to be tucked in, if not then one side would be sacrificed, with repeated 
imaging following the same protocol and excluding the same anatomy, as this 
will affect the BMD result. 
 
Scanning begins at the superior aspect of the scan field moving in sweeps 
towards the patient’s feet, the scan may be stopped once the scanner arm has 
cleared the patient’s feet [406]. 
 
LUMBAR SPINE POSITIONING 
The patient lies supine on the scanner table with their arms either side, with no 
rotation, and their ASIS should be equidistant. They should be straight in order 
to make sure the spine is in the midline of the scanning field with equal amounts 
of soft tissue on either side of the spinal column. The knees are raised onto a 
supporting pad flexing them at 90° to reduce the lumbar lordosis and open the 
intervertebral spaces [406]. 
 
The laser positioning crosshair is centred in the midline 1.5 cm below the iliac 
crests as to include half of the fifth lumbar vertebrae [406]. Scanning starts at 
this level and goes towards the patient’s head, ending at the top of twelfth 
thoracic vertebrae [406]. 
 
FEMORAL HIP POSITIONING 
The patient is placed supine on the table; rotation is checked via the ASIS being 
equidistant from the tabletop. The patient’s arms are placed on their chest away 
from the scanning area. The foot support is placed between the patient’s legs, 
abducting the leg to be scanned approximately 15° away from the midline. The 
whole leg is then internally rotated through 15° and strapped into place [406]. 
 
This abduction of the leg separates the ischium of the pelvis from the lesser 
trochanter of the femur, as to not include it in the analysis. Furthermore, the 
internal rotation of the whole leg brings the lesser trochanter posterior and the 
greater trochanter anteriorly, with the femoral neck ending up parallel to the 
scanner table top, this avoids a foreshortening effect of the neck which can 
cause BMD measurements to be falsely elevated [406]. It must also be 
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acknowledged that in slender individuals, if necessary, rice bags should be 
placed either side of the upper femur to simulate soft tissue. This prevents edge 
detection artefacts that result in false measurements [406]. 
 
The laser positioning crosshair is then centred two inches below the greater 
trochanter and is on the medial side of the femoral shaft [407]. 
 
PATIENT PREPARATION 
Prior to any DXA scans the patient should be asked if they have undergone any 
recent nuclear medicine scans, as gamma rays emitted by any remaining 
radionuclide will cause an additional erroneous signal in the detectors of the 
DXA scanner which might affect the accuracy of the BMD measurements [406]. 
Furthermore, any recent X-ray examination using contrast media should also be 
investigated [408], as a radiopaque contrast medium will most likely produce 
additional attenuation of the DXA scanner X-ray beam, affecting the accuracy of 
the BMD measurements. Any contrast media within the bone will falsely 
increase the reported BMD, while contrast media in any adjacent soft tissue will 
affect the soft tissue reference comparator, resulting in a falsely low BMD 
measurement [406]. 
 
All metal should be removed from the patient prior to scanning in order that no 
artefacts are in the regions of interest being scanned; this again is similar to 
contrast media in which the metal can falsely elevate the BMD causing spurious 
measurements as well as artefacts on the image. 
 
DXA QA 
Prior to, and throughout the study the DXA scanner underwent Quality 
Assurance (QA) via a daily precision BMD block and a manufacturer-supplied 
aluminium weekly spine phantom (number 15867). Over the period of the study 

























In addition to the QA block, a COV was calculated for the spine phantom over 
the same period (pre-COVID), with a reported score of 0.39 % COV this is 














Figure 5.2. Showing the phantom QA spine BMD for L1-L4 over the study 
period of 3/07/17 to 6/10/19 (Pre-COVID). 
Figure 5.1. Showing the QA precision BMD block deviation over the study 





The precision results from both QA tools are well within the reported precision 
errors and these ensured safe and accurate operation throughout the study. 
Once QA checks had been completed and a participant had arrived, their 
identity was checked utilising the checklist (appendix 8) and they were given a 
brief description of the scan and any issues/questions were addressed. 
Furthermore, their date of birth and ethnicity were inputted into the scanner as 
well as their height (Seca, Germany) to the nearest 0.1 m, and weight (Seca 
877, Germany) to the nearest 0.1 kg, which was measured by the researcher 
prior to the scan. 
 
APPOINTMENTS 
Dual Energy X-ray Absorptiometry scans (this time includes the DXA knee scan 
as well, stated in chapter six) took approximately 90-120 minutes per session, 
with future scans arranged at dates and times that coincided with their 
physiotherapy, consultation, and other scans (x-ray and CT; which will be 
mentioned in subsequent chapters); this was done to reduce participant travel 
fatigue. All participants were provided parking, with the option of a wheelchair 
escort or crutches in order make their way to the scanner (approximately a five 
minute walk from the parking area).  
 
5.4.2 TIME SCALE FOR SCANS 
After rTKR surgery participants had follow up DXA and physiotherapy 
appointments at six weeks post operation (this was defined as one week before 
or one week after the exact six week post-op date), and then at three (defined 
as one week before and two weeks after the exact three month date), six 
(defined as one week before and two weeks after the exact six month date), 
and 12 months (defined as two weeks before and four weeks after the exact 12 
month date).  
 
 
5.5 ANALYSIS OF IMAGING  
 
5.5.1 DXA TOTAL BODY, LUMBAR SPINE, AND BILATERAL HIPS ANALYSIS  
All DXA scans followed the positioning protocol already stated in section 5.3.1, 
will all images were analysed using the GE Lunar enCORE™ 2005 software 
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(version 9.30.044). This software automatically detects the bone edges of the 
regions of interest (ROI), and subdivides those regions, in conjunction with 
categorising bone, soft tissue, air, and artefact. It must be noted that manual 
modification to the images was undertaken by the researcher (MG), in order 
that correct anatomy or artefact was classified. All BMD figures were recorded 
in a Microsoft Excel spreadsheet, and a DXA report with their T-score was 
created (an example is shown in appendix 9) by KK, which was sent to the 
referring physician AT as was the analysed data.  
 
The DXA scan report utilised the data from the total body (figure 5.3), bilateral 






























































Figure 5.3. Shows a standard total body DXA scan (the software has highlighted the 
knee replacements as artefacts in blue), the total body is divided into ROI with each 
region reporting a BMD (g/cm2) as well as a total score for the body. These ROI can 





Figure 5.4. DXA scan of standard bilateral hips. Each hip is divided into ROI with each 
region reporting a BMD (g/cm2) as well as a total hip score. These ROI can be moved or 























The 37 participants DXA images across all five appointments were separated 
into their participant groups: with cones, and non-cones (24 and 13 
respectively). The 24 participants with cones had their DXA images 
intracompared between the anatomical sites at the pre-op and each post-op 
visit. Total body scans were compared from each visit to their original pre-op 
baseline, and all BMD differences between each scan recorded in a Microsoft 
Excel spreadsheet. The hip BMD underwent the same comparison for both the 
ipsilateral and contralateral hip, with additional data collected via sub regions of 
the hip: the trochanter, neck of femur, wards triangle, femoral shaft, and the 
total hip BMD, again all compared to their pre-op scan. The lumbar spine scan 
was intracompared per lumbar vertebrae for L1, L2, L3, L4, and as a total of L1-
L4. These differences in BMD were re-calculated as a percentage difference for 
each visit, either as a gain or a loss when compared to their pre-op data. 
 
A mean, standard deviation (SD) and standard error (SE) was calculated for 
both the BMD difference and the calculated percentage difference as well as a 
Figure 5.5. DXA scan of a standard lumbar spine (PA). The lumbar spine is divided 
into ROI with each region reporting a BMD (g/cm2) and a total lumbar spine (L1-L4) 






95 % CI. A paired samples t-test (assuming normal distribution as reported in 
similar studies [23]) was also undertaken to compare the differences, to see if 
the changes were statistically significant, and a p-value recorded.  
 
All of these visit comparisons to the pre-op scan involved overlaying the original 
region data from the pre-op DXA scans and manually modifying (if needed) the 
ROI to correctly cover the anatomy of the latest scan, an example of this is 




























Figure 5.6. DXA scan showing lumbar spine (PA) original pre-op ROI (A) 
overlaid on the six week post-surgery scan (B). This overlap is represented by a 
redish line seen in image B, the overlap is nearly perfect except for some slight 





Figure 5.7. DXA scan of the hip showing the original pre-op ROI (A) overlaid on 
the three month post-surgery scan (B). The redish outline on image B 
represents the ROI from image A i.e near the ischium of B the overlap is less 




The 13 non-cone participants underwent the same intracomparison analysis, 
calculated mean, SD, SE, and the same statistical paired samples t-test and p-
value. 
 
Both groups also had this mean percentage difference compared between the 
ipsilateral and contralateral hip (with the contralateral hip acting as a control), at 
each of the appointments. Again, a SD, SE and a paired samples t-test was 
utilised and a p-value created. Any participants who had a THR on either side 
meant their other hip data were automatically excluded from this direct 
comparison between the ipsilateral and contralateral hip (due to no comparison 
being able to be made).  
 
Additionally, as well as the comparisons of the percentage changes (when 
compared to baseline), the direct mean BMD results were reported and 
compared in the hip data between the ipsilateral and contralateral of each 
participant at each visit for both cone and non-cone participants with a mean 
BMD calculated, SD, SE and t-critical score and p-value.   
 
The data analysis has so far compared the total body, lumbar spine, and 
bilateral hips to their pre-op baseline data, in addition to the ipsilateral hip data 
being compared to the contralateral hip data for each group, in both percentage 
change and BMD. A comparison between the cone and non-cone group for 
each appointment visit was also performed. Therefore at six weeks the mean 
percentage difference (compared to baseline) cone data for the total body, 
lumbar spine, ipsilateral and contralateral hip was compared to the non-cone 
percentage difference (compared to baseline) six week data for the same 
regions, this will be repeated for the three, six and 12 months with a SD, SE, as 
well as an independent t-test assuming unequal variance producing a t-critical 
score and p-value.  
 
Furthermore, the reported mean BMD for each region was also compared 
between cone and non-cone including the pre-op score.  This gave me 
additional data not just on the percentage changes but the actual absolute 
values that were involved, a SD, SE, as well as an independent t-test assuming 
unequal variance and p-value was again produced. 
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5.6 BMD DXA RESULTS OF THE TOTAL BODY AND LUMBAR SPINE 
This section will now report the BMD results for the total body and lumbar spine 
(the hip results will follow on in section 5.7). The results follow the analysis 
stated previously, with data compared between each participant’s visits (six 
week, three month, six month and 12 month) to their baseline (pre-op) scan, 
with an average difference in both g/cm2 and percentage change calculated for 
both the cone and non-cone group, these results were then compared between 
the two groups. 
 
Table 5.6. Shows the average baseline (pre-op) BMD (g/cm2) for the total body, 
and lumbar spine for the cone group (N=22) and non-cone group 













 CONE (N=22) 
AVERAGE 1.225 1.147 1.273 1.349 1.375 1.292 
SD 0.147 0.239 0.264 0.296 0.318 0.273 
SE 0.031 0.051 0.056 0.063 0.068 0.058 
 NON-CONE (N=13) 
AVERAGE 1.230 1.036 1.171 1.301 1.331 1.220 
SD 0.128 0.161 0.186 0.218 0.251 0.188 
SE 0.036 0.045 0.052 0.060 0.070 0.052 
 
Table 5.6 shows the mean BMD in g/cm2 baseline results of the 35 pre-op 
participants, it must be noted that the comparisons to baseline in the following 
results tables and figures involved comparing the participants BMD visit score 















5.6.1 BMD PERCENTAGE DIFFERENCE WHEN COMPARED TO PRE-OP 
FOR TOTAL BODY AND LUMBAR SPINE FOR CONE AND NON-CONE 
GROUPS 
 
Table 5.7. Shows the results for the cone group compared to baseline, for 
percentage change, confidence intervals (95 %), t-test, and p-value. 













0.018 1.491 0.648 2.330 1.826 0.430 3.337 0.004 
L1 (g/cm2) -0.004 -0.195 -2.060 1.680 4.046 0.954 -0.417 0.682 
L2 (g/cm2) 0.003 0.334 -2.110 2.770 5.285 1.246 0.188 0.853 
L3 (g/cm2) -0.010 -0.486 -2.070 1.090 3.427 0.808 -0.852 0.406 
L4 (g/cm2) 0.007 0.610 -1.040 2.260 3.574 0.842 0.550 0.590 
L1-L4 (g/cm2) -0.001 0.060 -1.200 1.320 2.725 0.642 -0.083 0.935 













0.016 1.220 0.790 1.220 1.709 0.403 3.063 0.007 
L1 (g/cm2) -0.015 -1.169 -3.690 1.350 5.448 1.284 -0.917 0.372 
L2 (g/cm2) -0.014 -1.006 -3.130 1.110 4.587 1.081 -1.000 0.331 
L3 (g/cm2) -0.006 -0.363 -1.430 0.707 2.309 0.544 -0.868 0.397 
L4 (g/cm2) -0.010 -0.641 -1.720 0.439 2.333 0.550 -1.248 0.229 
L1-L4 (g/cm2) -0.012 -0.810 -1.500 -0.123 1.487 0.351 -2.349 0.031 













0.013 1.012 0.262 1.760 1.578 0.383 2.593 0.020 
L1 (g/cm2) -0.001 -0.086 -2.660 2.480 5.414 1.313 -0.070 0.945 
L2 (g/cm2) -0.009 -0.697 -2.570 1.170 3.926 0.952 -0.783 0.445 
L3 (g/cm2) -0.002 0.231 -1.480 1.940 3.599 0.873 -0.205 0.840 
L4 (g/cm2) -0.001 0.313 -1.920 2.540 4.685 1.136 -0.035 0.972 
L1-L4 (g/cm2) -0.003 -0.079 -1.250 1.090 2.456 0.596 -0.409 0.688 













0.015 1.187 0.489 1.890 1.379 0.356 3.300 0.005 
L1 (g/cm2) 0.003 0.544 -1.370 2.450 3.772 0.974 0.305 0.765 
L2 (g/cm2) 0.006 0.671 -1.870 3.210 5.010 1.294 0.393 0.701 
L3 (g/cm2) -0.007 -0.207 -2.360 1.940 4.248 1.097 -0.484 0.636 
L4 (g/cm2) 0.012 0.975 -0.645 2.600 3.195 0.825 0.980 0.344 
L1-L4 (g/cm2) 0.004 0.440 -0.940 1.820 2.719 0.792 0.415 0.684 
 
Table 5.7 reports the changes in the cone group when compared to their 
baseline measurement, BMD in the total body in the cone group increases at six 
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weeks, but starts to drop after this period, until at 12 months were there is a 
slight increase (1.187 % (p-value 0.005)) compared to six months (1.012 %). 
The lumbar spine reports small amounts of changes primarily BMD loss, with 
the highest loss in L1 and L2 at three months, with an overall L1-L4 change of -
0.810 %, although this has recovered by six months to -0.079 % and is reported 
as a positive at 12 months of 0.440 %. 
 
Table 5.8. Shows the results for the non-cone group compared to baseline, for 
percentage change, confidence interval (95 %), t-test, and p-value. 













0.008 0.567 -0.663 1.800 1.774 0.627 1.031 0.337 
L1 (g/cm2) 0.005 0.385 -2.460 3.220 4.093 1.447 0.316 0.761 
L2 (g/cm2) 0.040 2.984 -0.486 6.450 5.003 1.769 1.836 0.110 
L3 (g/cm2) 0.031 1.987 -1.610 5.590 5.129 1.813 1.032 0.337 
L4 (g/cm2) 0.028 1.863 0.043 3.680 2.631 0.930 1.650 0.143 
L1-L4 (g/cm2) 0.026 1.752 -0.158 3.660 2.757 0.975 1.650 0.143 













0.008 0.655 -0.575 1.890 1.772 0.626 1.052 0.333 
L1 (g/cm2) -0.004 -0.254 -4.380 3.880 5.953 2.105 -0.203 0.845 
L2 (g/cm2) 0.018 1.158 -3.470 5.790 6.687 2.364 0.651 0.536 
L3 (g/cm2) 0.009 0.543 -2.350 3.430 4.165 1.473 0.421 0.687 
L4 (g/cm2) 0.038 3.212 -1.080 7.500 6.192 2.189 1.309 0.232 
L1-L4 (g/cm2) 0.016 1.280 -0.610 3.170 2.734 0.967 1.261 0.248 













0.002 0.155 -1.020 1.330 1.697 0.600 0.323 0.756 
L1 (g/cm2) -0.020 -1.916 -3.980 0.144 2.978 1.053 -1.847 0.107 
L2 (g/cm2) -0.002 -0.869 -6.170 4.430 7.654 2.706 -0.070 0.946 
L3 (g/cm2) 0.020 1.543 -2.830 5.910 6.305 2.229 0.774 0.464 
L4 (g/cm2) 0.029 2.038 -1.400 5.480 4.959 1.753 1.300 0.235 
L1-L4 (g/cm2) 0.009 0.448 -1.460 2.360 2.757 0.975 0.719 0.495 













-0.006 -0.458 -1.260 1.670 1.634 0.618 -0.740 0.487 
L1 (g/cm2) 0.005 0.491 -2.260 3.240 3.715 1.404 0.331 0.752 
L2 (g/cm2) 0.031 2.104 -1.780 5.980 5.236 2.013 1.229 0.684 
L3 (g/cm2) 0.007 -0.019 -4.530 4.490 6.093 2.303 0.203 0.846 
L4 (g/cm2) 0.019 1.391 -1.070 3.850 3.321 1.255 1.097 0.684 





























































PRE-OP             6 WEEKS             3 MONTHS     6 MONTHS             12 MONTHS
Cone participants mean percentage BMD difference for 
lumbar spine (L1, L2, L3 and L4) compared to pre-op 
baseline
L1 L2 L3 L4
Table 5.8 reports the changes in the non-cone group when compared to their 
baseline measurement, BMD in the total body increases at six weeks but by 
0.567 %, resulting in a loss by 12 months of -0.458 %. The lumbar spine shows 
small amounts of changes primarily BMD increases, with the highest gain 
reported at L4 of 3.212 % (p-value of 0.232) at three months, although none of 
the changes are statistically significant. 
Figure 5.8. Shows total body mean BMD changes across 12 months for cone 














Figure 5.9. Shows individual lumbar spine for cone participants as reported 












































PRE-OP             6 WEEKS             3 MONTHS             6 MONTHS             12 MONTHS
Mean percentage BMD difference for total body 




Figure 5.10. Shows individual lumbar spine for non-cone participants as 
reported mean BMD changes over 12 months, error bars are SE 
 
Figure 5.11. Shows total lumbar spine mean BMD changes across 12 months 





























































PRE-OP             6 WEEKS             3 MONTHS        6 MONTHS      12 MONTHS
Non-cone participants mean percentage BMD difference 
for lumbar spine (L1, L2, L3 and L4) compared to pre-op 
baseline



















































PRE-OP             6 WEEKS             3 MONTHS             6 MONTHS             12 MONTHS
Mean percentage BMD difference for lumbar spine 




The data shown in tables 5.7 and 5.8 is expressed visually in figures 5.8-5.11 to 
show the trends of BMD change in the cone and non-cone group over a 12 
month period, for the total body and lumbar spine.   
 
5.6.2 COMPARISON BETWEEN CONE AND NON-CONE GROUPS FOR BMD 
PERCENTAGE DIFFERENCE AND BMD MEAN, FOR TOTAL BODY AND 
LUMBAR SPINE  
A direct comparison between the cone and non-cone group for BMD percentage 
change and absolute BMD difference is shown in tables 5.9 and 5.10. 
 
Table 5.9. Shows percentage differences between visits compared between 
cone and non-cone compared to their pre-op baseline 
























TOTAL BODY 1.491 0.567 -1.215 0.244 TOTAL BODY 1.220 0.655 -0.759 0.462 
L1 -0.195 0.385 0.335 0.743 L1 -1.169 -0.254 0.371 0.717 
L2 0.334 2.984 1.225 0.241 L2 -1.006 1.158 0.832 0.425 
L3 -0.486 1.987 1.246 0.241 L3 -0.363 0.543 0.577 0.578 
L4 0.610 1.863 0.998 0.332 L4 -0.641 3.212 1.707 0.126 
L1-L4 0.060 1.752 1.450 0.171 L1-L4 -0.810 1.280 2.033 0.073 























TOTAL BODY 1.012 0.155 -1.204 0.250 TOTAL BODY 1.187 -0.046 2.307 0.044 
L1 -0.086 -1.916 -1.087 0.289 L1 0.491 0.544 0.031 0.975 
L2 -0.697 -0.869 -0.060 0.954 L2 2.104 0.671 -0.599 0.561 
L3 0.231 1.543 0.548 0.597 L3 -0.019 -0.207 -0.074 0.943 
L4 0.313 2.038 0.825 0.424 L4 1.391 0.975 -0.277 0.787 














Table 5.10. Shows the BMD differences at all visits compared between cone 


















TOTAL BODY 1.225 0.147 0.031 1.230 0.128 0.036 -0.005 -0.106 0.916 
L1 1.147 0.239 0.051 1.036 0.161 0.045 0.112 1.653 0.108 
L2 1.273 0.264 0.056 1.171 0.186 0.052 0.101 1.324 0.195 
L3 1.349 0.296 0.063 1.301 0.218 0.060 0.048 0.550 0.586 
L4 1.375 0.318 0.068 1.331 0.251 0.070 0.044 0.449 0.656 


















TOTAL BODY 1.254 0.146 0.034 1.247 0.162 0.057 0.007 0.098 0.924 
L1 1.170 0.221 0.052 1.070 0.160 0.056 0.100 1.303 0.209 
L2 1.301 0.269 0.063 1.232 0.241 0.085 0.069 0.652 0.524 
L3 1.381 0.278 0.066 1.362 0.304 0.107 0.020 0.155 0.879 
L4 1.433 0.295 0.070 1.376 0.322 0.114 0.057 0.428 0.676 


















TOTAL BODY 1.251 0.153 0.036 1.247 0.147 0.052 0.004 0.071 0.945 
L1 1.159 0.223 0.053 1.061 0.141 0.050 0.098 1.356 0.190 
L2 1.284 0.263 0.062 1.210 0.245 0.086 0.074 0.692 0.500 
L3 1.385 0.287 0.068 1.340 0.279 0.099 0.045 0.375 0.713 
L4 1.415 0.289 0.068 1.386 0.282 0.100 0.029 0.243 0.811 


















TOTAL BODY 1.254 0.157 0.038 1.209 0.145 0.051 0.046 0.715 0.486 
L1 1.185 0.233 0.057 0.981 0.181 0.064 0.204 2.382 0.028 
L2 1.303 0.266 0.065 1.114 0.267 0.094 0.189 1.654 0.120 
L3 1.399 0.274 0.067 1.292 0.281 0.099 0.107 0.896 0.386 
L4 1.434 0.286 0.069 1.344 0.309 0.109 0.090 0.692 0.501 


















TOTAL BODY 1.251 0.159 0.041 1.247 0.155 0.059 0.004 0.061 0.953 
L1 1.169 0.216 0.056 1.086 0.152 0.057 0.083 1.043 0.312 
L2 1.298 0.276 0.071 1.248 0.250 0.094 0.050 0.427 0.677 
L3 1.368 0.287 0.074 1.359 0.321 0.121 0.009 0.059 0.954 
L4 1.434 0.316 0.082 1.376 0.319 0.121 0.058 0.399 0.697 




Table 5.9 and 5.10 show the comparison between both groups for BMD and 
percentage changes, the results show that at six weeks the total body BMD 
results were very similar (1.225 g/cm2 and 1.230 g/cm2), showing a lack of 
difference in BMD even though the percentage change between six weeks and 
pre-op shows an increase of 1.491 % in the cone group and 0.567 % in the non-
cone group. The difference in BMD between the groups shows the cone group 
having a mean BMD higher than the non-cone group at every visit  and at every 
region (except total body pre-op), with two statistically significant, one at six 
months in the L1 region reporting a BMD difference of 0.204 g/cm2, this concurs 
with the percentage change, that for the same region and visit reports a score of 
-0.086 % with the cone group (when compared to baseline) and the non-cone 
group reporting a score of -1.916 % (the highest loss of the non-cone group), 
especially as the majority of the lumbar spine data report an increase compared 
to baseline. The second is the total body score reported as a gain of 1.187 % in 
the cone group and a loss of -0.458 % in the non-cone group (p-value 0.04).  
 
 
5.7 HIP DATA ANALYSIS 
The results in the following section are from the hip DXA analysis BMD data, 
both compared to the baseline measure for the ipsilateral and contralateral hip 
and between the hips and groups. Table 5.11 show the reported BMD at the hip 
















Table 5.11. Shows the mean baseline/pre-op BMD for the rTKR ipsilateral and 






Ipsilateral   
(mean) 
SD SE  Contralateral 
(mean) 
SD SE 
BMD Neck (g/cm2) 0.953 0.123 0.028  0.985 0.155 0.034 
BMD Wards (g/cm2) 0.731 0.166 0.037  0.730 0.148 0.032 
BMD Troch (g/cm2) 0.882 0.197 0.044  0.878 0.197 0.043 
BMD Shaft (g/cm2) 1.169 0.187 0.042  1.163 0.185 0.040 







SD SE  Contralateral 
(mean) 
SD SE 
BMD Neck (g/cm2) 0.943 0.161 0.047  0.936 0.173 0.048 
BMD Wards (g/cm2) 0.680 0.180 0.052  0.719 0.181 0.050 
BMD Troch (g/cm2) 0.819 0.238 0.069  0.853 0.210 0.058 
BMD Shaft (g/cm2) 1.156 0.221 0.064  1.195 0.206 0.057 
BMD Total (g/cm2) 0.982 0.192 0.055  1.014 0.183 0.051 
 
Baseline results of the 35 pre-op participants are shown in table 5.11, these 
show that on average the ipsilateral hip has an overall lower BMD compared to 
the contralateral, in both groups. It must be noted that the comparisons to 
baseline in the following results involved directly comparing the participants 
BMD with their baseline BMD as with the previous total body and lumbar spine 
analysis. Therefore, as participants dropped out at post-op intervals the overall 
baseline would reflect only the participants who remained. 
 
5.7.1 RESULTS OF CONE PARTICIPANTS IPSILATERAL AND 
CONTRALATERAL HIP REGIONS 
Table 5.12 and figure 5.12 show the results from the cone participants in the 
ipsilateral hip when compared to their baseline score, and the subsequent 
percentage changes reported between visits. It must be noted that one of the 
cone participants had a TKR in their contralateral knee between the six and 12 







Table 5.12. Shows the BMD ipsilateral cone results to 3 d.p. including 
percentage change, confidence intervals (95 %), t-test, and p-value 













0.036 3.580 1.520 5.640 4.469 1.117 3.381 0.004 
BMD Wards 
(g/cm2) 
0.020 2.102 -0.078 4.280 4.727 1.182 2.167 0.047 
BMD Troch 
(g/cm2) 
-0.018 -2.043 -3.190 -0.893 2.496 0.624 -2.844 0.012 
BMD Shaft 
(g/cm2) 
-0.009 -0.864 -1.900 0.176 2.248 0.562 -1.360 0.194 
BMD Total 
(g/cm2) 
-0.004 -0.469 -1.200 0.265 1.589 0.397 -0.950 0.357 













0.018 1.807 -0.583 4.200 4.884 1.221 1.612 0.128 
BMD Wards 
(g/cm2) 
0.003 0.333 -1.950 2.610 4.660 1.165 0.337 0.741 
BMD Troch 
(g/cm2) 
-0.018 -2.345 -3.880 -0.815 3.123 0.781 -2.848 0.012 
BMD Shaft 
(g/cm2) 
-0.012 -1.090 -2.290 0.110 2.446 0.611 -1.649 0.120 
BMD Total 
(g/cm2) 
-0.010 -1.068 -2.020 -0.112 1.952 0.488 -2.115 0.051 













-0.001 -0.125 -2.050 1.800 3.939 0.985 -0.073 0.943 
BMD Wards 
(g/cm2) 
-0.004 -0.652 -2.360 1.060 3.500 0.875 -0.617 0.547 
BMD Troch 
(g/cm2) 
-0.009 -1.025 -4.530 2.480 7.134 1.783 -0.681 0.506 
BMD Shaft 
(g/cm2) 
-0.019 -1.698 -2.980 -0.418 2.614 0.653 -2.564 0.021 
BMD Total 
(g/cm2) 
-0.015 -1.562 -2.760 -0.362 2.450 0.613 -2.567 0.021 













































Figure 5.12. BMD changes in the ipsilateral hip regions across 12 months (error 
bars are SE) 
 
The biggest BMD change is reported at six weeks with a reported increase of 
3.58 % at the neck region, there is also a gain of 2.102 % in the wards region, 
at 3 months this is reduced to 1.807 % and 0.333 %, at six month this is a loss -
0.125 % and -0.652 %., at 12 months there is an increase in these two regions 
of 0.097 % and 0.109 %. There is also a reported loss throughout the study in 
the trochanter at all visits, with statistically significant results at: six weeks, three 
months, and 12 months, reporting figures of -2.043 % (p-value 0.01), -2.345 % 
(p-value 0.01) and -1.89 % (p-value 0.05) respectively. The total BMD reports a 
gradual loss starting at six weeks (compared to baseline) -0.469 %, then -1.068 
%, -1.562 % (p-value 0.02), then at 12 months this loss has recovered slightly 
reporting a change of -1.365 % (p-value 0.05). Both the neck and wards trends, 



































baseline           6 weeks               3 months             6 months           12  months
Mean BMD g/cm2 percentage change for cone participants in 
regions of the ipsilateral hip across 12 months
BMD Neck (g/cm2) BMD Wards (g/cm2) BMD Troch (g/cm2)
BMD Shaft (g/cm2) BMD Total (g/cm2)
247 
 
Table 5.13. Shows the BMD contralateral cone results but to 3 d.p. including 
percentage change, confidence intervals (95 %) t-test, and p-value 











-0.009 -0.647 -2.490 1.190 3.973 0.964 -0.833 0.417 
BMD Wards 
(g/cm2) 
-0.001 -0.520 -3.140 2.100 5.674 1.376 -0.075 0.941 
BMD Troch 
(g/cm2) 
0.010 1.290 -0.920 3.500 4.777 1.159 1.032 0.318 
BMD Shaft 
(g/cm2) 
0.007 0.561 -0.578 1.880 2.867 0.695 0.865 0.400 
BMD Total 
(g/cm2) 
0.006 0.551 -0.559 1.660 2.404 0.583 0.976 0.343 











0.007 0.919 -2.030 3.870 6.197 1.503 0.402 0.693 
BMD Wards 
(g/cm2) 
0.011 1.604 -1.470 4.670 6.463 1.568 1.030 0.318 
BMD Troch 
(g/cm2) 
0.003 0.150 -1.890 2.190 4.286 1.040 0.379 0.710 
BMD Shaft 
(g/cm2) 
0.012 1.017 -0.423 2.460 3.025 0.734 1.367 0.910 
BMD Total 
(g/cm2) 
0.009 0.808 -0.040 1.660 1.783 0.432 1.934 0.071 











0.010 1.272 -2.010 4.550 6.693 1.673 0.570 0.577 
BMD Wards 
(g/cm2) 
-0.001 0.001 -3.130 3.130 6.380 1.595 -0.061 0.952 
BMD Troch 
(g/cm2) 
-0.004 -0.665 -3.120 1.790 4.992 1.248 -0.355 0.728 
BMD Shaft 
(g/cm2) 
0.014 1.220 -0.570 3.010 3.660 0.915 1.250 0.231 
BMD Total 
(g/cm2) 
0.007 0.684 -0.596 1.960 2.607 0.652 0.981 0.342 











































Figure 5.13. BMD changes in the contralateral hip regions across 12 months 
(error bars are SE) 
 
Table 5.13 and figure 5.13 show the changes reported in the contralateral hip in 
the cone group. At six weeks the wards and neck region report a loss of -0.647 
% and -0.520 % respectively. Although at three months there is an increase of 
0.919 % in neck, and the largest change reported in the contralateral hip is 
reported in the wards region, with a reported gain of 1.604 %, at 12 months this 
change is reported as -0.200 % (wards) and 0.136 % (neck). The total BMD 
was reported as an increase in all visits, reporting figures of 0.551 %, 0.808 %, 
0.684 % and 0.388 %, although it must be noted none of the results in the 
contralateral hip are statistically significant. 
 
5.7.2 RESULTS OF NON-CONE PARTICIPANTS IPSILATERAL AND 
CONTRALATERAL HIP REGIONS 
Table 5.14 and figure 5.14 show the results from the non-cone participants in 
the ipsilateral hip following the same analysis as previously stated. It must be 
noted that one of the non-cone participants had a rTKR on their contralateral 





























baseline           6 weeks               3 months             6 months           12  months
Mean BMD g/cm2 percentage changes for cone participants in 
regions of the contralateral hip compared to baseline
BMD Neck (g/cm2) BMD Wards (g/cm2) BMD Troch (g/cm2)
BMD Shaft (g/cm2) BMD Total (g/cm2)
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Table 5.14. Shows the ipsilateral BMD non-cone results to 3 d.p. including 
percentage change, confidence intervals (95 %), t-test and p-value 
 













0.004 0.084 -1.870 2.030 2.813 1.063 0.401 0.702 
BMD Wards 
(g/cm2) 
0.023 4.213 -2.740 11.200 9.385 3.547 1.242 0.261 
BMD Troch 
(g/cm2) 
-0.002 0.043 -2.550 2.630 3.496 1.321 -0.145 0.889 
BMD Shaft 
(g/cm2) 
-0.004 -0.492 -2.010 1.030 2.050 0.775 -0.519 0.627 
BMD Total 
(g/cm2) 
0.002 0.135 -1.190 1.460 1.778 0.672 0.335 0.749 













0.003 -0.043 -2.800 2.720 3.725 1.408 0.188 0.857 
BMD Wards 
(g/cm2) 
0.015 2.933 -4.360 10.200 9.842 3.720 0.814 0.447 
BMD Troch 
(g/cm2) 
0.010 1.013 -1.740 3.940 3.834 1.449 0.691 0.515 
BMD Shaft 
(g/cm2) 
0.001 -0.115 -1.990 1.760 2.528 0.956 0.085 0.935 
BMD Total 
(g/cm2) 
0.002 -0.021 -1.930 1.890 2.575 0.973 0.207 0.843 













-0.020 -1.944 -4.360 0.480 3.266 1.234 -1.473 0.191 
BMD Wards 
(g/cm2) 
0.010 1.727 -7.120 10.600 11.949 4.516 0.382 0.715 
BMD Troch 
(g/cm2) 
0.003 -0.500 -4.050 3.050 4.796 1.813 0.193 0.853 
BMD Shaft 
(g/cm2) 
-0.009 -0.916 -2.500 0.664 2.137 0.808 -1.016 0.349 
BMD Total 
(g/cm2) 
-0.003 -0.570 -2.280 1.140 2.314 0.875 -0.414 0.693 













-0.032 -3.363 -5.150 -1.570 2.237 0.913 -4.588 0.006 
BMD Wards 
(g/cm2) 
-0.003 -0.377 -6.910 6.150 8.159 3.331 -0.163 0.878 
BMD Troch 
(g/cm2) 
0.013 0.612 -3.840 5.060 5.567 2.273 0.041 0.969 
BMD Shaft 
(g/cm2) 
-0.009 -1.372 -4.140 1.400 3.465 1.415 -0.025 0.981 
BMD Total 
(g/cm2) 





Figure 5.14. BMD changes in the ipsilateral hip regions across 12 months (error 
bars are SE) 
 
The biggest BMD change was reported at six weeks with an increase of 4.2 % 
at the wards triangle region. There was also a reported loss at six and 12 
months in the neck, reported as -1.944 % and 3.363 % (p-value 0.01) 
respectively. The total BMD shows a small gain at six weeks of 0.135 %, the 








































baseline           6 weeks               3 months             6 months           12  months
Mean BMD g/cm2 percentage changes for non-cone participants in 
regions of the ipsilateral hip compared to baseline
BMD Neck (g/cm2) BMD Wards (g/cm2) BMD Troch (g/cm2)
BMD Shaft (g/cm2) BMD Total (g/cm2)
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Table 5.15 Shows the contralateral BMD non-cone results to 3 d.p. including 
percentage change, confidence intervals (95 %), t-test and p-value  











0.019 2.057 0.847 3.270 1.750 0.619 2.953 0.021 
BMD Wards 
(g/cm2) 
-0.004 -0.580 -3.840 2.680 4.705 1.663 -0.361 0.729 
BMD Troch 
(g/cm2) 
0.014 1.694 -0.166 3.550 2.688 0.950 1.678 0.137 
BMD Shaft 
(g/cm2) 
0.003 0.019 -0.991 1.030 1.457 0.515 0.369 0.723 
BMD Total 
(g/cm2) 
0.008 0.760 -0.179 1.700 1.335 0.472 1.555 0.164 











-0.021 -2.160 -4.610 0.290 3.540 1.252 -2.079 0.076 
BMD Wards 
(g/cm2) 
-0.020 -3.047 -4.850 -1.250 2.595 0.917 -3.615 0.009 
BMD Troch 
(g/cm2) 
0.002 0.287 -2.140 2.720 3.505 1.239 0.176 0.865 
BMD Shaft 
(g/cm2) 
-0.002 -0.431 -1.980 1.120 2.242 0.793 -0.166 0.873 
BMD Total 
(g/cm2) 
-0.007 -0.694 -2.030 0.646 1.936 0.684 -1.072 0.319 











0.015 1.718 -3.520 6.960 7.555 2.671 0.597 0.570 
BMD Wards 
(g/cm2) 
-0.003 -0.358 -4.760 4.040 6.354 2.246 -0.178 0.864 
BMD Troch 
(g/cm2) 
-0.005 -0.880 -3.680 1.920 4.042 1.429 -0.513 0.624 
BMD Shaft 
(g/cm2) 
-0.001 -0.177 -2.630 2.270 3.541 1.252 -0.063 0.951 
BMD Total 
(g/cm2) 
0.001 0.251 -1.640 2.140 2.728 0.964 0.178 0.864 











-0.032 -3.232 -4.640 -1.820 1.760 0.719 -4.387 0.007 
BMD Wards 
(g/cm2) 
-0.023 -3.631 -7.810 0.549 5.225 2.133 -1.956 0.108 
BMD Troch 
(g/cm2) 
0.016 1.578 -1.900 5.060 4.354 1.777 1.082 0.328 
BMD Shaft 
(g/cm2) 
-0.005 -0.590 -2.060 0.880 1.842 0.752 -0.539 0.613 
BMD Total 
(g/cm2) 





Figure 5.15. BMD changes in the contralateral hip regions across 12 months 
(error bars are SE) 
 
Table 5.15 and figure 5.15 show the results from the non-cone participants in 
the contralateral hip.  There is an increase percentage change at the neck of 
just over 2 % at six weeks compared to baseline, this increase was reported as 
a loss of just over -2 % at three months, although there was an increase at six 
months of 1.7 % and a loss of -3.232 % at 12 months (p-value 0.01). Wards 
triangle reports losses throughout all visits, with the highest loss at three months 
with a reported loss of just over 3 %. The total BMD reports a gain at six weeks 
a loss at three months and a gain at 12 months. 
 
5.7.3 COMPARISON BETWEEN CONE VS NON-CONE IPSILATERAL AND 
CONTRALATERAL HIPS 
The percentages created between comparisons of post-op visits to pre-op from 
tables 5.12, 5.13, 5.14 and 5.15, were themselves compared between the two 
groups, for the ipsilateral and contralateral hip differences. This comparison was 
done in the singular direction with the non-cone figure subtracted from the cone 
figure. A positive percentage meant the cone percentage figure was higher than 
the non-cone group, with a minus percentage figure reporting that the non-cone 



























baseline           6 weeks               3 months             6 months           12  months
Mean BMD g/cm2 mean percentage changes for non-cone 
participants in regions of the contralateral hip  compared to 
baseline
BMD Neck (g/cm2) BMD Wards (g/cm2) BMD Troch (g/cm2)
BMD Shaft (g/cm2) BMD Total (g/cm2)
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Table 5.16 reports this comparison between the ipsilateral percentage changes 
(compared to baseline) in the cone group (table 5.12) compared against the 
ipsilateral percentages changes (compared to baseline) in the non-cone group 
(table 5.14).  
 
Table 5.16. Shows the mean BMD percentage difference compared to baseline 
at different visits, in the ipsilateral hip of the cone group vs the non-cone group 
to 3 d.p. including percentage difference (between groups), t-test, and p-value. 
6 WEEK BMD % DIFFERENCE IN IPSILATERAL HIP CONE (16) VS NON-CONE (7) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 3.496 -2.111 -2.086 -0.371 -0.604 
T-CRITICAL 2.267 -0.565 -1.427 -0.388 -0.774 
P VALUE 0.036 0.590 0.187 0.704 0.457 
3 MONTH BMD % DIFFERENCE IN IPSILATERAL HIP CONE (16) VS NON-CONE (7) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 1.850 -2.600 -3.358 -0.975 -1.048 
T-CRITICAL 0.992 -0.667 -2.040 -0.860 -0.962 
P VALUE 0.337 0.526 0.069 0.408 0.361 
6 MONTH BMD % DIFFERENCE IN IPSILATERAL HIP CONE (16) VS NON-CONE (7) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 1.818 -2.379 -0.525 -0.782 -0.992 
T-CRITICAL 1.152 -0.517 -0.206 -0.752 -0.929 
P VALUE 0.269 0.624 0.839 0.464 0.371 
12 MONTH BMD % DIFFERENCE IN IPSILATERAL HIP CONE (14) VS NON-CONE (6) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 3.460 0.486 -2.502 -0.210 -0.793 
T-CRITICAL 2.190 0.133 -1.037 -0.135 -0.572 
P VALUE 0.042 0.898 0.340 0.900 0.585 
 
Table 5.16 shows the results of the comparison differences between ipsilateral 
hips of the two groups, there is a greater difference in the neck in the cone 
group and a greater difference in the wards area in the non-cone group at six 
weeks, although both groups had increases compared to baseline. The 
difference of 3.496 % was due to the larger increase in BMD in the neck in the 
cone group, likewise the -2.111 % reported in the wards triangle was due to the 
increase of 4.20 % ( in the non-cone group) compared to the 2.10 % increase in 
the cone group. At 12 months the difference between cone and non-cone was 
reported as 3.460 % (p-value 0.04) in the neck and 0.486 % in the wards, this 
was due to the non-cone group data reporting a loss of -3.363 % and -0.377 % 
at 12 months, whilst the cone group reported slight increases of 0.097 % and 
0.109 %. The trochanter difference is more prominent in the cone group 
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compared to the non-cone group, with the largest difference (excluding the 
neck) reported as -3.358 % at three months.  
 
Table 5.17 shows the results of the contralateral percentage changes 
(compared to baseline) in the cone group (table 5.12) compared to the 
contralateral percentages changes (compared to baseline) in the non-cone 
group (table 5.15). 
 
Table 5.17. Shows the mean BMD percentage difference compared to baseline 
at different visits in the contralateral hip of the cone group vs the non-cone 
group to 3 d.p. including percentage difference (between groups), t-test, and p-
value. 
6 WEEK BMD % DIFFERENCE IN CONTRALATERAL HIP CONE (17) VS NON-CONE (8) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE -2.704 0.060 -0.404 0.542 -0.209 
T-CRITICAL -2.361 0.028 -0.269 0.626 -0.279 
P VALUE 0.027 0.978 0.790 0.538 0.783 
6 MONTH BMD % DIFFERENCE IN CONTRALATERAL HIP CONE (16) VS NON-CONE (8) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE -0.446 0.360 0.215 1.397 0.434 
T-CRITICAL -0.142 0.131 0.113 0.901 0.373 
P VALUE 0.890 0.898 0.911 0.382 0.715 
3 MONTH BMD % DIFFERENCE IN CONTRALATERAL HIP CONE (17) VS NON-CONE (8) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 3.079 4.651 -0.137 1.448 1.502 
T-CRITICAL 1.574 2.561 -0.085 1.341 1.855 
P VALUE 0.130 0.017 0.933 0.197 0.086 
12 MONTH BMD % DIFFERENCE IN CONTRALATERAL HIP CONE (13) VS NON-CONE (6) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 3.369 3.431 -1.399 1.501 0.924 
T-CRITICAL 1.159 1.373 -0.674 1.292 0.857 
P VALUE 0.150 0.203 0.517 0.215 0.403 
 
Table 5.17 shows that the contralateral hips are similar, but the non-cone group 
reported a higher percentage difference at six weeks, with the difference being 
reported as -2.704 % although at three months both the neck and wards triangle 
report greater differences of 3.079 % and 4.651 % (with the wards difference 
being statistically significant, this is due to the 3.047 % increase in the cone 
group compared to the -1.604 % in the non-cone group see tables 5.12 and 
5.14). Although at six months this change is negligible, at 12 months there is 
difference of 3.369 %, and 3.431 % in the neck and wards triangle respectively. 
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The total hip data also showed a difference of 0.924 % at 12 months, although 
strongly influenced by the neck and wards triangle differences. Again these 
figures are just reflecting the percentage changes compared to baseline in both 
groups, and these large differences in the wards are due to increases in BMD at 
three months in the cone group and a loss in the non-cone group.  
 
5.7.4 IPSILATERAL VS CONTRALATERAL HIP PERCENTAGE DIFFERENCE 
IN CONE AND NON-CONE PARTICIPANTS  
The percentages created between comparisons of post-op visits to pre-op 
baseline figures, were also compared between ipsilateral and contralateral hip 
within each group. This comparison, as with section 5.7.3 was done in the 
singular direction with the contralateral percentage figure subtracted from the 
ipsilateral figure. A positive percentage means the ipsilateral percentage figure 
was higher than the contralateral, with a minus percentage figure reporting that 
the contralateral hip region had the higher value. 
 
Table 5.18 reports this ipsilateral vs contralateral hip percentage change 
(compared to baseline) (table 5.12 compared to table 5.13), with the same 
comparison done for the non-cone group (table 5.14 compared to table 5.15) 


















Table 5.18. Shows the mean BMD percentage difference between ipsilateral 
and contralateral percentage changes compared to baseline at different visits in 
the cone group 3 d.p. t-test, SD, SE and p-value. 
6 WEEK BMD % IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 4.775 2.340 -2.730 -1.464 -0.997 
MEAN BMD DIFFERENCE (g/cm2) 0.050 0.019 -0.025 -0.016 -0.010 
SD 5.324 5.952 4.088 4.399 2.947 
SE 1.375 1.537 1.056 1.136 0.761 
T-CRITICAL 3.474 1.523 -2.586 -1.289 -1.311 
P VALUE 0.004 0.150 0.022 0.218 0.211 
3 MONTH BMD % IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 1.736 -1.258 -2.602 -2.428 -1.973 
MEAN BMD DIFFERENCE (g/cm2) 0.020 -0.008 -0.023 -0.027 -0.020 
SD 4.767 7.619 4.971 4.840 2.733 
SE 1.231 1.967 1.283 1.250 0.706 
T-CRITICAL 1.410 -0.640 -2.027 -1.943 -2.797 
P VALUE 0.180 0.533 0.062 0.072 0.014 
6 MONTH BMD % IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE -0.125 -0.347 -0.669 -2.722 -2.136 
MEAN BMD DIFFERENCE (g/cm2) 0.001 -0.001 -0.008 -0.030 -0.021 
SD 6.022 5.802 9.236 5.051 4.092 
SE 1.555 1.498 2.385 1.304 1.056 
T-CRITICAL -0.080 -0.232 -0.281 -2.087 -2.021 
P VALUE 0.937 0.820 0.783 0.056 0.063 
12 MONTH BMD % IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=12) 
 NECK WARDS TROCH SHAFT TOTAL 
MEAN PERCENTAGE DIFFERENCE 1.965 0.640 -2.559 -1.651 -1.222 
MEAN BMD DIFFERENCE (g/cm2) -0.014 0.015 -0.014 -0.007 -0.008 
SD 8.900 5.134 4.747 3.879 3.761 
SE 2.569 1.482 1.370 1.120 1.086 
T-CRITICAL 0.765 0.432 -1.867 -1.474 1.126 
P VALUE 0.461 0.674 0.089 0.168 0.284 
 
Reviewing the difference between the ipsilateral and contralateral, the neck and 
wards both report differences of 4.775 % and 2.34 % at six weeks, and at 12 
months the neck was reported as 1.965 % and wards 0.640 %. The trochanter 
at six weeks also reported the greatest difference of -2.730 %, with a 
percentage difference of -2.559 % at 12 months. The total was reported as a 
difference of nearly -1 %, changing to -1.973 % at three months (p-value 0.01), 




Table 5.19. Shows the mean BMD percentage difference between ipsilateral 
and contralateral percentage changes compared to baseline at different visits in 
the non-cone group 3 d.p. t-test, SD, SE and p-value 






MEAN PERCENTAGE DIFFERENCE -1.798 5.911 -1.320 -0.551 -0.500 
MEAN BMD DIFFERENCE (g/cm2) -0.014 0.032 -0.013 -0.008 -0.005 
SD 2.394 8.063 4.120 2.216 1.989 
SE 0.905 3.048 1.557 0.838 0.752 
T-CRITICAL -1.987 1.940 -0.848 -0.658 -0.664 
P VALUE 0.094 0.101 0.429 0.535 0.531 






MEAN PERCENTAGE DIFFERENCE 2.228 5.805 0.819 0.716 0.945 
MEAN BMD DIFFERENCE (g/cm2) 0.025 0.034 0.009 0.007 0.012 
SD 5.990 9.528 2.608 2.596 2.223 
SE 2.264 3.601 0.986 0.981 0.840 
T-CRITICAL 0.984 1.612 0.831 0.730 1.125 
P VALUE 0.363 0.158 0.438 0.493 0.304 






MEAN PERCENTAGE DIFFERENCE -3.403 3.092 1.079 -0.350 -0.355 
MEAN BMD DIFFERENCE (g/cm2) -0.033 0.018 0.013 -0.004 -0.001 
SD 10.138 14.083 3.966 4.358 4.560 
SE 3.832 5.323 1.499 1.647 1.724 
T-CRITICAL -0.888 0.581 0.720 -0.212 -0.206 
P VALUE 0.409 0.582 0.499 0.839 0.843 






MEAN PERCENTAGE DIFFERENCE -0.493 -0.927 -2.993 -1.472 -1.036 
MEAN BMD DIFFERENCE (g/cm2) -0.002 -0.003 -0.019 -0.011 -0.006 
SD 2.587 2.646 5.246 2.568 2.685 
SE 1.157 1.183 2.346 1.148 1.201 
T-CRITICAL -0.462 -0.783 -1.276 -1.282 -0.863 
P VALUE 0.692 0.477 0.271 0.269 0.437 
 
Table 5.18 shows the difference between the ipsilateral and contralateral hip 
BMD in the non-cone group, wards triangle shows a large difference of 5.9 % at 
six weeks, although this drops at every visit (5.8 % at three months, 3.092 % at 
six months), finally reported as -0.927 % at 12 months. The neck data started at 
a difference of -1.798 % at six weeks and increases at three months (2.228 %), 
and then a loss of 3.403 % at six months, until at 12 months it was reported as -
0.493 %. The trochanter reports a difference of -1.32 % at six weeks, although 
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this increases to 1.079 % by six months, and was reported as -2.993 % at 12 
months. There is little change in the shaft throughout, and the total reports both 
losses and gains in difference, although at 12 months it reports a difference of -
1.472 %.  
 
5.7.5 BMD REPORTED IPSILATERAL HIP AND CONTRALATERAL HIP FOR 
THE CONE VS NON-CONE GROUPS 
Tables 5.20 and 5.21 report the absolute BMD figures rather than the 
percentage change, this is in order to show the reported absolute BMD figures 




























Table 5.20. Shows the mean BMD for the ipsilateral hip with a comparison 
between cone and non-cone group at each visit, reported as to 3 d.p. t-test, SD, 



















NECK 0.953 0.123 0.028 0.943 0.161 0.047 0.011 0.195 0.848 
WARDS 0.731 0.166 0.037 0.680 0.180 0.052 0.050 0.788 0.439 
TROCH  0.882 0.197 0.044 0.819 0.238 0.069 0.062 0.765 0.453 
SHAFT 1.169 0.187 0.042 1.156 0.221 0.064 0.013 0.176 0.862 



















NECK 1.010 0.138 0.035 0.975 0.217 0.082 0.035 0.393 0.705 
WARDS 0.777 0.193 0.048 0.711 0.232 0.088 0.066 0.660 0.524 
TROCH  0.895 0.200 0.050 0.876 0.255 0.096 0.019 0.172 0.867 
SHAFT 1.187 0.204 0.051 1.155 0.277 0.105 0.032 0.273 0.791 



















NECK 0.993 0.133 0.033 0.974 0.214 0.081 0.019 0.214 0.836 
WARDS 0.760 0.168 0.042 0.703 0.228 0.086 0.057 0.595 0.566 
TROCH  0.895 0.213 0.053 0.887 0.271 0.102 0.007 0.063 0.951 
SHAFT 1.184 0.199 0.050 1.160 0.283 0.107 0.023 0.197 0.848 



















NECK 0.974 0.130 0.032 0.941 0.183 0.069 0.033 0.434 0.675 
WARDS 0.753 0.171 0.043 0.690 0.232 0.088 0.063 0.649 0.532 
TROCH  0.904 0.207 0.052 0.827 0.256 0.097 0.077 0.702 0.499 
SHAFT 1.177 0.203 0.051 1.125 0.267 0.101 0.052 0.459 0.657 



















NECK 0.956 0.127 0.034 0.964 0.205 0.084 -0.008 -0.090 0.931 
WARDS 0.720 0.156 0.042 0.695 0.255 0.104 0.025 0.219 0.833 
TROCH  0.885 0.220 0.059 0.904 0.305 0.124 -0.019 -0.137 0.895 
SHAFT 1.159 0.203 0.054 1.173 0.325 0.133 -0.014 -0.101 0.922 






Table 5.21. Shows the mean BMD for the contralateral hip with a comparison 
between cone and non-cone group at each visit, reported as to 3 d.p. t-test, SD, 



















NECK 0.985 0.155 0.034 0.936 0.173 0.048 0.049 0.836 0.412 
WARDS 0.730 0.148 0.032 0.719 0.181 0.050 0.011 0.191 0.850 
TROCH 0.878 0.197 0.043 0.853 0.210 0.058 0.025 0.346 0.732 
SHAFT 1.163 0.185 0.040 1.195 0.206 0.057 -0.032 -0.461 0.649 



















NECK 0.987 0.149 0.036 0.958 0.222 0.079 0.029 0.331 0.748 
WARDS 0.740 0.174 0.042 0.713 0.237 0.084 0.027 0.288 0.779 
TROCH 0.906 0.200 0.048 0.901 0.225 0.080 0.005 0.054 0.958 
SHAFT 1.186 0.201 0.049 1.184 0.273 0.096 0.002 0.023 0.982 



















NECK 1.002 0.155 0.038 0.918 0.211 0.074 0.084 1.008 0.335 
WARDS 0.752 0.156 0.038 0.697 0.235 0.083 0.056 0.607 0.557 
TROCH 0.899 0.213 0.052 0.889 0.228 0.081 0.010 0.107 0.916 
SHAFT 1.191 0.200 0.048 1.180 0.279 0.099 0.011 0.101 0.921 



















NECK 1.018 0.155 0.039 0.942 0.212 0.075 0.077 0.910 0.382 
WARDS 0.742 0.157 0.039 0.700 0.223 0.079 0.043 0.486 0.637 
TROCH 0.913 0.200 0.050 0.842 0.216 0.076 0.071 0.779 0.450 
SHAFT 1.200 0.198 0.050 1.169 0.267 0.094 0.031 0.289 0.778 




















NECK 0.991 0.137 0.038 0.968 0.215 0.088 0.023 0.243 0.815 
WARDS 0.708 0.134 0.037 0.743 0.263 0.107 -0.035 -0.308 0.769 
TROCH 0.921 0.201 0.056 0.919 0.271 0.111 0.002 0.019 0.986 
SHAFT 1.180 0.212 0.059 1.221 0.303 0.124 -0.041 -0.298 0.774 
TOTAL 1.038 0.188 0.052 1.054 0.259 0.106 -0.016 -0.136 0.896 
 
The results in table 5.20 show the changes in BMD difference in the ipsilateral 
hip in the cone and non-cone group, the BMD differences report that the 
261 
 
ipsilateral cone side has a higher BMD than the non-cone group at every region 
in 20 out of 20 results, except at 12 months where the mean BMD is lower in 
four of the five regions, although none of results report a statistical significance 
p-value.  
 
The results in table 5.21 show a similar trend, with 19 out of 20 regions and 
visits, reporting a higher BMD in the cone group than non-cone group. Except at 
12 months where the BMD is lower in the cone group in three out of five 
regions, but again with no statistical significance. 
 
5.7.6 BMD REPORTED IPSILATERAL HIP VS CONTRALATERAL HIP FOR 
THE CONE AND NON-CONE GROUPS 
The data shown in tables 5.22 and 5.23 show the absolute BMD differences 
between the ipsilateral and contralateral hip regions, for the cone and non-cone 
groups. Due it being a comparison between ipsilateral and contralateral this 
meant all pre-op participants who underwent a DXA scans were included. 
Furthermore, the participants although allocated to cone and non-cone (at pre-




















Table 5.22. Shows the mean BMD difference between ipsilateral and 
contralateral changes at different visits in the cone group 3 d.p. t-test, SD, SE 
and p-value 
PRE-OP BMD IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=19) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.045 -0.004 -0.005 -0.001 -0.008 
SD 0.078 0.063 0.042 0.056 0.041 
SE 0.018 0.014 0.010 0.013 0.009 
T-CRITICAL -2.481 -0.245 -0.551 -0.099 -0.833 
P VALUE 0.023 0.809 0.588 0.9225 0.416 
6 WEEK BMD IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
0.012 0.030 -0.020 -0.009 -0.008 
SD 0.051 0.064 0.029 0.059 0.033 
SE 0.013 0.017 0.007 0.015 0.009 
T-CRITICAL 0.938 1.777 -2.697 -0.586 -0.969 
P VALUE 0.364 0.097 0.017 0.568 0.349 
3 MONTH BMD IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.018 0.003 -0.018 -0.020 -0.019 
SD 0.065 0.071 0.037 0.044 0.031 
SE 0.017 0.018 0.009 0.011 0.008 
T-CRITICAL -1.056 0.138 -1.901 -1.735 -2.323 
P VALUE 0.309 0.892 0.078 0.105 0.036 
6 MONTH BMD IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=15) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.037 0.010 -0.003 -0.022 -0.019 
SD 0.101 0.068 0.056 0.053 0.040 
SE 0.026 0.017 0.014 0.014 0.010 
T-CRITICAL -1.405 0.581 -0.198 -1.628 -1.843 
P VALUE 0.182 0.571 0.846 0.126 0.087 
12 MONTH BMD IN CONE IPSILATERAL VS CONTRALATERAL HIP (N=12) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.014 0.015 -0.014 -0.007 -0.008 
SD 0.071 0.080 0.042 0.051 0.041 
SE 0.020 0.023 0.012 0.015 0.012 
T-CRITICAL -0.681 0.652 -1.148 -0.462 -0.676 








Table 5.23. Shows the mean BMD difference between ipsilateral and 
contralateral changes at different visits in the cone group 3 d.p. t-test, SD, SE 
and p-value 
PRE-OP BMD IN NON-CONE IPSILATERAL VS CONTRALATERAL HIP (N=12) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.005 -0.053 -0.043 -0.045 -0.041 
SD 0.073 0.054 0.056 0.060 0.046 
SE 0.021 0.016 0.016 0.017 0.013 
T-CRITICAL -0.226 -3.413 -2.633 -2.594 -3.086 
P VALUE 0.826 0.006 0.023 0.025 0.010 
6 WEEKS BMD IN NON-CONE IPSILATERAL VS CONTRALATERAL HIP (N=7) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE 
-0.003 -0.022 -0.042 -0.036 -0.034 
SD 0.071 0.066 0.075 0.079 0.065 
SE 0.027 0.025 0.028 0.030 0.025 
T-CRITICAL -0.107 -0.887 -1.500 -1.187 -1.366 
P VALUE 0.919 0.409 0.184 0.280 0.221 
3 MONTH BMD IN NON-CONE IPSILATERAL VS CONTRALATERAL HIP (N=7) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
0.036 -0.020 -0.021 -0.021 -0.017 
SD 0.099 0.071 0.070 0.060 0.053 
SE 0.037 0.027 0.026 0.023 0.020 
T-CRITICAL 0.973 -0.756 -0.776 -0.937 -0.857 
P VALUE 0.368 0.478 0.467 0.385 0.425 
6 MONTH BMD IN NON-CONE IPSILATERAL VS CONTRALATERAL HIP (N=7) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.018 -0.028 -0.025 -0.045 -0.037 
SD 0.098 0.119 0.079 0.061 0.063 
SE 0.037 0.045 0.030 0.023 0.024 
T-CRITICAL -0.493 -0.616 -0.830 -1.947 -1.532 
P VALUE 0.640 0.561 0.439 0.100 0.176 
12 MONTH BMD IN NON-CONE IPSILATERAL VS CONTRALATERAL HIP (N=6) 
  NECK WARDS TROCH SHAFT TOTAL 
MEAN ABSOLUTE BMD 
DIFFERENCE (g/cm2) 
-0.024 -0.089 -0.067 -0.049 -0.053 
SD 0.086 0.043 0.077 0.074 0.056 




 -4.641  -1.970  -1.500  -2.110 
P-VALUE 0.568  0.009  0.120  0.209  0.102 
 
The data in tables 5.22 and 5.23 report the absolute BMD rather than 
percentage change experienced by participants in the hip of the cone and non-
cone groups. The cone group data in table 5.22 reports negative differences at 
pre-op between ipsilateral and contralateral, showing the contralateral hip to 
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have higher BMD, at six weeks there is a positive difference in the ipsilateral hip 
in the neck and wards, as is the ward region difference reported at 12 months. 
The trochanter reports a negative difference at six weeks which reduces 
throughout each visit. The total difference is reported as a difference of -0.008 
g/cm2 at pre-op and six weeks, increasing to -0.019 g/cm2 at three months and 
six months, resulting in a BMD difference of -0.008 g/cm2 at 12 months, similar 
to the percentage change reported in the previous section. 
 
Table 5.23 reports the difference between the ipsilateral and contralateral hip 
BMD in the non-cone group, wards triangle shows a difference at six weeks of -
0.022 g/cm2 which is an increase on the pre-op of -0.053 g/cm2, although this 
gradually decreases reporting a six month and 12 month difference of -0.028 
g/cm2 and -0.089 g/cm2 (p-value 0.01) respectively, compared to the pre-op 
difference the trend fits the percentage change difference already reported. 
 
The neck data reported also reflects the percentage change data, starting at a 
difference of a loss -0.003 g/cm2 at six weeks and increases at three months 
(0.036 g/cm2) and then a loss of -0.018 g/cm2 at six months, until at 12 months 
it was reported as -0.024 g/cm2. The trochanter again reports a similar trend to 
the percentage data already stated, a difference of -0.042 g/cm2 at six weeks, is 
reported, along with -0.067 g/cm2 at 12 months. The total reports a negative 





5.8.1 PARTICIPANTS  
Considering the cohort of participants were elderly, often frail, and facing 
daunting revision surgery, the burden of the research requirements must not be 
over looked. Furthermore, there was often a long delay between initial contact 
regarding the study and admission (and thus study consent). Therefore, a 
repeat phone call nearer the time of admission for surgery might reduce those 





In total 37 participants were consented for the study as per the CONSORT 
diagram in Table 5.3, although only 22 completed the 12 month scan (four 
participants could not undergo their 12 month scan due to COVID-19 and thus 
the DXA scanner being inaccessible (two did not undergo a pre-op scan; one 
changed their mind due to the amount of scans after consenting, and one was 
discovered to be on bisphosphonates after consenting), and was withdrawn. 
Issues with attrition post consent were addressed prior to the commencement of 
the study, appointments were organised in advance and in the majority of cases 
organised on a single day (i.e. participants would undergo the DXA scan, 
physiotherapy appointment, and knee x-rays, on the same day), which we 
believed helped address these potential attrition issues. Unfortunately, this did 
mean that appointments were not always precisely at six weeks or three, six or 
12 months, especially due to participant holidays, work, and other 
commitments. Therefore, an approximation was used to define each period; six 
weeks was defined as within a week either side, three months was one week 
prior two weeks post, six months was one week prior two weeks post, and 12 
months two weeks prior four weeks post. So the results gathered are not perfect 
and represent a range.   
 
Further to this, five participants who attended the pre-op had to undergo a 
different surgical procedure and be withdrawn from the study, which is reflected 
in the results in tables 5.4 and 5.5. The comparison data between those who 
under a standard rTKR and those who were withdrawn, reported minimal 
differences in the total body and contralateral hip, although a difference is 
reported in the lumbar spine (an increase in the standard rTKR group), this 
could be simply due to the osteophytes and degenerative changes impacting 
BMD [409]. 
 
Interestingly the ipsilateral BMD average is higher in the group of participants 
who underwent the standard rTKR compared to the withdrawn group, with 
results across all regions of the hip reporting higher values. These hip BMD 
differences could be related to the withdrawal of the participants, with low BMD 
in the ipsilateral hip regions at pre-op correlating to their subsequent lack of 
BMD in the distal femur [410], and ultimately not being suitable to undergo the 
cone surgical procedure (lack of BMD in the distal femur was one of the 
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reasons two participants were withdrawn). Although, it is important to note that 
differences between the groups are not statically significant, involve a very 
small sample size, and contain a wide SD, therefore the results are more likely 
to just be standard variations within the groups. 
 
5.8.2 TOTAL BODY AND LUMBAR SPINE DISCUSSION 
The total body percentage in the cone group increases at six weeks (1.491 % 
compared to baseline) but then gradually decreases throughout each visit until 
12 months reported as 1.187 % (p-value 0.01). This change could be a result of 
the cement used in the knee revision process falsely elevating the BMD, 
although we addressed this by classifying the rTKR (including the stems) and 
the surrounding area as artefact (excluding it from BMD calculations), it is 
possible not all the cement was not directly classified due to poor visualisation 
of it on the image.  
 
Furthermore, this gain in BMD could be because the revised knee is no longer 
included as part of the BMD figures (as stated it was classified as artefact), as 
with the pre-op score, only the TKR replacement part was excluded (no stems 
had been implanted yet), and the BMD along the mid shaft of the tibia and 
femur were included in the total body calculation, having now undergone the 
revision, the stem (classified as artefact) is now situated in this region, 
excluding the region from being part of the overall BMD, which previously might 
have been reducing the overall mean BMD.  Although, if this were the case we 
would expect to see similar increases in the BMD of the non-cone group (having 
undergone the same cement revision and varying stem lengths), and although 
there is an increase, this is demonstrated as just over 0.5 % (compared to the 
cone reporting nearly 1.5 %), and at six months this figure is 0.16 % (the cone 
group reporting 1.012 %), at 12 month it is -0.458 % (non-cone) (with the cone 
group reporting 1.187 %). With a statistical significance at 12 months when the 
two groups were compared (p-value of 0.04). 
 
Therefore, it is worth considering that the changes in BMD in the cone group 
might be related to stabilisation and weight bearing, cone implantation has 
shown to demonstrate good stabilisation [229], which might result in the 
participants being more active post-surgery due to the possible stabilising 
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factors of the cone implant, thus increasing weight bearing and BMD [404]. This 
is further supported by the total body results reporting a statistically significant 
increase at every visit in the cone group (whereas the non-cone group reported 
no statistically significant changes when compared to pre-op). Additionally, it 
must be noted no activity monitoring or pedometers were recorded in this study, 
and although both groups were given the same physiotherapy regime it is 
unknown if the participants adhered to these instructions, with a systematic 
review reporting that non-adherence to physiotherapy has been stated between 
14-70 % [411]. This adherence is not reported in this study, but participants from 
both groups did have physiotherapy appointments post-op as part of their 
standard patient pathway.  
 
Unfortunately, there is a lack of comparison evidence reporting changes in total 
body BMD post rTKR, as well as a lack of TKR or TKA data, so it is unknown if 
the trend in the non-cone group is reflective of participants clinically who also 
undergo a revision. There is some control data, for instance 36 post-
menopausal Greek women aged between 55 and 65 years old were studied 
over a 12 month period for changes in their total body BMD. At 12 months they 
reported losses of 0.008 g/cm2 (-0.71 %) compared to baseline figures [412]. A 
study involving 99 men aged 57+/-10 were also studied over a 12 month period, 
reported total body BMD loss of approximately -0.1 % compared to baseline 
[413]. 
 
For the lumbar spine data the cone group changes are small compared to 
baseline, although at three months the cone group does report a statistically 
significant change (p-value 0.03) at the L1-L4 region of - 0.810 %, although at 
six months this has returned to a baseline levels. In the non-cone group the 
lumbar spine changes were mainly increases, although none with statistically 
significance. The differences reported in the lumbar spine of both groups might 
be due to either osteophytes or sclerotic changes within individual participants 
elevating their BMD, with extensive literature reporting this link [409]. This is 
why clinically in DXA reporting, two vertebral bodies free from osteophytes or 





When directly comparing the two groups percentage difference, there was no 
statistically significant result, although the absolute BMD differences does report 
one at L1 at six months with the cone group reporting a higher BMD than the 
non-cone group (a difference of 0.204 g/cm2 (p-value of 0.028)). This is 
reflected in the percentage change with the non-cone reporting its highest 
lumbar spine loss of -1.916 % when compared to baseline.  
 
For the overall total spine (L1-L4) the cone group reports a loss of 0.08 % at six 
months and a gain of 1 % at 12 months, in the non-cone group they report an 
increase of 1.3 % at six and 12 months. Other research investigating changes in 
L1-L4 over 12 months have shown decreases [23] (compared to baseline/pre-
op) in both TKR and control groups, with a reported change of -0.013 g/cm2 at 
six months (-1.07 %) and -0.011 g/cm2 at 12 months (-0.91 %) in the TKR 
group, and -0.005 g/cm2 (-0.44 %) and -0.004 g/cm2 (-0.35 %) in the control 
group [23]. Although these differences might be for the degenerative disease 
reasons already stated, especially as this study included revision participants 
who were an older age group, and thus more likely to develop osteophytes and 
degenerative disease [415]. 
 
HIP BMD CHANGES IN CONE GROUP  
The ipsilateral hip in the cone group compared to the baseline figures show 
statistically significant changes from the start, at six weeks there is an increase 
in BMD in the neck and wards (0.036 g/cm2 or 3.580 %, and 0.020 g/cm2 or 
2.102 %), but a loss in the trochanter of -2.043 % (-0.018 g/cm2), resulting in an 
overall total hip loss. The increases in the wards triangle and neck region might 
be due to the high concentration of trabecular within the wards triangle which 
makes up the majority of bone remodelling and turnover [416]. It is also highly 
metabolically active and has a high surface area to volume ratio [389, 390]. This 
turnover might be the reason there is an increase at 6 weeks in these regions, 
as the participants become more stable and weight bear more, it promotes 
more remodelling. Although the total hip data report a loss (-0.469 %), this 
figure is possibly due to the losses in the slower cortical bone turnover 





At three month the increases in the wards and neck, have diminished 
(compared to six weeks) reporting gains of 1.807 % (0.018 g/cm2) and 0.333 % 
(0.003 g/cm2), this might be due to more equal weight bearing and a more 
balanced gait, with the trochanter still reporting a statistically significant loss (-
2.345 % or -0.018 g/cm2).  Overall the total loss has also increased from just 
under 0.5 % (-0.004 g/cm2) to just over 1 % (0.010 g/cm2) most likely due to the 
increased loss in the trochanter. 
 
At six months there are losses reported by every region, with the shaft and total 
hip reporting statistically significant losses of -1.698 % (-0.019 g/cm2) and -
1.562 % (-0.015 g/cm2) respectively. At 12 months the total loss was reported as 
-1.365 % (-0.013 g/cm2) (p-value 0.05), and there is minimal change in the 
wards and neck (compared to baseline), and a loss in the trochanter of just 
under 2 % (p-value 0.05). 
 
These changes in the baseline comparison data are supported by the literature: 
Soininvaara et al [26] reported at 12 months a loss of -0.012 g/cm2 in the 
femoral neck (compared to baseline), -0.023 g/cm2 in the trochanter, and a loss 
of -0.013 g/cm2 in the total hip, and Hopkins et al [23] reported a loss of -0.016 
g/cm2 in the neck, and -0.015 g/cm2 in the total hip. As stated our data report a 
similar 12 month figure in the trochanter -0.014 g/cm2 (-1.890 %), and matches 
the reported figure from Soininvaara et al [26] of -0.013 g/cm2 in the total (-
1.365 %).Although in our data there are minimal changes in the neck and wards 
of 0.001 g/cm2 (0.097 %) and 0.003 g/cm2 (0.109 %). 
 
For the contralateral hip data there is a reported loss at six weeks compared to 
baseline in the wards and neck, and an increase in the total hip, this is 
complimentary to the ipsilateral data, in that there is an increase in the 
ipsilateral and loss in the contralateral (in the wards and neck), and a decrease 
in total hip in the ipsilateral and an increase in the contralateral. Overall the total 
hip changes in the contralateral are just over 0.5 % (six weeks 0.006 g/cm2), to 
0.8 % (three months 0.009 g/cm2), to just over 0.6 % (0.007 g/cm2) at six 
months, and 0.388 % at 12 months (0.004 g/cm2). These results in the cone 
group reported throughout the visits could be because of dominant use post-op 
in the ipsilateral hip especially in the first six weeks maybe due to modified gait, 
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and then reverting back to the contralateral with weight bearing becoming a 
more equal. Unfortunately, Soininvaara et al [26] did not record six week data, 
and Hopkins et al [23] did record femoral neck data (a loss 0.07 g/cm2), and 
total hip (-0.011 g/cm2) there was no recorded wards or trochanter.   
 
If we look at the comparisons directly between the ipsilateral and contralateral 
hips in the cone group, there are three regions of statistical significance: at six 
weeks the neck difference is 4.78 % (p-value 0.004) in support of the ipsilateral 
hip and -2.730 % in the trochanter (p-value 0.02), the reasons for these possible 
changes have already been stated. At three months the total hip is a difference 
of -1.973 % this is due to the accumulation of BMD losses in the hip regions, as 
all four visits report total hip losses of between 1 and 2 %. At 12 months the 
reported differences were neck 1.965 % (-0.014 g/cm2), wards 0.64 % (0.015 
g/cm2), trochanter -2.56 % (-0.014 g/cm2), shaft -1.651 % (-0.007 g/cm2) and 
total -1.222 % (-0.008 g/cm2). 
  
Due to the reported change in BMD and the absolute figures, it is argued that at 
12 months in the cone group the BMD has not started to plateau yet.  
 
This is supported by the literature that has shown that in control groups the 
ipsilateral and contralateral hips have similar BMD figures, as Rao et al [418] 
stated that there was a highly significant correlation between the BMD of the 
two hips at the femoral neck, trochanter, and wards triangle. This is further 
supported by Soininvaara et al in 2004 [26] who reported BMD changes in TKA 
participants between the ipsilateral and contralateral at 12 months post-
operation, reporting a loss of -0.029 g/cm2 (femoral neck), -0.039 g/cm2 
(trochanter), -0.030 g/cm2 (shaft) and -0.032 g/cm2 in the total hip (although they 
also report -0.026 g/cm2 (wards), which does not match these data). This trend 
is similar in Hopkins et al study [23] investigating TKR reported a difference 
between the ipsilateral and contralateral total hip at 12 months was reported as 
-0.027 g/cm2, although an increase of 0.002 g/cm2 was reported at the femoral 






HIP BMD CHANGES IN THE NON-CONE GROUP  
In the non-cone ipsilateral data there is a similar trend to the cone data, with an 
increase in the neck (0.08 %) and wards (4.2 %) at six weeks, and gradually 
decreasing at every visit, until reporting -3.363 % (neck, p-value 0.01) and -
0.377 % (wards) at 12 months.  
 
The total hip BMD figures show a similar trend again to the cone group, with the 
highest difference reported at six weeks (0.135 % (0.002 g/cm2) and this figure 
continuing to drop throughout, reporting a 12 month figure of -0.572 % (-0.001 
g/cm2). The total hip BMD has most likely been influenced by the wards results 
of 4.2 % for the six week visit, with the changes in the neck and wards triangle 
paralleling the total hip changes, which is mimicked in the cone data, so is 
probably for the same reasons i.e. increased weight bearing post-op on the 
ipsilateral hip, and thus increased turnover in those hip regions.  
 
The non-cone ipsilateral trochanter data reports only one minus figure at all 
visits (unlike in the cone group), although at six months there are losses 
reported by every region (except one) showing a similar trend to the six month 
cone ipsilateral data. It must be noted that the non-cone group figures are not 
statistically significant. 
 
For the contralateral comparison data between cone and non-cone there is 
more variation; in the wards triangle at six weeks there is a loss (-0.580 % (-
0.004 g/cm2)) this would agree with the cone contralateral data, although the 
non-cone contralateral femoral neck data report a statistically significant 
increase of just over 2 % (0.019 g/cm2) compared to the negative result of the 
cone group. At three months there is a reported statistically significant loss of 
BMD in the wards triangle at three months (-3.047 % -0.020 g/cm2) in the 
contralateral hip. Although, at six months the neck figure reports a positive of 
0.015 g/cm2 (non-cone) (as does the same region in  the cone group, 0.010 
g/cm2), with the 12 month data both contralateral hip totals reporting a loss 
(although more severe in the non-cone data).  
 
The trochanters show a similar a pattern to the contralateral cone group, 
reporting an increase of just less than 1.7 % at six weeks, reducing to an 
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increase of 0.287 % at three months, a loss reported at six months, and an 
increase at 12 months. The total hip data follow a similar trend to the 
contralateral hip cone data, at six weeks and six months there is an increase 
(0.76 % (0.08 g/cm2), and 0.251 % (0.001 g/cm2)). Furthermore, it must be 
stated that at 12 months the total for the contralateral non-cone hip was -0.536 
% (-0.004 g/cm2) compared to the 0.388 % (0.004 g/cm2) in the cone 
contralateral group, although there was no statistical significance between these 
two groups, except in the two regions mentioned. 
 
Investigating the comparison between the ipsilateral and contralateral in the 
non-cone data, again there a similar traits, at six weeks there is a difference of 
5.9 % (0.032 g/cm2) in the wards (like in the cone group) but there is a negative 
difference in the neck reporting just under -1.8 % (-0.014 g/cm2) were the cone 
group reported a positive, the total reported for the difference was -0.5 % (-
0.005 g/cm2) (with the cone group reporting -1 %). By six months the neck is 
reported as a difference of -3.4 % (-0.033 g/cm2) in the neck and 3.09 % 0.018 
g/cm2) in the wards, this trend is similar in the cone group as in comparison to 
the six week figures both the neck and wards have been reduced. At 12 months 
the neck has increased (compared to six months) with a reported difference of -
0.493 % (-0.002 g/cm2), although the wards has decreased further (-0.927 % or 
-0.003 g/cm2), the trochanter regions have dropped to its highest difference at 
12 months reporting a difference of -2.993 % -0.019 g/cm2). Finally, the total is 
reported as -1.036 % (-0.006 g/cm2). Looking at the 12 month absolute BMD 
(so the reported BMD not the change) as we did with the cone group the 
differences between ipsilateral and contralateral is reported as: -0.024 g/cm2 
(neck), -0.089 g/cm2 (wards), -0.067 g/cm2 (trochanter), -0.049 g/cm2 (shaft) 
resulting in a total BMD difference of -0.053 g/cm2. These absolute figures 
would again agree with the data already mentioned from Soininvaara et al [26] 
and Hopkins et al study [23]. Although none of the ipsilateral vs contralateral 
non-cone data were statistically significant and did include large SD and a small 
sample size.  
 
Overall, when comparing the cone and non-groups; at six weeks the non-cone 
group had a greater increase in the wards triangle 4.20 % vs 2.10 %, but the 
cone group had a greater increase in the neck 3.58 % vs 0.08 %, with the neck 
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result difference reported as statistically significant between the two ipsilateral 
hip groups. Both groups show a gain at six weeks of BMD in the wards triangle 
region, and then a loss from that six week position, with the neck trend again 
being similar between the two groups, the shaft reports a loss compared to 
baseline for every visit in both groups. The total BMD shows similar trends as 
well, both reporting their most positive figure at six weeks, then starting to 
decrease at three months and six months until 12 months were the cone group 
changes from -1.50 % to -1.36 %, and the non-cone group go -0.570 % at six 
months to -0.572 % at 12 months.  
 
These changes reported in the total hip in both groups could be the beginning of 
the hip BMD starting to return to a plateau, and that by the 24 months both 
groups could be back at their baseline figures. This would correlate with the 
TKR knee BMD data reported from the systematic review data across several 
studies [178, 292, 300, 305]. Furthermore, the four papers that investigated the 
lumbar spine [23, 301] and hip changes [23, 26, 301] in TKR, all reported BMD 
losses at 12 months when compared to baseline both for the hip and lumbar 
spine, although it must be noted these data are extremely limited. 
 
 
5.9 LIMITATIONS OF THE STUDY 
 
5.9.1 LIMITATIONS TO TOTAL BODY AND LUMBAR SPINE 
Limitations in the total body analysis was the inability to visualise the cement 
fully on the image making artefact classification an issue, to address this the 
revision implant and some of the area around it were manually classified as 
artefact.  
 
For the lumbar spine data, it was originally proposed to remove those lumbar 
vertebrae which had pre-op reported sclerotic bodies or degenerative change 
(via the DXA radiographers report), and re-analyse the data. Unfortunately, a 
high majority of participants (most likely due age) had sclerotic or osteophytic 
issues with their lumbar spine (with some participants having their entire lumbar 
spine excluded from the report), thus exclusion and re-analysis of the data was 
deemed impractical due to the small number of participants to start with, being 
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diluted further, this would have resulted in excluding approximately half of the 
lumbar spine vertebrae. Furthermore, this would also have required each scan 
from each visit to be re-reported on due to the possibility of future sclerotic 
changes impacting those additional scans, with further vertebrae excluded 
throughout the visits. Therefore, as the issue was across both groups it was 
concluded to include all vertebral bodies of the participants individually, and as 
a whole, especially as this was comparing changes to their own baseline. With 
a larger cohort exclusions could be implemented and a more robust result could 
have been attained. 
 
5.9.2 LIMITATIONS OF HIP STUDY 
Unfortunately, there are no data for rTKR participants from DXA scans, so it is 
unknown if the trends reported in both groups was consistent, as there is no 
direct data to correlate this. Furthermore, the comparisons to the additional 
studies are of a small sample size, especially with this study only having 22 
complete the 12 month appointment (Hopkins et al [23] N=19) (Soininvaara et al 
[26] N=69).  
 
Moreover, the participants involved underwent different procedures, Hopkins et 
al recruited TKR participants, and Soininvaara et al [26] recruited TKA patients. 
Although it must be noted that the participants from the Hopkins et al [23] study 
where from the same area and scanned on the same DXA equipment, although 
additionally. Hopkins et al study did not include male participants, and 
Soininvaara et al [26] study did, but only 29 % were male of the 69 participants.  
 
It is unknown if the differences reported in the cone group compared to the TKR 
and TKA studies are simply due to revision participants recovering sooner due 
to previous experience of having a TKR, or the impact of the physiotherapy 
changes, so it is possible participants had a greater understanding, and less 
apprehension about limitations and functionality, and those who were more 
actively engaged in the physiotherapy may have thus recovered their BMD 
more quickly. Although this change is not entirely seen in the non-cone group, 
who received the same physiotherapy instructions (although as stated it is 
unclear which participants were completely compliant in adhering to the 




Furthermore, it must be acknowledged that the non-cone groups sample size 
was much smaller, and possibly with greater numbers would result in similar 
figures and trends reported. Unfortunately, the loss of five participants due to 
bone loss, could not be predicted, and there was no reported difference 
between their group and the group that continued, and only the advent of 
additional visual inspection by other orthopaedic surgeons creating a consensus 
during AORI classification could possibly reduce this attrition. The reported 
changes are also subject to precision errors as discussed in a previous chapter, 
although this would mean the total hip result is more prominent due to its lower 
precision error and its utilisation in reporting on outcomes of BMD figures when 




The lumbar spine data although higher in the non-cone group than the cone 
group, is unlikely to be definitively influenced by the cone vs non-cone 
comparison, this is due to the influence of sclerotic and degenerative changes 
in the lumbar spine most likely falsely elevating the BMD. The total body BMD 
data show an association to the cone group reporting increases across all visits; 
this is even in conjunction with the increased BMD results of the lumbar spine 
across multiple visits in the non-cone group. This would support the idea that 
those in the cone group are undergoing weight bearing exercise earlier, 
although without knowledge of adherence to physiotherapy, this cannot be 
definitive.  
 
This BMD data as reported via the DXA scans would suggest that there is early 
remodelling in rTKR patients at six weeks in the wards and neck, and that by 12 
months, although there were still reported losses, there was the beginning of a 
move towards a plateau, and that by 24 months equilibrium might be reached. 
This is supported by the absolute change in the cone group and the total hip 
cone data. This is less clear in the non-cone group, and it is unknown if this is 
due to the impact of the cone on stabilisation or the small numbers in the non-
cone group, based on the six week data also support the remodelling increase 
in the wards and hip, I would conclude it is more likely the latter.  
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Finally, these data for the total body, lumbar spine, and bilateral hips should be 
treated with reservations due to the limitations of the small sample size in both 
groups, and the lack of comparative rTKR BMD DXA hip data.  
 
 
5.11 FUTURE WORK 
Moving forward towards the full trial, the DXA modality has produced strong 
evidence of BMD change, with comparisons between groups and appointments 
due to the overlap ROI function providing accurate evidence. Therefore, it would 
be recommended as the main tool for determining BMD change during the 
study. That being said, consistent positioning is still required and caution should 
be used when interpreting the lumbar spine changes due to the osteophytic and 























CHAPTER 6: MAIN STUDY – BMD CHANGES IN PA AND LATERAL 
KNEES– A COMPARISON BETWEEN BASELINE, IPSILATERAL AND 
CONTRALATERAL, AND CONE VS NON-CONE FOR RTKR PARTICIPANTS  
 
 
6.1 INTRODUCTION  
This chapter will outline the methods utilised, and the analysis used in the main 
study. This study utilised the same participants as the chapter five with the 
addition of DXA knee imaging and knee regional analysis. This was in order to 
identify BMD changes in the ipsilateral and contralateral knees in and around 
the implant at certain time intervals over a period of one year. 
 
From the systematic review data, it has been shown that there are minimal 
studies investigating ipsilateral BMD change in rTKR surgery via DXA imaging. 
Although there are some reported data regarding replacements and 
arthroplasties. In the systematic review there were only two papers that 
investigated rTKR and BMD in DXA imaging, and both were from Jensen et al 
[178, 179]. Furthermore, no study involving this new type of Stryker cone has 
been investigated, although Jensen et al 2012 [178] did investigate their own 
type of cone and its impact in rTKR on BMD; this was a different construction 
and style of cone.  
 
6.1.1 AIM 
To investigate the BMD changes in rTKR participants in and around regions of 
the distal femur and proximal tibial areas at post-op intervals, with comparisons 
between baseline measurements (defined as six weeks post-op) and their 
subsequent visits.  Percentage changes throughout the visits were calculated in 




Participants, grouping, randomisation and recruitment are exactly the same 
group as mentioned in chapter five section 5.2. This resulted in 37 participants 




6.3 METHOD, IMAGING 
 
6.3.1 DXA IMAGING METHOD 
Prior to their rTKR all 37 participants were invited to undergo a pre-operative 
BMD evaluation via a DXA scan (GE Lunar prodigy, Bedford, MA). This 
involved scanning their ipsilateral and contralateral knees in the PA and lateral 
projection.  
 
DXA KNEE POSITIONING 
Knee positioning in DXA is relatively new but follows the densitometric analysis 
positioning protocol [255]. For the PA knee scan this requires the patient to be 
supine and straight, with the scan done with the knee in full extension with 15° 
internal rotation, this is maintained via the foot scan device used in hip DXA 
imaging which maintains internal rotation for repeated imaging by strapping the 
foot in place. Lateral DXA knee scans are done with the patient on their right or 
left lateral decubitus, with the knee in 20° flexion checked via a goniometer 
[255], a pad is placed under the ankle to superimpose the femoral condyles 
more easily. Furthermore, both the PA and lateral are supported with rice bags 
due to the need for a soft tissue substitute around the knee area [255] due to 
edge detection artefacts. Additionally, all DXA knee scans are produced on the 
spine “thin” mode setting, as there is no pre-defined knee setting. 
 
Laser crosshair positioning in both the PA and lateral is dependent on stem or 
replacement length under investigation, as the whole implant should be 
included.  Please note patient preparation and DXA QA are the same as the 
previous chapter. DXA knee scans with total body, lumbar spine, and bilateral 
hips were conducted at pre-op, six weeks post operation (this was defined as 
one week before or one week after the exact six week post-op date), and then 
at three (defined as one week before and two weeks after the exact three month 
date), six (defined as one week before and two weeks after the exact six month 
date), and 12 months (defined as two weeks before and four weeks after the 






6.4 ANALYSIS OF KNEE DXA IMAGING  
 
6.4.1 DXA KNEE ANALYSIS 
The DXA knee scans were done on a PA thin spine setting (which is the 
standard setting as previously stated), due to this setting the DXA analysis on 
the PA and lateral knee scans  resulted in some miscategorisations by the DXA 





















Therefore, modifications were required to manually alter the classifications of 
soft tissue and bone, the definition of the artefact (the blue in the image in figure 
6.1) was not altered as it highlighted the implants within the patient, the lateral 
images were annotated and classified in the same way (figure 6.2 and 6.3 show 
an annotated set with ROI).  
 
Due to this manual classification of soft tissue and bone on the lateral and PA 
images, a COV was calculated to determine variation in the researcher’s (MG) 
Figure 6.1 PA (A) and lateral (B) knee DXA image, with the software defining 






ability to define soft tissue and bone on multiple identical images. Therefore 10 
random PA revision knee images, and 10 random lateral revision knee images 
were chosen, the bone and soft tissue were then manually classified on the 
individual image and BMD result recorded, the image was wiped of the 
classification and this was repeated for 10 times resulting in a calculated COV 
























After correct classification of the PA and lateral knee images, the knees were 
subdivided into ROI as shown in figures 6.2 and 6.3. This ROI subdivision knee 
analysis was based on standard format which has been shown in previous BMD 
knee research [178, 255, 260, 419]. 
 
Figure 6.2. DXA PA knee image, 




Figure 6.3. DXA lateral knee image, 







The region selections were kept consistent between each individual participants 
scans, with the ROI maps saved from the original scan, reloaded onto future 
appointments and then slight modifications applied to allow correct overlap of 
the anatomy. The regions were kept anatomically consistent across all regions 
(table 6.1).  
 
 
PA (figure 6.2)                                               Lateral (figure 6.3) 
Region 1 –Femoral medial condyle Region 1 – Superimposed femoral condyles 
Region 2 – Femoral lateral condyle Region 2 – Femoral stem 
Region 3 – Femoral stem  Region 3 – After stem 
Region 4 – After femoral stem  Region 4 – Superimposed tibial condyles  
Region 5 – Tibial medial condyle Region 5 – Tibial stem  
Region 6 – Tibial lateral condyle Region 6 – After tibial stem 
Region 7 – Tibial stem    
Region 8 - After tibial stem    
 
It must be noted these regions were kept consistent regardless of PA left or PA 
right, with the ROI flipped when needed.  
 
For the lateral data the regions were kept consistent, but were rotated to 
become parallel with the patients femur and tibia, with further minor adjustments 
made to fit the correct recorded regions. 
  
After application of the ROI in both the PA and lateral images, the fibula in both 
the PA and lateral images were classified as artefact if it was in any ROI box, 
this did not affect any overall BMD, and was applied so it would not interfere 
with the true BMD of the tibia (an example of this is shown in figure 6.4), this 
was seen as a more optimum solution than modifying each ROI individually and 


































All regions (both PA and lateral) were kept consistent across all images when 
intra comparing patient visits; although these regions were slightly modified to 
always reflect the correct anatomical region. Thus, patients with short stems 
would have a smaller region seven but this would be consistent when intra 
comparing between their visits. It must be acknowledged that post processing of 
the knee scans was administered in the form of checking the correct 
classification of soft tissue, bone and artefact within the image, although this 
processing was done prior to any regional analysis in order to reduce bias of 
selection.  
 
The BMD of the regions for the ipsilateral knee were compared to the six week 
post-op rather than the pre-op, this was done for several reasons, firstly due to 
there being no definitive regions in the pre-op scan until the implant was in 
place, and thus would have provided erroneous data. Secondly, we were 
Figure 6.4. PA DXA knee image before fibula classification (A), PA DXA knee 





primary investigating the impact of the cone on BMD post-surgery in the knee, 
thus for all knee BMD data the six week scan was utilised. 
 
As with the other anatomical regions, the ipsilateral knee per region was 
intracompared at each visit to the baseline six week post-op. This BMD change 
was recorded on a Microsoft Excel spreadsheet as an absolute change as well 
as calculated percentage change for each visit, an overall mean difference, SD 
and 95 % CI was calculated for each region and a paired samples t-test and p-
value created for each comparison. This analysis was repeated for the 
contralateral knee as well, again compared to its six week post-op BMD 
regional result. 
 
This analysis was repeated for the non-cone group, including scans of both the 
ipsilateral and contralateral knee for all 12 month visits, this allowed 
comparisons between the ipsilateral BMD changes in the cone group and 
ipsilateral changes in the non-cone group at each visit, as well as changes in 
the contralateral knee. This was in order to investigate if contralateral knee 
changes in both groups were also similar. In comparing groups an independent 
t-test assuming unequal variance, p-value, SD, SE was calculated. 
 
Furthermore, mean BMDs between the ipsilateral and contralateral were not 
compared directly (unlike in the hip analysis), and only compared as a 
percentage change compared to baseline, this was simply due to the ipsilateral 
containing the revision and fixation cement so having a more highly elevated 
BMD.  
 
Due to the nature of repeated t-tests leading to increased probability of type one 
errors a statistician was consulted (Dr Obi Ukoumunne) who suggested using a 
linear regression analysis. This was performed on the absolute BMD figures per 
region from the PA and lateral knee data. Participant ID was used as the 
random effect, obtaining maximum likelihood estimate score per region. Any 
data missing (due to lack of attendance) was left blank. Data were coded as 
such; participant ID number, group (cone group 1, non-cone group 0), and time 
period (6 week baseline = 0, three months = one, six months = two, 12 months 
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= three). With the STATA (version 16) used to analyse the figures resulting in a 
coefficient, 95 % CI and overall p-value.  
 
6.4.2 INTRAOPERATOR REGIONAL ANALYSIS OF THE KNEE 
Due to the selective nature of the ROI over the DXA images, especially in the 
PA and lateral DXA knee images, it was decided to calculate a COV for the ROI 
selected, thus an intraoperator repeated ROI study was conducted. This 
involved five PA and five lateral ipsilateral knee DXA images, five PA and five 
lateral non-cone ipsilateral images, and five PA and five lateral random 
contralateral knee images. Each image was analysed as per the method stated 
in section 6.5.1.1 with the regions utilised in table 6.1, with these images re-
analysed, this was repeated until 10 repeats were created for each group and 
orientation with a COV created for each ROI. 
 
 
6.5 RESULTS  
 
6.5.1 INTRAOPERATOR RESULTS - COV FOR COLOURISATION OF DXA 
KNEE IMAGES 
The method involved collecting 10 random PA knee images and 10 random 
lateral knee images (post standard software application), any corrections to soft 
tissue or bone was then applied and the BMD recorded for that image, this was 
to be repeated 10 times over several weeks. A COV was to be calculated to 
create a precision score for the manual modifications/classifications of bone and 
soft tissue (although it must be noted that some images required only slight 
modification). Unfortunately, due to COVID-19 and campus lockdown, access to 
the DXA room was suspended, thus classifications and repeated visits could not 
be undertaken, and thus no COV precision for manual modification could be 
calculated. It must be acknowledged that DXA software is unique and only on 
the DXA computer (following compliance with the General Data Protection Act), 






6.5.2 INTRAOPERATOR RESULTS- COV ROI ANALYSIS FOR PA AND 
LATERAL KNEE IN DXA IMAGES 
The method was to create a COV for the ROI on the PA ipsilateral and lateral 
cone images, the PA ipsilateral and lateral non-cone images and for PA and 
lateral contralateral knee images. This (similar to the COV colourisation) was to 
involve several visits and repeats over several weeks. Unfortunately, as per 
6.5.1, COVID-19 restricted access to the campus and the DXA room, not only 
stopped participant recruitment, but meant that a COV ROI precision could not 
be completed due to inaccessibility of the facilities.  
 
 
6.6 BMD DXA RESULTS OF THE PA KNEE  
In total 37 participants consented to pre-op, 26 completed six weeks, 26 at 
three months, 25 at six months, with 22 participants completing 12 months (15 
cone, seven non-cone). As stated previously, one participant received a femoral 
cone (so not a tibial cone like the other “cone” participants), therefore their DXA 
knee data was treated as non-cone data for the tibial regions (having had no 
implant in the tibia, other than the revision), with the femoral data were excluded 
from the analysis altogether. Furthermore, two participants underwent knee 
operations prior to their 12 month visit, both on their contralateral knee (a 
revision and replacement), therefore their contralateral BMD data for the PA 
and lateral knee data were excluded. Due to the impact on the participant 
numbers the cone group was not divided into the long and short stems, and 
instead was kept together as the “cone” group. In total the cone group reported 
15 short stems and eight long stems (one cone group participant withdrew prior 
to receiving either length making 24 cone participants), the non-cone group 
reported four short stems nine long stems making 13 non-cone participants at 
pre-op (37 total).  
 
This section will now report the BMD results for the PA knee in DXA images, 
with the lateral knee DXA data following in the next section. The data was 
compared between each participant’s visits (three month, six month, and 12 
month) to their baseline (six week post-op) score, with a mean percentage 
change calculated for both the cone and non-cone group, with these percentage 
results then compared between the two groups.  
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Table 6.2. Shows the mean baseline (6 week) BMD (g/cm2) for the PA knee, for 
the cone group (N=17) and non-cone group (N=9) 
N=17 (CONE GROUP) 6 WEEKS (BASELINE) 
IPSILATERAL 
6 WEEKS (BASELINE) 
CONTRALATERAL 
  Mean 
(g/cm2) 
SD SE Mean 
(g/cm2) 
SD SE 
Medial femoral condyle 0.834 0.208 0.050 1.116 0.487 0.118 
Lateral femoral condyle 0.916 0.257 0.062 1.015 0.244 0.059 
Femoral stem 1.455 0.181 0.044 1.084 0.281 0.068 
Beyond stem 1.974 0.333 0.081 1.501 0.485 0.118 
Medial tibial condyle 1.167 0.298 0.072 1.027 0.242 0.059 
Lateral tibial condyle 1.193 0.283 0.069 1.012 0.228 0.055 
Tibial stem 1.955 0.222 0.054 1.399 0.249 0.060 
Beyond stem 2.449 0.189 0.046 1.689 0.352 0.085 
N=9 (NON-CONE GROUP)       
Medial femoral condyle 0.835 0.198 0.070 0.959 0.292 0.097 
Lateral femoral condyle 0.708 0.242 0.086 0.835 0.277 0.092 
Femoral stem 1.515 0.243 0.086 1.024 0.418 0.139 
Beyond stem 2.139 0.561 0.212 1.525 0.601 0.200 
Medial tibial condyle 1.150 0.318 0.106 0.840 0.318 0.106 
Lateral tibial condyle 1.266 0.260 0.087 0.951 0.380 0.127 
Tibial stem 1.911 0.185 0.062 1.398 0.309 0.103 
Beyond stem 2.351 0.381 0.127 1.828 0.447 0.149 
 
Table 6.2 show the mean BMD in g/cm2 baseline (six week) results of the 26 
(17 cone, nine non-cone) participants who underwent a DXA scan at six weeks. 
It must be noted that the comparisons to baseline in the following results tables 
and figures, involved comparing the participants BMD visit score with their own 
baseline score to report a direct change with this BMD change converted into a 
percentage for each participant, with an overall mean percentage calculated for 
that group. It must also be acknowledged that the high baseline figures in the 
stem and beyond stem sections of both the tibia and femur are primarily due to 
the addition of fixation cement in these areas, hence why there will be no direct 
BMD comparisons, only the reported percentage changes. 
 
6.6.1 BMD PERCENTAGE DIFFERENCE IN PA KNEE WHEN COMPARED 
TO BASELINE, FOR IPSILATERAL AND CONTRALATERAL CONE GROUP 
These data compare the BMD percentage results compared to baseline in the 






3 MONTHS (N=17) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
-0.002 0.612 -6.24 7.46 14.425 3.499 0.08 0.93 
Lateral femoral 
condyle (g/cm2) 
0.043 4.931 0.71 9.11 8.825 2.140 -2.11 0.05 
Femoral stem 
(g/cm2) 
0.003 0.118 -2.27 2.51 5.026 1.219 -0.19 0.85 
Beyond femoral 
stem (g/cm2) 
0.046 2.411 0.62 4.20 3.760 0.912 -2.63 0.02 
Medial tibial 
condyle (g/cm2) 
-0.046 -4.101 -8.36 0.16 8.953 2.171 1.88 0.08 
Lateral tibial 
condyle (g/cm2) 
0.026 2.461 -2.1 7.00 9.542 2.314 -1.01 0.32 
Tibial stem  
(g/cm2) 
0.007 0.535 -2.36 3.44 6.099 1.479 -0.25 0.81 
Beyond tibial 
stem (g/cm2) 
-0.012 -0.486 -3.39 2.41 3.116 0.756 0.63 0.54 
6 MONTHS (N=16) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.018 2.560 -5.01 10.10 15.082 3.771 -0.64 0.53 
Lateral femoral 
condyle (g/cm2) 
-0.040 -3.084 -10.70 4.49 15.451 3.863 1.02 0.32 
Femoral stem 
(g/cm2) 
-0.013 -0.979 -4.24 2.28 6.653 1.663 0.55 0.59 
Beyond femoral 
stem (g/cm2) 
0.009 0.625 -2.06 3.31 5.460 1.365 -0.33 0.75 
Medial tibial 
condyle (g/cm2) 
-0.059 -5.336 -13.50 2.84 16.687 4.172 1.15 0.27 
Lateral tibial 
condyle (g/cm2) 
0.007 0.538 -5.19 6.27 11.688 2.922 -0.21 0.83 
Tibial stem  
(g/cm2) 
-0.021 -1.112 -4.84 2.62 7.622 1.906 0.59 0.56 
Beyond tibial 
stem (g/cm2) 
0.016 0.650 -1.74 3.04 4.876 1.219 -0.53 0.60 
12 MONTHS (N=14) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.010 2.114 -7.89 12.10 19.107 5.107 0.23 0.83 
Lateral femoral 
condyle (g/cm2) 
-0.010 0.132 -8.46 8.72 16.931 4.525 -0.23 0.82 
Femoral stem 
(g/cm2) 
-0.041 -2.847 -6.67 0.97 7.285 1.947 -1.46 0.17 
Beyond femoral 
stem (g/cm2) 
0.089 4.495 2.10 6.89 4.575 1.269 3.54 0.00 
Medial tibial 
condyle (g/cm2) 
-0.099 -8.979 -19.50 1.520 19.999 5.345 -1.59 0.14 
Lateral tibial 
condyle (g/cm2) 
0.054 3.695 -3.15 10.50 13.057 3.490 1.42 0.18 
Tibial stem  
(g/cm2) 
-0.050 -2.930 -6.21 0.35 6.256 1.672 -1.52 0.15 
Beyond tibial 
stem (g/cm2) 
-0.038 -1.653 -4.21 0.907 4.885 1.305 -1.22 0.25 
Table 6.3. Shows the ipsilateral PA knee compared to baseline (6 week) BMD 





3 MONTHS (N=17) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.019 2.767 -1.47 7.01 8.925 2.165 -1.04 0.31 
Lateral femoral 
condyle (g/cm2) 
0.007 1.398 -4.66 7.46 12.753 3.093 -0.28 0.78 
Femoral stem 
(g/cm2) 
0.017 1.178 -1.07 3.43 4.735 1.148 -1.37 0.19 
Beyond femoral 
stem (g/cm2) 
0.004 0.102 -1.42 1.62 3.189 0.773 -0.38 0.71 
Medial tibial 
condyle (g/cm2) 
-0.001 -0.123 -2.35 2.11 4.687 1.137 0.12 0.91 
Lateral tibial 
condyle (g/cm2) 
0.009 0.408 -2.07 2.89 5.214 1.265 -0.77 0.46 
Tibial stem  
(g/cm2) 
0.024 1.515 -0.38 3.40 3.981 0.966 -1.63 0.12 
Beyond tibial 
stem (g/cm2) 
0.033 1.978 -0.84 4.80 5.923 1.436 -1.24 0.23 
6 MONTHS (N=16) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.002 0.798 -3.02 4.62 7.798 1.949 -0.12 0.90 
Lateral femoral 
condyle (g/cm2) 
0.014 0.855 -4.37 6.07 10.645 2.661 -0.50 0.63 
Femoral stem 
(g/cm2) 
-0.007 -0.729 -3.33 1.87 5.297 1.324 0.50 0.62 
Beyond femoral 
stem (g/cm2) 
-0.018 -1.554 -3.84 0.74 4.681 1.170 1.24 0.23 
Medial tibial 
condyle (g/cm2) 
-0.010 -1.098 -3.85 1.65 5.620 1.405 0.75 0.46 
Lateral tibial 
condyle (g/cm2) 
0.021 1.597 -1.16 4.36 5.627 1.407 -1.50 0.16 
Tibial stem  
(g/cm2) 
-0.001 0.082 -1.78 1.94 3.790 0.948 0.08 0.94 
Beyond tibial 
stem (g/cm2) 
0.002 0.424 -1.69 2.53 4.306 1.076 -0.08 0.93 
12 MONTHS (N=13) 1 PARTICIPANT UNDERWENT TKR ON CONTRALATERAL KNEE SO THESE DATA HAS BEEN 
EXCLUDED 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.013 3.931 -4.39 12.30 15.311 4.246 0.41 0.69 
Lateral femoral 
condyle (g/cm2) 
-0.012 -1.498 -9.17 6.17 14.118 3.916 -0.30 0.77 
Femoral stem 
(g/cm2) 
0.000 -0.196 -2.80 2.40 4.781 1.326 -0.02 0.98 
Beyond femoral 
stem (g/cm2) 
0.002 -0.060 -2.50 2.38 4.482 1.243 0.09 0.93 
Medial tibial 
condyle (g/cm2) 
0.003 0.496 -7.51 6.51 12.897 3.577 0.11 0.92 
Lateral tibial 
condyle (g/cm2) 
-0.001 -0.333 -4.52 3.86 7.175 1.990 -0.05 0.96 
Tibial stem  
(g/cm2) 
0.001 0.217 -2.95 3.39 5.831 1.617 0.04 0.97 
Beyond tibial 
stem (g/cm2) 
-0.006 0.049 -3.16 3.26 5.900 1.636 -0.22 0.83 
Table 6.4. Shows the contralateral PA knee compared to baseline (6 week) BMD 






Figure 6.5. Shows bar graph for BMD (%) changes in the cone group ipsilateral 
knee in different ROI throughout visits, error bars are SE 
Figure 6.6. Shows bar graph for BMD (%) changes in the cone group 








































Cone group ipsilateral knee changes throughout visits







































Cone group contralateral knee changes throughout visits
3 months 6 months 12 months
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Table 6.3 and figure 6.5 show the ipsilateral cone group changes throughout the 
visits. The medial femoral condyle shows increases at all three visits, with the 
highest reached at six months with a reported score of 2.56 %, the lateral 
femoral condyle has the greatest gain of all regions, with a reported increase at 
three months of 4.9 % (with a p-value of 0.05) (although this is a loss at six 
months and a slight gain by 12 months). The femoral stem shows very little 
change across all visits, beyond the femoral stem shows an increase across all 
visits with a large score of 4.495 % at 12 months (0.00 p-value).  
 
The tibial ipsilateral data involve the two regions around the cone, the medial 
and lateral tibial condyles. In the tibial medial condyle, the loss in BMD is seen 
throughout each visit, gradually getting worse; -4.1 % (three months, p-value 
0.08), -5.3 % (six months, p-value 0.27), -8.979 % at 12 months (p-value 0.14). 
In the lateral tibial condyle, the BMD reports the opposite, reporting increases at 
every visit; 2.5 % (three months) 0.5 (six months), and 3.695 % at 12 months. In 
the tibial stem there is a small increase at three months, and then gradually 
decreases reporting a loss of -2.93 % at 12 months. Beyond the tibial stem 
reports a small decrease at three months, a gradual increase at 6 months, with 
a final change of -1.653 % at 12 months. Although it must be noted only three 
figures reported a statistical significant p-value: the lateral femoral condyle at 
three months (4.931 %, p-value 0.05), beyond femoral stem also at three 
months (2.411 %, p-value 0.02), and again at the femoral stem at 12 months 
(4.495 % (p-value 0.00)). 
 
Table 6.4 and figure 6.6 report the contralateral cone group changes throughout 
the visits. The medial femoral condyle shows increases throughout each visit, 
with a reported figure of 2.77 % at three months, and an increase of 3.39 % at 
12 months. The lateral femoral condyle shows increases at three and six 
months (1.4 % and 0.86 % respectively) and a decrease at 12 months of -1.498 
%. The femoral stem and beyond the femoral stem, show small increases and 
decreases throughout with a reported 12 month figure of -0.196 % (femoral 
stem), -0.060 % (beyond the femoral stem). 
 
In the tibial regions the medial tibial condyle reports small changes throughout, 
reporting just over -1 % at six months, but -0.1 % and 0.496 % for three and 12 
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month respectively. In the lateral tibial condyle region, there are also small 
changes reported as 0.41 % at three months, and -0.333 % at 12 months, with 
the six month reported as a gain of 1.60 %. The tibial stem again is similar in 
the changes it reports, disclosing small changes at six and 12 months (0.08 % 
and -0.217 % respectively), with a reported increase of 1.5 % at three months. 
Under the tibial stem there was a small increase of 0.42 % (six months), with 
large increases of just under 2 % at three months, and at 12 months as 0.049 
%. 
 
It must be stated that none of the contralateral knee cone data reported a 
statistically significant change of a p-value of 0.05.  
 
6.6.2 BMD PERCENTAGE DIFFERENCE IN PA KNEE WHEN COMPARED 
TO BASELINE, FOR IPSILATERAL AND CONTRALATERAL FOR THE NON-
CONE GROUP 
These data compare the BMD percentage results compared to baseline in the 






















3 MONTHS (N=9) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
-0.022 -3.391 -9.39 2.61 9.183 3.247 0.77 0.47 
Lateral femoral 
condyle (g/cm2) 
0.005 0.976 -6.22 8.18 11.019 3.896 -0.17 0.87 
Femoral stem 
(g/cm2) 
-0.013 -0.808 -4.04 2.42 4.950 1.750 0.51 0.62 
Beyond femoral 
stem (g/cm2) 
-0.011 -1.119 -4.31 2.07 4.889 1.848 0.32 0.76 
Medial tibial 
condyle (g/cm2) 
-0.052 -3.061 -12.80 6.70 14.938 4.979 0.99 0.35 
Lateral tibial 
condyle (g/cm2) 
-0.035 -3.717 -8.86 1.42 7.875 2.625 1.05 0.32 
Tibial stem  
(g/cm2) 
-0.100 -5.219 -9.36 -1.08 6.339 2.113 2.42 0.04 
Beyond tibial 
stem (g/cm2) 
-0.021 -0.398 -3.60 2.80 4.901 1.634 0.58 0.58 
6 MONTHS (N=8)  
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
-0.020 -2.962 -13.90 7.94 15.800 5.972 0.40 0.70 
Lateral femoral 
condyle (g/cm2) 
0.008 0.912 -3.99 5.81 7.065 2.670 -0.38 0.72 
Femoral stem 
(g/cm2) 
-0.041 -2.913 -5.57 -0.25 3.832 1.448 1.83 0.12 
Beyond femoral 
stem (g/cm2) 
0.041 2.055 -1.25 5.37 4.777 1.950 -0.85 0.43 
Medial tibial 
condyle (g/cm2) 
-0.034 -1.373 -11.90 9.13 15.183 5.368 0.52 0.62 
Lateral tibial 
condyle (g/cm2) 
0.009 -0.783 -9.23 7.67 12.200 4.313 -0.14 0.89 
Tibial stem  
(g/cm2) 
-0.028 -1.310 -5.96 3.34 6.704 2.370 0.60 0.56 
Beyond tibial 
stem (g/cm2) 
0.048 2.429 -2.23 7.09 6.722 2.377 -0.92 0.39 
12 MONTHS (N=8) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.017 2.189 -13.10 17.50 22.020 8.323 0.28 0.79 
Lateral femoral 
condyle (g/cm2) 
0.008 2.733 -5.49 11.00 11.856 4.481 0.38 0.72 
Femoral stem 
(g/cm2) 
-0.028 -1.619 -5.12 1.88 5.047 1.908 -0.89 0.41 
Beyond femoral 
stem (g/cm2) 
0.010 0.223 -1.14 1.58 1.961 0.801 0.60 0.58 
Medial tibial 
condyle (g/cm2) 
-0.066 -3.856 -13.50 5.79 13.920 4.921 -1.18 0.28 
Lateral tibial 
condyle (g/cm2) 
-0.010 -2.015 -8.14 4.12 8.853 3.130 -0.19 0.85 
Tibial stem  
(g/cm2) 
-0.074 -3.496 -8.21 1.21 6.793 2.402 -1.48 0.18 
Beyond tibial 
stem (g/cm2) 
-0.013 -0.252 -3.52 3.02 4.720 1.669 -0.31 0.77 
Table 6.5. Shows the ipsilateral PA knee compared to baseline (6 week) BMD 





3 MONTHS (N=9) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
-0.075 -7.686 -11.90 -3.51 6.397 2.132 3.29 0.01 
Lateral femoral 
condyle (g/cm2) 
0.037 5.810 -6.19 17.80 18.388 6.129 -0.85 0.42 
Femoral stem 
(g/cm2) 
-0.009 -0.662 -3.27 1.95 3.998 1.333 0.66 0.53 
Beyond femoral 
stem (g/cm2) 
-0.063 -2.907 -5.70 -0.12 4.277 1.426 1.73 0.12 
Medial tibial 
condyle (g/cm2) 
0.027 2.088 -1.37 5.55 5.295 1.765 -1.29 0.23 
Lateral tibial 
condyle (g/cm2) 
0.008 0.953 -2.92 4.82 5.927 1.976 -0.44 0.67 
Tibial stem  
(g/cm2) 
-0.009 -0.868 -5.01 3.27 6.330 2.110 0.33 0.75 
Beyond tibial 
stem (g/cm2) 
-0.025 -1.975 -6.11 2.15 6.324 2.108 0.69 0.51 
6 MONTHS (N=8) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
0.007 2.679 -7.52 12.90 14.648 5.179 -0.16 0.88 
Lateral femoral 
condyle (g/cm2) 
0.015 3.154 -5.51 11.80 12.495 4.418 -0.47 0.65 
Femoral stem 
(g/cm2) 
0.014 1.152 -1.80 4.10 4.255 1.505 -1.16 0.28 
Beyond femoral 
stem (g/cm2) 
-0.018 -1.681 -4.42 1.06 3.956 1.399 1.22 0.26 
Medial tibial 
condyle (g/cm2) 
0.035 4.894 0.514 9.27 6.320 2.234 -2.06 0.08 
Lateral tibial 
condyle (g/cm2) 
0.009 0.409 -4.24 5.06 6.706 2.371 -0.44 0.67 
Tibial stem  
(g/cm2) 
-0.007 -0.827 -5.94 4.28 7.377 2.608 0.20 0.85 
Beyond tibial 
stem (g/cm2) 
-0.031 -2.378 -7.01 2.25 6.681 2.362 0.89 0.40 
12 MONTHS (N=7) 1 PARTICIPANT UNDERWENT TKR ON CONTRALATERAL KNEE SO THESE DATA HAS BEEN 
EXCLUDED 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Medial femoral 
condyle (g/cm2) 
-0.062 -5.997 -14.1 2.14 10.993 4.155 -1.60 0.16 
Lateral femoral 
condyle (g/cm2) 
0.048 5.825 -4.14 15.80 13.456 5.086 1.04 0.34 
Femoral stem 
(g/cm2) 
-0.024 -2.577 -8.35 3.19 7.783 2.942 -0.59 0.58 
Beyond femoral 
stem (g/cm2) 
-0.016 -2.636 -8.24 2.96 7.566 3.089 -0.38 0.72 
Medial tibial 
condyle (g/cm2) 
0.060 4.547 -1.75 10.80 8.500 3.213 1.50 0.18 
Lateral tibial 
condyle (g/cm2) 
-0.031 -2.380 -8.39 3.63 8.114 3.067 -0.75 0.48 
Tibial stem  
(g/cm2) 
0.006 -0.590 -7.19 6.01 8.916 3.370 0.13 0.90 
Beyond tibial 
stem (g/cm2) 
-0.011 -2.256 -9.80 5.28 10.182 3.848 -0.17 0.87 
Table 6.6. Shows the contralateral PA knee compared to baseline (6 week) BMD 





Figure 6.7. Shows bar graph for BMD (%) changes in the non-cone group 
ipsilateral knee in different ROI throughout visits, error bars are SE 
 
 
Figure 6.8. Shows bar graph for BMD (%) changes in the non-cone group 
contralateral knee in different ROI throughout visits, error bars are SE 
 
Tables 6.5 and figure 6.7 report the changes between visits of the ipsilateral 
knee in the non-cone group. The medial femoral condyle reported -3.4 % at 









































Non-cone group ipsilateral knee changes throughout visits









































Non-cone group contralateral knee changes throughout visits
3 months 6 months 12 months
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In the lateral femoral condyle there is an increase at three and six months of 
just under 1 %, increasing to 2.733 % at 12 months. The femoral stem shows 
decreases at all visits (-0.81 %, -2.9 % at six months p-value 0.12, and -1.619 
% at 12 months). Beyond the femoral stem, reports a loss of just over -1 % at 
three months then an increase of 2 % at six months, finishing on a change of 
just over 0.2 % at 12 months. 
 
For the tibial ipsilateral non-cone data, the medial tibial condyle shows losses 
throughout all visits with a maximum of -3.856 % (0.28 p-value) at 12 months (-
1.37 % at six months, and -3.06 % at three months). The lateral tibial similarly 
shows losses throughout each visit (-3.7 % at three months, -0.78 % at six 
months, and -2.015 % 12 months). The tibial stem also reported losses at every 
visit: -5.2 % at three months (p-value 0.04), -1.31 % at six months, and -3.496 
% at 12 months. Beyond the tibial stem showed variations throughout (-0.4 % at 
three months, 2.4 % at six months, and -0.252 % at 12 months).  
 
Only the tibial stem reported as -5.2 % (p-value 0.04) at three months stated a 
statistically significant p-values of 0.05 or under.  
 
Table 6.6 and figure 6.8 show the changes between visits of the contralateral 
knee in the non-cone group. The Medial femoral condyle reported -7.69 % (p-
value 0.01) at three months, increasing to 2.68 % at six months, with a final 
increase of just under 6 % at 12 months (0.16 p-value). The lateral femoral 
condyle is reported as an increase at every visit (5.81 % at three months, 3.15 
% at six months and 5.83 % at 12 months). The femoral stem shows increases 
and decreases, reported as -0.67 % at three months, 1.15 % at six months, and 
-2.58 % at 12 months. Beyond the femoral stem reported losses throughout all 
visits reporting the highest at three months of -2.91 %. 
 
For the tibial contralateral non-cone knee data, the medial tibial condyle shows 
increases at all visits, with a reported increase of 2.09 % at six weeks, 4.89 % 
(p-value 0.08) at six months, and 4.55 % at 12 months. The lateral tibial shows 
small differences at three and six months (+0.95 % at three months, -0.4 % at 
six months), and a loss of -2.38 % at 12 months. The tibial stem also reported 
losses at every visit (-0.87 % at three months, -0.83 % at six months, and -0.59 
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% at 12 months). Beyond the tibial stem showed decreases throughout (-1.98 % 
at three months, -2.38 % at three months, and -2.26 % at 12 months).  
 
Only the medial femoral condyle reported as -7.69 % (p-value 0.01) at three 
months, states a p-value of statistical significance (0.05 or under).  
 
6.6.3 BMD PERCENTAGE DIFFERENCE IN PA IPSILATERAL KNEE WHEN 
COMPARED BETWEEN CONE AND NON-CONE GROUP 
Table 6.7 conveys the ipsilateral percentage changes (compared to baseline) in 
the cone group when compared directly to ipsilateral percentages changes 
(compared to baseline) in the non-cone group. If there is no difference between 
groups the two figures should be similar, and thus report a 0 % difference, a 
positive difference is in support of the cone group and negative difference is in 























Table 6.7. Shows the mean BMD percentage difference compared to baseline 
at different visits, in the ipsilateral knee of the cone group vs the non-cone 
group to 3 d.p. including percentage difference (between groups), t-test and p-
value 
3 MONTHS CONE (N=17) AND NON-CONE 
(N=9)  





















-0.075 0.01 0.99 
Lateral femoral 
condyle (g/cm2) 




-2.601 -0.41 0.69 
Femoral stem 
(g/cm2) 




-1.228 -0.45 0.66 
Beyond femoral 
stem (g/cm2) 




4.272 2.85 0.01 
Medial tibial 
condyle (g/cm2) 




-5.123 -0.71 0.49 
Lateral tibial 
condyle (g/cm2) 




5.711 1.22 0.24 
Tibial stem  
(g/cm2) 
5.754 -2.23 0.04 
 
Tibial stem  
(g/cm2) 
0.566 0.19 0.85 
Beyond tibial 
stem (g/cm2) 


















Table 6.7 reports the comparison between the cone and non-cone group for the 
ipsilateral knee percentage difference at each visit. In the femoral condyle the 
difference at three months is +4.00 %, and +5.52 % at six months, but a 
negative difference at 12 months of -0.075 %. In the lateral femoral condyle it is 
reported as: +3.96 % (three months), -4.00 % (six months) and -2.601 % (12 
months). The difference reported in the femoral stem is greater in the cone 







5.522 -0.78 0.45 
Lateral femoral 
condyle (g/cm2) 
-3.996 0.85 0.40 
Femoral stem 
(g/cm2) 
1.934 -0.88 0.39 
Beyond femoral 
stem (g/cm2) 
-1.430 0.60 0.56 
Medial tibial 
condyle (g/cm2) 
-3.964 0.58 0.57 
Lateral tibial 
condyle (g/cm2) 
1.321 0.40 0.80 
Tibial stem  
(g/cm2) 
0.199 -0.07 0.95 
Beyond tibial 
stem (g/cm2) 
-1.779 0.67 0.52 
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group at three and six months, and then is greater in the non-cone group at 12 
months. Beyond the femoral stem reports +3.53 % (three months) and then  
-1.43 % (six months), and then +4.27 % at 12 months.  
 
The tibial medial condyle reported -1.04 % at three months, -3.96 % (six 
months), -5.123 % (12 months). The lateral tibial condyle at three months 
reports the highest difference across all visits and regions, reporting a 
difference between cone and non-cone of +6.18 % (p-value 0.09). Although this 
was reported as +1.32 % at six months, and a score of +5.71 % at 12 months. 
The tibial stem shows a difference of +5.75 % (p-value 0.04) at three months, 
but reports small differences at six and 12 months (0.20 % and 0.56 % 
respectively). Beyond the tibial stem shows a small difference at three months, 
and larger ones at six and 12 months, reported as -1.78 % and 1.402 % 
respectively. 
 
Table 6.7 reports only two statistically significant values, and that is at the tibial 
stem with an increase of +5.75 % at three months (p-value 0.04), and beyond 
the femoral stem at 12 months reporting a score of +4.27 (p-value 0.01). 
 
6.6.4 BMD PERCENTAGE DIFFERENCE IN PA CONTRALATERAL KNEE 
WHEN COMPARED BETWEEN CONE AND NON-CONE GROUP 
Table 6.8 reports the contralateral knee percentage changes (compared to 
baseline) in the cone group, now directly compared to the contralateral 
percentages changes (compared to baseline) in the non-cone group. Again, if 
there is no difference between groups, it should be reported as 0 % with 
positive figures in support of the cone group and negative figures in support of 









Table 6.8. Shows the mean BMD percentage difference compared to baseline 
at different visits, in the contralateral knee of the cone group vs the non-cone 
group to 3 d.p. including percentage difference (between groups), t-test and p- 
value 
 







10.453 -3.44 0.00 
Lateral femoral 
condyle (g/cm2) 
-4.412 0.64 0.53 
Femoral stem 
(g/cm2) 
1.839 -1.01 0.31 
Beyond femoral 
stem (g/cm2) 
3.009 -1.86 0.09 
Medial tibial 
condyle (g/cm2) 
-2.211 1.05 0.31 
Lateral tibial 
condyle (g/cm2) 
-0.545 0.23 0.82 
Tibial stem  
(g/cm2) 
2.383 -1.03 0.33 
Beyond tibial 
stem (g/cm2) 


















Table 6.8 shows the comparisons between contralateral cone and contralateral 
non-cone knee percentages. The femoral medial condyle reports the biggest 
difference in the contralateral knee region of +10.45 % with a p-value of 0.00, 
but reporting a difference of -1.88 % at six months, and increasing again to a 
figure of +9.928 % at 12 months (p-value 0.11). The lateral femoral condyle 
shows the opposite with negative differences at all visits (-4.41 %, -2.30 % and -







9.928 1.67 0.11 
Lateral femoral 
condyle (g/cm2) 
-7.323 -1.14 0.27 
Femoral stem 
(g/cm2) 
2.382 0.74 0.48 
Beyond femoral 
stem (g/cm2) 
2.576 0.77 0.46 
Medial tibial 
condyle (g/cm2) 
-4.051 -0.84 0.41 
Lateral tibial 
condyle (g/cm2) 
2.047 0.56 0.59 
Tibial stem  
(g/cm2) 
0.807 0.42 0.83 
Beyond tibial 
stem (g/cm2) 
2.305 0.55 0.60 







-1.881 0.34 0.74 
Lateral femoral 
condyle (g/cm2) 
-2.299 0.45 0.66 
Femoral stem 
(g/cm2) 
-1.881 0.94 0.36 
Beyond femoral 
stem (g/cm2) 
0.127 -0.07 0.95 
Medial tibial 
condyle (g/cm2) 
-5.993 2.27 0.04 
Lateral tibial 
condyle (g/cm2) 
1.188 -0.43 0.67 
Tibial stem  
(g/cm2) 
0.909 -0.33 0.75 
Beyond tibial 
stem (g/cm2) 
2.802 -1.08 0.31 
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7.32 % at 12 months respectively). The femoral stem shows +1.84 % three 
month, -1.88 % at six months, +2.6 % at 12 months. Beyond the femoral stem 
there is a difference of +3.01 % (p-value 0.09) at three months, -1.88 % at six 
months and +2.58 % at 12 months. 
 
The medial tibial condyle shows negative differences; reporting -2.11 % at three 
months, -5.99 % at six months with a p-value of 0.04, and -4.05 % at 12 
months. Lateral tibial condyle -0.55 % at three months, six months +1.19 %, 12 
months this was reported as +2.047 %. The tibial stem shows positives across 
all visits, reporting +2.38 % at three months, 0.91 % at six months and 0.81 % 
at 12 months. Beyond the tibial shows positive differences across all visits 
reported as 3.95 % at three months, 2.80 % at six months, and 2.31 % at 12 
months. 
 
Table 6.8 reports two statistically significant values, one is at the medial femoral 
condyle reporting a difference of +10.45 % at three months (p-value 0.00), and 
the other is medial tibial condyle -5.99 % at six months (p-value 0.04).  
 
6.6.5 STATISTICAL ANALYSIS OF THE PA KNEE USING A RANDOM 
EFFECTS LINEAR REGRESSION MODEL 
The data from both groups for both the ipsilateral and contralateral PA knee is 















Table 6.9. Shows the coefficient score comparing both groups across all visits 




Coefficient at 3m (CI in 
brackets) 
Coefficient at 6m (CI in 
brackets) 




Medial femoral condyle  0.0197 (-0.072 to 0.111) 0.0367 (-0.059 to 0.132) -0.0166 (-0.118 to 0.085) 0.77 
Lateral femoral condyle  0.0597 (-0.038 to 0.157) -0.0287 (-0.130 to 0.073) 0.0026 (-0.105 to 0.110) 0.38 
Femoral stem  0.0110 (-0.059 to 0.0812) 0.0178 (-0.055 to 0.091) -0.0149 ('-0.093 to 0.063) 0.87 
Beyond femoral stem  0.0342 (-0.159 to 0.227) -0.0586 (-0.261 to 0.144) 0.0382 (-0.179 to 0.2554) 0.81 
Medial tibial condyle  0.0086 (-0.107 to 0.124) -0.1897 (-0.139 to 0.101) -0.0202 ('-0.147 to 0.107) 0.96 
Lateral tibial condyle  0.0564 (-0.032 to 0.145) -0.0061 (-0.098 to 0.0857) 0.0458 (-0.051 to 0.143) 0.45 
Tibial stem   0.1131 (0.019 to 0.207) 0.0134 (-0.840 to 0.111) 0.0481 (-0.055 to 0.151) 0.10 
Beyond tibial stem  0.0164 (-0.065 to 0.098) -0.0177 ('-0.102 to 0.067) -0.0139 (-0.103 to 0.076) 0.87 
     
CONTRALATERAL KNEE 
Region 
Coefficient at 3m (CI in 
brackets) 
Coefficient at 6m (CI in 
brackets) 




Medial femoral condyle 0.1172 (-0.061 to 0.296) 0.0316 (-0.153 to 0.217) 0.0415 (-0.157 to 0.240) 0.63 
Lateral femoral condyle -0.0132 ('-0.104 to 0.077) 0.0055 (-0.088 to 0.099) -0.0390 ('-0.139 to 0.061) 0.84 
Femoral stem  0.0341 (-0.101 to 0.169) -0.0005 ('-0.141 to 0.139) 0.0409 (-0.109 to 0.191) 0.92 
Beyond femoral stem  0.0641 (0.127 to 0.255) 0.0119 (-0.187 to 0.211) 0.0314 (0.190 to 0.252) 0.92 
Medial tibial condyle  -0.0224 ('-0.082 to 0.037) -0.0499 ('-0.112 to 0.012) -0.0468 (-0.113 to 0.0191) 0.36 
Lateral tibial condyle  0.0091 ('-0.113 to 0.131) 0.0341 (-0.093 to 0.161) 0.0270 (-0.109 to 0.163) 0.95 
Tibial stem   0.0335 (-0.055 to 0.122) 0.0108 ('-0.081 to 0.103) 0.0069 ('-0.091 to 0.106) 0.90 
Beyond tibial stem  0.0508 (-0.054 to 0.156) 0.0255 (-0.083 to 0.134) 0.0091 (-0.107 to 0.125) 0.80 
 
Table 6.9 indicates the sample mean change between baseline and visits at 
three, six and 12 months. The majority of ipsilateral data indicate the 
intervention group is greater, 24 data points 15 show the difference is greater in 
the cone group. The highest being 0.0597 (lateral femoral condyle, three 
months) and 0.0564 (lateral tibial condyle, months), and -0.1897 (medial tibial 
condyle, six months). For the contralateral data 18 data points indicate that the 
difference is greater in the cone group, with a difference of 0.1172 in the medial 




6.7 BMD DXA RESULTS OF THE LATERAL KNEE  
This section will report the lateral knee DXA data, and go through the same 





Table 6.10. Shows the average baseline (6 week) BMD (g/cm2) for the lateral 
knee, for the cone group (N=17) and non-cone group (N=9) 
CONE GROUP (N=17)  
6 WEEKS (BASELINE) IPSILATERAL 6 WEEKS (BASELINE) CONTRALATERAL 
 Mean 
(g/cm2) 
SD SE Mean 
(g/cm2) 
SD SE 
Femoral condyle 2.026 0.347 0.084 1.408 0.537 0.130 
Femoral stem 1.842 0.318 0.077 1.274 0.299 0.073 
Beyond femoral stem 2.163 0.422 0.102 1.596 0.424 0.103 
Tibial condyles 1.163 0.394 0.096 1.164 0.286 0.069 
Tibial stem 1.710 0.285 0.069 1.166 0.245 0.059 
Beyond tibial stem 1.874 0.215 0.052 1.336 0.270 0.065 
NON-CONE GROUP (N=9)  
Femoral condyle 2.028 0.537 0.190 1.174 0.401 0.134 
Femoral stem 1.802 0.391 0.148 1.224 0.438 0.146 
Beyond femoral stem 2.157 0.582 0.220 1.560 0.538 0.179 
Tibial condyles 1.398 0.307 0.102 1.027 0.353 0.118 
Tibial stem 1.663 0.200 0.067 1.107 0.307 0.102 
Beyond tibial stem 1.830 0.291 0.097 1.429 0.432 0.144 
 
Table 6.10 shows the mean BMD in g/cm2 baseline (six week) results of the 26 
six week participants from their lateral DXA knee data. It must be noted that the 
comparisons to baseline in the following results tables and figures involved 
comparing the participants’ knee BMD visit data directly to their own six week 
baseline data, in order to report a direct change. It must also be acknowledged 
that the high BMD figures in some of the regions have been addressed in the 














6.7.1 BMD PERCENTAGE DIFFERENCE IN THE LATERAL KNEE WHEN 
COMPARED TO BASELINE, FOR IPSILATERAL AND CONTRALATERAL 
CONE GROUP 
Table 6.11. Shows the ipsilateral lateral knee compared to baseline (6 week) 
BMD (g/cm2) for the cone group 
3 MONTHS (N=17) 
 




-0.085 -3.702 -9.72 2.32 12.663 3.071 1.30 0.21 
Femoral stem 
(g/cm2) 
-0.062 -3.136 -7.26 0.98 8.675 2.104 1.79 0.09 
Beyond femoral 
stem (g/cm2) 
-0.017 -0.748 -4.10 2.60 7.045 1.709 0.47 0.65 
Tibial condyles 
(g/cm2) 
-0.004 0.526 -4.03 5.09 9.599 2.328 0.15 0.88 
Tibial stem 
(g/cm2) 
0.007 0.446 -1.83 2.73 4.790 1.162 -0.32 0.75 
Beyond tibial 
stem (g/cm2) 
0.053 2.895 1.16 4.63 3.653 0.886 -3.02 0.01 
6 MONTHS (N=16) 
 




0.069 3.715 -1.91 9.34 11.473 2.868 -1.27 0.22 
Femoral stem 
(g/cm2) 
0.006 0.295 -4.33 4.92 9.429 2.357 -0.16 0.87 
Beyond femoral 
stem (g/cm2) 
0.061 2.619 -0.218 5.52 5.913 1.478 -2.21 0.04 
Tibial condyles 
(g/cm2) 
0.009 0.718 -3.66 5.10 8.932 2.233 -0.38 0.71 
Tibial stem 
(g/cm2) 
0.004 0.335 -1.79 2.46 4.331 1.083 -0.22 0.83 
Beyond tibial 
stem (g/cm2) 
0.056 2.928 0.798 5.06 4.344 1.086 -2.88 0.01 
12 MONTHS (N=14) 
 




0.085 5.462 -0.32 11.20 11.037 2.950 1.51 0.15 
Femoral stem 
(g/cm2) 
-0.062 -3.314 -8.27 1.65 9.478 2.533 -1.36 0.20 
Beyond femoral 
stem (g/cm2) 
0.019 0.982 -2.58 4.54 6.789 1.814 0.54 0.60 
Tibial condyles 
(g/cm2) 
-0.014 0.164 -5.68 6.00 11.150 2.980 -0.39 0.70 
Tibial stem 
(g/cm2) 
-0.017 -0.662 -3.15 1.83 4.758 1.272 -0.69 0.50 
Beyond tibial 
stem (g/cm2) 





Table 6.12. Shows the contralateral lateral knee compared to baseline (6 week) 
BMD (g/cm2) for the cone group 
3 MONTHS (N=17) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
0.008 0.914 -0.70 2.52 3.384 0.821 -0.59 0.57 
Femoral stem 
(g/cm2) 
0.032 2.402 0.44 4.36 4.113 0.998 -2.31 0.03 
Beyond femoral 
stem (g/cm2) 
0.037 2.050 0.24 3.86 3.804 0.923 -2.17 0.05 
Tibial condyles 
(g/cm2) 
0.021 1.869 0.55 3.19 2.785 0.675 -2.61 0.02 
Tibial stem 
(g/cm2) 
0.011 1.080 -0.21 2.37 2.719 0.659 -1.32 0.21 
Beyond tibial 
stem (g/cm2) 
0.000 0.003 -1.52 1.52 3.198 0.776 0.00 1.00 
6 MONTHS (N=16) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
-0.008 -0.152 -1.77 1.47 3.302 0.826 0.52 0.61 
Femoral stem 
(g/cm2) 
0.023 1.796 -0.21 3.81 4.110 1.027 -2.16 0.05 
Beyond femoral 
stem (g/cm2) 
0.005 0.274 -1.03 1.57 2.653 0.663 -0.55 0.59 
Tibial condyles 
(g/cm2) 
0.003 0.212 -1.41 1.83 3.298 0.824 -0.37 0.72 
Tibial stem 
(g/cm2) 
0.009 0.773 -0.75 2.29 3.100 0.775 -1.14 0.27 
Beyond tibial 
stem (g/cm2) 
0.006 0.397 -1.15 1.95 3.154 0.789 -0.61 0.55 
12 MONTHS (N=13) 1 PARTICIPANT UNDERWENT TKR ON CONTRALATERAL KNEE SO THESE DATA HAS BEEN 
EXCLUDED 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
-0.004 0.286 -2.68 3.26 5.466 1.516 -0.15 0.88 
Femoral stem 
(g/cm2) 
0.042 3.271 -0.05 6.59 6.103 1.693 2.23 0.05 
Beyond femoral 
stem (g/cm2) 
0.039 2.138 0.04 4.24 3.854 1.069 2.05 0.06 
Tibial condyles 
(g/cm2) 
0.010 1.104 -1.85 4.05 5.422 1.504 0.62 0.55 
Tibial stem 
(g/cm2) 
0.000 -0.020 -2.52 2.12 4.274 1.185 -0.01 1.00 
Beyond tibial 
stem (g/cm2) 







Figure 6.9. Shows bar graph for BMD (%) changes in the cone group lateral 
ipsilateral knee in different ROI throughout visits, error bars are SE 
 
Figure 6.10. Shows bar graph for BMD (%) changes in the cone group lateral 
contralateral knee in different ROI throughout visits, error bars are SE 
 
Table 6.11 and figure 6.9 show the ipsilateral knee lateral BMD in the cone 
group compared to their baseline score, with percentage changes calculated.  
 
Femoral changes reported a condyle change of -3.70 % at three months, 
although this increases to a positive of 3.72 % at six months, increasing to 
5.462 % at 12 months. The femoral stem reports similar losses at three and 12 
months (-3.314 %), with a 0.30 % increase at six months. Beyond the femoral 
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Cone group lateral ipsilateral knee changes throughout visits
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Cone group lateral contralateral knee changes throughout visits
3 months 6 months 12 months
306 
 
12 months, with the highest increase reported as 2.62 % at six months (p-value 
of 0.04).  
 
The tibial condyles show increases at all visits although nothing of significance, 
with the highest difference reported as 0.72 % (p-value 0.71). The tibial stem 
reports small increases at three and six months, and a loss at 12 months of just 
under -1 %. Beyond the tibial stem is where the biggest change in the tibia is 
reported, all visits report an increase at beyond the tibial stem; reported as 2.90 
% (p-value 0.01) at three months, 2.93 %, at six months (p-value 0.01), and 
1.19 % at 12 months. Table 6.12 and figure 6.10 show the contralateral knee 
lateral BMD in the cone group compared to their baseline score, with 
percentage changes calculated.  
 
For the femoral data the condyles report minimal changes with both increases 
and decreases, with the highest difference reported as 0.91 %. The femoral 
stem reports the most statistical change of the contralateral lateral knee, with an 
increase of 2.40 % (p-value 0.03) at three months, and 1.80 % (p-value 0.05), 
with an increase of 3.271 % (0.05 p-value) at 12 months. Beyond the femoral 
stem there were increases at all visits, with large increases at three (2.05 % p-
value 0.05) and 12 months (2.14 %, 0.06 p-value). 
 
For the tibial data, at the condyles there is an increase of 1.87 % (p-value 0.02), 
although this reduces at six months returning to just over 1 % by 12 months. 
The tibial stem data report an increase at three months of just over 1 %; this is 
reduced to 0.77 % at six months, reaching a near baseline level by 12 months. 
For beyond the tibial stem there is very little change in percentage at three, six, 
and 12 months, with the highest difference reported as just under -0.405 %. 
 
Across both figures and tables there are a few statistically significant results. 
The most consistent in the ipsilateral knee appears to be the increases beyond 
the tibial stem in the ipsilateral knee reported at three and six months (2.90 % 
and 2.93 %). although beyond the femoral stem also reports a statistically 
significant figure at six months (2.62 %). In the contralateral knee there are 
increases reported at all three visits in the femoral stem (2.40 %, 1.80 % 3.27 
%). There are a further two statistically significant results in the contralateral 
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data, both at 3 months; one in beyond the femoral stem (2.05 %) and the other 
reported in the tibial condyles (1.87 %). 
 
6.7.2 BMD PERCENTAGE DIFFERENCE IN THE LATERAL KNEE WHEN 
COMPARED TO BASELINE, FOR IPSILATERAL AND CONTRALATERAL 
FOR THE NON-CONE GROUP 
Table 6.13. Shows the ipsilateral lateral knee compared to baseline (6 week) 
BMD (g/cm2) for the non-cone group 
3 MONTHS (N=9) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral 
condyles (g/cm2) 
-0.102 -5.127 -8.90 -1.36 5.773 2.041 2.25 0.06 
Femoral stem 
(g/cm2) 
-0.079 -3.614 -7.92 1.60 7.284 2.753 1.58 0.16 
Beyond femoral 
stem (g/cm2) 
-0.005 0.540 -4.09 5.17 7.080 2.676 0.09 0.93 
Tibial condyles 
(g/cm2) 
-0.004 0.155 -5.96 6.27 9.346 3.115 0.10 0.92 
Tibial stem 
(g/cm2) 
-0.019 -1.163 -3.98 1.66 4.324 1.441 0.78 0.46 
Beyond tibial 
stem (g/cm2) 
-0.003 0.152 -3.61 3.91 5.753 1.918 0.07 0.94 
6 MONTHS (N=8)  
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral 
condyles (g/cm2) 
-0.113 -3.215 -12.40 6.00 13.927 5.264 1.18 0.28 
Femoral stem 
(g/cm2) 
-0.044 -1.416 -5.69 2.85 6.166 2.517 1.27 0.26 
Beyond femoral 
stem (g/cm2) 
0.066 3.204 1.43 4.97 2.551 1.041 -2.56 0.05 
Tibial condyles 
(g/cm2) 
-0.026 -1.349 -8.46 5.76 10.257 3.626 0.56 0.59 
Tibial stem 
(g/cm2) 
-0.053 -3.058 -8.09 1.97 7.252 2.564 1.27 0.24 
Beyond tibial 
stem (g/cm2) 
0.003 0.554 -4.30 5.40 6.992 2.472 -0.07 0.95 
12 MONTHS (N=8) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral 
condyles (g/cm2) 
-0.097 -5.213 -14.30 3.88 13.114 4.957 -1.00 0.36 
Femoral stem 
(g/cm2) 
-0.079 -3.983 -8.71 0.75 6.832 2.789 -1.40 0.22 
Beyond femoral 
stem (g/cm2) 
0.057 2.960 -1.55 7.47 6.507 2.656 0.93 0.40 
Tibial condyles 
(g/cm2) 
-0.100 -7.547 -15.60 0.513 11.631 4.112 -1.83 0.11 
Tibial stem 
(g/cm2) 
-0.090 -5.425 -8.07 -2.77 3.818 1.350 -4.09 0.00 
Beyond tibial 
stem (g/cm2) 




Table 6.14. Shows the contralateral lateral knee compared to baseline (6 week) 
BMD (g/cm2) for the non-cone group 
3 MONTHS (N=9) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
-0.020 -1.530 -4.00 0.94 3.777 1.259 1.19 0.27 
Femoral stem 
(g/cm2) 
-0.010 -1.129 -3.90 1.64 4.247 1.416 0.52 0.62 
Beyond femoral 
stem (g/cm2) 
-0.001 -0.710 -3.53 2.11 4.322 1.441 0.04 0.97 
Tibial condyles 
(g/cm2) 
-0.022 -2.584 -5.21 0.05 4.031 1.344 1.80 0.11 
Tibial stem 
(g/cm2) 
-0.025 -2.668 -5.60 0.26 4.485 1.495 1.99 0.08 
Beyond tibial 
stem (g/cm2) 
-0.039 -2.601 -6.62 1.42 6.152 2.051 1.52 0.17 
6 MONTHS (N=8) 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
0.001 0.370 -2.72 3.46 4.466 1.579 -0.08 0.93 
Femoral stem 
(g/cm2) 
-0.004 -0.669 -4.13 2.79 4.992 1.765 0.31 0.76 
Beyond femoral 
stem (g/cm2) 
-0.034 -2.904 -5.74 -0.06 4.099 1.449 2.44 0.05 
Tibial condyles 
(g/cm2) 
0.005 0.253 -3.37 3.87 5.226 1.848 -0.35 0.74 
Tibial stem 
(g/cm2) 
-0.010 -1.043 -3.45 1.37 3.478 1.230 0.99 0.35 
Beyond tibial 
stem (g/cm2) 
-0.025 -1.455 -4.50 1.59 4.407 1.558 1.06 0.33 
12 MONTHS (N=7) 1 PARTICIPANT UNDERWENT TKR ON CONTRALATERAL KNEE SO THESE DATA HAS BEEN 
EXCLUDED 
 
BMD Change % Change 95 % CL SD SE T-Critical P-Value 
Femoral condyles 
(g/cm2) 
-0.082 -6.122 -14.20 1.97 10.919 4.127 -1.31 0.24 
Femoral stem 
(g/cm2) 
-0.022 -2.646 -7.67 2.37 6.774 2.560 -0.71 0.51 
Beyond femoral 
stem (g/cm2) 
-0.032 -3.059 -7.65 1.53 6.195 2.341 -1.06 0.33 
Tibial condyles 
(g/cm2) 
-0.022 -2.881 -6.84 1.08 5.351 2.023 -1.12 0.30 
Tibial stem 
(g/cm2) 
-0.016 -2.514 -7.05 2.03 6.123 2.314 0.78 0.47 
Beyond tibial 
stem (g/cm2) 





Figure 6.11. Shows bar graph for BMD (%) changes in the non-cone group 
lateral ipsilateral knee in different ROI throughout visits, error bars are SE 
 
 
Figure 6.12. Shows bar graph for BMD (%) changes in the non-cone group 
lateral contralateral knee in different ROI throughout visits, error bars are SE 
 
Table 6.13 and figure 6.11 shows the ipsilateral knee lateral BMD data in the 
non-cone group compared to their baseline score, with percentage changes 
calculated.  
 
The femoral condyles report losses throughout each visits, reported as -5.13 % 
at three months (p-value 0.06), -3.22 % (p-value 0.28), -5.21 % at 12 months (p-
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months, -1.42 % and -3.98 % (for six and 12 months respectively). Beyond the 
femoral stem reports increases at all visits, with a statistically significant score 
at six months, reporting an increase of 3.20 % (p-value 0.05), with a reported 12 
month score of 2.96 %. 
 
The tibial condyles report an increase at three months of 0.16 %, as a loss of -
1.35 % at six months, and with the largest difference of all the lateral tibial data 
reporting a loss of -7.547 % (0.11 p-value) at 12 months. As for the tibial stem 
this region reports large losses across all visits (-1.16 %, -3.06 % and -5.43 % 
(0.00 p-value) respectively).  Beyond the tibial stem there is little to no change, 
with the largest difference reported as 0.55 %.  
 
Table 6.14 and figures 6.12 shows the non-cones group contralateral knee 
lateral BMD compared to their baseline score, with percentage changes 
calculated. For the femoral data the condyles show both increases and 
decreases at three and six months, with a large loss of -6.12 % (p-value 0.24) at 
12 months. The femoral stem reports decreases at every visit, with the biggest 
decrease reported as -2.65 % at 12 months. Beyond the femoral stem also 
reported decreases at all visits, reporting -0.710 (three months) -2.90 % (six 
months p-value 0.05), -3.06 % (12 months). 
 
For the tibial data, at the condyles there is a decrease at three months of -2.58 
%, as 0.25 at six months, and -2.88 % by 12 months. The tibial stem and 
beyond the tibial stem each show decreases across all visits. With both 
reporting -2.67 % and -2.60 % at three months, reducing to -1.04 % and -1.46 
% at six months, increasing back to -3.47 % and -2.51 % at 12 months.  
 
Across both figures and tables there are a few statistically significant results, the 
most consistent appears to be the femoral stem at 12 months 3.27 %, and there 
are increases beyond the femoral stem in the ipsilateral knee reported at 6 
(3.20 %), and beyond the femoral stem in the contralateral, reporting a 





6.7.3 BMD PERCENTAGE DIFFERENCE IN LATERAL IPSILATERAL KNEE 
WHEN COMPARED BETWEEN CONE AND NON-CONE GROUP 
Table 6.14 shows the ipsilateral percentage changes (compared to baseline) in 
the cone group now compared to the ipsilateral percentage’s changes 
(compared to baseline) in the non-cone group and reporting the difference. If 
there is no difference between groups the two figures should be similar, and 
report a 0 % difference, a positive difference is in support of the cone group, 
and negative difference is in support of the non-cone group. 
 
Table 6.15.Shows the mean BMD percentage difference compared to baseline 
at different visits, in the ipsilateral knee of the cone group vs the non-cone 
group to 3 d.p. including percentage difference (between groups), t-test and p-
value 
3 MONTHS CONE (N=17) AND NON-CONE (N=9) 
 


















10.675 1.85 0.09 
Femoral stem 
(g/cm2) 




0.670 0.18 0.86 
Beyond femoral 
stem (g/cm2) 




-1.978 -0.62 0.55 
Tibial condyles 
(g/cm2) 




7.711 1.52 0.15 
Tibial stem 
(g/cm2) 




4.764 2.57 0.02 
Beyond tibial 
stem (g/cm2) 




0.658 0.29 0.77 







6.930 -1.16 0.27 
Femoral stem 
(g/cm2) 
1.711 -0.50 0.63 
Beyond femoral 
stem (g/cm2) 
-0.585 0.32 0.75 
Tibial condyles 
(g/cm2) 
2.067 -0.49 0.64 
Tibial stem 
(g/cm2) 
3.392 -1.22 0.25 
Beyond tibial 
stem (g/cm2) 
2.373 -0.88 0.40 
 
Table 6.15 reports the comparison between the cone and non-cone group for 
the ipsilateral knee percentage difference at each visit in the lateral DXA view. 
In the femoral condyle there is a reported positive difference between the two 
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groups at every visit; reporting +1.43 % at three months, +6.93 % (p-value 
0.27), and +10.68 % (0.09 p-value) at 12 months. In the femoral stem all visits 
report a positive difference, with the highest reaching +1.71 % at six months. 
Beyond the femoral stem reported a negative difference at every visits when 
comparing the two groups directly, with the highest difference being -1.98 % at 
12 months. 
 
The tibial condyle showed a positive difference at each visit, reaching the 
largest difference of +7.71 % at 12 months (0.15 p-value). The tibial stem 
reports a similar pattern with positive differences at each visit, reaching its 
largest at 12 months reported as +4.76 % (p-value 0.02). Beyond the tibial stem 
also reports a positive difference at all visits, although not as dramatic, it reports 
+2.74 % (three months), +2.37 % (six months), and +0.658 % at 12 months.  
 
Table 6.15 shows one statistically significance in the 12 month data, which is in 
the tibial stem, reported as a difference of +4.76 %. 
 
6.7.4 BMD PERCENTAGE DIFFERENCE IN LATERAL CONTRALATERAL 
KNEE WHEN COMPARED BETWEEN CONE AND NON-CONE GROUP 
Table 6.15 shows the contralateral percentage changes (compared to baseline) 
in the cone group now compared to contralateral percentages changes 
(compared to baseline) in the non-cone group again following the same format 















Table 6.16. Shows the mean BMD percentage difference compared to baseline 
at different visits, in the contralateral knee of the cone group vs the non-cone 
group to 3 d.p. including percentage difference (between groups), t-test and p-
value 
 







-0.522 0.29 0.78 
Femoral stem 
(g/cm2) 
2.465 -1.21 0.25 
Beyond femoral 
stem (g/cm2) 
3.179 -1.99 0.07 
Tibial condyles 
(g/cm2) 
-0.041 0.02 0.98 
Tibial stem 
(g/cm2) 
1.816 -1.25 0.23 
Beyond tibial 
stem (g/cm2) 
1.851 -1.06 0.31 
 
Table 6.16 shows the comparisons between contralateral cone and 
contralateral non-cone knee lateral data. The femoral condyles report a 
difference at three months of +2.44 % (p-value 0.12), as -0.52 % at six months, 
and is again a positive at 12 months (+6.41 %). The femoral stem shows 
positive differences at all visits, with the highest at 12 months reporting +5.917 
% (p-value 0.08). Beyond the femoral stem also showed this trend also, with 
positive difference at all visits, the highest again being recorded at 12 months 
reporting +5.198 % (p-value 0.07).  
 







2.444 -1.63 0.12 
Femoral stem 
(g/cm2) 
3.531 -2.04 0.06 
Beyond femoral 
stem (g/cm2) 
2.760 -1.61 0.13 
Tibial condyles 
(g/cm2) 
4.453 -2.96 0.01 
Tibial stem 
(g/cm2) 
3.748 -2.29 0.04 
Beyond tibial 
stem (g/cm2) 
2.604 -1.19 0.26 







6.408 1.46 0.18 
Femoral stem 
(g/cm2) 
5.917 1.93 0.08 
Beyond femoral 
stem (g/cm2) 
5.198 2.02 0.07 
Tibial condyles 
(g/cm2) 
3.985 1.58 0.14 
Tibial stem 
(g/cm2) 
2.495 0.96 0.36 
Beyond tibial 
stem (g/cm2) 
3.063 0.92 0.39 
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The tibial condyle data show positive differences at three and 12 months 
reported as +4.45 % (p-value 0.01) and +3.99 % (p-value 0.14) respectively, 
although there is a difference of -0.04 % at six months. The tibial stem again 
shows positive difference, this time across all visits, reporting +3.75 % (p-value 
0.04) at 3 months, +1.82 % at six months, and +2.495 % at 12 months. Beyond 
the tibial again also shows positive differences across all visits reported as 
+2.60 % at three months, +1.85 % at six months, +3.063 % at 12 months. In 
contralateral lateral DXA data there are reported statistically significant results 
in the tibial condyles and tibial stem at three months (+4.45 % and +3.75 %). 
 
6.7.5 STATISTICAL ANALYSIS OF THE LATERAL KNEE USING A RANDOM 
EFFECTS LINEAR REGRESSION MODEL 
The data from both groups for both the ipsilateral and contralateral lateral knee 
is shown in table 6.17. 
 
Table 6.17. Shows the coefficient score comparing both groups across all visits 
via linear regression model.  
 
Table 6.17 indicates the sample mean change between baseline and visits at 
three, six and 12 months. The majority of ipsilateral data indicate the 
IPSILATERAL KNEE 
Region 
Coefficient at 3m (CI in 
brackets) 
Coefficient at 6m (CI in 
brackets) 




Femoral condyles 0.0163 (-0.184 to 0.217) 0.1748 (-0.034 to 0.384) 0.1208 (-0.103 to 0.344) 0.32 
Femoral stem 0.0281 (-0.180 to 0.236) 0.0726 (-0.146 to 0.291) -0.1344 ('-0.353 to 0.085) 0.37 
Beyond the 
femoral stem 
-0.0107 (-0.300 to 0.278) 0.0178 (-0.286 to 0.322) -0.2673 ('-0.572 to 0.374) 0.28 
Tibial condyles -0.0355 ('-0.202 to 0.131) -0.0020 ('-0.174 to 0.170) 0.0457 (-0.137 to 0.229) 0.87 
Tibial stem 0.0326 (-0.082 to 0.147) 0.0593 ('-0.059 to 0.178) 0.0642 (-0.0616 to 0.191) 0.71 
Beyond tibial 
stem 
0.0596 (-0.140 to 0.133) 0.0468 (-0.030 to 0.123) 0.0258 (-0.055 to 0.107) 0.42 
     
CONTRALATERAL KNEE 
Region 
Coefficient at 3m (CI in 
brackets) 
Coefficient at 6m (CI in 
brackets) 




Femoral condyles 0.0587 (-0.137 to 0.254) 0.0411 (-0.161 to 0.243) 0.0962 (-0.120 to 0.313) 0.85 
Femoral stem 0.0475 (-0.093 to 0.188) 0.0440 (-0.102 to 0.190) 0.0698 (-0.086 to 0.226) 0.83 
Beyond the 
femoral stem 
0.0426 (-0.143 to 0.228) 0.0465 (-0.146 to 0.239) 0.0771 (-0.129 to 0.284) 0.90 
Tibial condyles 0.0605 (-0.067 to 0.188) 0.0204 (-0.112 to 0.152) 0.0387 (-0.103 to 0.180) 0.82 
Tibial stem 0.0433 (-0.060 to 0.147) 0.0289 (-0.079 to 0.136) 0.0184 (-0.097 to 0.133) 0.87 
Beyond tibial 
stem 
0.0272 (-0.103 to 0.157) 0.0248 (-0.110 to 0.160) 0.0205 (-0.124 to 0.165) 0.98 
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intervention group is greater, 18 data points 13 show the difference is greater in 
the cone group. The highest being 0.1748 (femoral condyle) and -0.2673 
(beyond the femoral stem). For the contralateral data all 18 data points indicate 
that the difference is greater in the cone group. Although none of this data (in 





6.8.1 FEMORAL AND TIBIAL IPSILATERAL BMD CHANGES IN THE CONE 
GROUP 
In the cone ipsilateral group, nine from a total of 12 BMD data points (four 
regions across three visits) of the femoral regions reported increases, with 
some reporting consistent results across visits. The reported changes in the 
medial femoral condyle and beyond the femoral stem each show increases at 
every visit. The lateral femoral condyle reported a statistically significant 
increase at three months although this is just over -3 % by six months and is 
similar to baseline by 12 months (0.13 %). The femoral stem shows a loss at six 
and 12 months.  
 
The lateral DXA image data in the ipsilateral cone group, supports these 
changes reported on the PA image, reporting five of none data points as 
increases (three regions across three visits), for example the femoral condyles 
(superimposed on the lateral image) report increases at six and 12 months 
(although not statistically significant), the lateral data show losses at the femoral 
stem at 12 months, and increases at beyond the femoral stem, similar to the PA 
result. The main difference between the lateral and PA data is at the three 
month visit; the lateral data reports losses at all three regions, yet the PA data 
report increases at those corresponding sites, it must be noted that all three 
regions at three months in the lateral data report non statistical significance, and 
precision errors are greater in the lateral data series than the PA, due to issues 
of rotation and flexion affecting the femoral position, and thus BMD [420]. 
 
The tibial PA regions report six increases across 12 data points. In the main two 
regions around the cone (the lateral and medial tibial condyles) there is 
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consistency throughout the visits. The medial tibial condyle reports large losses 
increasing at every visit (-8.98 % at 12 months). With the opposite in the lateral 
tibial condyle, which reported increases at every visit (+4.495 % at 12 months p-
value 0.00). The tibial stem also reports losses at six month and at 12 months, 
with beyond of the stem reporting increases at six and 12 months.  
 
The tibial lateral data changes report eight of the nine data points as BMD 
increases, with the one loss reported in the tibial stem at 12 months. The lateral 
DXA data matches the reported PA data, the tibial condyles show a slight 
increase in the lateral DXA data, which supports the idea from the PA image 
that reports an increase in lateral tibial condyle and decrease in medial tibial 
condyle, thus when superimposed would report an averaged small increase 
(0.53 %, 0.72 %, and 0.16 % at three, six and 12 months respectively). The 
tibial stem, and beyond the tibial stem data also supports the changes reported 
in the PA data, reporting increases at three months, a decrease at 12 months in 
the tibial stem, and increases at six and 12 months beyond the tibial stem. 
 
The figures and changes reported in both the femoral regions and tibial regions 
could be due to several influences, the increases shown in all three visits 
beyond the femoral stem as reported in the PA data could be due to altered WB 
forces being channelled through the joint along the stem to beyond the stem, 
this would increase early bone turnover in the beyond the stem region due to 
adaptive bone remodelling. This remodelling of the periprosthetic bone is well 
known and is described in Wolff’s law [421], in which the bone remodels to 
adapt to altered mechanical loads.  
 
In 2010 Jensen et al [179] investigated femoral BMD changes in rTKR patients 
(a cemented revision with either a constrained condylar prosthesis (N=12) or a 
posterior stabilised implant (N=4)). They investigated BMD changes along the 
stem and beyond the stem; unfortunately they did not investigate the femoral 
condyles. For the stem data they reported increases of +3.4 %, +4.7 % and 
+4.0 %, at three, six, and 12 month visits, although we reported decreases at 
six and 12 months. With beyond the stem reported an increase at 12 months of 
+0.4 % which is similar to our data, although we report a greater number (4.495 
317 
 
%), (although Jensen et al [179] did report small losses of -0.7 % and -0.8 % at 
three and six months respectively) were we reported increases.   
 
It must be acknowledged that there is a lack of rTKR BMD DXA data, as 
reported the systematic review search. Jensen et al 2010 [179] even states 
within their paper “to our knowledge there exists no published studies on BMD 
changes in the distal femur after rTKR. With most studies evaluating BMD 
around the femoral component after a TKR and not a rTKR”. So there is a lack 
of femoral BMD data, the differences reported in Jensen et al 2010 [179] might 
be due to both studies having low number of participants (16 for Jensen 2010 
[179], 17 cone participants in our research) and/or variations between our two 
groups of participants.  
 
Although the change beyond the stem has been reported in another revision 
study albeit a simulated study [422], in which they studied bone remodelling 
patterns of four femoral components: two primary TKAs and two stemmed 
revision prostheses. They found that in the ROI beyond the stem (comparable 
with the ROI we used in this study); there was a predictable increase in BMD in 
the most proximal ROI beyond the stem [422]. Although it must be noted this 
was a simulated study and they did report increases along the stem as well as 
beyond the stem. 
 
The increases in the femoral condyle regions could be due to alignment issues 
in the knee and reformed gait, or due to increased activity post operation 
increasing bone turnover, especially given as these participants had already 
undergone TKR and understand the recuperation and physiotherapy demands, 
it must be acknowledged that Jensen et al 2010 [179] did not investigate 
alignment in the hip or knees. Furthermore, a systematic review investigating 
BMD change in the distal femur in TKR in 2019 investigated changes in the 
femoral intracondylar, supracondylar and combined regions, across several 
studies – at three months -9.32 % combined (11 studies), supracondylar -5.98 
% (eight studies) intracondylar -11.68 % (seven studies), at six months 
combined -13.19 % (10 studies), supracondylar -11.01 % (eight studies), 
intracondylar -16.93 % (seven studies), and at 12 months -15.75 % combined 
(11 studies), supracondylar -13.18 % (nine studies) and intracondylar -18.43 % 
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(eight studies) [423]. Our data do not conform to the TKR data gathered via the 
systematic review, as stated this could simply be due to these being revision 
participants having greater understanding of recovery, or due to the cones 
effects of stabilisation. Furthermore, this systematic review data, although 
useful did not include rTKR, and included studies using dual photon 
absorptiometry. Moreover, the studies utilised different ROI from our study 
[423], making comparisons difficult. 
 
The tibial condyle changes could be due to the influences of the cone in and 
around that area, and the subsequent integration of BMD, although the lateral 
condyle increase is not complemented by the medial condyle BMD loss. This 
BMD change could be a result of alignment of the hip and/or knee and thus 
exacerbating load bearing within the tibial plateau, or due to stress shielding, 
with the medial tibial condyle under less stress than previously so have 
significantly reduced bone turnover [163, 165]. The possible issue of alignment 
will be discussed in the next chapter were we investigated this further.  
 
Currently there is only one other paper (Jensen et al 2012 [178]) that 
investigated cone implantation in rTKR in the tibial region using DXA BMD data. 
In their study at three months they reported a loss of -3.7 % in the lateral tibial 
region, at six months this had increased to +2.1 % but by 12 months was a 
reported loss of -1.0 %.  In the medial tibial region it was reported as -3.5 % at 
three months, -3.0 % at six months, and -2.3 % at 12 months. The data from 
Jensen et al (2012 [178]) in the tibial medial region mimics what we have 
reported in our study, although our data report a larger loss than Jensen et al 
(2012) [178], both studies were a similar group number (N=17). As for the 
lateral tibial region there is a reported increase at six months with Jensen et al 
(2012) [178] (although there is a decrease at three and 12 months which do not 
match our data reporting all increases). This difference could be due to the type 
of cone implanted, or the variations in the small sample sizes.   
 
Prior to Jensen et al 2012 study, Jensen et al in 2010 [179] investigated rTKR 
and BMD changes in the tibia, reporting figures of -2.5 % at three months, -4.4 
% at six months and -1.3 % at 12 months although with high SD (9.5, 5.6 and 
7.7 respectively). The regions themselves are not comparable to this study 
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(reported as distal tibial region which was just above the ankle joint) although it 
does show the losses reported after a rTKR.   
 
Investigating changes in the tibial regions in TKR/A studies show decreases at 
both condyle regions, under the component and combined regions, across all 
three visits (three, six and 12 months) [17, 29, 287, 291, 296, 306]. Although a 
study by Winther et al [226] reported increases in the condyles throughout all 
visits (three, six and 12 months) across two different types of implant group, 
reported as 1.9 %, 1.12 % (three months medial condyle), 4.1 %, 8.2 % (three 
months lateral condyle), six months 2.2 % and 8.6 % (medial condyle), 2.1 % 
6.6 % (lateral condyle), 12 months 2.4 % and 8.1 % (medial condyle), 3.1 % 
and 6.5 % (lateral condyle). This study used novel porous titanium construct 
Regenerex and the PPS style implants, in which the periprosthetic BMD 
changes was attributed by the author to the novel implants utilised, which might 
be the case with our study. 
 
Additionally, these are TKR and not revision studies, and as stated there are 
only Jensen et al studies, whose results, including the ones within this research, 
are from a small sample size, and only include a few statistically significant 
differences.  
 
6.8.2 FEMORAL AND TIBIAL IPSILATERAL BMD CHANGES IN THE NON-
CONE GROUP 
The femoral PA data from the non-cone group reports five increases across 12 
data points. Reporting a consist decrease in the femoral stem. The lateral 
femoral condyle shows increases across all visits. The medial femoral condyle 
reports decreases at three and six months then an increase at 12 months. 
Beyond the stem has a similar baseline score at 12 months after undergoing a 
decrease and an increase.  
 
The lateral femoral DXA data, show similar trends, reporting increases in three 
of nine data points (all from beyond the stem), although the femoral condyles 
show losses at every visit, (most likely due to a combination of the 
superimposition of the lateral and medial condyles and the precision errors of 
lateral DXA scans). The lateral femoral stem shows similar data to the PA data, 
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with both reporting losses at every visit; with the beyond the femoral stem 
reporting increases in the lateral data, a similar score at six months, and both 
show an increase at 12 months. 
 
The tibial data from the non-cone group reports only one increase across all 12 
data points, with it reported at beyond the tibial stem region, the tibial medial 
and lateral condyles all report losses at every visit, the highest reported at 12 
months of -3.86 % in the medial tibial condyle, the tibial stem all report losses 
as well.  
 
The lateral tibial DXA data report increases in four out of nine data points 
(although none of these are over 0.55 %, and three are in the beyond the tibial 
region). The tibial condyles show losses throughout very similar to the medial 
and lateral PA data, reporting the biggest difference in the non-cone lateral data 
at 12 months of -7.55 % which is supports the reported medial tibial condyle -
3.86 % in the PA data. The lateral data reporting the tibial stem almost matches 
the same values as the PA data, with both reporting losses at every visit; 
beyond the stem has a similar pattern reporting increases at six and 12 months 
in both the lateral and PA data.  
 
This increase from three months to 12 months in the PA DXA images in lateral 
and medial femoral condyles could be due to more weight bearing activities and 
thus higher turnover of bone remodelling [424]. Both the femoral and tibial stem 
report losses, which agree with the cone data and lateral and PA data for both 
groups. The losses reported in the non-cone group around the tibial condyles 
might be due to differential load bearing or alignment issues, or the cone 
implantation, as in the non-cone group there are losses reported in both tibial 
condyles at every visit, so if they were favouring a side due to alignment, we 
would expect to see an increase on one side [425].  
 
In the only other cone rTKR study investigating BMD via DXA (Jensen et al 
(2012) [178], they included non-cone participants (N=19) in their data, they 
reported the lateral tibial condyle as -0.4 % (three months), +0.3 % (six months), 
+0.5 % (12 months), and the medial tibial aspect was reported as -1.1 % (three 
months) -1.4 % (six months) -1.8 % (12 months). These share similar losses 
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reported in our study in the medial tibial aspect, although it does not account for 
the increases reported in Jensen et al’s study compared to the losses reported 
in our study in the lateral tibial condyle. 
 
6.8.3 COMPARISONS BETWEEN CONE AND NON-CONE 
In the cone group the PA tibial and femoral stem changes both show almost 
identical trends, both reporting a small increase at three months, and then 
decreases that gets worse at six and 12 months. This stem trend is also seen in 
the non-cone data as well, with decreases reported at every visit for both the 
femoral and tibial stems (no increase at three months like the cone data), with 
the tibial stem in the cone group reporting a difference of +5.75 % at three 
months, this is due to a high loss in the non-cone group and a slight increase in 
the cone group. 
 
For beyond the femoral stem data both the cone and non-cone group report 
increases, although in the cone group there is a great increase in BMD change 
resulting in a difference between the groups of 4.27 %. For the beyond the tibial 
stem both groups show the same trend (decrease at three months, increase at 
six and decrease at 12 months) with no statistical difference between the 
groups. 
 
As stated these trends in both the tibial and femoral stem and beyond data 
might be due to bone remodelling and transference of loading through the stem 
to beyond it. Furthermore, the differences between the two groups might be due 
to the stabilisation of the tibial cone resulting in the cone group load bearing 
earlier, although there is only one statistically significant figure comparing 
groups, thus the difference may be due to the small group in the non-cone data.  
 
Interestingly the similarities between the tibia and femur is not seen in the 
medial and lateral aspects as clearly, both groups report increases in the lateral 
femoral condyles, with both groups having similar increases in the medial 
femoral condyle at 12 months.   
 
The most notable difference between both groups is in comparing the lateral 
and medial tibial condyles, both groups show large decreases in the medial 
322 
 
tibial condyle region, with both groups reaching their highest loss at 12 months, 
the difference between the groups is 5.12 %, with the cone group having 
reported higher losses in the medial tibial condyle (this agrees with the Jensen 
et al data [178], which reports losses in both their cone and non-cone 
participants in the medial tibial condyle.  
 
This similarity between the two studies and the change in BMD in the medial 
tibial condyle is most likely due to the alignment positioning (which will be 
explored in the next chapter), as stated over 90 % of OA patients have a varus 
position deformity [163]. This results in higher BMD in the medial aspect due to 
load bearing [163], once this deformity is corrected (with a rTKR), there is no 
longer this stress on the medial area, with stress shielding involved this reduces 
the BMD in the medial tibial aspect of both cone and non-cone participants 
across both studies, with this alignment data investigated in the next chapter, 
although unfortunately Jensen et al [178] did not state the alignment of their 
participants, so this cannot be concluded.  
 
In the lateral tibial condyle the cone group reports increases at all visits, whilst 
the non-cone group report losses at all visits, accumulating in a difference of 
5.71 % in support of the cone group. In the Jensen et al study this is harder to 
ascertain, as both groups report losses and increases, when comparing the 
groups directly Jensen et al showed there was no difference between groups, 
with the author concluding the bone remodelling pattern to be almost identical at 
two years post-surgery [178, 426].   
 
As stated, both of these changes could be due to knee alignment issues, in the 
tibial medial condyle the loss is similar (although more severe in the cone 
group), with these losses reported extensively in the TKR literature [17, 29, 287, 
291, 296, 306]. Furthermore, this possible difference in alignment might be the 
reason for the increases in the lateral tibial condyle, as stated tibial BMD 
changes are influenced by knee alignment [425, 427]. Additionally, these could 
be due to the variations due to the sample cohort, especially given as the non-




Additionally, it must be noted that the linear regression data showed no 
statistical difference between the groups when compared across all visits to 




The main limitation was recruitment and attrition, with participants withdrawing 
post- surgery due to requiring a different type of implant, and with several 
participants not completing the 12 month follow-up. Further to this one 
participant in the study attended their six month DXA appointment but had failed 
to attend their others (excluding pre-op), eventually withdrawing at 12 months, 
this six month knee data could not then be used in the comparison to baseline 
(six week) data due to this participant not having a baseline figure.  
 
The advent of COVID-19 resulted in cancelled DXA imaging resulting in four 
participants 12 month imaging to be cancelled, and the inability for me to 
complete the COV analysis. Additionally, due to such a small sample size the 
separation between the stem lengths was not addressed, which in itself might 
influence the BMD changes. As of the 26 who attended at six weeks, four had a 
cone and a long stem, 13 had a cone and a short stem, five non-cone and long 
and four non-cone and short. So it is unknown if the short stem group being 
more prominent in the cone group is influencing the BMD changes.  
 
Additionally, the baseline data for the DXA knee scores were the six week 
scans; this was due to the issues of cementation used in the revision process, 
falsely elevating BMD, and the inability to separate it from bone. Therefore, 
there is no comparison data between pre-op and six weeks, yet there is 
research in TKR (where no fixation cement was used) studies that state there is 
large BMD loss between two and five weeks post-op [16]. So it is unknown what 









For the knee BMD data, it is shown that along the tibial stem there are 
decreases throughout the visits in both groups, in the beyond the femoral stem 
data there are increases throughout the visits, and this is seen in the PA and 
lateral DXA data in both groups. The medial tibial condyles are similar with both 
groups reporting losses at every visit which agrees with the minimal literature. 
Although there are increases in the tibial lateral condyle in the cone group which 
is paralleled by losses in the non-cone group.  
 
The combination of the tibial BMD increase changes in the lateral region, I 
would conclude that there is a sign of osteointegration in and around the cone 
region with increased BMD. The increases in BMD around the knee might be 
due to the stabilisation of the cone, thus earlier WB exercising. Additionally, it 
must be noted that none of the cone group required further surgery, although 
one participant in the non-cone group did require a further revision due to a 
knee infection.  
 
Data across all the DXA imaging shows no negative impact, although not 
significant, it is in support of cone implantation. However, this study contained a 
very small sample size, which makes the results less generalisable, resulting in 
a lack of statistical significance; add to this the issue of a lack of comparative 
cone BMD studies and rTKR DXA data in the research, means these data 
should be interpreted with caution.  
 
 
6.11 FUTURE WORK 
Recommendations for the full study, the DXA knee scanning and regional 
analysis shows promise as a viable methodology and analysis technique in 
determining BMD change. In order to address the issues of the possible plateau 
effect raised by the literature, the addition of 24 month data would have to be 
acquired. Addressing attrition, the use of possible public and patient 
involvement focus groups might communicate some of the attrition issues. Also 
widening the defined terms of appointment dates would allow for a much larger 
range for scanning participants, meaning cancelled or missed appointments 
could still be rearranged and completed, rather than losing that data. 
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7.1 INTRODUCTION  
This chapter will build upon the DXA knee data results, outlining and utilising x-
ray imaging, investigating pixel values of several regions within the knee (via 
long leg x-rays), and alignment of the ipsilateral knee (via long leg x-rays). This 
will involve data from both the distal femur and proximal tibial areas, with 
comparisons between baseline measurements (defined as three months post-
op for when exploring the pixel values, and pre-op scans in the alignment data) 
and their subsequent visits.  Percentage changes throughout the visits were 
calculated in the DXA data, and differences between cone and non-cone groups 
were also investigated.  
 
7.1.1 AIM 
To investigate pixel value changes and hip knee ankle alignment within x-ray 
imaging, comparing the difference between visits and between cone and non-




The participants who underwent DXA imaging also underwent x-ray imaging, 
with the majority scanned on the same day. So the same cohort was utilised, 
although it must be noted that some patients missed their appointments or their 
data were incomplete and could not be included.  
 
 
7.3 METHOD, IMAGING 
Those who were eligible and who had consented were sent a pre-op letter with 
the date and time for a physiotherapy appointment, DXA scan and x-ray 






7.3.1 X-RAY IMAGING METHOD 
 
KNEE POSITIONING 
Patient is erect, with their leg internally rotated 3-5 degrees [428]. The centring 
point for the AP knee is 2.5 cm below the apex of the patella [324], the distal 
third of femur and proximal third of tibia and fibula are included with outer skin 
margins laterally and medially, done at a distance of 100 cm with a kVp and 
mAs of 60 and 4 (as per Royal Devon and Exeter hospital (RD&E) protocols) on 
a cassette size of 18 x 24 cm in the portrait orientation.  
 
The lateral is a similar set up with the patient side on to the cassette. Rotation of 
the patient should be checked by reviewing that the femoral condyles are 
laterally superimposed, with the patient flexing their knee. Additionally, the 
horizontal beam lateral might also be performed if the patient is unable to 
weight bear, as such the positional set up follows the same rules but with the 
patient lying supine.  
 
X-RAY LONG LEG POSITIONING 
These are normally produced to assess limb alignment prior to and after a 
TKR/A, or rTKR [429]. Long leg radiographs are normally obtained using a long 
length vertical cassette holder containing three to four 14×17 inch cassettes 
[429, 430], with the X-ray beam centred at the knee at a distance of 72- 94 
inches [429, 430]. The beam is parallel to the floor and the machine's settings 
are at between 100-200 mAs (for approximately 0.05 second exposure) and a 
kVp of between 90 and 115 [429, 430], although this depends on tissue 
characteristics and limb size [430]. The patient is made to weight bear on both 
feet whilst in the erect position with the back of their knee against the cassettes; 




Patient preparation in x-ray imaging is similar to DXA, as artefacts can produce 





Prior to surgery the patient  attended an x-ray appointment and underwent a 
long leg x-ray scan as part of routine care using one cassette that acquired 
three images, and then the three radiographs were stitched together to create 
one image. A pre-set kVp of 85 but no mAs setting was utilised, in order to 
employ the automatic exposure controls (AEC). A working distance set at a 
consistent 260 cm for all long leg imaging was set for all participants. 
 
Although there is no specific centring point for a long leg view (as this varies 
based on height of the patient), consistence was maintained via same 
repeatable set up between patient imaging. Additionally, due to possibilities in 
variations in exposures in the x-ray image, each radiograph contained an 
aluminium step wedge of a known density (1-12 mm per step), in order to allow 
standardisation and thus intercomparison across images. Aluminium step 
wedges are used both daily and annually in QA of x-ray equipment [431], and 
this type of technique has been used in knee x-ray imaging before [269] as well 
using similar standardisations [326, 432]. Additionally, the position of the step 
wedge does affect the correlation to density [269]. 
 
 
7.4 ANALYSIS OF X-RAY IMAGES 
 
7.4.1 ANALYSIS OF PIXEL DENSITY CHANGES IN LONG LEG X-RAY 
IMAGES 
Images were identified via patient information by the Picture Archive and 
Communications System (PACS) team at the RD&E and burnt onto CD. All 
images were in the Digital Imaging and Communications in Medicine (DICOM) 
format and imported into imageJ (version 1.53a) via the Bioformats importer 
(version 6.5.0). The canvas was standardised across all x-ray images to 3000 
pixels wide to 7500 pixels in height (so all pixels were the same size). The 
window width and widow level were constant for each image, recorded as 
WW4095 and WL 2048, and each image was converted to 8 bit, this process 
builds upon the one mentioned previously in the bovine model (chapter three). 
Region selection was utilised to investigated pixel changes and 
osteointegration. These regions were chosen to cover the three zones of 
fixation from Morgan-Jones et al [433], the epiphysis, the metaphysis, and the 
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diaphysis in order to investigate growth into the implant (figure 7.1). Therefore, 
ROI was set up covering five regions as shown in figure 7.2 (with a further 
region over the step wedge; in order to standardise the density across all 
images (as stated all x-ray images included a step wedge). Region four 
represented the joint surface, regions two and three the metaphysis of the 
femur and tibia (where in the tibial image in the cone group the metaphyseal 
cone resides) and regions five and six the diaphysis (region one was the step 
wedge). 
 
These ROI were saved within a ROI manager program within imageJ at their 
three month visit, and applied and modified to subsequent images as per the 



















Each pixel density score was recorded in a Microsoft Excel spreadsheet and an 
average pixel density of the step wedge region one for each participant was 
calculated, the regional data (two-six) then had a normalisation coefficient 
applied to each figure based off the step wedge data. This new standardised 
pixel density figure was then subtracted from the calculated average pixel 
Figure 7.1. Shows the zones of fixation from Morgan-
Jones et al [376] 
 
 
Figure 7.2. Long leg 
showing all regions 




density and this difference was recorded for that participant, region, and visit. 
Thus for each visit, region, and participant there was a pixel density figure, the 
participant data were then separated into groups (cone and non-cone) and the 
mean pixel density difference calculated for each visit and region (along with a 
SD). Those data were then intracompared between three months and six 
months, and three months and 12 months post–op, a paired samples t-test was 
also applied. Furthermore, the mean differences between three and six months, 
and six and 12 months, were compared between the cone and non-cone group 
and an unpaired samples t-test of unequal variance applied.  
 
This was repeated for all cone and non-cone participants, a mean (and SD) was 
calculated for each group (cone and non-cone participants), at each visit, and 
the mean differences compared, a mean change was recorded as was a SD. 
 
Consistent placement of region of interest were also investigated in the long leg 
pixel analysis x-rays, this involved five random cone and five random non-cone 
six month long leg x-rays having their three month regions placed over them 
and modified to fit the specific regions, the pixel density score of each region 
was recorded in a Microsoft Excel spreadsheet, and then the process repeated 
10 times for each group, a COV precision score was calculated for each 
participant and then a mean figure calculated for the COV for each region for 
the five cone participants, and the five non-cone participants. 
 
7.4.2 ANALYSIS OF ALIGNMENT OF KNEE AND HIP IN LONG LEG X-RAY 
IMAGES 
Using the same long leg x-ray DICOM images taken at pre-op and three, six 
and 12 months post-op. It was decided to calculate the ipsilateral alignment of 
the overall hip knee ankle (HKA) angle, the lateral distal femoral angle (LDFA), 
and the medial proximal tibial angle (mPTA) (see figure 7.3). This was 
undertaken to determine any alignment differences between the visits, and 
between cone and non-cone groups as this has been reported to impact BMD 
via weight bearing variations due to varus and valgus deformities [164]. The 
alignment and angulation was determined utilising a piece of software called 
MicroDicom viewer (version 3.1.4 [434]), following the same measurement 
technique as stated in previous research [435, 436], with the use of a 180° 
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alignment system being very familiar to all orthopaedic surgeons [436]. Each 
long leg x-ray was loaded into the viewer and using the MicroDicom 
measurement angulation tool, the HKA, LDFA, and mPTA were measured, as 


























These measurements were performed for all cone participants and non-cone 
participants at pre-op, three, six and 12 months, a mean angulation for each 
visit was calculated for all cone and non-cone participants (as was a SD), and a 
comparison was made between pre-op and three months, pre-op and six 
months, pre-op and 12 months, as well as comparisons made between three 
and six months, and three and 12 month (with these three month comparisons 
Figure 7.4. Shows 
long leg x-ray with 
overall hip knee ankle 





Figure 7.3. Positions of 
the LDFA, mPTA and 
HKA angle is the line 




Figure 7.5. Shows long leg 
x-ray with lateral distal 
femoral angle and medial 
proximal tibial angle 





to create direct post-op changes), with a paired samples t-test performed for the 
intracomparison, and a t-test of unequal variance performed for the comparison 
between groups for their data at pre-op, three, six and 12 months.  
 
7.4.3 INTRAOPERATOR ANALYSIS OF THE KNEE 
Consistent placement of pixel density regions and placement of alignment lines 
was also investigated in the x-ray long leg data. For the pixel density data this 
involved 10 repeats of five random cone long leg images and 10 repeats from 
five non-cone participants, with the ROI placed over the correct areas. For the 
alignment data this involved loading five random six month cone participants 
and five random six month non-cone participants long leg x-rays, applying 
alignment angulation as demonstrated in figure 7.4 and 7.5, and repeating this 
10 times for each participant. For both COV calculations the result recorded 
were recorded in a Microsoft Excel spreadsheet, a COV precision score was 
calculated for each participant, and then a mean figure calculated for the COV 
for the HKA, LDFA, and mPTA, for the cone group, and the non-cone group.  
 
 
7.5 RESULTS  
 
7.5.1 COV ROI ANALYSIS FOR PIXEL DENSITY ROI LONG LEG X-RAY 
IMAGES 
 
The COV for ROI placement in long-leg x-ray pixel density analysis involved 10 
repeats (of five random x-ray images), for the cone and non-cone groups was 
conducted over a mean separation of 1.44 days (range 1-4 days), with a COV 
calculated for each region per participant and then these figures averaged as 










Table 7.1. COV for pixel difference in the cone and non-cone group  
COV FROM 10 REPEATS OF 5 RANDOM CONE PARTICIPANTS 
Region number 1 2 3 4 5 6 
Participant 06 COV (%) 0.21 0.08 0.14 0.26 0.05 0.21 
Participant P08 COV (%) 0.27 0.13 0.11 0.17 0.09 0.29 
Participant P13 COV (%) 0.33 0.20 0.40 0.15 0.30 0.07 
Participant P15 COV (%) 0.46 0.29 0.24 0.16 0.33 0.08 
Participant P19 COV (%) 0.48 0.21 0.19 0.57 0.25 0.15 
AVERAGE (COV %) 0.35 0.18 0.22 0.26 0.21 0.16 
SD 0.12 0.08 0.11 0.18 0.13 0.09 
 
Table 7.1 shows the COV for the region placement in the long leg x-rays for the 
pixel density data. The cone groups highest COV precision percentage is 0.35 
% in region one (the step wedge), and the lowest precision figure of 0.16 % in 
region six (the femoral diaphysis). In the non-cone data, the highest COV 
precision percentage is in region two (tibial metaphysis) reported as 0.32 %, the 
lowest is reported in region six the femoral diaphysis (0.12 %). From the 
reported data both groups report very low COV precision scores, across all 
regions, showing reliable and repeatable ROI placement, especially in the 
femoral diaphysis. Interestingly the tibial metaphysis reported as the highest in 
the non-cone data (0.32 %) which might be due to cone placement influencing 
region placement consistency (that region in the cone group was reported as 
0.18 %), thus meaning that ROI placement might be more consistent in the 
cone group. Although as stated all COV precision scores are very low, with no 
real stated difference between the two groups.  
 
7.5.2 COV ROI ALIGNMENT ANALYSIS FOR LONG LEG X-RAY IMAGES 
The COV for alignment placement in long-leg x-ray analysis involved 10 repeats 
(of five random x-ray images), for the cone and non-cone groups over a mean 
separation of 1.44 days (range one to four days), with a COV calculated for 
COV FROM 10 REPEATS OF 5 RANDOM NON-CONE PARTICIPANTS   
REGION number 1 2 3 4 5 6 
Participant P04 (COV %) 0.51 0.49 0.23 0.31 0.11 0.46 
Participant P12 (COV %) 0.11 0.21 0.20 0.18 0.21 0.03 
Participant P24 (COV %) 0.12 0.25 0.18 0.16 0.11 0.02 
Participant P27 (COV %) 0.21 0.36 0.34 0.23 0.29 0.02 
Participant P37 (COV %) 0.18 0.28 0.16 0.10 0.12 0.09 
AVERAGE (COV %) 0.23 0.32 0.22 0.20 0.17 0.12 
SD 0.16 0.11 0.07 0.08 0.08 0.19 
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each alignment measurement, per participant and then these figures averaged 
as shown in table 7.2.  
 
Table 7.2. COV for alignment in the cone and non-cone group  
COV FROM 10 REPEATS OF 5 RANDOM 
CONE PARTICIPANTS 
COV FROM 10 REPEATS OF 5 RANDOM NON-
CONE PARTICIPANTS 
 Participant number HKA LDFA mPTA  Participant number HKA LDFA mPTA 
P06 COV (%) 0.29 0.46 0.60 P04 (COV %) 0.24 0.38 0.54 
P08 COV (%) 0.09 0.35 0.42 P12 (COV %) 0.21 0.57 0.67 
P13 COV (%) 0.24 0.58 0.52 P24 (COV %) 0.32 0.56 0.56 
P15 COV (%) 0.26 0.60 0.59 P27 (COV %) 0.16 0.56 0.44 
P19 COV (%) 0.23 0.41 0.81 P37 (COV %) 0.29 0.58 0.34 
AVERAGE (COV %) 0.22 0.48 0.59 AVERAGE (COV %) 0.25 0.53 0.51 
SD 0.08 0.11 0.14 SD 0.06 0.08 0.13 
 
Table 7.2 reports the COV for the alignment values in the hip knee ankle (HKA) 
angle, the lateral distal femoral angle (LDFA), and the medial proximal tibial 
angle (mPTA. For the cone group the highest COV precision percentage is 0.59 
% for the mPTA alignment, and the lowest precision is 0.22 % for the HKA. In 
the non-cone data the highest COV precision percentage is reported as 0.53 % 
in the LDFA, the lowest is reported in the HKA. From the reported data both 
groups report very low COV precision scores, across all alignment, reporting 
repeatable alignment positioning, especially in the overall HKA reported as the 
lowest in both groups of 0.22 % and 0.25 %.  
 
7.5.3 X-RAY PIXEL DENSITY RESULTS IN LONG LEG X-RAY IMAGES 
All participants who underwent a long leg x-ray had per the protocol a step 
wedge included in the image. This was used to standardise the pixel densities 
(using a normalisation coefficient as stated in the method), the three month long 
leg data was used as a comparator to the six and 12 month data, therefore only 
participants who had a three month long leg x-ray and had subsequent long leg 
scans (at either six or 12 months) were included in the analysis. Therefore, only 
long leg images which contained the step wedge were included, therefore eight 
long leg x-ray images were excluded from the analysis due to not including a 
step wedge, as the pixel values could not be standardised. Additionally, four 
participants could not attend their 12 month appointment due to the COVID-19 
pandemic. The participant who had a femoral cone implanted had their long leg 
femoral data excluded with the tibial data classified as non-cone data, just as 
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with the DXA data. In total the number of participants who attend their long leg 
x-ray scan, who also had three month data, and had step wedges included was: 
three months 18 participants (11 cone and seven non-cone), six month 17 
participants (11 cone and six non-cone) and 12 months six participants (four 
cone and two non-cone).  
  
Table 7.3. Cone and non-cone group pixel density differences on long leg x-
rays at 3 and 6 month visits, including t-test and p-value 










3 month (N=11) (mean 
pixel value) 
19.12 34.79 39.19 43.13 33.81 
SD 23.34 24.02 26.39 27.63 26.38 
6 month (N=11) (mean 
pixel value) 
19.24 37.14 40.67 44.36 31.43 
SD 16.84 16.25 18.03 18.94 16.52 
T-Critical between 3 and 
6 months (p-value) 
-0.02 (0.98) -0.39 (0.70) -0.23 (0.82) -0.18 (0.86) 0.48 (0.64) 










3 month (N=6)(N=5 
femoral data) (mean 
pixel value) 
22.16 34.14 37.93 39.83 39.39 
SD 33.48 29.35 34.53 34.44 36.43 
 6 month (N=6) (N=5 
femoral data) (mean 
pixel value) 
14.61 31.26 34.94 31.97 34.29 
SD 28.90 20.90 27.14 33.83 29.66 
T-Critical between 3 and 
6 months (p-value) 
0.73 (0.50) 0.21 (0.85) 0.20 (0.85) 0.63 (0.56) 0.33 (0.76) 
 
The results in table 7.3 report that for the cone group at six months there is an 
increase across all regions (except the femoral diaphysis); the greatest 
difference was an increase of 2.35 in mean pixel density in the femoral 
metaphyseal region. In the non-cone group, there is a loss in mean pixel density 
across all regions, with the highest being in the tibial regions pixel density loss 






Table 7.4. Cone and non-cone group pixel density differences on long leg x-
rays of those who completed 3 and 12 month visits, including t-test and p-value 










3 month (N=4) 37.02 48.43 58.01 63.14 50.78 
SD 27.82 31.95 34.99 33.14 33.91 
12 month (N=4) 18.00 28.83 34.49 39.18 30.66 
SD 20.76 23.65 25.28 23.04 25.31 
T-Critical between 6 and 
12 months (p-value) 
(paired to only those 4) 
3.30 (0.05) 2.48 (0.09) 2.49 (0.09) 2.46 (0.09) 2.62 (0.08) 










3 month (N=2)(N=1 
femoral data) 
24.83 56.52 68.55 47.69 71.75 
SD 40.57 - - 43.84 - 
12 month (N=2)(N=1 
femoral data) 
19.88 57.23 72.11 47.99 79.13 
SD 44.50 - - 54.38 - 
T-Critical between 6 and 
12 months (p-value) 
(paired to only those 2) 
1.78 (0.33) - - 0.04 (0.97) - 
 
For the 12 month data (table 7.4), there was a very small sample size (four on 
the cone group and two in the non-cone group, which is only one participant for 
the femoral data) and large SDs, the p-values reported are a misnomer due to 
such small group sizes i.e. four participants (cone) report a 12 month pixel 
density score increase of 61.79 compared to another participants increase 













Table 7.5. Cone vs non-cone group pixel density differences between 3 and 6 
months on long leg x-rays, including t-test and p-value 










Average difference in mean 
pixel value between 3 and 6 
months (N=11) 
0.12 2.35 1.48 1.23 -2.38 
SD 18.11 19.94 21.21 22.66 16.53 
      










Average difference in mean 
pixel value between 3 and 6 
months (N=6)(N=5 femoral 
data) 
-7.55 -2.88 -2.99 -7.86 -5.10 
SD 25.49 31.15 33.62 30.48 34.23 













Difference in mean pixel 
value 
7.67 5.23 4.46 9.09 2.72 
T-Critical (P-value) -0.65 (0.53) -0.34 (0.74) -0.27 (0.79) -0.64 (0.54) 0.44 (0.87) 
 
Comparing the two groups in table 7.5, shows that even on the one region in 
the cone group that a loss was reported (femoral diaphysis), the loss was larger 
in the non-cone group (-2.38 compared to -5.10). The biggest difference 
between the two groups is in the tibial regions (metaphysis and diaphysis) 
reporting a difference of 7.67 and 9.09 respectively. Although it must be noted 









Table 7.6. Cone vs non-cone group pixel density differences between 3 and 12 
months on long leg x-rays, including t-test and p-value 











between 3 and 12 months 
(N=4) 
-6.38 -8.84 -9.03 -8.36 -7.71 
SD 7.87 14.40 17.98 13.00 10.11 
      











between 3 and 6 months 
(N=2) (N=1 femoral data) 
-2.17 0.71 3.56 7.76 7.38 
SD 7.74 - - 7.16 - 













Difference -4.21 -9.55 -12.59 -16.12 -15.08 




0.45 (0.88) 2.98 (no 
data) 
 
Table 7.6 reports the 12 month data; this has been included for completion of 
the data, but as stated due to the lack of participant numbers making 
comparisons between the two groups difficult. Further to this, some of the 
comparison data does not report a p-value due to there only being one data 
point in the non-cone femoral data.  
 
7.5.4 ALIGNMENT RESULTS FOR CONE AND NON-CONE PARTICIPANTS 
This section will now report the alignment results for the knee in the long leg x-
ray images. The data was recorded at each participant’s visits (pre-op, three 
month, six month, and 12 month), with a mean angulation calculated for overall 
hip knee ankle (HKA) angle, the lateral distal femoral angle (LDFA), and the 
medial proximal tibial angle (mPTA), these figures were then compared 
between the two groups. It must be noted the participant who had a femoral 
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cone but not a tibial cone was placed into the non-cone group, and their femoral 
and overall HKA data excluded (so only their tibial angle was included), this 
matches the same method used in the DXA results and x-ray pixel analysis; 
with the femoral BMD/pixel density excluded, but the tibial data included as non-
cone.  
 
28 participants (18 cone participants and 10 non-cone participants) in total 
attended at least one long leg x-ray appointment, for pre-op it was: 17 cone 
participants and nine non-cone (26 total), at three months it was 15 cone and 
nine non-cone (24 total), at six months it was 13 cone and six non-cone (19 
total) and 12 months seven cone and four non-cone (11 total). 
 
As for appointments; the average three month visit was a mean +6.75 days 
away from the exact three month post-op date (range -16 to +32), for six 
months the mean was +5.16 days (range -30 to +28), and for 12 months the 
mean was +5.92 days (range -92 to +42). 
 
Datasets were compared between the pre-op figure and the three, six and 12 
month visits, and between three months to six, and three months to 12 months 
to investigate post-op changes. Furthermore, the data were compared between 
cone and non-cone to discern differences between the two groups. 
 
Table 7.7. Pre-op angulation for the overall hip knee angle (HKA), lateral distal 
femoral angle (LDFA) and medial proximal tibial angle (mPTA) 
 PRE-OP  
 CONE GROUP (N=17) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 
 HKA (°) LDFA (°) mPTA (°) 
AVERAGE 2.48 -0.44 1.03 
SD 4.94 2.74 2.63 
 NON-CONE GROUP (N=9) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 
 HKA (°) LDFA (°) mPTA (°) 
AVERAGE -1.18 0.70 -0.76 
SD 4.72 3.09 2.73 
T-CRITICAL  
(P-VALUE) 
1.778 (0.010) -0.885 (0.39) 1.611 (0.13) 
 
Table 7.7 reports the pre-op angles of the HKA, LDFA, and mPTA, on average 
the HKA in the cone group was 2.48° (177.52° varus) with the non-cone group 
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reporting -1.18° (181.18°), valgus alignment, so there is a difference in the pre-
op data (although not statistically significant, but one of the eight non-cone 
participants has a reported HKA of 188.14°). Interestingly this is agreed upon in 
additional data, in the LDFA the cone group this is reported as 0.44° varus 
(90.44°), but with the non-cone group it was reported as 0.70° valgus (89.30°), 
with the tibial data mPTA reporting 1.03° varus (88.97°) for the cone group, and 
0.76° valgus (90.76°) in the non-cone group. 
 
CONE PRE-OP ALIGNMENT COMPARED TO OTHER VISITS 
In this section the cone group compared the pre-op long leg x-ray with each 
visits long leg x-ray (three, six and 12 months), and then the cone group was 


























Table 7.8. Cone group long leg compared to pre-op at each visit for HKA, LDFA 
and mPTA, including t-test and p-value 
CONE GROUP (N=14) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 3 MONTH VISIT 
  PRE-OP 3 MONTH DIFFERENCE 
T-CRITICAL (P-
VALUE) 
HKA (mean °) 2.88 -2.16 -5.04 2.642 (0.01) 
SD 5.43 4.23 6.45   
LDFA (mean °) -0.53 1.39 1.92 -1.930 (0.08) 
SD 2.99 1.87 3.59   
mPTA (mean °) 0.80 -1.15 -1.96 2.000 (0.07) 
SD 2.68 2.53 3.66   
   
 
CONE GROUP (N=7) 12 MONTH VISIT 
  PRE-OP 12 MONTH DIFFERENCE 
T-CRITICAL (P-
VALUE) 
HKA (mean °) 3.63 -1.65 -5.28 1.826 (0.09)  
SD 6.14 4.57  5.70   
LDFA (mean °) -1.65 1.43 3.08  -2.602 (0.04) 
SD 3.05 1.71 3.14    
mPTA (mean °) 1.20 -0.64 -1.84 1.089 (0.32) 
SD 2.87 3.62 4.46    
 
Data from table 7.8 reports changes in the cone group between pre-op and the 
subsequent visits, the HKA reports a reduction in degrees at each visit, with the 
largest difference in the HKA reported at six months with a figure moving from 
3.53° to -2.28° (p-value 0.01). LDFA reports increases throughout each visit, the 
most significant difference is -0.93° at pre-op and 1.33° at six months this was 
reported as a p-value of 0.05, at 12 months this was reported as going from a 
pre-op of -1.65° to 1.43° (p-value 0.04). For the mPTA data reported a 
consistent pattern as well at each visit, this time reporting the opposite i.e. a 
positive score into a negative, e.g. 1.26° at pre-op to a six month score of -1.62° 
(p-value 0.01), this was seen in the 12 month data as well, reporting 1.20° at 
pre-op to -0.64° at 12 months 
CONE GROUP (N=12) 6 MONTH VISIT 
  PRE-OP 6 MONTH DIFFERENCE 
T-CRITICAL (P-
VALUE) 
HKA (mean °) 3.53 -2.28 -5.80 2.994 (0.01) 
SD 5.13 4.33 6.15   
LDFA (mean °) -0.93 1.33 2.26 -2.256 (0.05) 
SD 2.74 1.71 3.47   
mPTA (mean °) 1.26 -1.62 -2.88 3.072 (0.01) 
SD 2.46 3.31 3.24   
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Table 7.9. Cone group long leg compared to 3 month at each visit for HKA, 
LDFA and mPTA, including t-test and p-value  
CONE GROUP (N=13) 3 MONTH COMPARED TO 6 MONTH DATA 
  3 MONTH 6 MONTH DIFFERENCE 
T-CRITICAL (P-
VALUE) 
HKA (mean °) -1.45 -1.90 -0.45 0.027 (0.79) 
SD 4.30 4.36    
LDFA (mean °) 1.25 1.24 -0.01 0.043 (0.97) 
SD 1.89 1.68     
mPTA (mean °) -0.86 -1.45 -0.59 0.925 (0.37) 
SD 2.59 3.23     
 
CONE GROUP (N=7) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 3 MONTH 
COMPARED TO 12 MONTH DATA 
  3 MONTH 12 MONTH DIFFERENCE 
T-TEST (P-
VALUE) 
HKA (mean °) -2.11 -1.65 0.46 -0.176 (0.86)  
SD 5.10 4.57     
LDFA (mean °) 1.36 1.43 0.07 -0.143 (0.89) 
SD 1.48 1.71     
mPTA (mean °) -1.19 -0.64 0.55 -0.739 (0.49)   
SD 3.35 3.62     
 
Table 7.9 data report changes in the cone group between three month post-op 
and the subsequent six and 12 month visits, there is no statistically significant 
difference, the HKA reports a difference of -0.45° at six months to 0.46° at 12 
months. LDFA figure shows no real change at six or 12 months when compared 
to three months, mPTA reports differences at six and 12 months of -0.59° and 
0.55° respectively, this is reflected in the HKA data. 
 
NON-CONE PRE-OP ALIGNMENT COMPARED TO OTHER VISITS 
In this section the non-cone group compared the pre-op long leg x-ray to each 
subsequent visit (three, six and 12 months), and then the cone group was also 









Table 7.10. Non-cone group long leg compared to pre-op at each visit for HKA, 
LDFA and mPTA, including t-test and p-value  
NON-CONE GROUP (N=8) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 3 MONTH DATA 
  PRE-OP 3 MONTH DIFFERENCE 
T-CRITICAL P-
VALUE 
HKA (mean °) -2.26 -2.11 0.15 -0.079 (0.94) 
SD 3.87 2.95 5.05   
LDFA (mean °) 1.13 1.37 0.24 -0.338 (0.75) 
SD 3.06 1.78 1.87   
mPTA (mean °) -0.81 -0.87 -0.06 0.041 (0.97) 
SD 2.92 1.74 4.15   
 
NON-CONE GROUP (N=5) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 6 MONTH DATA 
  PRE-OP 6 MONTH DIFFERENCE 
T-CRITICAL P-
VALUE 
HKA (mean °) -2.79 -1.31 1.49 -2.02 (0.11) 
SD 4.18 3.71 1.35   
LDFA (mean °) 1.09 1.26 0.17 -0.118 (0.91) 
SD 4.07 1.96 2.81   
mPTA (mean °) -0.34 -1.46 -1.13 1.09 (0.34) 
SD 3.03 1.04 2.32   
 
NON-CONE GROUP (N=4) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 12 MONTH DATA 
  PRE-OP 12 MONTH DIFFERENCE 
T-CRITICAL 
P-VALUE 
HKA (mean °) 1.86 -1.33 -3.19 1.277 (0.33)  
SD 2.93 4.22 4.32   
LDFA (mean °) 0.01 1.03 1.02 -0.934 (0.45)  
SD 2.29 1.96  1.89   
mPTA (mean °) 0.88 -1.08 -1.96 1.444 (0.24)  
SD 1.82 2.58  2.71   
 
Data from table 7.10 report changes in the non-cone group between pre-op and 
the subsequent visits, the HKA reports a pre-op of -2.26° to -2.11° at three 
months, at 12 months this is reported as -1.33° from 1.86°). For the LDFA it 
reports an increase at each visit starting from a positive pre-op score, with the 
greatest difference reported at 12 months of 1.01° (0.01° to 1.03°). For the 
mPTA there is the same pattern at every visit resulting in a negative score at 






Table 7.11. No-cone group long leg compared to 3 month at each visit for HKA, 
LDFA and mPTA, including t-test and p-value 
 
NON-CONE GROUP (N=6) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 3 MONTH COMPARED 
TO 6 MONTH DATA 
  3 MONTH 6 MONTH DIFFERENCE 
T-CRITICAL P-
VALUE 
HKA (mean °) -1.04 -1.00 0.04 -0.022 (0.98) 
SD 2.25 3.29    
LDFA (mean °) 0.73 0.93 0.21 -0.578 (0.59) 
SD 1.71 1.84     
mPTA (mean °) -0.57 -1.29 -0.71 2.220 (0.08) 
SD 0.83 1.03     
  
NON-CONE GROUP (N=3) (ONLY TIBIAL DATA FOR 1 PARTICIPANT) 3 MONTH COMPARED TO 
12 MONTH DATA 
  3 MONTH 12 MONTH DIFFERENCE 
T-CRITICAL P-
VALUE 
HKA (mean °) -2.82 -2.16 0.66 -0.125 (0.91)  
SD 4.80 5.61     
LDFA (mean °) 1.23 1.25 0.02  -0.468 (0.94) 
SD 2.43 2.72     
mPTA (mean °) -1.26 -0.80 0.46 -0.178 (0.89)  
SD 1.44 3.08     
 
Table 7.11 data report changes in the non-cone group between three month 
and the subsequent six and 12 month visits, giving a comparison to post-op 
changes the results show. The difference reported in the HKA increases 
compared to three months with the greatest difference reported as 0.66° (-2.82° 
to -2.16°, the LDFA reports both positive changes, reported as 0.73° pre-op to 
0.93° at six month, and 1.23° to 1.25° at 12 months. The mPTA data also report 
differences at each visit, for six months (pre-op -0.57 to -1.29°) and at 12 
months of -1.26° to -0.80°. 
 
ALIGNMENT COMPARISON BETWEEN CONE AND NON-CONE DATA 
In this section the cone group was compared to non-cone group at three, six 







Table 7.12. Cone vs non-cone group long leg at each visit for HKA, LDFA and 
mPTA, including t-test and p-value 
 

















HKA (mean °) 176.47 182.28 182.80 181.31 0.97 0.431 (0.68) 
SD 5.13 4.33 3.98 3.71     
LDFA (mean °) 90.93 88.67 88.91 88.74 -0.08 0.069 (0.95) 
SD 2.74 1.71 4.07 1.96     
mPTA (mean °) 88.74 91.62 90.34 91.46 0.16 -0.146 (0.89) 
SD 2.46 3.31 3.03 1.04     
 

















HKA (mean °) 176.37 181.65 178.14 181.33 0.32 
0. 108 
(0.92) 
SD 6.14 4.57 3.97 4.22     
LDFA (mean °) 91.65 88.57 89.99 88.97 -0.40 
0.310 
(0.78)  
SD 3.05 1.71 2.29 1.96     
mPTA (mean °) 88.80 90.64 89.12 91.08 -0.44 
 0.231 
(0.82) 
SD 2.87 3.62 1.82 2.58     
 
Table 7.12 reports the comparison data between the two groups, there is no 
reported statistical significance between the groups. Pre-op the cone group are 
in the varus position and the non-cone group in the valgus (177.12° and 
CONE (N=14) AND NON CONE (N=8) (ONLY TIBIAL DATA FOR 2 PARTICIPANTS 1 CONE 1 NON-
















HKA (mean °) 177.12 182.16 182.26 182.11 0.05 0.029 (0.98) 
SD 5.43 4.23 3.87 2.95     
LDFA (mean °) 90.53 88.61 88.87 88.63 -0.02 0.027 (0.98) 
SD 2.99 1.87 3.06 1.78     
mPTA (mean °) 89.20 91.15 90.81 90.87 0.29 -0.312 (0.76) 
SD 2.68 2.53 2.92 1.74     
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182.26°), but by three months both groups report very similar figures (182.16° 
and 182.11°), at six month for the HKA both groups have again are closer to the 
180° ideal than at pre-op, the cone group now reporting 182.28° and the non-
cone reporting 181.31°. At 12 months the cone group reports 181.65° and the 
non-cone group reports a figure of 181.33°.  
 
The LDFA comparison data at three months reports the cone and non-cone 
group are nearly identical reporting 88.61° and 88.63°, at six months 88.67° and 
88.64° and at 12 months it is reported as 88.57° and 88.97°. It must be noted 
that the pre-op alignment in the cone group is over 90° reporting a varus 
alignment, the non-cone group pre-op is always as valgus alignment (under 
90°) and is similar to the pre-op at each visit.  
 
The mPTA data reported the cone at three months of 91.15°, 1.15° into valgus 
alignment; this was with a reported 89.20° at pre-op. The non-cone data show 
little change between pre-op and three months post-op reporting 90.87° from a 
pre-op score of 90.81°. At six months the cone group has increased, as has the 
non-cone group to 91.62° and 91.46°. At 12 months this is reported as 90.64° in 





7.6.1 X-RAY PIXEL DENSITY CHANGES 
Examining the six month data compared to the three month data, the cone 
group reports an increase in all regions (except one), and the non-cone group 
reporting losses at each region, the greatest deficient between the two groups 
was in the non-cone group in the tibial region, with reported losses of 7.67 
(metaphyseal) and 9.09 (diaphyseal) in mean pixel density.  
 
These changes could be due to the cone osteointegration and stabilisation 
around the joint at six months, thus increasing BMD within and around it (which 
is not seen in the non-cone group), especially as in the DXA results from the 
previous chapter the cone implant is classified as artefact, so cannot report the 
346 
 
BMD changes penetrating the cone or directly around it, only the changes in the 
surrounding area.  
 
This idea of cone osteointegration is further supported due to the data 
demonstrating that the second greatest loss in the non-cone is in the tibial 
metaphyseal region, which is where the cone is situated (in the cone group), 
which as already stated was reported as an increase in pixel density in the cone 
group. This increase in pixel density could be due to osteointegration. Research 
has reported osteointegration of cones demonstrated on radiographs [218, 437, 
438, 439], with no radioluciencies identified [218, 222, 440, 441]. Unfortunately, 
the reported literature do not report pixel densities, but rather state: “cones 
show osteointegration as defined radiographically as absence of radiolucent 
lines” [218] or “absence of radiolucency lines between the cone and the host” 
[442] or “as absence of a lucent line between the bone and cone” [443], with a 
high majority of cone studies showing good osteointegration after one year. Due 
to these issues, there is limited correlation data on BMD scores and pixel 
density changes. Kinds et al [269] did investigate this with cadavers, showing 
that accurate BMD measurements were possible from standard x-ray images 
(radiographs) with a step wedge. Although correlation between the two is used 
a lot in dentistry, a study by Nackaerts et al [444] investigated the correlation 
between mandibular BMD and pixel values on intra-oral radiographs using an 
aluminium step wedge and reported good observer agreement between the 
two. Concluding that the pixel values are likely representing the BMD changes 
in some capacity, although without robust correlation, this cannot be truly 
concluded in our study. 
 
Regrettably, although there is 12 month data it only involves four participants 
(cone group), additionally, these four participants had losses at six months 
compared to the three month as well, so without 12 month data from the rest of 
the participants it is unknown osteointegration has happened overall. 
Furthermore, only two non-cone participants completed 12 months, with only 
one of those having femoral data, so there is a lack of direct comparison data. 
 
It must be noted these pixel density changes may be for other reasons, 
although the region placement was accurate, with a reported COV precision 
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range of 0.09 % to 0.35 %, there is the possibility of rotation of the joint and 
other variations in positioning of the long leg x-ray, which may also be 
influencing the reported figures. For example, foot rotation in long leg x-rays has 
been reported to affect long leg x-rays and alignment results [445]. 
 
As stated previously there was at least eight long leg x-rays that could not be 
included due to not containing the step wedge in the image. Four participants 
could also not complete the 12 month long leg x-ray due to the COVID-19 
pandemic. Additionally, no lateral data were used due to variations and a lack of 
consistency in the x-ray settings and positioning, in addition to this we did not 
have six week long leg comparisons, although this would have given us a more 
accurate baseline, and allowed direct comparisons to the DXA data. So it is 
unknown if there is an increase between pre-op and three months. It must be 
noted that a six week long leg was not part of routine care, and would have 
added to the issues of attrition, due to the need for additional scanning.  
 
7.6.2 ALIGNMENT ANALYSIS CONE AND NON-CONE GROUP 
As with the DXA data some participants missed their three, six and/or 12 month 
appointments, with only seven cone and four non-cone participants completing 
12 months. 
 
The average pre-op scores for the HKA in the cone (177.52° SD 4.94, 2.48°) 
and non-cone group (181.18° SD 4.72, -1.18°) both are similar to the reported 
5° variation from 180° reported in the literature as defined as normal mechanical 
alignment [436], although some do state it should be 180° ± 3° [446, 447]. With 
both groups reporting figures closer to 180° at three, six and 12 months, than at 
pre-op, showing a parallel to normal alignment. This is in agreement with a 
report by Mizu-Uchi et al who reported their HKA as 178.2° ± 1.5° (173.9° to 
181.8°) in TKR patients [448], although one study involving cone implantation in 
rTKR patients the reported HKA was 178° ± 6° (163° to 194°) preoperatively, 
and 180° ± 4° (172° to 191°) at two year post-op [443]. Moreover, some have 
reported a greater difference in alignment in pre-op revision patients, with one 
report stating a mean difference of 7.3° valgus in pre-op revision patients [449]. 
Furthermore, research has shown that alignment within the range of 3° 
varus/valgus is associated with better survival of the prosthesis [450, 451, 452, 
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453, 454]. Additionally, although protocols were followed, there is the possibility 
of rotation in positioning, which can produce greater perceived varus alignment, 
and increased mechanical axis deviation from the knee joint centre [445]. 
 
In comparing this rTKA data to other studies it must be noted that a high 
majority of papers only define the degrees as valgus or varus, and do not 
stipulate exact degrees, a paper by Kamath et al [221] reviewed all articles 
published in Clinical Orthopaedics and Related Research, The Journal of 
Arthroplasty, and The Journal of Bone and Joint Surgery (American edition) 
from January 2008 to December 2009. Their results after exclusion/inclusion 
reported 96 articles involving alignment from radiographs, of which over 90 % of 
the papers (90 articles) used a variation on the varus/valgus system without a 
strict definition often using terms like ‘‘X degrees from/of varus’’ or ‘‘Y degrees 
from/of valgus” [221], with only 2 % of papers stating the degrees from 180°. 
 
The LDFA data are reported in the cone group as -0.44° (90.44°) at pre-op, and 
0.70° (89.30°) in the non-cone group (reported (when comparing to three month 
data) as 90.53° and 88.78°). This is within the same alignment as TKR patients, 
reporting 89.0° ± 1.4° (85.5° to 92.8°) [448]. Reviewing the changes at three, six 
and 12 months, all changes in the cone group resulted in a varus to valgus 
degree change. In the non-cone group there is a similar pattern but the 
alignment was already starting in a valgus position.  
 
Data for the mPTA in TKR research reports similar alignment scores, with the 
mPTA reported in the tibial component as 89.2° ± 1.0° (87.4° to 91.6°) [448], 
with a reported pre-op of 88.97° (1.03°) in the cone group and 90.76° (-0.76°) in 
the non-cone group. For the cone group trend, the pre-op is in the varus and 
ends in the valgus position at each visit, with the 12 month data reporting a pre-
op 1.20° to 12 month of -0.64°. For the non-cone the mPTA data the pattern is 
similar. 
 
Both the LDFA and mPTA in the cone and non-cone data show both groups 
ending up in negative position (over 90°) in the LDFA, and in the positive 
position in the mPTA (under 90°), the main difference being their starting 
alignment position. Thus, the cone group seems to start in a more varus 
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misaligned position at pre-op, but by their first long leg x-ray at three months 
due to surgery this seems to have been rectified, this is the same in the mTPA 
data.  
 
When directly comparing the two groups as stated there is little difference 
between them across all three visits, and no statistical significance with a high 
majority of p-values reported, although the difference at pre-op is noticeable 
(although not statistically significant) by three month the reported HKA is nearly 
identical. This is lack of statistical significance is most likely due to the issues of 
reduced data, and the problems already discussed in the DXA and pixel density 
data regarding recruitment and attrition exacerbated by the COVID-19 
pandemic. This lack of difference between groups supports that the cone is not 
impacting alignment, and that the data demonstrated supports the importance 
of correct alignment in rTKR patients, as correction of malalignment via surgery 
has resulted in similar results between cone and non-cone data at three, six, 
and 12 months. It must be noted that these similarities between alignment 
measurements is very important, as malalignment can lead to implant failure, 
joint instability, and the need for further surgery [455, 456, 457, 458, 459].  
 
Other revision alignment research has also supported reduced malalignment 
post-surgery, a study by Nakasone et al reported a pre-op tibiofemoral angle 
was 7.3° of valgus, and the average post-op tibiofemoral angle was 6.7° of 
valgus [460]. This change was reported in the femoral and tibial components as 
well; the femoral component angle reported 8.6° of valgus pre-op, with the 
average post-op angle being 6.5° valgus. The average pre-op tibial component 
angle was 1.4° of varus and the average post-op tibial component angle was 




Across the methods (pixel density, and alignment), as with the DXA imaging,  
the main limitation was recruitment and attrition, with participants withdrawing 
post- surgery due to requiring a different type of implant, and with several 
participants not completing the 12 month follow-up. In the pixel density method 
there was the issue of the step wedge not being included in the imaging, 
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although it was in the protocol I was not in the department, and a busy 
department combined with possibly new staff and long gaps between scans (i.e. 
six month to 12 month) meant this might have been overlooked during the 
imaging. This resulted in data that could not be included in the pixel density 
analysis, although this data could still be used in the alignment method. 
Moreover, the advent of COVID-19 resulted in cancelled x-ray and DXA imaging 
resulting in four participants 12 month imaging to be cancelled, and the inability 
for me to complete the COV analysis. Additionally, due to such a small sample 
size the separation between stem lengths was not addressed, which in itself 
might influence the pixel changes. So it is unknown if the short stem group 
being more prominent in the cone group influencing the BMD changes. 
 
For the alignment analysis a different measurement such as anatomical 
alignment could have been used; although both mechanical and anatomical will 
always have variation in measurements, the mechanical axis has reported 
variations in the central axis of the knee [460], and in anatomical alignment 
there are inaccuracies in identifying the true centre of the intramedullary canal 
[460]. However, these variables will exist in any measuring system and possibly 
may be reduced by recording true angular measurements [360]. 
 
Finally, there was a lack of comparison baseline census, having a baseline of 
six weeks post-op across all methods would make the possibility of 
intercomparision easier; unfortunately the long-leg data was recorded at three 
months post-op. Given the large amount of scans, a six week long leg scan is 





Given the alignment results reporting a lack of difference between the cone and 
non-cone groups at three, six and 12 months, I would conclude that the 
alignment is only affecting the BMD difference minimally. That being said the 
difference between pre-op and three months in alignment cannot be ignored, 
and it is unknown if those changes may have influenced BMD early on. 
Unfortunately, there is no alignment data for the six week post-op long leg to 
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compare these changes directly to, so comparisons between modalities is 
difficult.  
 
The lack of alignment impact in the data, and the supportive pixel density 
changes reported via the long leg x-rays in the tibial diaphysis, I would conclude 
that there is a sign of osteointegration in and around the cone region which 
coincides with the previous BMD reported figures. 
 
The increases in pixel density around the knee might be due to the stabilisation 
of the cone, thus earlier WB exercising, and less about the alignment of the 
revision. Although it must be noted there is no complete overlap of those 
participants that attended DXA and those who attended the long leg x-ray. 
 
Data across all these two methods shows no negative impact in the pixel, or 
alignment data, and that the data demonstrated, although not significant, is in 
support of cone implantation. However, this study contained a very small 
sample size, which makes the results less generalisable, resulting in a lack of 
statistical significance; add to this the issue of a lack of comparative data in the 
research, means these data should be interpreted with caution.  
 
 
7.9 FUTURE WORK 
Finally, moving into recommendations for the future full study, the pixel density 
changes show promise as a method and parallel the DXA BMD data. Although 
this data is limited, with two main issues, a lack of correlation data directly 
linking the pixel changes to BMD changes, and a lack of useable scan data as 
not all long leg images contained a step wedge. To address this, a phantom of 
known BMD could be utilised and imaged via DXA and x-ray and a more direct 
correlation created between these two modalities. Furthermore, and more 
importantly during the full study the research should be presented to the 
radiography department, to show the importance of the step wedge being within 
the images. This might help engage the radiography community and reduce this 
issue. Additionally, as with the DXA imaging, the addition of 24 month long leg 




CHAPTER 8: CT IMAGING 
 
 
8.1 INTRODUCTION  
This chapter will outline the methods used in the CT imaging. This was in order 
to investigate bone in-growth into the implant using Dual Energy CT (DECT). 
This was chosen due to its ability to suppress beam hardening, scatter, and 
metal artefacts [278]. The conal implants being studied are composed of 
titanium so the degradation should be less pronounced and there should be 
reduced streaking [279, 280]. Computed Tomography has also been used via 
micro-CT investigating bone ingrowth in porous implants [271, 272, 273, 274] 
with some directly testing bone ingrowth in TKR in CT images [275]. 
 
8.1.1 AIM  
To investigate CT imaging as a method for the potential bone in-growth into 




Only those who had a cone inserted were eligible for a CT scan. Of the 37 
participants who consented (24 in the cone group) 13 attended the six month 
CT scan. As previously stated some participants had already left the study prior 
to the six month scans.  
 
 
8.3 METHOD CT IMAGING 
Those who were eligible and who had consented were sent a letter in time for 
their six month appointment, with the date coinciding with the six month 
physiotherapy appointment, x-ray, and DXA scan. This allowed, where possible, 
all scans to be done on the same day. 
 
PATIENT PREPARATION 
The CT patient preparation was similar to x-ray and DXA, with patients 
removing all metal artefacts, this was due to metal producing streaking artefacts 
on the image [461]. 
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KNEE POSITIONING IN CT 
The patient was placed in the supine position with their feet first, with their knee 
in the centre, in some cases the feet were taped together to stabilise the knee in 
place [416]. The area was collimated to the distal femoral metadiaphysis to the 
proximal tibial metadiaphysis [416], including the entire stem length and implant 
component [416]. Slices were taken at approximately 2 mm intervals [416], 
using the CT cone study knee protocol for dual energy CT (see appendix 11). 
This was performed in order to provide information regarding bone in-growth 
into the cone implant itself, and compare it against the DXA and x-ray data. 
 
8.3.1 CT ANALYSIS AND RESULTS 
Upon reviewing several CT images, it was decided that due to burst artefact 
and no baseline CT images as a comparator, it was determined that bone in-
growth would be too inconclusive on the images produced in this study.  They 
are however being utilised by engineering colleagues using advanced shape 





Only those who had cone implantation were invited as part of the six month CT 
scan, meaning although participants were blinded to their group, participants 
could potentially deduce their group from this appointment. Furthermore, this 




The data are not useable in this instance, due to too much artefact on the image 
making in-growth unable to be determined.  
 
 
8.6 FUTURE WORK 
Recommendations for the full trial would be to not include the six month CT 
scan, although models are being developed utilising the CT data compared to 
the DXA data. For this particular study there is no definitive ingrowth.  
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CHAPTER 9: RESULTS OF QUESTIONNAIRES 
 
 
9.1 INTRODUCTION  
This chapter will help investigate the psychological and physiological metrics 
pre and post rTKR in the form of questionnaires, as well as addressing possible 
variables between groups such as medications and pathological diseases. This 
included the Bone Health questionnaire (appendix 10), mental health wellbeing 
via the Hospital Anxiety and Depression Score (HADS) questionnaire (appendix 
12), lower leg functionality investigated via the Lower Extremity Functionality 
Scale (LEFS) questionnaire (appendix 13), quality of life through the EQ-5D-3L 
questionnaire (appendix 14) and knee pain was assessed through the Oxford 
Knee Score (OKS) (appendix 15). 
 
9.1.1 AIM 
To investigate mental health and functionality changes in rTKR patients, at 
different stages post surgery. Additionally investigating differences between the 




As stated previously 37 participants were consented, with a total of 35 
participants who attended their pre-op DXA appointment (two participants 
consented then withdrew prior to the pre-op, hence 37 registered but 35 
attended). As per randomisation 22 received cone implantation as part of their 
rTKR, and 13 received no cone (non-cone control group). 
 
Please note that some participants missed DXA appointments but were sent the 




Five questionnaires were utilised in this study, these were selected for their 
precision, reliability, and relevance in addressing different aspects of the study 
parameters such as pain and depression, quality of life, functionality and 
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manoeuvrability. Certain questionnaires were completed at home for ease of 
time, especially in cases where the participant could not attend their 
appointment.  
 
9.3.1 BONE HEALTH QUESTIONNAIRE 
This was un-validated questionnaire, although it had been administered in 
previous TKR research studies [23]. This questionnaire (appendix 10) covered 
questions regarding previous or current diseases (e.g. OA, RA, cancer) 
ethnicity, current medications, previous fracture, previous falls, history of other 
disease in the family, history of orthopaedic surgery, and other medical and 
social variables that might impact participants’ bone quality. The questionnaire 
sent to participants as part of the pre-op DXA appointment letter and filled in by 
the participant at their leisure. It was then brought with them to their pre-op 
(first) DXA scan appointment. After pre-op subsequent appointments only asked 
follow-up bone health questions (e.g. falls and fractures since last appointment, 
changes in medication, and any additional orthopaedic surgery). Throughout the 
study the questionnaire was reviewed, with any ambiguity in language or 
information addressed with the researcher (MG) prior to starting the scan. 
 
This provided important co-variables that might influence or impede BMD 
development with the links between disease, medication and social factors 
already established in chapter one. It also addressed the issue of variables 
between the two groups (cone and non-cone).  
 
9.3.2 LOWER EXTREMITY FUNCTIONAL SCALE (LEFS) 
The LEFS (appendix 13) is a validated and precise questionnaire developed by 
Binkley et al in 1997 and published in 1999 [462], it is used to asses recovery 
and functionality of the lower extremity. It is made up of 20 activity questions 
each with a difficulty score of zero to four (four being no pain or issue, and zero 
being unable to perform the task). Participants can rate each activity on the 
scale, with a total score calculated; a score of 80 indicates someone who is fully 
functional in all activities. This questionnaire was administered at each DXA 
visit, although in certain cases the participant was unable to attend the DXA 




9.3.3 HOSPITAL AND ANXIETY SCORE (HADS) 
The HADS (appendix 12) was administered to determine depression and 
anxiety directly, this was both due to the potential impact of mood disorders on 
BMD and the impact the rTKR might have. The HADS questionnaire has been 
used in several other studies [463, 464]. It is a brief, reliable and validated 
metric [463, 465], and has even been translated and validated in other 
languages [466]. The questionnaire contains 14 questions divided into seven 
statements for both anxiety and depression, each item on the questionnaire is 
given a response between zero and three, and this means that a participant can 
score between zero and 21 for either anxiety or depression, with a higher score 
depicting a worse psychological condition [461].  
 
9.3.4 QUALITY OF LIFE (EQ-5D-3L) 
The EQ-5D-3L (appendix 14) was administered to assess difficulties with self-
care, mobility, usual activities, pain, discomfort, and anxiety and depression. A 
score out of hundred was provided by each participant at each visit based on 
their perceived quality of life, with a hundred being the best possible state of 
health (as they perceive it) and zero being the worst. 
 
9.3.5 OXFORD KNEE SCORE (OKS) 
The OKS (appendix 15) is a reliable, widely used and valid self-administered 
patient questionnaire that enables assessment of knee quality after a TKR or 
rTKR [462, 463]. The OKS contains 12 questions on activities of daily living. 
The OKS was developed and validated specifically to assess function and pain 
after a TKR [464]. A score between 0 (worst outcome) and 48 (best outcome) 
can be reported, with divided sub sections linked to knee severity: 
 
00 to 19 - May indicate severe knee arthritis 
20 to 29 - May indicate moderate to severe knee arthritis 
30 to 39 - May indicate mild to moderate knee arthritis 
40 to 48 satisfactory joint function.  








9.4.1 BONE HEALTH QUESTIONNAIRE 
Bone health questionnaire data were given no weighting for duration or level of 
medications, treatments or medical conditions therefore the data were recorded 
and converted into categorical data, any participant who had previous medical 
issues were recorded as 1, with any without recorded as 0. The data recorded 
were expressed in as a percentage of those who had the condition in question. 
The cone group data were compared to the non-cone group data via a chi 
square test for categorical data and a t-test of unequal variance was performed 
for the comparisons of weight, height, BMI and age. Resulting in percentage 
differences and p-vales between participants for each co-morbidity. 
 
9.4.2 LEFS, EQ-5D-3L, OKS AND HADS 
Data from the LEFS, HADS, OKS and EQ-5D-3L were intercompared between 
each of the participant’s visits (pre-op, six weeks post, three months, six months 
12 months), with a graph plotted to show the functionally, quality of life, knee 
pain, and depression and anxiety changes at each visit with the mean 
differences (and SD) between visits, a paired t-test was applied for each visit 
comparison, with results reported via a p-value, and median scores. 
 
Comparisons were also made between the cone and non-cones at each visit 
score, with the calculated mean difference for each visit (compared to their pre-
op score) compared between the cone and non-cone group via an unpaired t-
test assuming unequal variance and p-value.  
 
 
9.5 RESULTS FROM QUESTIONNAIRES 
Most questionnaires were done in person at either the physiotherapy 
appointment or the DXA appointment. So those who attended their DXA also 
completed their LEFS questionnaire or updated details on their bone health 
questionnaire. 
 
Those who failed to attend their appointment but were still happy to be part of 
the research and continue were posted the questionnaires. Unfortunately, in 
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some instance’s participants failed to return these questionnaires or possibly 
they were lost within the postal system, either upon being sent or on return to 
the research team. In total 17 questionnaires from the cone group data were 
lost for this reason; a percentage of 1.05 % (372 questionnaires, 355 
completed). Five questionnaires of the non-cone group also were not 
completed, a percentage of 1.03 % (192 of 197 questionnaires completed). It 
must be noted that due to this some data were gathered via the phone, these 
data were included in the “completed questionnaires” section, even though the 
participant did not manually fill in the questionnaire themselves.  
 
9.5.1 BONE HEALTH QUESTIONNAIRE RESULTS 
Table 9.1 below present the participants characteristics from the bone health 
questionnaire, at both pre-op and at six weeks, both results were included due 
to the drop out between pre-op and six weeks. Table 9.2 and table 9.3 reports 
the participants history of medical conditions and medications at pre-op (table 






















Table 9.1. Participant’s characteristics at pre-op and 6 weeks DXA scans 














Age mean (years) 
(SD) 
69.82 (4.16) 71.00 (7.63) 0.94 69.56 (7.72) 70.88 (9.01) 0.73 
weight (kg) (SD) 85.96 (17.32) 89.25 (21.51) 0.64 
84.67 
(16.68) 
93.39 (26.02) 0.40 
Height (m) (SD) 1.69 (0.10) 1.69 (0.11) 0.51 1.69 (0.09) 1.72 (0.10) 0.42 
Body mass index 
(BMI) mean (SD) 
29.82 (4.16) 31.19 (6.64) 0.67 29.34 (4.43) 30.86 (6.60) 0.57 
Sex percentage 
male  
59.09 61.54 - 55.56 75 - 
Ethnicity 
percentage white 
100 100 - 100 100 - 
Alcohol 
consumption % 
            
Never 31.82 23.08 - 33.33 25 - 
Less than weekly 27.27 0 - 22.22 0 - 
1-5 units 13.64 46.15 - 16.67 50 - 
6-10 units 13.64 23.08 - 11.11 25 - 
11-15 units 0 0 - 0 0 - 
16-20 units 4.55 0 - 5.56 0 - 
more than 20 
units 
9.09 7.69 - 11.11 0 - 
Caffeine 
consumption % 
            
None 13.64 0 - 16.67 0 - 
1-5 cups/cans 63.64 61.54 - 66.67 37.5 - 
6-10 cups/cans 22.73 38.46 - 16.67 62.5 - 
11-15 cups/cans 0 0 - 0 0 - 
More than 15 
cups/cans 
0 0 - 0 0 - 
Previous fracture 
% 
40.91 46.15 - 38.89 37.5 - 
Falls in last year 
% 






3.55 2.62 - 3.33 2.88 - 
Average length in 
years since 
original TKR 
13.67 12.23 - 13.94 12.50 - 
% who had TKR 
on other side 
50.00 30.77 0.27 61.11 37.50 0.27 
Smoking %             
Ex-smoker 54.55 46.15 - 55.56 50 - 
current smoker 0 7.69 - 0 12.5 - 
Never smoked  45.45 46.15 - 44.44 37.5 - 
Time spent 
exercising % 
            
None 9.09 23.08 - 5.56 25 - 
Some but less 
than half an hour 
40.91 23.08 - 44.44 25 - 
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Half to one hour 31.82 30.77 - 27.78 37.5 - 
More than one 
hour 





























































27.27 23.07 0.78 
Average disease 
duration in years 
15.75 7.00 - 
 
    




9.09 0 0.27 
Average disease 
duration 
19.67 16.75 - 
 
    
Ankylosing 
spondylitis (%) 
0 0 - 
 
Diuretics (%) 4.55 15.38 0.27 
Diabetes -type 1 – 
insulin dependent 
(%) 




4.55 7.69 0.70 
Diabetes – type 2 
(%) 





0 7.69 0.18 
Overactive thyroid 
(%) 
0 0 - 
 
Heparin (%) 4.55 7.69 0.70 
Underactive thyroid 
(%) 
22.73 15.38 0.60 
 
Thyroxine (%) 22.73 15.38 0.60 





0 0 - 





4.55 0 0.44 
Paget’s disease of 
bone (%) 




0 0 - 





0 0 - 




0 0 - 




0 0 - 
Lactose intolerance 
(milk allergy) (%) 




0 0 - 
Crohn’s disease 
(%) 





0 0 - 
Coeliac disease 
(%) 





0 0 - 
Irritable bowel 
syndrome (%) 




9.09 0 0.26 
Malabsorption 
syndrome (%) 
4.55 7.69 0.70 
 
Calcium (%) 13.64 7.69 0.59 
Osteomalacia 
(rickets) (%) 




13.64 0 0.16 
Osteogenesis 
Imperfecta (%) 
0 0 - 
    
 
Hypogonadism (%) 0 0 - 





0 0 - 
    
 
Eating disorder e.g. 
anorexia nervosa 
(%) 
0 0 -  
 
   
 
Table 9.2. Participant’s history of medical conditions and medications, at pre-op 





























27.78 25.00 0.88 
Average disease 
duration in years 
15.75 7.00 - 
 
    




11.11 0 0.33 
Average disease 
duration in years 
20.11 22.50 - 
 
    
Ankylosing 
spondylitis (%) 
0 0 - 
 
Diuretics (%) 11.11 12.50 0.92 
Diabetes -type 1 – 
insulin dependent 
(%) 




11.11 0 0.33 
Diabetes – type 2 
(%) 





0 0 - 
Overactive thyroid 
(%) 
0 0 - 
 
Heparin (%) 11.11 0 0.33 
Underactive thyroid 
(%) 
16.67 12.50 0.79 
 
Thyroxine (%) 16.67 12.50 0.79 





0 0 - 





0 0 - 
Paget’s disease of 
bone (%) 




0 0 - 





0 0 - 




0 0 - 




0 0 - 
Lactose intolerance 
(milk allergy) (%) 




0 0 - 





0 0 - 





0 0 - 
Irritable bowel 
syndrome (%) 




11.11 0 0.33 
Malabsorption 
syndrome (%) 
5.56 0 0.48 
 
Calcium (%) 11.11 12.50 0.92 
Osteomalacia 
(rickets) (%) 




16.67 0 0.22 
Osteogenesis 
Imperfecta (%) 
0 0 - 
  
    
 
Hypogonadism (%) 0 0 - 
    
 
Chronic malnutrition 
/ malabsorption (%) 
0 0 - 
    
 
Eating disorder e.g. 
anorexia nervosa 
(%) 
0 0 - 
    
 
Table 9.3. Participant’s history of medical conditions and medications, at six 




Table 9.1 and 9.2 show the original pre-op bone health questionnaire results 
gathered prior to their DXA scan (35 participants). Compared between groups 
they share several homogeneous qualities, for instance: height (average of 1.69 
m for both), age (reported as 69.82 and 71 years), BMI (29.82 and 31.19), and 
with no statistically significant between the two groups for characteristics or 
medical conditions. 
 
Table 9.1 and 9.3 report the bone questionnaire results of the 26 participants 
who underwent the six DXA week scan, these results are a more accurate 
reflection upon the participants involved in the study as they do not include the 
ones who were withdrawn after pre-op, these six weeks results also are useful 
for the knee BMD comparison data which utilised six week scans as baselines. 
These six week results are similar again to the pre-op, and there are no 
statistically significant differences between the groups, although with the smaller 
sample sizes they are more prominent; the non-cone group is made up of 75 % 
male participants (six out eight) whilst the cone group is 55.56 % (10 out of 18), 
more of the cone group have had a fall in the last year, and difference in weight 
between groups shows that the non-cone group is nearly nine kg heavier 
(although with similar BMI due to the non-cone group being taller on average). 
All participants were white and from the south west area representing the type 
of participants undergoing a rTKR in the Exeter area. 
 
There is one medical condition that shows some difference between the groups 
(but is not statistically significant), the medical condition osteoarthritis with 61.11 
% (11 out of 18 had the disease for an average of 20.11 years) and 25 % (two 
out of eight had the disease for an average of 22.50 years) in the non-cone 
group. It must be noted for RA in the cone group it was reported as 22 % (four 
out of 18) who on average had the disease for 15.75 years, and for the non-
cone group was 12.5 % (one out of eight) who had had the disease for seven 
years.  
 
Regarding participants who previously underwent a TKR, 61.11 % of cone 
participants had previously had a TKR on their contralateral knee, with this 
occurring in 37.50 % in the non-cone group, with a reported p-value of 0.27 
when comparing the two groups. 
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BONE HEALTH QUESTIONNAIRE CHANGES REPORTED BETWEEN VISITS 
Participants were asked at each following visit if there were any changes in their 
bone health questionnaire answers since the pre-op. Therefore, questions 
regarding additional orthopaedic surgery, any changes in medication or 
supplements, any fractured bones, and any falls were recorded. 
 
During the 12 months one participant believed they fractured their toe (no 
treatment was administered); otherwise no other participants sustained any 
fractures. Four participants underwent orthopaedic surgery (one for an 
aspiration of their knee, one as a joint replacement in their right hand, one had a 
TKR in their contralateral knee and one had a rTKR in their contralateral knee - 
resulting in the 12 month contralateral knee data not being included of those 
two participants). There were also no medication changes reported throughout 
the study that potentially influenced the BMD as selected within the bone health 
questionnaire. 
 
Regarding falls, at six weeks two cone participants reported three falls in total 
(two falls from one participant), in the non-cone group one participant reported 
one fall. At three months a total of four cone participants reported five falls (one 
participant reported two falls); with the non-cone group this was reported as two 
falls from two participants. At six months there were a reported five falls from 
four participants in the cone group, and five falls from one participant in the non-
cone group (this participant was discovered to have an infection prior to their 12 
month scan and was withdrawn after six months). At 12 months the cone group 
reported five falls from four participants, in the non-cone group there were two 
falls (one participant). 
 
9.5.2 LEFS QUESTIONNAIRE RESULTS 
At pre-op 35 participants completed the LEFS questionnaire, of those 35, 28 
completed at least one follow up LEFS questionnaire. Therefore those seven 
who did not complete any questionnaire data post-op were withdrawn from the 
analysis due to lacking comparison data (as stated previously these participants 




The data recorded both the absolute mean scores, and more importantly the 
mean changes between pre-op and post-op visits, with the latter being used for 
comparison t-test data (both paired for pre-op comparison data, and t-test 
assuming unequal variance between groups), to compare both to the baseline 
and between the two groups to investigate statistical significance, with the LEFS 
form stating that the minimal level of detectable change was 9 +/- points for 90 
% confidence. Please note the maximum score that could be reported with 
LEFS was 80. 
 
At pre-op the mean cone group score was 30 (SD 14.67, N=18) with a non-
cone group score of 25 (SD 12.17, N= 10), at six weeks the mean cone group 
score was 34.06 (SD 15.81, N =18) with the non-cone group reporting a score 
of 33.20 (SD 16.21, N=10). At three months the score was 42.39 (SD 16.00, 
N=18) for the cone group and 39.10 (SD 17.37, N=10) for the non-cone group. 
At six months the cone group reported a score of 48.29 SD 17.47, N=17) the 
non-cone group score was 41.10 (SD 17.37, N=10), finally at 12 months the 
cone group score was reported as 45.47 (SD 19.81, N=17), with the non-cone 
group reported as 47.38 (SD 15.66, N=8). 
 
The results are shown in figure 9.1 and table 9.4 which state the difference 
between visits (six weeks, three months, six months or 12 months) compared to 


























Figure 9.1. LEFS mean changes throughout the visits for cone and non-cone 
data (error bars are SE) 
 
Table 9.4. Shows the results expressed in figure 9.1, and also the comparison 
data between the two groups. 








CONE MEAN SCORE 
DIFFERENCE 
0.00 4.06 12.39 17.82 15.00 
CONE SE 0.00 2.98 3.61 4.05 4.70 
CONE SD 0.00 12.66 15.34 16.68 19.36 
P-VALUE - 0.19 0.003 0.001 0.002 
      
NON CONE MEAN SCORE 
DIFFERENCE 
0.00 8.20 14.10 16.10 19.38 
NON CONE SE 0.00 3.70 4.88 3.53 5.27 
NON CONE SD 0.00 11.69 15.42 11.16 14.91 
P-VALUE - 0.05 0.017 0.001 0.004 
      
MEAN DIFFERENCE CONE 
VS NON-CONE 
- -4.14 -1.71 1.72 -4.38 
P-VALUE - 0.39 0.78 0.75 0.54 
 
Data from figure 9.1 and table 9.4 show large differences between their pre-op 
scores and post-op throughout, with a gradual increase throughout the visits 
until six months which demonstrates the greatest mean improvement in the 
cone group, reporting an increase of 17.82 (16.10 in the non-cone group), at 12 
months the non-cone group is highest reported as 19.10. Nearly all 
comparisons to pre-op data points showed statistical significance (only the cone 




































PRE-OP                6 WEEKS         3 MONTHS        6 MONTHS      12 MONTHS
Mean difference LEFS score changes over 12 months 




no statistical significance, with both groups reporting similar improvements to 
their pre-op scores, with the non-cone group reporting the higher figure.  
 
9.5.3 HADS QUESTIONNAIRE RESULTS 
Similar to the LEFS questionnaire, participant data that only included pre-op 
with no further visits were excluded in the analysis, this was due to the lack of 
comparison data between visits. For these results the HADS questionnaire data 
were divided into its two sub sections of anxiety and depression scores, with a 
paired samples t-test used for the comparisons to pre-op and a t-test of unequal 
variance used for comparisons between groups. 
 
ANXIETY RESULTS 
A participant can score a maximum of 21 for anxiety, with a higher score 
relating to a more anxious participant.  
 
The mean anxiety score overall was at its highest at pre-op in the cone group 
with a score of 5.53 (SD 4.59 N=19), at six weeks the reported mean was 4.83 
(SD 3.62 N=18), at three months demonstrated as a mean of 3.78 (SD 3.96 
N=18), at six months this is demonstrated as 3.13 (SD 3.98 N=16), at 12 
months it is reported as 4.47 (SD 4.03 N=17). For the non-cone group, the 
mean pre-op score was 6.10 (SD 3.38 N=10), at six weeks it was 4.90 (SD 2.69 
N=10) and at three months it was reported as 6.89 (SD 5.40 N=9), at six 
months it was 5.8 (SD 3.39 N=10) and finally at 12 months it was reported as 
5.44 (SD 2.83 N=9). 
 
The results shown in figure 9.2 and table 9.5 show the mean difference 
between the visits (six weeks, three months, six months or 12 months) and the 
pre-op score, alongside a paired t-test p-value.  
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Figure 9.2. Shows the anxiety mean score changes post-surgery for cone and 
non-cone data (error bars are SE) 
 
Table 9.5. Shows the anxiety score data from figure 9.2 but with the inclusion of 
p-value comparison data. 








CONE MEAN SCORE 
DIFFERENCE 
0.00 -0.06 -1.11 -1.88 -0.59 
CONE SE 0.00 0.74 0.74 0.71 0.56 
CONE SD 0.00 3.13 3.16 2.85 2.29 
P-VALUE - 0.94 0.15 0.02 0.31 
      
NON CONE MEAN SCORE 
DIFFERENCE 
0.00 -1.20 1.11 -0.30 -0.22 
NON CONE SE 0.00 1.07 1.33 0.70 0.83 
NON CONE SD 0.00 3.38 3.98 2.21 2.49 
P-VALUE - 0.25 0.43 0.68 0.80 
      
MEAN DIFFERENCE CONE 
VS NON-CONE 
- 1.14 -2.22 -1.58 0.24 
P-VALUE - 0.36 0.17 0.18 0.72 
 
Data from figure 9.2 and table 9.5 show reductions in mean anxiety for both 
groups, interestingly the cone group has a gradual reduction in anxiety 
throughout the first three visits, with the greatest difference reported at six 
months with a mean of -1.88, at 12 months this difference has been reduced. 
The non-cone group shows a slightly different change, with the greatest 
difference reported at six weeks post-op, reporting a mean of -1.20, and at six 







































PRE-OP             6 WEEKS             3 MONTHS             6 MONTHS             12MONTHS
Mean difference anxiety score changes over 12 




by six months there is a reduction again, similarly at 12 months. When 
comparing both groups together there is no statistical significance. 
 
DEPRESSION RESULTS 
A participant can score a maximum of 21 for depression, with a higher score 
relating to a more depressed participant.  
 
Mean depression scores were at their highest pre-op in the cone group with a 
score of 6.89 (SD 4.74 N=19), at six weeks as a mean of 4.89 (SD 3.77 N=18), 
at 3 months as a mean of 4.28 (SD 3.63 N=18), at six months as 4.13 SD (4.03 
N=16), at 12 months it is reported as 5.41 (SD 5.48 N=17). For the non-cone 
group, the mean pre-op score was 6.20 (SD 3.33 N=10), at six weeks it was 4.8 
(SD 3.12 N=10) and at three months it was reported as 6.33 (SD 5.83 N=9), at 
six months it was 6.30 (SD 38 N=10) and finally at 12 months it was reported as 
5.67 (SD 4.18 N=9). 
 
Figure 9.3. Shows the depression mean score changes post-surgery for cone 













































PRE-OP             6 WEEKS             3 MONTHS            6 MONTHS           12MONTHS
Mean difference depression score changes over 12 




Table 9.6. Shows the depression score data from figure 9.3 but with the 
inclusion of p-value comparison data. 











0.00 -1.56 -2.17 -2.44 -1.24 
CONE SE 0.00 0.72 0.89 0.83 1.16 
CONE SD 0.00 3.07 3.79 3.33 4.76 
P-VALUE - 0.046 0.026 0.01 0.30 
      
NON CONE MEAN 
SCORE 
DIFFERENCE 
0.00 -1.40 0.56 0.10 -0.44 
NON CONE SE 0.00 0.97 1.40 0.97 0.60 
NON CONE SD 0.00 3.06 4.19 3.07 1.81 
P-VALUE - 0.18 0.70 0.92 0.48 




- -0.16 -2.73 -2.54 -1.68 
P-VALUE - 0.90 0.12 0.06 0.55 
 
The depression mean numbers shown in figure 9.3 and table 9.6 report a 
reduction in depression for the cone group throughout the visits with  gradual 
reduction in depression until reaching its lowest at six months (-2.44), with all 
these results being statistically significant with a p-value of 0.01. The non-cone 
group has a reduction in depression at six weeks (-1.40) but then starts to 
increase at three and six months, finally reporting a mean difference score of -
1.68 at 12 months, although none of these data are statistically significant.  
 
Comparing the two groups together there was no statistically significance, 
although the six month data are close, reporting a p-value of 0.06, due to the 
high loss in the cone group and the increase in the non-cone group. 
 
9.5.4 EQ-5D-3L QOL RESULTS 
Quality of life was scored by the participant between 0 and 100 (100 being the 
highest possible quality of life and 0 being the lowest). 
 
Mean QOL scores were at their lowest pre-op in the cone group with a score of 
63.87 (SD 25.05 N=19), at six weeks as a mean of 71.32 (SD 17.19 N=17), at 
three months as a mean of 73.94 (SD 19.57 N=17), at six months as 75.00 (SD 
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19.61 N=16), at 12 months as 71.56 (SD 18.93 N=18). For the non-cone group, 
the mean pre-op score was reported at its lowest with a score of 52.50 (SD 
29.46 N=10), at six weeks it was 65.20 (SD 25.65 N=10) and at three months it 
was reported as 69.06 (SD 25.89 N=9), at six months it was 66.20 (SD 24.63 
N=10) and finally at 12 months it was reported as 73.11 (SD 17.84 N=9). 
 
Figure 9.4. QOL mean score changes for cone and non-cone data (error bars 
are SE) 
 
Table 9.7. Shows the depression score data from figure 9.4 but with the 
inclusion of p-value comparison data. 











0.00 5.82 10.42 12.75 6.92 
CONE SE 0.00 5.75 6.82 6.06 6.18 
CONE SD 0.00 28.10 28.96 24.25 26.21 
P-VALUE - 0.41 0.15 0.05 0.28 
      
NON CONE MEAN 
SCORE 
DIFFERENCE 
0.00 12.70 15.17 13.70 15.89 
NON CONE SE 0.00 7.36 6.86 6.14 7.61 
NON CONE SD 0.00 23.27 20.59 19.41 22.82 
P-VALUE - 0.12 0.06 0.05 0.07 




- -6.88 -4.75 -0.95 -8.97 





































PRE-OP             6 WEEKS             3 MONTHS            6 MONTHS           12 MONTHS
Mean difference QOL score changes over 12 




The EQ5D3L QOL mean value in figure 9.4 table 9.7 reported an increase for 
the cone group throughout the visits with a gradual increase until reaching its 
highest difference at six months (12.75), with this six month figure reporting a p-
value 0.05, this figure was then reported as an increase of 6.92 at 12 months. 
Similarly the non-cone group has an increase across all visits, reporting higher 
figures than the cone group, with the six month figure also being statistically 
significant (13.70) and the final 12 month figure (15.89) being the highest 
difference reported throughout all visits, although not statistically significant (p-
value 0.07). 
 
Comparing the differences between cone and non-cone, both groups show 
increases, although at six weeks the score is a difference of -6.88 in support of 
the non-cone group, and at three months the difference is -4.75, and at six 
months of -0.95, and at 12 months was -8.97. Although there was no significant 
difference between the two groups.  
 
9.5.5 OKS QUESTIONNAIRE RESULTS 
As with all previous questionnaire results, only the data which had at least one 
post-op OKS questionnaire result were included. This questionnaire consisted 
of a series of 12 questions about issues and pain within their knee, resulting in a 
total score, with a lower total score being related to more severe function and 
pain issues within the knee. 
 
Mean OKS scores were at their lowest pre-op in the cone group with a score of 
20.42 (SD 9.70 N=19), at six weeks as a mean of 22.79 (SD 8.30 N=19), at 
three months as a mean of 29.33 (SD 11.16 N=18) at six months this is 
reported as 34.94 (SD 8.23 N=16), at 12 months as 31.17 (SD 11.37 N=18). For 
the non-cone group, the mean pre-op score was also at its lowest with a score 
of 17.70 (SD 6.09 N=10), at six weeks it was 24.10 (SD 10.15 N=10) and at 
three months it was reported as 27.33 (SD 11.69 N=9), at six months it was 





Figure 9.5. OKS mean score changes for cone and non-cone data (error bars 
are SE) 
 
Table 9.8. Shows the OKS data from figure 9.5 but with the inclusion of p-value 
comparison data. 








CONE MEAN SCORE 
DIFFERENCE 
0.00 2.37 8.17 14.63 10.94 
CONE SE 0.00 2.51 2.70 2.46 2.84 
CONE SD 0.00 10.94 11.44 9.85 12.05 
P-VALUE - 0.36 0.01 0.00 0.00 
      
NON CONE MEAN SCORE 
DIFFERENCE 
0.00 6.40 10.00 12.6 16.67 
NON CONE SE 0.00 2.85 3.10 3.38 2.93 
NON CONE SD 0.00 9.01 9.29 10.70 8.80 
P-VALUE - 0.05 0.01 0.00 0.00 
      
MEAN DIFFERENCE CONE VS 
NON-CONE 
- -4.03 -1.83 2.03 -5.73 
P-VALUE - 0.30 0.66 0.63 0.18 
 
Figure 9.5 and table 9.8 show similar trends with increases in the OKS 
throughout the visits, with both groups reporting a statistical significant change, 
the highest difference in the cone group was reported at six months of 14.63 (p-
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Mean difference OKS score changes over 12 months 




When compared together both groups show no statistical significance, so 
although both show a statistical gradual improvement in the OKS, there is no 
statistical difference between the two groups. 
 
 
9.6 DISCUSSION OF QUESTIONNAIRE DATA 
 
9.6.1 BONE HEALTH QUESTIONNAIRE  
Both groups showed similar characteristics but with no statistically significant 
differences that would influence the data. One important piece of data were 
reported at six weeks with 11 out of 18 participants (61 %) in the cone group 
reporting OA, with the non-cone group reporting only 25 % (two out of eight 
participants), when compared, these figures were reported as a p-value of 0.09 
(six weeks). Although it must be acknowledged that the participants stated if 
they had been diagnosed with OA, and no check to corroborate or contradict 
that information was addressed, therefore the reported OA disparity between 
the groups may be due to miscategorising the disease or being unaware of the 
condition (possibly stating RA instead). This is supported by the literature that 
reports OA as the primary cause of TKR in 80-90 % of cases [125, 126, 127, 
128]. Additionally, this difference might simply be due to the small sample size.  
 
It must be also be noted that RA was reported by 22 % (four out of 18) in the 
cone group, and 12.5 % (one out of eight) in the non-cone group. Although this 
difference like with OA was not statistically significant between the two groups. 
Furthermore, due to the true randomisation of the study, and the limited 
numbers between the groups these sections were not further subdivided. 
Although it must be noted that unlike OAs association with increase BMD, RA 
has associated bone loss with the disease [465], and that the severity of either 
OA or RA could influence the results, this severity was also not recorded.  
 
An issue with this self-reporting in this study was that we had no access to the 
patients’ medical records, and like the patient’s disease history their 
prescriptions were also self-reported, therefore it is likely medication and 
disease histories are incomplete and this could be reason for variations 
presented in the data 
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9.6.2 LEFS QUESTIONNAIRE 
Both groups showed improvements throughout the visits reaching a height at 
six months, with a change in excess of the nine point difference required for a 
90 % confidence level, with the six month figure reported as an increase of 
17.82 (cone group) and 16.10 (non-group), both statistically significant figures. 
At 12 months the cone group reported a 15 point increase, and the non-cone 
group a 19.38 increase (again both statistically significant). When the groups 
were compared against each other, there was no reported statistically 
significant difference, with the lowest p-value reported as 0.39. 
 
The trend reported in both groups is similar in the Hopkins et al study [23] that 
reported a LEFS baseline score of 30, at six weeks 33, six months of 51 and 12 
months 52.  
 
Another study investigated TKA and also showed an increased LEFS score 
trend, with the greatest improvement at three months, with little improvement 
beyond the six month visit [466]. Although, these two studies investigated TKR 
and TKA, and not revisions. Studies dealing with cone implants in revisions 
have been investigated with these utilising similar robust rating systems 
regarding functionality. These studies reported increased scores in functionality 
the cone group (37 to 73 for cone compared to 24 to 58 in non-cone [178], and 
52 to 85 in another study [467] (a higher number means greater functionality). 
This increase in functionality would parallel the data in our study, of increased 
functionality post-surgery. 
 
Results of the LEFS questionnaire show that rTKR are successful and helpful in 
regaining mobility and functionality in the lower extremity, with both groups 
reporting statistically significant changes between visits. But it is unclear of the 
positive impact that cones have on these figures, as these trends are also seen 
in the non-group, and as stated there is no statistical significance between the 







9.6.3 HADS QUESTIONNAIRE 
 
ANXIETY  
The cone group anxiety score decreased at each visit, and significantly at six 
months (a loss of 1.88 reporting a p-value 0.02) reporting a reduction in anxiety 
amongst this cohort. The non-cone group reports a slightly different trend, with 
an increase in anxiety by three months and their highest reduction being at six 
weeks (both with non-statistical significance). 
 
Comparing the two groups, at six weeks both show a reduction, although at 
three months the cone value is -1.11 with non-cone 1.11 (a p-value of 0.17 
when compared), at six months this difference is -1.88 cone and -0.3 non-cone 
(p-value 0.18), at 12 months both show a loss, but It must be noted there is no 
statistical difference between the groups across all visits.  
 
The trend in both groups of a reduction in anxiety matches the pattern reported 
in the TKR literature [466, 468] with one study reporting a decline of 10.48 pre-
op to 2.36 at three months. Although this difference is less dramatic in the rTKR 
group, with the TKR participants reporting a higher starting anxiety score (5.53 
and 6.10 in this research, compared to 10.48 in the TKR study), this might be 
due to participants undergoing a revision and not a replacement, with those 
undergoing replacements reported as experiencing high levels of anxiety before 
surgery because of the possibility of surgery-related complications or death 
[469] as the revision group has experienced a TKR so may have allayed such 
fears.  
 
Additionally, it must be acknowledged that the mean pre-op anxiety score was 
6.10 in the non-cone group, and 5.56 in the cone group, meaning the starting 
score should not have influenced the change i.e. if the cone group had a score 
of 20 it would be easier to reduce this figure, yet both scores were similar.  
 
Results of the HADS report both groups have a reduction in anxiety post-
surgery, with the cone group more prominent (with one figure significant at six 





The depression score parallels the anxiety score both with decreases 
throughout, reaching its lowest at six months in the cone group (-2.44), with 
each figure showing statistical significance except 12 months. The non-cone 
group reports decreases only at six weeks and 12 months (although none of the 
figures are statistically significant).  
 
There is also no statistical significance between groups in the depression 
results, although at six months the p-value is 0.06 with a reduction of 
depression in the cone group reported as -2.44, compared to the increase in 
depression of 0.10 reported by the non-cone group. Additionally, just like with 
the anxiety score data the pre-op mean figures are also similar between the two 
groups – although again the small sample size of nine (who completed 12 
months) in the non-cone group cannot be ignored.  
 
This reduction is similar to reported data, with a study by Shalaby et al who 
showed that at three months post-op the reported scores went from 9.60 to 4.72 
[466]. Other studies investigating HADS in TKA showed a mean reduction at six 
months and 12 months; reporting a reduction of -1.16 and -1.08 [470] 
respectively, a further study also supports this decrease in depression rates at 
six weeks and 12 months [468].  
 
The results from the depression scores show rTKR can reduce post-op 
depression scores, although the cone group is more prominent across all visits, 
the non-cone group does report reductions at six weeks and 12 months. 
Although it is unknown if these changes are due to a greater sample size in the 
cone group, or the possible influences of the cone increasing confidence in the 
joint and thus reducing depression. 
 
These anxiety and depression changes are especially important given their 
association with heightened pain in TKR [471, 472]. A systematic review 
investigating anxiety, depression, and knee pain, reported that depression has a 
significant impact in knee pain [473]. If participants are in less pain they might 
be more active, which in itself might lower their anxiety and depression further 
[474, 475]. Although it must be noted no pedometer readings were gathered 
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during this study, and although the physiotherapy protocols were the same for 
each participant, it was not recorded if these sessions were undertaken by all 
participants. 
 
Additionally, studies by Blalock et al and Hauser et al have shown there is an 
association between joint instability and pain [476, 477], thus the cone fixation 
or the knee revision itself might be increasing stabilisation of the knee joint 
leading to less pain, resulting in less anxiety and depression about the joint. 
This stabilisation is especially important as in a systematic review of TKA and 
balance, they reported that proprioception and knee extension strength have 
not fully recovered post-TKA and directly influence balance performance for up 
to one year post-surgery [478]. 
 
These differences might be due to the small sample size who completed 12 
months; nine (non-cone) and 16 (cone), which is also reflective in the SD 
scores, and the lack of significant difference between the groups.  
 
9.6.4 EQ-5D-3L QOL QUESTIONNAIRE  
In the quality of life data, the results show a gradual increase over all visits, with 
two statistical significant results in both group reported at six months, with the 
cone group reporting an increase of 12.75, and 13.70 for the non-cone. For the 
12 month data there is an increase in the non-cone group to 15.89 and an 
increase of 6.92 in the cone group.  
 
Comparing the two groups, there is no statistical significance. Although both 
groups showed statistical significance when compared to baseline. This change 
in quality of life is supported by other studies, with a systematic review 
investigating quality of life (QOL), showed that patients who underwent TKA 
improved in their QOL [424]. Although, some data show that 30 % of 
participants are still unsatisfied after their knee replacement [479].  
 
In this case the results show that it can be concluded that quality of life 
improves post knee revision, although the impact of cone implantation on 




9.6.5 OKS QUESTIONNAIRE  
Both the cone and non-cone group show statistically significant improvements 
at each visit, reaching the largest difference at six months for the cone group 
reported as an increase of 14.63, for the non-cone it was an increase of 16.67 
at 12 months. 
 
The difference between the groups was not statistically significant, but both 
show an increase in the OKS with statistically significant results, with results of 
the OKS questionnaire showing that rTKR are successful and helpful in 
regaining joint functionality, this is supported by the research that shows 
increases of between 14.5 and 22 points six months post TKR [480, 481, 482, 
483], as well as reporting similar starting OKS pre-op [481]. This is further 
supported by revision research that reported a pre-op score of 20.1 and a post-
op score of 30.2 [484]. There is no statistical difference between the two 
groups, so it is unclear of the impact that cones have on these figures, as these 
trends are also seen in the non-group. Additionally, it must be noted there have 
been cone studies utilising similar questionnaires reporting similar functionality 
improvements and reduced pain post-op [216, 218, 221, 437].  
 
 
9.7 LIMITATIONS OF STUDY 
As previously stated, the sample size was small due to attrition, recruitment 
issues and COVID-19, which most likely impact the statistical significance of 
certain groups. Additionally, due to the repeated measures of statistical tests via 
the questionnaire comparison data, this increases the likelihood of type one 
errors. Therefore, interpretation of any statistical significant results should be 
treated with caution.  
 
Moreover, it must be stated that there were pieces of missing data; this was due 
to several reasons. Firstly, some participants could not attend their 
appointments, but they still completed the questionnaires, as these were sent 
via the post. Although small the compliance of those who failed to return their 
questionnaire data could have been followed up or an electronic option 
provided, although it must be noted the average age was 70 and some of these 
participants did not have phones or email contacts.  
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Additionally, it was recorded that all participants in the study were white, and all 
from the south west area, this limited generalisability of the study, it must be 
noted that as black women have a reported higher BMD, these results cannot 
be generalised to other ethnicities or demographics [98]. Furthermore, it must 
be stated this was not due to exclusion, but simply a reflection upon the 
demographics of the recruitment area available.  
 
All questionnaires were based on self-administration which might reflect the 
issues discussed regarding the reported OA diagnosis, access to the patients’ 
medical records could have addressed this issue or directly comparing 
medications to medical conditions. Although misinformation due to self-
administration on the questionnaire regarding their medication would not be 
helped by the NHS database. Moreover, participants may have been subject to 
demand characteristics, although participants were blinded to the type of 




9.8 CONCLUSION  
The trends show reductions in depression and anxiety scores, with statistical 
significance reported in the depression data between the cone group and 
baseline figures, the non-cone group does show some reduction in depression 
but not statistically significant. Furthermore, there is only one statistically 
significant figure in the anxiety data, again in the cone group reporting a 
reduction. This is especially important given the association of depression and 
anxiety with heightened pain [471,472]. 
 
There were also well reported improvement in functionality and quality of life via 
both groups, with these results paralleling other replacement and arthroplasty 
studies, including previous cone studies [178, 467]. 
 
Although as stated the small sample size, large SD, and missing data make it 
difficult to discern differences between the two groups. It can be concluded that 
the cone group is not negatively impacting the questionnaire results, and is 
statistically improving both anxiety and depression scores, which the non-cone 
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group does not report, although as stated there is no statistical difference 
between groups. 
 
In conclusion there is minimal difference between the groups, with both showing 
strong improvements in anxiety, depression, functionality and quality of life 
scores of those who undergo rTKR.  
 
 
9.9 FUTURE WORK 
Although the participants were randomised, and those who suffered with RA 
and OA were equally distributed within the two groups. For the full trial with a 
larger cohort, the BMD scores of the RA patients could be separated and 
analysed independently, severity could also be recorded. Additionally, the use 
of electronic questionnaires for those who are unable to complete or return 
them might help compliance, as might follow up phone calls, which were used in 
some instances. If possible, access to the medical records of the participants 
could also be introduced to address the issues of errors in the self-reported 
bone health questionnaire data, or at least checking the stated medications 
against NHS medicines databases and cross referencing the medication with 

















CHAPTER 10 SUMMARY OF RESULTS, CONCLUSIONS AND 
RECOMMENDATIONS 
The aim of this study was to investigate and develop different imaging methods 
and analysis, and investigate the impact of cone implantation in rTKR patients, 
in order to quantify BMD change and alignment, and to monitor recovery over a 
12 month period. This study involved recruiting participants and randomly 
assigning them to one of two groups; a cone group who received the implant, 
and the non-cone group (control), who received the standard revision.  
 
Bone mineral density changes were assessed from baseline against 
subsequent visits over a 12 month period, this involved utilising and adapting 
DXA imaging of the total body, lumbar spine, bilateral hips and bilateral knees.  
 
X-ray imaging was utilised and developed to investigate pixel density changes 
on long leg knee x-rays throughout the visits, additionally alignment angulation 
was also explored using x-ray imaging. Factors of depression, anxiety, function, 
quality of life, pain, treatments, health perceptions and mental wellbeing, that 
could potentially contribute to bone changes and recovery, were also 
investigated via questionnaire data. 
 
The primary goal was to provide information relating to imaging for cone 
implantation, and its impact on BMD in and around the implant. This feasibility 
study helped develop and adapt different imaging methods, in order that 
recommendations could be brought forward into a full clinical trial. Furthermore, 
using these methods within this feasibility study, cone implantation could be 
investigated, with impacts regarding mitigating bone loss, and improving 
physical and functional recovery. In order to achieve these aims, a number of 
techniques were employed utilising questionnaires and imaging, with these 




10.1 RESULTS – CHAPTER 3 THE BOVINE MODEL 
The results from this study are less important than the subsequent chapters, the 
primary reason for this chapter was to address and develop the imaging 
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methodology, in order to feed this information into the feasibility study. This 
raised and addressed several important issues such as region selection and 
pixel standardisation. Region selection in defining BMD and the importance of 
having lateral knee DXA images as well as PA to address BMD change due to 
anatomy being superimposed on the image. Pixel standardisation was also 
required moving forward, as the x-ray imaging required an object of known 
density for standardisation, in order to define pixel density change to determine 
in growth in and around the cone implant.  
 
 
10.2 RESULTS – CHAPTER 4 3D SHAPE MODELLING 
This chapter investigated an alternative method to standard imaging, including 
providing more depth analysis of the DXA imaging via 3D SHAPER modelling 
software. 
 
10.2.1 CONTROL GROUP 3D-SHAPER RESULTS 
For all control data there was minimal reported changes throughout for both the 
baseline and contralateral data, with some minimal changes reported as 
plausible natural bone changes. Although there was a statistically significant 
change at six months in the CSMI in the intertrochanteric ipsilateral hip region, 
this was matched in the contralateral hip, resulting in similar changes when 
compared. These control results reflected what we would expect to see in the 
control group supporting the idea that the software was accurate. 
 
10.2.2 RTKR GROUP 3D-SHAPER RESULTS 
In the rTKR group the cortical sBMD loss compared to baseline, got worse at 
six weeks and then started to recover at three months, but this loss continued at 
six and 12 months. In the trabecular vBMD recovery was seen immediately 
post-surgery within the rTKR group in the ipsilateral hip which continued 
throughout reaching an increase by 12 months. The integral vBMD showed a 
similar pattern in both baseline and comparison data and this was reflected in 
the combination of trabecular and cortical bone patterns.  
 
For the rTKR there was a similar trend for CSA and CSMI in the neck, reported 
as an increase at six weeks (in comparison to the pre-op), and then a 
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continuing loss at 12 months, this trend was seen in both the baseline and 
comparison data. The rTKR group for the intertrochanteric data again showed a 
similar trend to the TKR group for the intertrochanteric CSA and CSMI data, 
reporting a loss throughout, although there was no increase at 12 months 
compared to six months. 
 
The data demonstrated in the trabecular vBMD showed the impact of the higher 
turnover of trabecular bone, this was reflected within the subset rTKR group of 
the cone participants (of which these data are based), who reported increases 
in the wards triangle and femoral neck in the BMD cone data, both regions with 
a high concentration of trabecular bone. This was further supported by the 
cortical sBMD data that reported losses throughout all visits, this again was 
reflected in the BMD overall hip data, and the integral vBMD was a combination 
of these, unfortunately the CSMI and CSA were not recorded for this study so 
the changes cannot be compared.  
 
10.2.3 TKR GROUP RESULTS 
The TKR showed a similar trend to the rTKR group but without the recovery, 
and both groups end up on a similar sBMD cortical loss by 12 months in both 
the baseline and comparator data.  
 
The trabecular vBMD in the TKR group reports post-surgery decline but showed 
some recovery between six and 12 months. As with the rTKR data the integral 
vBMD reports similar patterns in both baseline and comparison data. In the TKR 
group in the CSA and CSMI neck region it was reported as a loss at six weeks, 
and an increase at 12 months when compared to the six months score. In the 
intertrochanteric ipsilateral baseline data for CSA and CSMI, the TKR group 
showed a loss throughout, but by 12 months there is an increase when 
compared to the six month data, again this is shown in the baseline and 
comparison data.  
 
Overall, both groups show cortical loss, adding weight to the cortical thinning 
issues and increase fracture risk reported [384, 386], and the loss of trabecular 
vBMD in the TKR group data also indicate increased fracture risk [387]. 
Moreover, the software’s ability to be applied to hip DXA imaging showed 
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promise; this was reflected in the control participant’s results showing minimal 
changes throughout. This was also supported by the trabecular vBMD data from 
the TKR group data agreeing with the reported BMD loss, as reported in the 
systematic review. The rTKR group data also supported this by reporting similar 
trends in hip BMD changes, and the CSA and CSMI data showing similar 
trends, due to their correlation in the femoral strength index. 
 
 
10.3 RESULTS – CHAPTER 5 DXA IMAGING, ANALYSIS OF THE TOTAL 
BODY, LUMBAR SPINE AND BILATERAL HIPS  
This chapter investigated the main DXA imaging methodology and reported on 
the BMD trends for the total body, lumbar spine, and bilateral hips. 
 
10.3.1 TOTAL BODY DXA 
The total body BMD was reported as higher in the cone group, with a statistical 
significance at 12 months between the two groups (the cone group reporting an 
increase of 1.187 %, and the non-cone group reporting -0.046 %).Therefore, the 
total body changes showed a possible association with the cone group, so there 
was the possibility of the cone impacting stabilisation and weight bearing, 
although it must be noted that the difference between the two groups was within 
the precision error range of LSC of 2.77 % (assuming a precision error of 1 % 
[258]). Unfortunately, there was also a lack of reported evidence in total body 
BMD changes in rTKR studies, so it is unknown if the reported decreases in the 
non-cone group are the standard change or if the increases in the cone group 
are the standard.   
 
10.3.2 LUMBAR SPINE DXA 
For the lumbar spine data the cone group changes are small compared to 
baseline, with a statistically significant change at three months in the L1-L4 
region. In the non-cone group the lumbar spine changes were mainly increases, 
although none with statistically significance changes. The changes reported in 
the lumbar spine of both groups were most likely due to degenerative changes 
within individual participants elevating their BMD, with extensive literature 
reporting this link [409], especially given their mean age of the groups involved 
being 69.82 and 71.00 years old. 
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10.3.3 HIP DXA RESULTS 
The BMD cone ipsilateral hip data reported early remodelling in rTKR patients 
at six weeks in the wards and neck (reporting a statistically significant change), 
and that by 12 months the participants had started to reach towards a plateau to 
that of the level of baseline. Although there are statistically significant losses 
reported in the trochanter, shaft, and overall hip at 12 months, which might be 
due to the impact of cortical to trabeculae bone ratios and their impact on BMD 
turnover.  
 
This trend is less clear in the ipsilateral non-cone group, which showed 
remodelling in the wards at six weeks which throughout trends towards the 
baseline figure at 12 months. Although the neck BMD reported losses 
increasing at each visit, reaching just over -3.23 % at 12 months (which was 
statistically significant). The non-cone group did report losses in the shaft and 
overall total, which mimic the cone results at three, six and 12 months. When 
both groups were compared there were only two statistically significant results, 
both in the neck of femur at six weeks and 12 months. It is unknown if this is 
due to the impact of the cone on stabilisation or the small numbers in the non-
cone group, based on the six week data also supporting the remodelling 
increase in the wards triangle area, I would conclude it is more likely the latter. 
Although, it must be noted that none of the hip data suggest a statistically 
significant negative association, when compared between the cone and non-




10.4 RESULTS – CHAPTER 6 DXA IMAGING, BMD ANALYSIS OF THE 
KNEE 
 
10.4.1 RESULTS - BMD KNEE ANALYSIS 
Along the tibial and femoral stems there were decreases in both the cone and 
non-cone groups when compared to baseline and beyond the femoral stem 
there are increases in both groups, this is seen in the PA and lateral DXA data. 
The medial tibial condyle were similar, with both groups reporting losses at 
every visit, the increases in the tibial lateral condyle in the cone group are 
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paralleled by the losses in the non-cone group.  As well as the difference in the 
lateral tibial condyle between groups, there was also a difference in the medial 
femoral condyles, as the cone group reported increases across all three visits, 
with the non-cone group reporting losses in two of the three visits for the same 
region. This increase might have been due to the stabilisation of the cone, 
earlier WB exercising, and less about the alignment of the revision.  
 
 
10.5 RESULTS – CHAPTER 7 X-RAY IMAGING OF THE KNEE, PIXEL 
DENSITY AND ALIGNMENT 
 
10.5.1 RESULTS - PIXEL DENSITY KNEE ANALYSIS 
The cone group reported an increase in pixel density mean in all regions 
(except one), and the non-cone group reported losses at each region, the 
greatest difference between the two groups was in the non-cone group in the 
tibial region, with large reported losses. 
 
Many studies have reported osteointegration of cones demonstrated on 
radiographs [218, 437, 438, 439], with no radioluciencies identified [218, 222, 
441, 442]. Unfortunately, the reported literature does not report pixel densities, 
only osteointegration. Moreover, it must be noted these pixel density changes 
may be for other reasons such as participant rotation during imaging or region 
placement, although the region placement had a reported COV precision range 
of 0.09 % to 0.35 %. There is the possibility of pixel density figures being used 
as a surrogate BMD results from DXA scans, although further research would 
be needed to create a robust association between the two. A feasibility study by 
Kinds et al [269] showed this was possible, and dentistry has researched 
something similar utilising an aluminium step wedge in determining BMD of the 
mandible.  
 
10.5.2 RESULTS - ALIGNMENT ANALYSIS 
Both the cone and non-cone HKA pre-op figures are similar, and close to the 
reported 5° variation from 180° [436]. Reported as 177.52° and 181.18° at pre-
op, these figures trends towards the 180° figure (compared to their pre-op), with 
little difference between the groups after pre-op. For the LDFA data are 
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reported in the cone group as 90.44° at pre-op, and 89.30° in the non-cone 
group, this was within the same alignment as TKR patients [448]. With both 
groups showing a similar trend throughout the visits, as for the mPTA in 
reported similar pre-op scores to the reported TKR alignment data [448], with 
again both groups showing a similar pattern.  
 
Both the LDFA and mPTA in the cone and non-cone data show both groups 
ending up in a negative position (over 90°) in the LDFA, and in the positive 
position in the mPTA (under 90°), the main difference being their starting 
alignment. When directly comparing the two groups as stated there was little 
difference between them across all three visits, and no statistical significance.  
 
The pre-op scores HKA report no statistical significance between groups, but 
the more pre-op varus position in the cone group (compared to the non-cone) 
might be the reason for the slightly higher BMD loss (both groups reported 
losses) in the medial tibial condyle region. Therefore, post-surgery, and with 
realignment established, there would be reduced stress shielding, meaning the 
tibial medial condyle no longer underwent stresses due to alignment, and thus 
reported losses of BMD throughout the following visits. 
 
 
10.6 RESULTS – CHAPTER 8 CT IMAGING OF THE KNEE 
This imaging method did not provide any additional information, with in-growth 
undefined due to excessive artefact on the image. Therefore recommendation is 
to not use this methodology in the full study until greater optimised CT imaging 
has been developed. 
 
 
10.7 RESULTS – CHAPTER 9 QUESTIONNAIRES 
Questionnaire results showed promise as a methodological proxy to patient 
experience regarding pain and quality of life. Although statistical significance 
should be interpreted with caution due to repeated analysis between visits.  
 
Bone health questionnaire – This questionnaire reported very similar traits for 
both groups, with no statistically significant differences between the two groups. 
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Although OA and RA were more prevalent in the cone group, neither had any 
statistical significance. 
 
LEFS questionnaire – Reported statistically significant increases in mobility and 
functionality post-op in both groups at nearly every visit (six week cone is the 
only one with a p-value above 0.05), with no statistical difference between the 
two groups.  
 
HADs questionnaire – Anxiety scores reported only one statistically significant 
result, reported in the cone group as a difference of -1.88 (p-value 0.02) at six 
months. All cone figures reported a reduction in anxiety post-op, in the non-
cone group there was an increase at three months. Although there was no 
statistical difference between the two groups.  
 
HADs questionnaire – Depression scores reported statistically significant results 
in the cone group at visits six weeks, three months and six months, as well as 
reporting decreases in depression across all visits. The non-cone also report 
decreases at six weeks and 12 months, not to a statistically significant level. 
There was no statistical difference between the two groups, although at six 
months the difference between the groups was a p-value of 0.06, with the cone 
group reporting a reduction in depression of -2.44 and the non-cone an increase 
of 0.10.  
 
EQ-5D-3L QOL questionnaire – Reported a mean increase in QOL at all visits 
post-op, in both groups, with both groups reporting statistically significant 
findings at 6 months, reported as increase in QOL scores in the cone and non-
cone group of 12.75 and 13.70 respectively. There was no statistical difference 
between the two groups.  
 
OKS questionnaire – This questionnaire reported statistically significant 
increases compared to baseline at every visit (except six weeks in the cone 
group), with the highest increase in cone group reported of 14.63 at six months, 
and 16.67 at 12 months in the non-cone group. There were no statistically 




The questionnaires used in this study were all well-known and validated, with 
the exception of the bone health questionnaire, although this questionnaire had 
been used in previous TKR research [23]. The questionnaires were all self-
administered, and with the reported low cases of OA stated by both groups in 
the bone health questionnaire (as stated previously OA is the primary reason for 
original TKR), it can be concluded that not all data reported within the 
questionnaires is entirely accurate. Additionally, there is the possibility of 
participants interpreting the same question in different ways. That being noted, 
the questionnaire data used in this study showed that the cone group reported 
statistically significant changes in: lower depression, lower anxiety, and 
increased functionality and mobility. Although no corrections were made to the 
repeated measures of the questionnaire data therefore the significance of these 
results should be treated with caution. Additionally there was no statistical 
difference between the two groups. I would conclude based on the 
questionnaire data that the cones do not negatively impact the participants, and 
actually improve mental wellbeing and functionality at least to a similar level of a 
standard rTKR, with no statistical difference between groups. 
 
 
10.8 LIMITATIONS   
The study had several limitations, most notably the difficulties involved with 
recruitment and attrition.   
 
The study showed some bias in the recruitment, as stated all participants were 
from the south west area, this was due to the participants having to attend 
multiple scans over multiple visits, so due to the intense nature of x-rays, DXA 
scans, CT images and physiotherapy, only those patients with appropriate 
support and within the area were able to take part. So longer distances were 
unlikely, although to reduce the impact of these visits, all scans/appointments 
were arranged of the same day were possible. The sample used in this study 
were all white Caucasian individuals, so these data are not representative of the 
country as a whole, therefore the results are limited in generalisability.  
 
Moreover, the sample size was small, especially at 12 months were there was 
attrition of participants, this sample size impacted the results creating larger SD 
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and SE margins in the 12 month data, making the data less robust. Therefore, it 
is feasible that a larger sample size might have resulted in a stronger significant 
association between the groups across the different imaging modalities. As 
stated previously this was due to several factors, with the advent of COVID-19 
affecting four participants’ data across all imaging. Therefore, caution should be 
used when interpreting these results, as those subjects who did remain in the 
study might have had a natural bias to due to volunteering at the beginning. 
Furthermore, they might have been susceptible to the Hawthorne effect, 
modifying their behaviour to improve their recovery. Although it must be noted 
both groups were blinded to which group they were in.  
 
Other limitations included the subjectivity of some of the questionnaires, 
particularly regarding quality of life, and mental health. Instructions in answering 
questions were as specific as possible, and these questionnaires have been 
validated, but some differences in participants’ interpretation would be 
unavoidable. In the bone health questionnaire the cone group had a higher 
prevalence of OA and RA, with both diseases impacting BMD turnover in 
different ways, these diseases could have been separated and analysed 
separately. Although it must be stated there was no statistical significance 
between the two groups. 
 
There was also the issue of a lack of data, not only from those who missed 
appointments or where the step wedge was not included, but there was also a 
lack of 24 month follow-up data, as stated this study included 12 month data, 
and although this study will continue to include 24 and 60 month data, this could 
not be included due to time commitments, this lack of data make conclusion 
regarding the 12-24 month plateau effect harder to ascertain, as well as long 
term changes. Although at a later date these additional data will be analysed 
and those questions answered.  
 
Unfortunately, there is also a lack of comparison data for rTKR participants and 
DXA scans, with only two papers both by Jensen et al [178, 179] investigating 
such changes (one paper investigated tibial changes and the other femoral 
changes). So it is unknown if the trends reported in this research is consistent, 
as there is no direct data to correlate this to, with most of the data compared 
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directly to TKR or TKA instead of rTKR. As stated although there are cone 
studies, only the Jensen et al study [178] included BMD DXA data, with most 
just reporting osteointegration by a reporting radiographer, again making 
comparisons to known datasets difficult. This makes these data unique, as a 
randomised control trial of knee BMD in rTKR, but also limits this data, as there 
is a lack of evidence for comparison studies. 
 
We are unsure of the impact of the physiotherapy instructions or exercise, 
although all patients received the same instructions it is unclear which 
participants were completely compliant in performing them, and if some 




The overall BMD results are incomplete after one year, and full recovery has not 
been established. The BMD data show an increase in the lateral tibial condyle 
in the cone group compared to a loss in the non-cone group; this is where the 
cone is situated. This difference is supported by the pixel density differences, 
and alignment data, which reports a lack of alignment difference between the 
cone and non-cone groups at all visits, although this alignment might be the 
reason for tibial medial condyle losses reported in both groups. Although it must 
be noted that there is no recorded alignment data for six weeks, so the impact 
during these weeks on alignment is unknown. Furthermore, the pixel density 
changes, although supporting the use of cones in osteointegration, used the 
three month long leg scan as a baseline (unlike the six week in DXA), and the 
lack of correlation data makes the comparisons between modalities more 
difficult. Additionally, the sample size is small, due to this the separation 
between the stem lengths was not established, so the influence of stem length 
is unaccounted for with the 26 who attended at six weeks, four had a cone and 
a long stem, 13 had a cone and a short stem, five non-cone and long, and four 
non-cone and short. Thus, this BMD change could be due to multiple complex 
reasons and could be impacted by early immobilisation and weight bearing.   
 
It is in this researcher’s opinion that the reported data across all three methods 
and questionnaires show no negative impact of cones in the DXA, pixel, or 
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alignment data. It is concluded that due to the already widely reported benefits 
of osteointegration and knee stabilisation of cones [218, 222, 381, 437, 438, 
439, 440], the promising management of severe tibial bone loss [221], as well 
the reported good short-term results of cone implantation [219], it is concluded 
that cone implantation would be beneficial. Furthermore, this is supported by 
the positive results in the questionnaire data, showing a reduction in depression 
and anxiety, and increases in quality of life and functionality. 
 
Additionally, cone implantation has been reported to reduce infection compared 
to other options [232], with the potential advent of increased fracture risk with 
low BMD, the use of implantation that can help increase or at least maintain 
BMD should be investigated further. 
 
 
10.10 FUTURE WORK/RECOMMENDATIONS 
Bringing this into a full trial several recommendations from the chapter should 
be implemented: 
 
If possible, further development of the 3D-SHAPER software should be 
undertaken, with additional validation and testing. This software provided 
additional in-depth data as an alternative methodology, and although it is in its 
infancy its results mimicked the BMD changes reported and the control data. 
The data from this 3D SHAPER software also allows a greater knowledge in 
defining the trabecular and cortical bone within the hip, an issue especially 
important with the impact of osteophytes and degenerative disease influencing 
BMD. Paralleled with the addition that this modelling software can be 
retrospectively applied without the bias of known groups by the software, means 
this is a high quality tool that should be used in the full study. If licencing or 
purchase of the product can be arranged.   
 
One of the main recommendations within this thesis from this feasibility study is 
regarding participation; although there were several issues (winter bed 
problems, delayed surgeries, and COVID-19). Moving forward attrition is an 
issue; the advent of using a focus group utilising public and patient involvement 
could be one plausible suggestion to address this issue. During the study, 
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reclassifying the appointment dates allows for a much larger range for scanning 
participants (e.g. the six month scan would still be a six month scan if it was 
closer to six months that 12 months, so eight months and 25 days would be 
classed as a six month scan). This increasing of the appointment window 
means COVID-19 cancellations and rearranged appointments would have less 
impact in losing that appointment data. The introduction of a follow up phone 
call prior to their appointment, to both check they had received their letter and to 
check they could still attend might help reduce the missed or cancelled 
appointments. Finally, the continued addition of paying for participants’ petrol, 
bus ticket, and providing parking will help to reduce this attrition further.  
 
Dual energy x-ray absorptiometry shows the greatest robustness out of the 
three main methodologies, having already established DXA knee positioning 
and being the gold standard for BMD investigations. In conjunction the 
systematic review data providing common ROI data that had been investigated 
within DXA knee imaging, albeit in TKR groups.  This makes DXA the primary 
modality moving forward. Although x-ray imaging should still be utilised, the 
pixel density changes reported in the feasibility study show promise as both a 
method and parallel to the DXA BMD data. Although this data is limited, with 
two main issues, a lack of correlation data directly linking the pixel changes to 
BMD changes, and a lack of useable scan data as not all long leg images 
contained a step wedge. To address this, a phantom of known BMD could be 
utilised and imaged via DXA and x-ray, and a more direct correlation created 
between these two modalities. More importantly during the full study the 
research should be communicated to the radiography department, to show the 
importance of the step wedge being within the images. This might help reduce 
the loss of data from lack of step wedge. Regarding six month CT scan the 
recommendation would be to not include it due to a lack of defined in-growth.  
 
Statistical analysis of the main BMD and questionnaire results should in part still 
use the continuation of paired t-tests which allows the understanding of the 
exact region or area that is significantly changing. Although due to repeated 
measures involved this should be used with caution, in which case the 
utilisation of the linear regression analysis model should be applied, as this was 




Moving forward, investigation beyond 12 months is also required, with 24 month 
appointment scans the changes in both cortical and trabecular bone would 
address issues that both the feasibility data and the systematic review have 
raised regarding plateau effects of BMD. Additionally, it must be noted that this 
full study will continue to 60 month visits and an extension to recruitment has 
been funded to ensure a sufficient sample size after accounting for participant 
attrition. Moreover, there should be investigations into the changes perceived 
between the rTKR and TKR groups, and the root cause for this possible 
difference and investigations into post-care influences. Although promising, 
additional research with a larger cohort of participant is required to truly reveal 
the impact of cone implantation in rTKR. 
Currently there is no DXA reference data to compare these data to. So a 
reference database needs to be created to make more sense of the knee 
measurements reported within this study. This could be facilitated by companies 
such as GE who could refine their knee DXA offering to make it easier and 
quicker to undertake and analyse and standardisation of DXA knee scans, 
rather than them being scanned on a DXA “thin” spine setting.  
 
Regarding the questionnaire data, for the full trial with a larger cohort, the BMD 
scores of the RA and OA participants could be separated and analysed 
independently, with severity also recorded, this could address some of the 
possible BMD changes reported in feasibility study. Additionally, the use of 
electronic questionnaires for those who are unable to complete or return them 
might help compliance, as might follow up phone calls for those who have failed 
to return the posted originals. Gaining access to the medical records of the 
participants could also be introduced moving forward; this would address the 
issues of errors in the self-reported bone health questionnaire data. But this was 
not possible, then checking the stated medications against NHS medicines 
database and comparing the medication with the medical condition could help 
reduce the errors. 
 
Overall, this feasibility study has allowed the development and trialling of useful 
imaging modalities and software, which can be employed in a wider context of a 
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full clinical trial, to help us better understand the impact of cone implantation in 























































Appendix 2. Standardised extraction from 
Source Study/First author:   
  Title:   
  Year of Publication:   
 
 
 Methods Study design (if stated):  
 
  
 Participants Total number of participants (sample 
size):   
  How were participants/patients/ 
recruited/gathered (if stated)   
  
Participants/patients demographics 
provided (e.g. age, gender): 
  
  
Any medications the participants might 
be on (if stated e.g. calcitonin or 
bisphosphonates)   
  
Setting (e.g. Chicago hospital, 
University of Exeter lab):   
 Country conducted in:  
 
  
 Intervention/Index test Specific intervention (e.g. TKR, TKA or 
rTKR):   
  
Details of intervention (e.g. anything 
specific about it, cone implants, long or 
short stems):   
  
Reference standard/comparator (e.g. 
matched control group, BMD baseline 
prior to surgery or contralateral leg to 
surgery):   
 
  
 Outcomes Main outcome from the study (e.g. 






















BMD score compared to comparator at 
the hips, spine, knees, or whole body 
(include subset anatomy if recorded 
i.e. greater trochanter greater BMD 
difference). Also include the time the 
data were recorded (e.g. 6 weeks, 6 
months, 2 years) 
  
  Stated point of BMD plateau (if any)   
 
  
Miscellaneous Key conclusions of the study authors:   
  









NEWCASTLE - OTTAWA QUALITY 
ASSESSMENT SCALE
Note: A study can be awarded a maximum of one star/dot for each 
numbered item within the Selection and Outcome categories. A 
maximum of two stars can be given for Comparability (see coding 
notes if unsure)
SELECTION                                                               
1) Representativemess of the exposed 
cohort
a) The participants/patients are a true representative of the 
average TKR/TKA/rTKR in the community ●
b) Somewhat representative of the average TKR/TKA/rTKR in the 
community ●
c) A selected group of users
d) No description of the derivation of the cohort
2) Selection of non-exposed cohort a) Are they drawn from the same community as the exposed 
cohort ●
b) Drawn from a difference source
c) No description of the derivation of the non-exposed cohort
3) Ascertainment of exposure a) Secure record (e.g. surgical records) ●
b) Structed interview ●
c) Written self report
d) No description
4) Demonstration that outcome of 




COMPARABILITY                                                     
1) Comparability of cohorts on the basis 
of the design or analysis
a) Study controls for (select most important factor) (e.g. age, BMI, 
gender etc) ●
b) Study controls for any additional factor (this criteria could be 
modified to indicate specific control for a second important factor) 
●
OUTCOME                                                                 
1) Assessment of outcome
a) Independent or blind assessment (e.g. by reference to secure 
records such as x-rays or medical record) ●
b) Record linkage (identified through ICD codes on database 
c) Self reported 
d) No description
2) Was follow-up long enough for 
outcome to occur          
a) Yes (select an adequate follow-up period for outcome of 
interest) ●
b) No
3) Adequacy of follow-up of cohorts a) Complete follow-up - all subjects accounted for ●
b) subjects lost to follow-up unlikely to introduce bias - small 
numbers lost ->_ % (select an adequate %) follow-up, or 
description provided of those lost) ●c) Follow up rate <_% (select an adequate %) and no description of 
those lostd) No sta ement
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Appendix 5. PIS 
                                                           
 
A Prospective, Randomised Pilot Study Investigating the Use of Metaphyseal Cones versus a 
Cemented Stem Construct in Revision Total Knee Replacement in Patients with AORI Grade 2 
Defects- a Comparison of Clinical, Functional and Radiological Outcome. 




We would like to invite you to take part in a study comparing 3 different ways of 
undertaking revision total knee replacement surgery. It is important that you understand 
both why we are doing this research and what being involved in it means for you. Please 
take some time to read this information leaflet and to ask us any questions you may have 
about being involved.  If you would like more time to think about this, or if you would like to 
discuss the research with your family, friends or GP, you do not have to make a decision 
now. We can contact you again at a later date if that is what you would prefer.  
 
This research study is NOT a trial of an untested product nor a new type of surgical 
technique. All of the joint replacement parts and surgical techniques are currently in routine 
use both in this hospital and around the world. The research is being carried out at the Royal 
Devon and Exeter Hospital and is an independent piece of research. 
 
Study details: 
Knee replacement surgery has been successfully carried out for many years. However, in 
time, some knee replacements will fail-usually either because of wear or loosening of the 
replacement parts. This may mean the patient has to undergo further surgery-this is known 
as revision total knee replacement (rTKR). This revision surgery is often more complex than 
the original operation and presents the operating surgeon with several technical challenges. 
When the old knee replacement is removed, a large cavity can be left in the bone. The new 
knee replacement has to be placed into this, but it is essential that it is immediately stable 
and secure. The large cavity has to be somehow either filled in or bypassed to ensure the 
new knee replacement is secure enough for early weight-bearing and long term success. 
Different techniques have been used for many years to overcome this problem. It may be 





Figure 1: new knee replacement cemented in place. 
 
An alternative to this is use a device called a “cone” which sits into the bony cavity and a 
new knee replacement can be cemented into the cone. See figure 2 below:  
 
Figure 2. 
Bone grows onto the cone to ensure its stability.   The new knee replacement that is 
cemented into the cone can either be a standard replacement as seen in figure 1 above, or a 
long stem replacement can be used which bypasses the bony defects and allow the new joint 
to achieve stability by cementing the stem that sits further down the length of the bone as 
shown in figure 2 above.  
All of these types of rTKR are presently in use throughout the UK. Currently, no-one knows 
which type is best. We are planning to run this study to see if we can identify which type of 
rTKR gives the best outcome for patients. We will measure the results using questionnaires 
to measure how well you feel your knee is performing, specific tests to measure knee 
function, and by using x-rays and scans. 
We will identify patients suitable for inclusion in the study from their medical notes, x-rays 
and scans. If you consent to be in the study, you will randomly be allocated to 1 of the 3 
Knee replacement parts 
Cement 
Cone device 
Cone placed within 
upper shin bone and 
new knee replacement 
with long stems 
cemented inside it 
Long stem to pass into 
thigh bone 




types of surgery- to receive either a cemented rTKR (with a short or long stem depending on 
the findings at the time of surgery), or a cone device with a short stemmed knee 
replacement or a cone device with a long stemmed knee replacement. We will monitor your 
progress for 5 years after the operation. We will not tell you which type of operation you 
have had done until the end of the study. 
What is the Purpose of the Study? 
We are trying to establish which way of performing this type of surgery is any better than 
the other. Before we can do this we have to run a pilot study of the project. The pilot study is 
to make sure we are collecting the right information and to see if there are going to be any 
unexpected difficulties in running a full study.   
If we can show that one method of doing this type of surgery is better than the others, it is 
likely that this would be the preferred surgical treatment in this hospital for patients having 
this operation in the future. We would inform our colleagues in the world of knee 
replacement surgery of the results so that they can improve the long term care for their 
patients also. At present, we do not know which type of operation is best and have no 
preference for one over another. All 3 methods of surgery are routinely used.  
Why have I been asked to be involved? 
You are being invited to participate in this study because your type of rTKR surgery meets 
the criteria for the question we are trying to answer. 
What is involved? How will it affect me? 
Every patient who is involved in this study has to sign a consent form which says that you are 
a willing participant and that you understand what it means to be involved.  
You will attend for preparation for surgery appointment usually a few weeks before your 
surgery to ensure you are fit to proceed and will have had x-rays of your knees undertaken. 
Both of these are part of routine rTKR care whether you are involved in the study or not 
In addition, you will be asked to attend the physiotherapy department here in Exeter for 
some tests that look at how well your knee is working before the operation. The tests 
include looking at the strength of your knee muscles, your balance, your speed and your 
walking ability. These tests are known as functional testing.  
You will be asked to complete some questionnaires which measure how much trouble your 
knee is giving you on an everyday basis. For example, questions are asked about pain, sleep 
disturbance and limitation of activity. These questionnaires are widely used throughout the 
world so that different departments of knee surgery are accurately able to compare their 
surgical results with others. 
Participants will be allocated to 1 of the 3 arms of the study- to receive either a cemented 
rTKR (with a short or long stem depending on the findings at the time of surgery), or a cone 
device with either a short or long stemmed knee replacement. This allocation is a random 
decision. A computer generated list has been drawn up and decides which treatment each 
patient will receive. Please remember that all 3 techniques are currently being routinely 
used so you are not being disadvantaged by having one treatment over another. 
After your surgery, your immediate post-operative care will be the same as routine care in 
our hospital. You will be seen in the orthopaedic out-patient clinic at 6 weeks and then at 1, 
2 and 5 years after the surgery. There will be an x-ray at the 1, 2 and 5 year appointment. We 
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will ask you to repeat the questionnaires that you did before your operation. Again, this is all 
routine care whether you are involved in the study or not. 
In addition to routine care, we will ask you to attend the physiotherapy department here in 
Exeter at 3, 6 12, 24 and 60 months after the operation so that we can repeat the functional 
testing that you did before your operation. This allows us to see on a practical basis how 
your new knee is performing. 
We will ask you to undergo 2 additional knee x-rays at 3 and 6 months after your operation 
and to complete 2 sets of additional patient questionnaires. 
We will ask you to attend the Department of Medical Imaging at Exeter University on 7 
occasions, once before your operation and then on 6 occasions afterwards-at 6 weeks, 3 
months, 6 months and 1, 2 and 5 years, for a test known as a DEXA scan. This is a type of 
radiological test that looks at the density of the bone immediately around your new knee 
replacement. You will also be asked some questions about your level of activity and function 
as well as anxiety and depression. It is known that these can all affect bone density. 
Some patients will be asked to attend the radiology department at the RD+E Hospital for a 
CT scan of the operated knee 6 months after your operation.  
Being involved in the study will not affect the length of time you are in hospital. Any patient 
undergoing this type of surgery-whether involved in the study or not- will receive post-
operative physiotherapy based on personal need.   
Do I Have to Take Part? 
No. Your participation in this study is entirely voluntary. If you choose not to take part, this 
will NOT affect your medical care in any way. Your rTKR surgery will go ahead as planned. If, 
at any time during the study, you change your mind and wish to withdraw from the study, 
you can do so. Again, this decision will have no impact on any of your future medical care. 
 
As you can see, participating in this study involves a time commitment from you. Over a 5 
year period, there will be 2 extra visits to the RD+E for knee x-rays, 6 extra visits to the 
physiotherapy department for functional testing, 1 visit for the CT scan for some patients 
and 7 visits to Exeter University for the DEXA scans. For these extra visits, we can contribute 
to travel expenses for you at public transport rates and also cover the cost of car parking.  
Despite this time commitment from yourself, we hope you can become involved in our 
research. It is only by undertaking studies such as this that we can improve patient care. 
We recognise that parking at the main RD+E Hospital Wonford site can be very difficult. The 
physiotherapy appointments are on the RD+E Heavitree site and the DEXA scans at St Lukes-
part of the University of Exeter campus (on the other side of the road from RD+E Heavitree). 






What Are the Possible Risks of Taking Part?  
As the 3 surgical techniques being examined are already in routine use in this hospital, we do 
not anticipate any adverse events as a result of being involved in the study other than those 
that can occur with any patient having this type of surgery.  
The 2 extra knee x-rays and DEXA scans add an additional dose of radiation exposure. This is 
calculated as being the equivalent to 33 days of background radiation (that which we are all 
exposed to in normal life) and is classed as minimal risk. For the patients also having a CT 
scan, their total increased radiation exposure is equivalent to 55 days of natural background 
radiation exposure to background radiation exposure and is classed as being very low risk. 
This has been calculated by our Medical Physics Expert, using the appropriate guidelines.  
 
 Are there any possible benefits? 
As a result of being in this study, you will be more closely monitored by the physiotherapy 
department than is usual. This will give you an opportunity to ask any extra questions if you 
have them. As all 3 types of operation being studied are performed anyway, you may not get 
any extra benefit to being involved in the study, but the results will influence how we do this 
type of surgery in the future and therefore of long-term  benefit of others. 
 
Ethical Approval of the Study:  
Before we were allowed to proceed with this study, we had to seek ethical approval to do 
so.  This was provided by the Health Research Authority. The North West - Greater 
Manchester West Research Ethics Committee  reviewed the study on their behalf and 
approved it. An ethics committee is made up of doctors, scientist and lay people who 
examine the study to ensure it has been carefully thought through, has minimised the 
possibility of risks to participants and ensures the highest standards of research safety. 
 
Data Collection: 
Using your hospital number (not your name) for identification, we will collect information 
regarding your progress. This information will be kept on encrypted and password protected 
RD+E Hospital computers. This information will be used only by hospital staff to allow us to 
analyse the results and also the regulatory authorities who ensure we meet all the 
requirements of the Health Research Authority in the conduct of our research.  It will not be 
given to any one else for any other purpose. At the end of the study, all of the information 
kept on the computer database will be archived and stored in a secure environment.  
If at any time during the study, you lose the capacity to provide on-going consent to 
continue in the study, we will withdraw you from the research at that time but will use any 





When the study is completed, we hope to present our findings at national and international 
meetings, and to publish them in an orthopaedic journal. We will also write to you with a 
summary of the findings. 
 
Complaints: 
Should you have cause for complaint about this research, please discuss this with Patrick 
Hourigan (details below), or with your Orthopaedic Consultant. If you are unhappy to speak 
to either of them, you can contact the Patients Advisory Liaison Service (PALS) at the 
hospital who will act on your behalf. In the unlikely event of you coming to serious harm as a 
result of negligence, such harm will be covered by the NHS indemnity. 
 
What Do I Do Now? 
One of the research team will contact you to ask if you have any questions about the study, 
to ask if you would like to be involved and to make arrangements for you to sign a consent 
form if you are happy to participate.  
If you would like to discuss the study further you can contact Patrick Hourigan via e-mail or 
in office hours on his number given below. Please note however, that Mr Hourigan is only 
able to answer your queries in relation to this piece of research. Any general queries about 
your operation should be made to your consultant knee surgeon’s secretary. 
Thank you very much for considering taking part in our research. Please discuss this 
information with your family, friends or GP if you wish. 
Contact for Matters Relating to this Research Project: 
Patrick Hourigan 
Clinical Research Co-ordinator 
Exeter Knee Reconstruction Unit 










Appendix 6. Consent form                                                          
 
Consent Form  
Name of patient/volunteer…………………………Hospital Number:……………………... 
Name of investigators: Mr A D Toms, Mr J R Phillips, Mr K S Eyres and Mr P Hourigan 
Title: A Prospective, Randomised Pilot Study Investigating the Use of Metaphyseal Cones 
versus a Cemented Stem Construct in Revision Total Knee Replacement in Patients with AORI 
Grade 2 Defects- a Comparison of Clinical, Functional and Radiological Outcome.  
This section to be completed by the patient. Please initial each statement below: 
1. I have read the version 1 (24/05/17) information sheet about this study    -------- 
2. I have had an opportunity to ask questions about this study                            --------                                  
3. I have received satisfactory answers to my questions                                        -------- 
4. I am satisfied with the information I have been given                                        ---------                                            
5. I understand my GP will be informed of my participation in this study          ---------                                                          
6. I understand that relevant sections of my medical notes and data  
collected during the study will only be looked at by individuals from the  
research team, from regulatory authorities or from the NHS Trust,  
where it is relevant to my taking part in this research. I give  
permission for these individuals to have access to my records                         --------- 
 
 This study has been explained to you by: …………………………………………. 
 I understand that am free to withdraw from the study: 
1. At any time               ----------                                                                             
2. Without having to give a reason            ----------                                          
3. Without affecting my future medical care  ----------                       
I agree to take part in this study                                                    
Patient’s signature…………………………………     Patient Name………………………     
Date………………….. 
I confirm that I have fully explained the nature of this trial to the above named patient 
Investigator’s signature………………………………..   Investigator Name………………………     
Date…………………….. 
CC Medial notes, patient 
410 
 
Appendix 7. DXA Appointment letter 






Dear Mr/s  
 
Re: Investigation of metaphyseal cones versus a cemented stem construct in 
revision total knee replacement patients 
  
Thank you for your interest in the above study.  An appointment has been made for you 
on  
 
Date:     - 
Time: - 
 
The appointment will be held in the Children’s Health and Exercise Research Centre 
(CHERC) at the School of Sport and Health Sciences (SSHS), Baring Court at St 
Luke’s campus.  
Directions to St Luke’s campus and to the CHERC are overleaf.    
 
The appointment should take no longer than 2 hours. 
 
Please wear (or bring) clothing that does not contain any metal or zips as these can 
obstruct the image during scanning.  
 
We are aware that you may be experiencing difficulty with walking following your 
treatment and, if required, we can arrange a reserved parking space for you and a 
wheel chair escort from your car to the scanner. Please could you contact the 
researcher Michael Gundry on 07973442892 or E-mail mg361@exeter.ac.uk around 
one week in advance of your appointment so that we can arrange this. Please note that 
this phone line is not manned full time and we would be grateful if you could leave a 
message with your name, telephone number and some convenient times to return your 
call. 
 
In addition to the appointment I have enclosed a questionnaire to be completed prior to 
your first appointment.  If you have any difficulties filling in this form you can discuss it 
with the researcher at your appointment. 
 
If you require any further information, please do not hesitate to contact me. 
 
If you are unable to make this appointment, please let us know as soon as possible so 








Room 1.26, South Cloisters, 
St Lukes 
Exeter 
EX1 2 LU 














Directions to St Luke’s campus: 
University of Exeter 
St Luke's Campus  
Heavitree Road 
Exeter EX1 2LU 
 
If you are travelling by car using satellite navigation please use post code EX2 4TE, 
additional information on directions to the campus can be found on: 
www.exeter.ac.uk/visit/directions/stlukes/ 
St Luke’s campus is shown below, number 5 (arrow) is Baring court where I will meet 
you outside the CHERC, once you arrive outside the building please ring me. If 
reserved parking is required please make sure you park in the area adjacent to the 
Magdalen entrance and ring me as soon as you arrive, and I will then meet you in the 















If you have any difficulty finding either the building or the campus please don’t hesitate 
to contact me on: 07973442892 or E-mail mg361@exeter.ac.uk 
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Date of birth (these 3 are needed to perform an identity check): ______________ 
Height: _____________ 
Weight:_____________ 
Stem length and side the knee revision is on (e.g. left or right): ____________________ 
Any previous hip replacement (including side) or metal work in spine:_______________ 
Date of revision surgery__________________ 
Has the participant had a DXA scan in the last 6 months__________________________ 






















UNIVERSITY OF EXETER 
MEDICAL SCHOOL 
 
South Cloister’s, St Luke’s Campus, 
Heavitree Road, Exeter, EX1 2LU 
 
t   +44 (0) 1392 724133 
e   K.M.Knapp@exeter.ac.uk 
                                                                                                                                  10th October 2020 
 
Mr A Toms 
Princess Elizabeth Orthopaedic Centre 






Re: Joe Bloggs, DoB 01/01/01 
3 BBBBB, Exx, Devon, EX1 111 
 
Your patient is enrolled in the Cones research study.   
Your patient’s bone mineral density results are outlined below: 
Site BMD (g/cm2) T-score 
Lumbar Spine    
Left Total Hip   
Right Total Hip   
Total body   
 
These results fall within the normal/osteopenic/osteoporotic range as defined by the WHO criteria 
(1994) for the diagnosis of osteoporosis. Details of any clinical risk factors /secondary causes should 




You may wish to consider treatment with 1st line Bisphosphonate or 2nd line treatment if appropriate 
Lifestyle advice is recommended to encourage your patient to take regular weight bearing 
exercise, follow a diet rich in calcium, and have sufficient safe sun exposure to promote Vitamin 
D.   
 
I would recommend a repeat scan in 2 years (osteoporosis)/3-5 years (osteopenia) to re-check their 
bone density/ A clinical follow-up scan is not required unless there is a change in your patient’s clinical 
presentation, which includes a clinical risk factor for osteoporosis.   
 





Karen Knapp BSc (Hons), PgCAP, PgC, PhD, SFHEA 





Appendix 10. Bone health questionnaire 
Bone Questionnaire  
   
Please complete all the appropriate sections, using the tick boxes where provided. 
 








Telephone Number (including area code)  ……….……………………………………… 
 
Date of Birth   …………………… (day/month/year) 
 
 
Gender   Female  /  Male 
 
 
Ethnic Background  White [  ]   Oriental  [  ] 
    Black   [  ] Mixed   [  ] 
    Asian   [  ]  Other   [  ] 
 
Height      …………………………..   Weight    
………….…………………………………...      
 





GP Name   ………………………………………………………….………. 
 
GP Address   …………………………………………………………….……. 
 
   …………………………………………………………….……. 
 
GP Telephone Number …………………………………………………………….……. 
 





1. Have you ever suffered from any of these conditions? 
 
No Yes 
Please state when diagnosed and 
duration of disease 
Rheumatoid arthritis    
Osteoarthritis    
Ankylosing spondylitis    
Diabetes -type 1 – insulin dependent    
Diabetes – type 2     
Overactive thyroid    
Underactive thyroid    
Breast cancer    
Other cancer    
Pagets disease of bone    
Liver disease    
Kidney disease    
Gastric surgery    
Lactose intolerance (milk allergy)    
Crohn’s disease    
Coeliac disease    
Irritable bowel syndrome    
Malabsorption syndrome    
Osteomalacia (rickets)    
Osteogenesis Imperfecta    
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Hypogonadism    
Chronic malnutrition / malabsorption    
Eating disorder eg anorexia nervosa    
 
2. Do you suffer from any other on-going disease?  Yes [  ]     No [  ] 
 





3. Did your mother or father ever fracture (break) their hip? 
 
Yes [  ]   No [  ] 
 
 
4. Do any other diseases run in your family? Yes [  ]   No [  ] 
 
 If yes, please state the disease, and the relatives affected                
            .………………………................................................... 
 
 
5.       Have you been immobilised for more than 6 wks (complete bed rest/. 
hospitalisation)?     Yes [  ]      No  [  ] 
 
              If yes, was this before the age of 25  [  ], or after the age of 25  [  ] 
 
6. Have you ever taken any of the following drugs? 
Drug No Yes For how long did you take them? 
Corticosteroids 
(Please state dose) 
   
Anticonvulsants    
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Diuretics    
Chemotherapy    
Immunosuppresive agents    
Heparin    
Thyroxine    
Fosamax (Alendtronate)    
Actonel (Risidronate)    
Teriparatide (PTH)    
Protelos (Strontium Ranalate)    
Pamidronate (infusions)    
Zolendronate (injection)    
Ibandronate    
Arimidex (anastrozole)    
Androgen deprivation therapy 
 
 
   
 
7.  Have you taken any other drugs for greater than 3 months in the past 5 years?  
 Yes [  ] No [  ] 







8.  Do you take any of the following dietary supplements? 
Supplement No Yes For how long 
Multivitamins    
Calcium    
Vitamin D    
Other (please state)    
 
 
9. Have you ever fractured (broken) any bones?    Yes [  ]  No [  ] 
If yes, please state how old you were,  which bone(s) you broke, and how it 
happened, (please be as accurate and specific as possible): 
 
Age Bone What Happened and how was it treated? 
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10. Do you, or have you in the past suffered from back pain? Yes [  ]      No [  ] 









11. Have you had any falls in the last year? Yes [  ]  No [  ] 
 If yes, now many and how did they happen? 
 
Fall No How did it happen Did you sustain any injuries? 
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12. Have you had any orthopaedic surgery? 
 










12. Please tick which best applies to you Never Smoked [  ] 
Current smoker [  ] 
       Ex-smoker  [  ] 
       Use a vaporizer [  ] 
  
 
13.  How much alcohol do you drink on average per week? 
 
(1 unit = ½ pint beer, a measure of spirits or a glass of wine) 
      Never             [  ]  11-15 units per week            [  ] 
Less than weekly       [  ]  16-20 units per week            [  ] 
1-5 units per week     [  ]  More than 20 units per week [  ] 





14.  Are you vegetarian?     Yes  [  ] No  [  ]        If yes, for how 
long?......…years 
 
  Are you vegan?       Yes  [  ] No  [  ]        If yes, for how 
long?......…years 
 
15.  How many cups or cans of caffeine-containing beverages (coffee, tea and soft 
 drinks such as cola) do you drink per day? 
None      [  ]  11 – 15 cups/cans per day  [  ] 
1 – 5 cups/cans per day[  ]  More than 15 cups/cans per day [  ] 
6-10 cups/cans per day [  ] 
 
16. How much time do you typically spend taking exercise (for example walking or 
cycling out of doors) each day?  
 
None      [  ] 
Some, but less than half an hour  [  ] 
Half to one hour    [  ] 
More than one hour    [  ] 
 
17. Please outline any sporting or other activities you do partake in, and for how 













The rest of the questionnaire is for completion by women only 
 
18.  How old were you when your periods started?………………………….. 
  Has there been any time when your periods have stopped for a time of  
  more than 6 months except during pregnancy?   Yes  [  ]      No [  ] 
If Yes, for how long did they stop?……………………………… 
 
 If Yes, did they stop due to contraceptive injections, implants, coils or tablets?  
Yes [  ]       No [  ] 
 
19.  Have you had a hysterectomy?   Yes [  ] No [  ] 
 If yes, at what age  and for what reason?  Age ………………………….. 
 Reason………………………………………………………………………….. 
 
 Have you had your ovaries removed? Yes  [  ]     No  [  ]     Don’t know  [  ]   
 If yes, was 1 ovary removed  [  ] or both removed  [  ]  How old were you? 
 
        
20.  Are you having regular periods?   Yes [  ] No [  ] 
 
21. If no, please state how often you have a period and any reason they may be 
irregular (ie contraceptive device) 
   
22.  Are you on, or have you ever taken the oral contraceptive pill, contraceptive 
implants, injections of coils?      
Yes  [  ] No  [  ] 
 If yes, for how long have you taken it?………………………………………. 
 Please state type (ie pill, injection etc.) and name if you know……………….. 
 
……………………………………………………………………………………….. 




23.  How many children have you had?……………………………………… 
  Did you breast feed your children?          Yes  [  ]    No   [  ] 
 If yes, for how many months did you breast feed each baby?  
  
Baby 1 2 3 4 5 
Months 
breast fed 
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Appendix 12. HADS Questionnaire 
Hospital Anxiety and Depression Scale (HADS) Date______    PID________ 
Tick the box beside the reply that is closest to how you have been feeling in the past 
week. 


















Please check you have answered all the 
questions Scoring: 
Total score: Depression (D)    Anxiety (A)     
0-7 = Normal 
8-10 = Borderline abnormal (borderline case)  
11-21 = Abnormal (case) 
D A  D A  
  I feel tense or 'wound up':   I feel as if I am slowed down: 
 3 Most of the time 3  Nearly all the time 
 2 A lot of the time 2  Very often 
 1 From time to time, occasionally 1  Sometimes 
 0 Not at all 0  Not at all 
      
  I still enjoy the things I used to 
enjoy: 
  I get a sort of frightened feeling like 
'butterflies' in the stomach: 
0  Definitely as much  0 Not at all 
1  Not quite so much  1 Occasionally 
2  Only a little  2 Quite Often 
3  Hardly at all  3 Very Often 
      
  I get a sort of frightened feeling as if 
something awful is about to 
happen: 
   
I have lost interest in my appearance: 
 3 Very definitely and quite badly 3  Definitely 
 2 Yes, but not too badly 2  I don't take as much care as I should 
 1 A little, but it doesn't worry me 1  I may not take quite as much care 
 0 Not at all 0  I take just as much care as ever 
      
  I can laugh and see the funny side 
of things: 
  I feel restless as I have to be on the 
move: 
0  As much as I always could  3 Very much indeed 
1  Not quite so much now  2 Quite a lot 
2  Definitely not so much now  1 Not very much 
3  Not at all  0 Not at all 
  Worrying thoughts go through my 
mind: 
  I look forward with enjoyment to 
things: 
 3 A great deal of the time 0  As much as I ever did 
 2 A lot of the time 1  Rather less than I used to 
 1 From time to time, but not too often 2  Definitely less than I used to 
 0 Only occasionally 3  Hardly at all 
      
  I feel cheerful:   I get sudden feelings of panic: 
3  Not at all  3 Very often indeed 
2  Not often  2 Quite often 
1  Sometimes  1 Not very often 
0  Most of the time  0 Not at all 
      
  I can sit at ease and feel relaxed:   I can enjoy a good book or radio or TV 
program: 
 0 Definitely 0  Often 
 1 Usually 1  Sometimes 
 2 Not Often 2  Not often 


































Appendix 14. EQ-5D-3L Questionnaire 
Quality of Life Questionnaire EQ-5D 
 
 



























By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed 􀂉 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
To help people say how good or bad a health state is, we have drawn a scale (rather like a 
thermometer) on which the best state you can imagine is marked 100 and the worst state you 
can imagine is marked 0. 
We would like you to indicate on this scale how good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the box below to whichever point on the scale 

































































  0 
Best imaginable health state 
















1: Which knee are you being reviewed for today? 
 
  □ Left  □ Right (go to #3)  □ Both: Please fill in a form for each knee (go to #2)  
 
 
2: Only if you are being reviewed for both knees: This form is for my… 
 
  □ …Left knee   □ …Right knee   (now please go to #3) 
 
 
3:  If you have already had your knee replacement, please select one of the 
sentences below that best describes how you feel about the treatment or 
operation you have had: 
 
 □  I am satisfied with the results of my surgery and I made the right choice in having the treatment 
 □  I am satisfied with the results of my surgery but I would not have it again or recommend it 
 □  I am not satisfied with the results of my surgery and / or I regret having the treatment 
 









Patient initials:  
 
 
WHAT TO DO NOW:  
If you have received this form by post before your appointment, please 
complete your questionnaire at home when received and bring it with 




OXFORD KNEE SCORE 
Please answer the following 12 multiple choice questions: 
 
 
K1: During the past four weeks, how would you describe the pain you 
usually have from your knee? 
 
  □ None   □ Very Mild   □ Mild   □ Moderate   □ Severe 
 
 
K2: During the past four weeks, have you had any trouble with washing and 
drying yourself (all over) because of your knee?  
 
□ No trouble at all   □ Very little trouble   □ Moderate trouble 
□ Extreme trouble   □ Impossible to do 
 
 
K3: During the past four weeks, have you had any trouble getting in and out 
of a car or using public transport (whichever you would tend to use) 
because of your knee?  
 
□ No trouble at all   □ Very little trouble   □ Moderate trouble 
□ Extreme difficulty   □ Impossible to do 
 
 
K4: During the past four weeks, for how long have you been able to walk 
before pain from your knee becomes severe? (with or without a stick) 
 
□ No pain for 30 minutes or more  □ 16 to 30 minutes  □ 5 to 15 minutes 






K5: During the past four weeks, after a meal (sat at a table), how painful has 
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it been for you to stand up from a chair because of your knee? 
 
  □ Not at all painful  □ Slightly painful  □ Moderately painful  □ Very painful  □ Unbearable 
 
 
K6: During the past four weeks, have you been limping when walking, 
because of your knee? 
 
□ Rarely/never  □ Sometimes, or just at first  □ Often, not just at first 
□ Most of the time  □ All of the time 
 
 
K7: During the past four weeks, could you kneel down and get up again 
afterwards? 
 
□ Yes, easily  □ With little or no difficulty  □ With moderate difficulty 
□ With extreme difficulty  □ No. Impossible 
 
 
K8: During the past four weeks, have you been troubled by pain from your 
knee in bed at night? 
 
□ No nights  □ Only 1 or 2 nights  □ Some nights  □ Most nights  □ Every night 
 
 
K9: During the past four weeks, how much has pain from your knee 
interfered with your usual work (including housework)? 
 
□ Not at all  □ A little bit  □ Moderately  □ Greatly  □ Totally 
 
 





suddenly "give way" or let you down? 
 
□ Rarely/never  □ Sometimes, or just at first  □ Often, not just at first 
□ Most of the time  □ All of the time 
 
 
K11: During the past four weeks, could you do the household shopping on 
your own? 
 
□ Yes, easily  □ With little difficulty  □ With moderate difficulty 
□ With extreme difficulty  □ No, impossible 
 
 
K12: During the past four weeks, could you walk down one flight of stairs? 
 
□ Yes, easily  □ With little difficulty  □ With moderate difficulty 






1. National Health Service Choices. Osteoporosis. 2016. Available at: 
http://www.nhs.uk/Conditions/Osteoporosis/Pages/Introduction.aspx. Accessed 
23rd March 2017 
 
2. International Osteoporosis Foundation. Facts and statistics. 2015.  Available 
at: https://www.iofbonehealth.org/facts-statistics. Accessed 23rd March 2017 
 
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability 
associated with osteoporotic fractures. Osteoporosis International. 
2006;17(12):17-26 
 
4. Kuru P, Akyüz G, et al. Fracture history in osteoporosis: Risk factors and its 
effect on quality of life. Balkan Medical Journal. 2014;31(4):295-301 
 
5. Sezer N, Tomruk-Sutbeyaz S, et al. Determinants of quality of life in 
postmenopausal osteoporosis. International Journal of Physics Medicine and 
Rehabilitation. 2009;12:19-25 
 
6. Legrand E, Chappard D, et al. Bone mineral density and vertebral fractures in 
men. Osteoporosis International. 1999;10:265-70 
 
7. Marshall D, Johnell O, et al. Meta-analysis of how well measures of bone 
mineral density predict occurrence of osteoporotic fractures. British Medical 
Journal. 1996;312(7041):1254-1259 
 
8. De Laet CE, Van Hout BA, et al. Bone density and risk of hip fracture in men 
and women: cross sectional analysis. British Medical Journal. 
1997;315(7102):221-225 
 
9. Cummings SR, Black DM, et al: Bone density at various sites for prediction of 





10. Cummings SR, Nevitt MC, et al: Risk factor for hip fracture in white women. 
The New England Journal of Medicine. 1995;332(12):767-774 
 
11. Melton LJ 3rd, Wahner HW, et al. Osteoporosis and the risk of hip fracture. 
American Journal of Epidemiology. 1986;124(2):254-261 
 
12. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are 
related to changes in bone density. The Journal of Clinical Endocrinology and 
Metabolism. 2000;85(1):231-236 
 
13. National Osteoporosis Society. The osteoporosis agenda England. 2015. 
Available at: https://nos.org.uk/media/1959/agenda-for-osteoporosis-england-
final.pdf Accessed 23rd March 2017 
 
14. Winter J. Hospital episode statistics, admitted patient care, England 2012-
13. Primary diagnosis. 2019. Available at: 
www.hscic.gov.uk/catalogue/PUB12566 Accessed 26th June 2020 
 
15. National Osteoporosis Society. Life with Osteoporosis: the untold story. 
2014. Available at: https://nos.org.uk/media/1859/life-with-osteoporosis.pdf 
Accessed 22nd January 2019 
 
16. Gazdzik TS, Gajda T, et al. Bone mineral density changes after total knee 
arthroplasty: one-year follow-up. Journal of Clinical Densitometry. 
2008;11(3):345-350 
 
17. Soininvaara TA, Miettinen HJ, et al. Periprosthetic tibial bone mineral 
density changes after total knee arthroplasty: one-year follow-up study of 69 
patients. Acta Orthopaedica Scandinavica. 2004;75(5):600-605 
 
18. Mau-Moeller A, Behrens M, et al. Modulation and predictors of 
periprosthetic bone mineral density following total knee arthroplasty. BioMed 




19. Järvenpää J, Soininvaara TA, et al. Changes in bone mineral density of the 
distal femur after total knee arthroplasty: a 7-year DEXA follow-up comparing 
results between obese and nonobese patients. The Knee Journal. 
2014;21(1):232-235 
 
20. Li MG, Nilsson KG. Changes in bone mineral density at the proximal tibia 
after total knee arthroplasty: A 2-year follow-up of 28 knees using dual energy 
X-ray absorptiometry. Journal of Orthopaedic Research. 2000;18(1):40-47 
 
21. Kim KK, Won YY, et al. Changes in bone mineral density of both proximal 
femurs after total knee arthroplasty. Clinics in Orthopaedic Surgery. 
2014;6(1):43-48 
 
22. Ishii Y, Yagisawa K, et al. Changes in bone mineral density of the proximal 
femur after total knee arthroplasty. The Journal of Arthroplasty. 2000;15(4):519-
522 
 
23. Hopkins SJ, Toms AD, et al. A study investigating short- and medium-term 
effects on function, bone mineral density and lean tissue mass post-total knee 
replacement in a Caucasian female post-menopausal population: implications 
for hip fracture risk, Osteoporosis International.  2016;27(8):2567-2576 
 
24. Petersen MM, Nielsen PT, et al. Changes in bone mineral density of the 
proximal tibia after uncemented total knee arthroplasty. A 3-year follow-up of 25 
knees. Acta Orthopaedica Scandinavica. 1995;66(6):513-516 
 
25. Beaupre LA, Rezansoff A, et al. Bone mineral density changes in the hip 
and spine of men and women 1-year after primary cemented total knee 
arthroplasty: prospective cohort study. The Journal of Arthroplasty. 
2015;30(15):2185-2189 
 
26. Soininvaara TA, Miettinen HJ, et al. Bone mineral density in the proximal 





27. Liu TK, Yang RS, et al. Periprosthetic bone mineral density of the distal 
femur after total knee arthroplasty. International Orthopaedics. 1995;19(6):346-
351 
 
28. Mintzer CM, Robertson DD, et al. Bone loss in the distal anterior femur after 
total knee arthroplasty. Clinical Orthopaedics and Related Research. 
1990;260:135-143 
 
29. Jaroma A, Soininvaara TA, et al. Periprosthetic tibial bone mineral density 
changes after total knee arthroplasty a 7-year follow-up of 86 patients. Acta 
Orthopaedica. 2016;87(3):268-273 
 
30. Lavernia CJ, Rodriguez JA, et al. Bone mineral density of the femur in 
autopsy retrieved total knee arthroplasties. The Journal of Arthroplasty. 
2014;29(8):1681-1686 
 
31. Lonner JH, Klotz M, et al. Changes in bone density after cemented total 
knee arthroplasty: influence of stem design. The Journal of Arthroplasty. 
2001;16(1)107-11 
 
32. Im GI, Kwon OJ, et al. The relationship between osteoarthritis of the knee 
and bone mineral density of proximal femur: a cross-sectional study from a 
Korean population in women. Clinics in Orthopaedic Surgery. 2014;6(4):420-
425 
 
33. Karbowski A, Schwitalle M, et al. Periprosthetic bone remodelling after total 
knee arthroplasty: Early assessment by dual energy X-ray absorptiometry. 
Archives of Orthopaedic and Trauma Surgery. 1999;119(5-6):324-326 
 
34. Levitz CL, Lotke PA, et al. Long-term changes in bone mineral density 





35. Van Loon CJ, Oyen WJ, et al. Distal femoral bone mineral density after total 
knee arthroplasty: A comparison with general bone mineral density. Archives of 
Orthopaedic and Trauma Surgery. 2001;121(5):282-285 
 
36. Hahn MH, Won YY. Bone mineral density changes after total knee 
replacement in women over the age of 65. Journal of Bone Metabolism. 
2013;20(2):105-109  
 
37. Petersen MM, Gehrchen PM, et al. Effect of hydroxyapatite-coated tibial 
components on changes in bone mineral density of the proximal tibia after 
uncemented total knee arthroplasty: a prospective randomized study using 
dual-energy x-ray absorptiometry. The Journal of Arthroplasty. 2005;20(4):516-
20 
 
38. Hopkins SJ, Smith CW, et al. A study investigating the long-term effects on 
function, bone mineral density and lean tissue mass post total knee 
replacement in a female postmenopausal population. Osteoporosis 
International. 2012;23:S552 
 
39. Mann T, Eisler T, et al. Larger femoral periprosthetic bone mineral density 
decrease following total hip arthroplasty for femoral neck fracture than for 
osteoarthritis: a prospective, observational cohort study. Journal of Orthopaedic 
Research. 2015;33(4):504-512 
 
40. Cameron HU, Cameron G. Stress-relief osteoporosis of the anterior femoral 
condyles in total knee replacement: a study of 185 patients. Orthopaedic 
Reviews. 1987;16(7):449-456 
 
41. Van Lenthe GH, de Waal Malefijt MC, et al. Stress shielding after total knee 
replacement may cause bone resorption in the distal femur. The Journal of 
Bone and Joint Surgery British Volume. 1997;79(1):117-122 
 
42. Meek RM, Norwood T, et al. The risk of peri-prosthetic fracture after primary 





43. Toogood PA, Vail TP. Periprosthetic fractures: a common problem with a 
disproportionately high impact on healthcare resources. The Journal of 
Arthroplasty. 2015;30(10):1688-1691 
 
44. Vala CH, Kärrholm J, et al. OC12 Risk for hip fracture ten years before and 
after total knee replacement surgery in the entire Swedish population. Abstract 
book: WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and 
Musculoskeletal Diseases, 14 -17 April 2016, Malaga, Spain Osteoporosis 
International. 2016;27(Suppl 1). Available at: http://2016.wco-iof-
esceo.org/sites/all/files/wco16/WCO16-AbstractBook.pdf. Accessed 23rd March 
2017 
 
45. Prieto-Alhambra D, Javaid MK, et al. Changes in hip fracture rate before 
and after total knee replacement due to osteoarthritis: a population-based 
cohort study. Annals of the Rheumatic Diseases. 2011;70(1):134-138 
 
46. Lalmohamed A, Opdam F, et al. Knee arthroplasty and risk of hip fracture: a 
population-based, case–control study. Calcified Tissue International. 
2012;90(2):144-150  
 
47. Cordeiro EN, Costa RC, et al. Periprosthetic fractures in patients with total 
knee arthroplasties. Clinical Orthopaedics Related Research. 1990;252:182-189 
 
48. Dennis DA. Periprosthetic fractures following total knee arthroplasty. Journal 
of Bone and Joint Surgery American Volume. 2001;83(1):120-130 
 
49. Merkel KD, Johnson EW Jr. Supracondylar fracture of the femur after total 
knee arthroplasty. Journal of Bone and Joint Surgery American Volume. 
1986;68(1):29-43 
  
50. Engh GA, Ammeen DJ, et al. Instructional course lectures, the american 
academy of orthopaedic surgeons - Periprosthetic fractures adjacent to total 
knee implants. Treatment and clinical results. Journal of Bone and Joint Surgery 




51. Beals RK, Tower SS. Periprosthetic fractures of the femur. An analysis of 93 
fractures. Clinical Orthopaedics and Related Research. 1996;327:238-246 
 
52. Matsumoto H, Okuno M, et al. Incidence and risk factors for falling in 
patients after total knee arthroplasty compared to healthy elderly individuals. 
Yonago Acta Medica. 2014;57(4):137-145 
 
53. Soison A, Riratanapong S, et al. Prevalence of fall in patients with total knee 
arthroplasty living in the community. Journal of the Medical Association of 
Thailand. 2014;97(12):1338-1343 
 
54. Ikutomo H, Nagai K, et al. Falls in patients after total hip arthroplasty in 
Japan. Journal of Orthopaedic Science. 2015;20(4):663-668 
 
55. Swinkels A, Allain TJ. Physical performance tests, self-reported outcomes, 
and accidental falls before and after total knee arthroplasty: an exploratory 
study. Physiotherapy Theory and Practice. 2013;29(6):432-442 
 
56. Swinkels A, Newman JH, et al. A prospective observational study of falling 
before and after knee replacement surgery. Age and Ageing. 2009;38(2):175-
181 
 
57. Patel A, Pavlou G, et al. The epidemiology of revision total knee and hip 
arthroplasty in England and Wales. The Bone and Joint Journal. 2015;97-
B:1076–1081 
 
58. Svedbom A, Hernlund E, et al. Osteoporosis in the European Union: A 
compendium of country-specific reports. Archives of Osteoporosis. 2013;8:136 
 
59. Tortora GJ, Derrickson B. Principles of anatomy and physiology. 13th 
edition. John Wiley and Sons. 2011 
 
60. Miller MD, Chhabra AB, et al. Orthopaedic surgical approaches. 2nd edition. 




61. Clarke B. Normal bone anatomy and physiology. Clinical Journal of the 
American Society of Nephrology. 2008;3(Suppl 3):S131-S139 
 
62. Sanders FWB. Denosumab discontinuation: rebound reabsorption, fragility 
fractures and possible prevention. Osteoporosis Review. 2017;25(1) 
 
63. Taichman RS: Blood and bone: Two tissues whose fates are intertwined to 
create the hematopoietic stem cell niche. Blood. 2005;105:2631-2639 
 
64. Betts JG, Young KA, et al. Anatomy and physiology. OpenStax. 2013. 
Chapter 6: Bone tissue and the skeletal system; p.221 
 
65. Walden M. Bone structure. 2020. Available at: 
http://www.teachpe.com/anatomy/bone_structure.php Accessed 4th July 2020 
 
66. Patton KT, Thibodeau GA. Anatomy and physiology. 9th edition. China: 
Elsevier. 2006: Chapter 11 Skeletal tissues; p.220 
 
67. Major Differences. Differences between compact and spongy bone. 2013. 
Available at: http://www.majordifferences.com/2017/02/difference-between-
compact-bone-and.html#.Wahm3tG1s2w  Accessed 4th July 2020 
 
68. Seladi-Schulman J. What is bone marrow, and what does it do?. 2018. 
Available at: https://www.healthline.com/health/function-of-bone-marrow 
Accessed 4th July 2020 
 
69. Morrison W. Bones: all you need to know. 2018. Available at: 
https://www.medicalnewstoday.com/articles/320444.php Accessed 4th July 2020 
 
70. Goswami T. Human musculoskeletal biomechanics. 2012: Chapter 4; 
Biomechanical characteristics of the bone; p.61 
 
71. Leali PT, Doria C, et al. Bone fragility: current reviews and clinical features. 




72. Egerer A, Abraham B, et al. Cement line quantity and porosity variation in 
human cadavaric tibiae and their relationship to bone strength. American 
Society of Biomechanics. Clemson University, South Carolina. 1997 
 
73. Davison KS, Siminoski K, et al. Bone strength: The whole is greater than the 
sum of its parts. Seminars in Arthritis and Rheumatism. 2006;36(1):22-31 
 
74. Ito M, Nishida A, et al. Contribution of trabecular and cortical components to 
the mechanical properties of bone and their regulating parameters. Bone. 
2002;31(3):351-8. 
 
75. Cesar R, Boffa RS, et al. Evaluation of trabecular microarchitecture of 
normal osteoporotic and osteopenic human vertebrae. Procedia Engineering. 
2013;59:6-15 
 
76. Ott SM. Cortical or trabecular bone: what’s the difference?. American 
Journal of Nephrology. 2018;47:373-375 
 
77. Challens A. Knee (non trauma) radiographic anatomy. 2011. Available at: 
http://www.wikiradiography.net/page/Knee+%28non+trauma%29+Radiographic
+Anatomy Accessed 10th July 2020 
 
78. New Health Advisor. Structure of the knee and how it works. 2020. Available 
at: http://www.newhealthadvisor.com/structure-of-the-knee.html Accessed 10th 
July 2020 
 
79. Challens A. Femur radiographic anatomy. 2011. Available at: 
 http://www.wikiradiography.net/page/Femur+Radiographic+Anatomy Accessed 
10th July 2020 
 
80. Gunn C. Bones and Joints; A guide for students. 5th edition: Churchill 
livingstone. Elsevier. 2007 
 
81. Morrison W. Overview of femoral neck fracture of the hip. Available at: 
444 
 




82. Johannesdottir F, Poole KE, et al. Distribution of cortical bone in the femoral 
neck and hip fracture: a prospective case-control analysis of 143 incident hip 
fractures; the AGES-REYKJAVIK Study. Bone. 2011;48(6):1268-1276 
 
83. Castillo RF, Gallegos RF. Study of different involutive changes in bone 
mineral density measured in ward's triangle and trabecular volume measured in 
iliac crest in relation to age. West Indian Medical Journal. 2015;64(2):108-112 
 
84. Yoshihashi AK, Drake AJ 3rd, et al. Ward's triangle bone mineral density 
determined by dual-energy x-ray absorptiometry is a sensitive indicator of 
osteoporosis. Endocrine Practice. 1998;4(2):69-72 
 
85. Hochberg MC. Ward's triangle in DEXA scans. 2002. Available at: 
 https://www.medscape.com/viewarticle/443945 Accessed 10th July 2020 
 
86. Moon RJ, Harvey NC. Should osteoporosis prevention start before birth?. 
Osteoporosis Review. 2015;23(2) 
 
87. Caetano-Lopes J, Canhão H, et al. Osteoblasts and bone formation. Acta 
Reumatólogica Portuguesa. 2007;32(2):103-110. 
 
88. Aarden EM, Nijweide PJ, et al. Function of osteocytes in bone. Journal of 
Cellular Biochemistry 1994;55(3):287-299 
 
89. Florencio-Silva R, Sasso GR, et al. Biology of bone tissue: structure, 
function, and factors that influence bone cells. BioMed Research International. 
2015;421746 
 
90. Boyce BF, Yao Z, et al. Osteoclasts have multiple roles in bone in addition 





91. Hadjidakis DJ, Androulakis II. Bone remodeling. Annals of the New York 
Academy of Sciences. 2006;1092:385-396 
 
92. Office of the Surgeon General (US). Bone health and osteoporosis: a report 
of the surgeon general. rockville (MD): office of the surgeon general (US); 2004. 
6, determinants of bone health. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK45503/ Accessed 10th July 2020 
 
93. Berger C, Goltzman D, et al. Peak bone mass from longitudinal data: 
implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. 
Journal of Bone and Mineral Research. 2010;25(9):1948-1957 
 
94. Bonjour JP, Theintz G, et al. Le pic de masse osseuse: réalités et 
incertitudes [Peak bone mass: facts and uncertainties]. Archives De Pediatrie. 
1995;2(5):460-468 
 
95. Berger C, Langsetmo L, et al. Change in bone mineral density as a function 
of age in women and men and association with the use of antiresorptive agents. 
Canadian Medical Association Journal. 2008;178(13):1660-1668 
 
96. Bonjour JP, Chevalley T, et al. The importance and relevance of peak bone 
mass in the prevalence of osteoporosis. Salud Publica de Mexico. 
2009;51(Suppl 1):S5-S17 
 
97. Recker RR, Deng HW. Role of genetics in osteoporosis. Endocrine. 2002 
Feb;17(1):55–66 
 
98. Osteoporosis: peak bone mass in women. National Institutes of Health 
Osteoporosis and Related Bone Diseases National Resource Cente. 2018;1-2. 
Available from:  
https://www.niams.nih.gov/health_info/bone/osteoporosis/bone_mass.asp 




99. Cummings SR, Black DM, et al. Study for osteoporotic fractures research 
group. Bone density at various sites for prediction of hip fractures. Lancet. 
1993;341(8837):72-75 
 
100. Araujo AB, Travison TG, et al. Race/ethnic differences in bone mineral 
density in men. Osteoporosis International. 2007;18(7):943-953 
 
101. Nam HS, Shin MH, Zmuda JM, et al. Race/ethnic differences in bone 
mineral densities in older men. Osteoporosis International. 2010;21(12):2115-
2123 
 
102. MacKelvie KJ, McKay HA, et al. A school-based exercise intervention 
augments bone mineral accrual in early pubertal girls. The Journal of Pediatrics. 
2001;139(4):501-508 
 
103. Reed SD, Scholes D, et al. Longitudinal changes in bone density in 
relation to oral contraceptive use. Contraception. 2003;68(3):177-182 
 
104. Tai V, Leung W, et al. Calcium intake and bone mineral density: systematic 
review and meta-analysis British Medical Journal. 2015;351:h4183  
 
105. Johnston CC Jr, Miller JZ, et al. Calcium supplementation and increases in 
bone mineral density in children. The New England Journal of Medicine. 
1992;327(2):82-87. 
 
106. Matkovic V, Kostial K, et al. Bone status and fracture rates in two regions 
of Yugoslavia. The American Journal of Clinical Nutrition. 1979;32:540-549. 
 
107. Sandler RB, Slemenda CW, et al. Postmenopausal bone density and milk 
consumption in childhood and adolescence. The American Journal of Clinical 
Nutrition. 1985;42:270-274 
 
108. Halioua L, Anderson JJ. Lifetime calcium intake and physical activity 
habits: independent and combined effects on the radial bone of healthy 
447 
 
premenopausal caucasian women. The American Journal of Clinical Nutrition. 
1989;49:534-541 
 
109. Webb AR, Kline L, et al. Influence of season and latitude on the cutaneous 
synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton 
will not promote vitamin D3 synthesis in human skin. The Journal of Clinical 
Endocrinology and Metabolism. 1988;67(2):373-378 
 
110. Kannus P, Haapasalo H, et al. Effect of starting age of physical activity on 
bone mass in the dominant arm of tennis and squash players. Annals of Internal 
Medicine. 1995;123(1):27-31. 
 
111. Muir JM, Ye C, et al. The effect of regular physical activity on bone mineral 
density in post-menopausal women aged 75 and over: a retrospective analysis 
from the Canadian multicentre osteoporosis study. BMC Musculoskeletal 
Disorders. 2013;14:253 
 
112. Alghadir AH, Gabr SA, et al. Physical activity and lifestyle effects on bone 
mineral density among young adults: sociodemographic and biochemical 
analysis. Journal of Physical Therapy Science. 2015;27(7):2261-2270 
 
113. Daniell HW: Osteoporosis of the slender smoker. Vertebral compression 
fractures and loss of metacarpal cortex in relation to postmenopausal cigarette 
smoking and lack of obesity. Archives of Internal Medicine. 1976;136:298-304. 
 
114. Jensen J, Christiansen C, et al. Cigarette smoking, serum estrogens, and 
bone loss during hormone-replacement therapy early after menopause. The 
New England Journal of Medicine. 1985;313:973-975 
 
115. Schapira D. Alcohol abuse and osteoporosis. Seminars in Arthritis and 
Rheumatology. 1990;19(6):371-376 
 
116. Sampson HW. Alcohol and other factors affecting osteoporosis risk in 




117. Felson DT, Zhang Y, et al. Alcohol intake and bone mineral density in 
elderly men and women: The Framingham Study. American Journal of 
Epidemiology. 1995;142(5):485-492 
 
118. Laitinen K, Lamberg-Allardt C, et al. Effects of 3 weeks’ moderate alcohol 
intake on bone and mineral metabolism in normal men. Bone and Mineral. 
1991;13(2):139-151 
 
119. Conlisk AJ, Galuska DA. Is caffeine associated with bone mineral density 
in young adult women? Preventive Medicine. 2000;31(5):562-568 
 
120. Heaney RP, Recker RR. Effects of nitrogen, phosphorus, and caffeine on 
calcium balance in women. Journal of Laboratory and Clinical Medicine. 
1982;99(1):46–55 
 
121. Osteoporosis. Medications that can cause bone loss, falls and/or fractures. 
Available from: https://osteoporosis.ca/about-the-disease/what-is-
osteoporosis/secondary-osteoporosis/medications-that-can-cause-bone-loss-
falls-andor-fractures/ Accessed 10th July 2020 
 
122. Donaldson LJ, Reckless IP, et al. The epidemiology of fractures in 
England. Journal Epidemiology and Community Health. 2008;62(2):174-180 
 
123. The state of musculoskeletal health 2019. Arthritis and other 
musculoskeletal conditions in numbers. 2019. Available from: 
https://www.versusarthritis.org/media/14594/state-of-musculoskeletal-health-
2019.pdf Accessed 10th July 2020 
 
124. Arthritis Research UK. Osteoarthritis in General Practice. 2013. Available 
from: https://www.versusarthritis.org/media/2115/osteoarthritis-in-general-
practice.pdf Accessed 10th July 2020 
 
125. Koskinen, Eskelinen A, et al. Comparison of survival and cost-
effectiveness between unicondylar arthroplasty and total knee arthroplasty in 
patients with primary osteoarthritis: a follow-up study of 50,493 knee 
449 
 
replacements from the Finnish Arthroplasty Register. Acta Orthopaedica 
2008;79(4):499-507 
 
126. Knutson K, Lewold S, et al. The Swedish knee arthroplasty register. A 
nation-wide study of 30,003 knees 1976–1992. Acta Orthopaedica 
Scandinavica 1994;65(4):375–386 
 
127. Hawker G, Wright J, et al. Health-related quality of life after knee 
replacement. The Journal of Bone and Joint Surgery America 1998;80(2):163-
173  
 
128. National Institute for Health and Care Excellence. Osteoarthritis: care and 
management in adults clinical guideline [CG177]. 2014. Available from: 
https://www.nice.org.uk/Guidance/CG177 Accessed 24th March 2017 
 
129. Foss MVL, Byers PD. Bone density, osteoarthritis of the hip, and fracture 
of the upper end of the femur. Annals Rheumatic Diseases 1972;31:259-264. 
 
130. Dequeker J, Aerssens J, et al. Osteoarthritis and osteoporosis: clinical and 
research evidence of inverse relationship. Aging Clinical and Experimental 
Research 2003;15(5):426-439  
 
131. Hart, Cronin C, et al. The relationship of bone density and fracture to 
incident and progressive radiographic osteoarthritis of the knee: the Chingford 
study. Arthritis and Rheumatology. 2002;46(1):92-99 
  
132. Nevitt MC, Lane NE, et al. Radiographic osteoarthritis of the hip and bone 
mineral density. The study of osteoporotic fractures research group. Arthritis 
and Rheumatology 1995;38(7):907-916  
 
133. Chaganti RK, Parimi N, et al. Bone mineral density and prevalent 
osteoarthritis of the hip in older men for the osteoporotic fractures in men 




134. Hochberg MC, Lethbridge-Cejku M, et al. Bone mineral density and 
osteoarthritis: Data from the baltimore longitudinal study of aging. Osteoarthritis 
and Cartilage 2004;12:45-48  
 
135. El Miedany YM, Mehanna AN, et al. Altered bone mineral metabolism in 
patients with osteoarthritis. Joint Bone Spine 2000;67(6):521-527  
 
136. Lethbridge-Cejku M, Tobin JD, et al. Axial and hip bone mineral density 
and radiographic changes of osteoarthritis of the knee: data from the Baltimore 
Longitudinal Study of Aging. The Journal of Rheumatology 1996;23(11):1943-
1947 
 
137. Arokoski JPA, Arokoski MH, et al. Estimation of femoral head bone density 
using magnetic resonance imaging: comparison between men with and without 
hip osteoarthritis. Journal of Clinical Densitometry 2004;7(2):183-191  
 
138. Varzi J, Gregory JS, et al. Relationships between self-reported 
osteoarthritis (OA), bone mineral density (BMD) and radiographic scores using 
dual energy X-ray absorptiometry (DXA). Scottish Medical Journal 
2015;60(3):25-33  
 
139. Vestergaard P, Rejnmark L, et al. Osteoarthritis and risk of fractures. 
Calcified Tissue International 2009;84(4):249–256  
 
140. Cumming RG, Klineberg RJ. Epidemiological study of the relation between 
arthritis of the hip and hip fractures. Annuals of Rheumatic Disease 
1993;52:707-710  
 
141. Arden NK, Griffiths GO, et al. The association between osteoarthritis and 
osteoporotic fracture: the Chingford Study. British Journal of Rheumatology 
1996;35:1299-1304 
 
142. Bergink AP, Van Der Klift, M, et al. Osteoarthritis of the knee is associated 
with vertebral and nonvertebral fractures in the elderly: the Rotterdam Study. 




143. Jones G, Nguyen T, et al. Osteoarthritis, bone density, postural stability, 
and osteoporotic fractures: a population based study. The Journal of 
Rheumatology 1995;22(5):921-925 
 
144. Chan MY, Center JR, et al. Bone mineral density and association of 
osteoarthritis with fracture risk. Osteoarthritis and Cartilage 2014;22(9):1251-
1258 
 
145. Arden NK, Crozier S, et al. Knee pain, knee osteoarthritis, and the risk of 
fracture. Arthritis and Rheumatology 2006;55(4):610-615 
 
146. Arden NK, Nevitt MC, et al. Osteoarthritis and risk of falls, rates of bone 
loss, and osteoporotic fractures. Arthritis and Rheumatology 1999;42(7):1378-
1385 
 
147. Jones G, Nquyen T, et al. A longitudinal study of the effect of spinal 
degenerative disease on bone density in the elderly. The Journal of 
Rheumatology 1995;22(5):932-936  
 
148. Vennu V, Bindawas SM. Relationship between falls, knee osteoarthritis, 
and health-related quality of life: data from the Osteoarthritis Initiative study. 
Journal of Clinical Interventions in Aging 2014;9:793-800 
 
149. Doré AL, Golightly YM, et al. Lower-extremity osteoarthritis and the risk of 
falls in a community-based longitudinal study of adults with and without 
osteoarthritis. Arthritis Care and Research 2015;67(5):633-639 
 
150. Lalmohamed A, Opdam F, et al. Knee arthroplasty and risk of hip fracture: 
a population-based, case–control study. Calcified Tissue International 
2012;90(2):144-150  
 
151. Prieto-Alhambra D, Javaid MK, et al. Changes in hip fracture rate before 
and after total knee replacement due to osteoarthritis: a population-based 




152. Lee S, Kim TN, et al. Knee osteoarthritis is associated with increased 
prevalence of vertebral fractures despite high systemic bone mineral density: a 
cross-sectional study in an Asian population. Modern Rheumatology 
2014;24(1):174-181 
 
153. Ding M, Odgaard A, et al. Changes in the three-dimensional microstructure 
of human tibial cancellous bone in early osteoarthritis. The Journal of Bone and 
Joint Surgery British Volume 2003;85(6):906-912 
 
154. Mansell JP, Bailey  AJ.  Abnormal cancellous bone collagen metabolism in 
osteoarthritis. Journal of Clinical Investigation 1998;101(8):1596-1603 
 
155. Legrand E, Chappard D, et al. Trabecular bone microarchitecture, bone 
mineral density, and vertebral fractures in male osteoporosis. Journal of Bone 
and Mineral Research 2000;15(1);13-19 
 
156. Birch C, Hunter D, et al. Development of a novel imaging process to 
determine the clinical applicability of bone mineral density assessment of the 
osteoarthritic knee: a research proposal. Working Papers in Health Sciences 
2014;1(9):1-7 
 
157. Chaganti RK, Parimi N, et al. Bone mineral density and prevalent 
osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men 
(MrOS) Study Group. Osteoporosis International 2010;21(8):1307-1316 
 
158. Liu G, Peacock M, et al. Effect of osteoarthritis in the lumbar spine and hip 
on bone mineral density and diagnosis of osteoporosis in elderly men and 
women. Osteoporosis International 1997;7(6):564-569 
 
159. Bousson V, Bergot C, et al. Trabecular bone score (TBS): available 





160. Hopkins SJ, Smith CW, et al. Relationship between spine bone mineral 
density and trabecular bone score in postmenopausal populations following 
total knee replacement or leg fracture. Osteoporosis International. 
2012;23:S582-582 
 
161. Demirağ MD, Özkan S, et al. Associations between obesity and the 
radiographic phenotype in knee osteoarthritis. Turkish Journal Medical Sciences 
2017;47(2):424-429 
 
162. Crowninshield RD, Rosenberg AG, et al. Changing demographics of 
patients with total joint replacement. Clinical Orthopaedics and Related 
Research. 2006;443:266-272 
 
163. Czerwiñski E, Kukielka RT, et al. Bone mineral density in proximal tibial 
epiphysis in knee osteoarthritis with varus deformity. Orthopaedic Proceedings. 
2018;84-B(Suppl 3) 
 
164. Hulet C, Sabatier JP, et al. Distribution of bone mineral density at the 
proximal tibia in knee osteoarthritis. Calcified Tissue International. 
2002;71(4):315-322 
 
165. Katsuragawa Y, Fukui N, et al. Change of bone mineral density with valgus 
knee bracing. International Orthopaedics. 1999;23(3):164-167 
 
166. Li MG, Nilsson KG. Changes in bone mineral density at the proximal tibia 
after total knee arthroplasty: a 2-year follow-up of 28 knees using dual energy 
X-ray absorptiometry. Journal of Orthopaedic Research. 2000;18(1):40-47 
 
167. Vyas UK. Risk of Development of Osteoporosis due to Depression in the 
Elderly Individuals: Review Article. British Journal of Medical Practitioners. 
2013;6(2):612 
 
168. Michelson D, Stratakis C, et al. Bone mineral density in women with 




169. Yang S, Shen X. Association and relative importance of multiple obesity 
measures with bone mineral density: the national health and nutrition 
examination survey 2005–2006. Archives of Osteoporosis 2015;10:14 
 
170. Papakitsou EF, Margioris AN, et al. Body mass index (BMI) and 
parameters of bone formation and resorption in postmenopausal women. 
Maturitas. 2004;47(3):185-193 
 
171. Manninen P, Riihimäki, H, et al. Overweigh gender and knee osteoarthritis. 
International Journal of Obesity. 1996;20(6):595-597  
 
172. Walsh JS, Vilaca T. Obesity, type 2 diabetes and bone in adults. Calcified 
Tissue International 2017;100(5):528-535 
 
173. Saito M, Kida Y, et al. Diabetes, collagen and bone quality. Current 
Osteoporosis Reports 2114;12(2):181-188 
 
174. Patsch JM, Burghardt AJ, et al. Increased cortical porosity in type 2 
diabetic postmenopausal women with fragility fractures. Journal of Bone and 
Mineral Research. 2013;28(2):313-324 
 
175. McNerny EMB, Nikolas TL. Bone quality in chronic kidney disease: 
definitions and diagnostics. Current Osteoporosis Reports 2017;15(3):207-213 
 
176. Glynn A, Austin MS. Revision total knee arthroplasty in patients with 
massive bone loss. Available from: 
www.boneandjoint.org.uk/content/focus/revision-total-knee-arthroplasty-
patients-massive-bone-loss Accessed June 20th 2018 
 
177. Engh GA. Knee arthroplasty handbook: techniques in total knee and 
revision arthroplasty. 2006: Chapter 9 classification of bone defects femur and 
tibia; p.116-132.  
 
178. Jensen CL, Petersen MM, et al. Bone mineral density changes of the 
proximal tibia after revision total knee arthroplasty. A randomised study with the 
455 
 
use of porous tantalum metaphyseal cones. International Orthopaedics. 
2012;36(9):1857-1863 
 
179. Jensen CL, Petersen MM, et al. Changes in bone mineral density of the 
distal femur after revision total knee arthroplasty with metaphyseal press-fit 
stem. Journal of Orthopaedics and Traumatology. 2010;11(3):143-148 
 
180. Lei PF, Hu RY, et al. Bone defects in revision total knee arthroplasty and 
management. Orthopaedic Surgery. 2019;11(1):15-24  
 
181. Drake MT, Clarke BL, et al. Cathepsin K inhibitors for osteoporosis: 
biology, potential clinical utility, and lessons learned. Endocrine Reviews. 
2017;38(4):325–350 
  
182. Carulli C, Civinini R, et al. The use of anti-osteoporosis drugs in total knee 
arthroplasty. Aging Clinical and Experimental Research 2011;23(2):38-39 
 
183. Prieto-Alhambra D, Javaid MK, et al. Bisphosphonate use and risk of post-
operative fracture among patients undergoing a total knee replacement for knee 
osteoarthritis: a propensity score analysis. Osteoporosis International 
2011;22(5):1555-1571 
 
184. Teng S, Yi C, et al. Bisphosphonate use and risk of implant revision after 
total hip/knee arthroplasty: a meta-analysis of observational studies. Public 
Library of Science 2015;10(10) 
 
185. Saita Y, Ishijima M, et al. Atypical femoral fractures and bisphosphonate 
use: current evidence and clinical implications. Therapeutic Advances in 
Chronic Disease. 2015;6(4):185-193  
 
186. Bjarnason NH, Hassager C, et al. Postmenopausal bone remodelling and 





187. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and 
prevention of nonvertebral fractures: a meta-analysis of randomized trials. The 
Journal of the American Medical Association 2001;285(22):2891-2897 
 
188. Lufkin EG, Wahner HW, et al. Treatment of postmenopausal osteoporosis 
with transdermal estrogen. Annals of Internal Medicine. 1992;117(1):1-9 
 
189. Legroux-Gerot I, Vignau J, et al. Factors influencing changes in bone 
mineral density in patients with anorexia nervosa-related osteoporosis: the 
effect of hormone replacement therapy. Calcified Tissue International. 
2008;83(5):315-323 
 
190. Beral V. Million women study collaborators. Breast cancer and hormone-
replacement therapy in the million women study. Lancet 2003;362(9382):419-
427 
 
191. Jordan N, Barry M, et al. Comparative effects of antiresorptive agents on 
bone mineral density and bone turnover in postmenopausal women. Clinical 
Interventions in Aging 2006;1(4):377-387 
 
192. Ettinger B, Black DM, et al. Reduction of vertebral fracture risk in 
postmenopausal women with osteoporosis treated with raloxifene: results from 
a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation 
(MORE) investigators. The Journal of the American Medical Association 
1999;282(7):637-645 
 
193. Romero A, Alonso C, et al. Risk of venous thromboembolic disease in 
women A qualitative systematic review. European Journal Obstetrics 
Gynecology and Reproductive Biology 2005;121(1):8-17 
 
194. Cosman F, Baz-Hecht M, et al. Short-term effects of estrogen, tamoxifen 
and raloxifene on hemostasis: a randomized-controlled study and review of the 




195. Brömme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and 
potential off-target effects. Expert Opinion on Investigational Drugs. 
2009;18(5):585-600 
 
196. Duong le T, Leung AT, et al. Cathepsin K Inhibition: A new mechanism for 
the treatment of osteoporosis. Calcified Tissue International. 2016;98(4):381-
397. 
 
197. Royal Osteoporosis Society: Drug treatments for osteoporosis: 
Denosumab (Prolia). Available from: 
https://strwebstgmedia.blob.core.windows.net/media/sxif4dxc/denosumab-
prolia-fact-sheet-octobe-2017.pdf Accessed June 20th 2020 
 
198. Miller PD. Denosumab: anti-RANKL antibody. Current Osteoporosis 
Report. 2009;7(1):18-22 
 
199. National Osteoporosis Society. Drug treatments for osteoporosis. 2016. 
https://nos.org.uk/media/1594/drug-treatments-for-osteoporosis-parathyroid-
hormone-treatment-january-2016.pdf. Accessed 23 March 2017 
 
200. Almeida MM, Nani EP, et al. Strontium ranelate increases osteoblast 
activity. Tissue Cell. 2016;48(3):183-188 
 
201. Abrahamsen B, Grove EL, et al. Nationwide registry-based analysis of 
cardiovascular risk factors and adverse outcomes in patients treated with 
strontium ranelate. Osteoporosis International. 2014;25(2):757-762 
 
202. Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. 
Maturitas. 2014;78(3):199-204 
 
203. Recker RR, Benson CT, et al. A randomized, double-blind phase 2 clinical 
trial of blosozumab, a sclerostin antibody, in postmenopausal women with low 





204. MacNabb C, Patton D, et al. Sclerostin Antibody Therapy for the Treatment 
of Osteoporosis: Clinical Prospects and Challenges. Journal of osteoporosis. 
2016;2016:6217286  
 
205. Salai M, Dudkiewicz I, et al. Bone allograft in revision total knee 
replacement. Cell and Tissue Banking. 2000;291–294 
 
206. Engh GA, Ammeen DJ. Use of structural allograft in revision total knee 
arthroplasty in knees with severe tibial bone loss. The Journal of Bone and Joint 
Surgery American Volume. 2007;89(12):2640-2647 
 
207. Kuchinad RA, Garbedian S et al. The use of structural allograft in primary 
and revision knee arthroplasty with bone loss. Advances in Orthopaedics. 2011. 
 
208. Lotke PA, Carolan GF, et al. Impaction grafting for bone defects in revision 
total knee arthroplasty. Clinical Orthopaedics and Related Research. 
2006;446:99-103 
 
209. Mankin HJ, Hornicek FJ, et al. Infection in massive bone allografts. Clinical 
Orthopaedics and Related Research. 2005;(432):210-216 
 
210. Jiang C, Qian W. Results of sleeves in revision total knee arthroplasty: an 
editorial comment on recently published in the Journal of Arthroplasty. Annals of 
Translational Medicine. 2015;3(20):317 
 
211. Long WJ, Scuderi GR. Porous tantalum cones for large metaphyseal tibial 
defects in revision total knee arthroplasty: a minimum 2-year follow-up. J 
Arthroplasty. 2009;24:1086-92. 
 
212. Watters TS, Martin JR, et al. Porous-coated metaphyseal sleeves for 
severe femoral and tibial bone loss in revision TKA. The Journal of Arthroplasty. 
2017; 32(11):3468-3473 
 
213. Dalury DF, Barrett WP. The use of metaphyseal sleeves in revision total 




214. Agarwal S, Azam A, et al. Metal metaphyseal sleeves in revision total knee 
replacement. The Bone and Joint Journal. 2013;95-B(12) 
 
215. Villanueva-Martínez M, De la Torre-Escudero B, et al. Tantalum cones in 
revision total knee arthroplasty. A promising short-term result with 29 cones in 
21 patients. The Journal of Arthroplasty. 2013;28(6):988-993 
  
216. Howard JL, Kudera LE, et al. Early results of the use of tantalum femoral 
cones for revision total knee arthroplasty. Journal of Bone and Joint Surgery. 
2011;93:478-484 
 
217. Ponzio DY, Austin MS. Metaphyseal bone loss in revision knee 
arthroplasty. Current Reviews in Musculoskeletal Medicine. 2015;8(4):361-367 
 
218. Lachiewicz B, Handerson RA, et al. Can tantalum cones provide fixation in 
complex revision knee arthroplasty? Clinical Orthopaedics and Related 
Research. 2012;470(1):199-204 
 
219. Long WJ, Scuderi GR. Porous tantalum cones for large metaphyseal tibial 
defects in revision total knee arthroplasty: a minimum 2-year follow-up. The 
Journal of Arthroplasty. 2009;24(7):1086-1092 
 
220. Derome P, Sternheim A, et al. Treatment of large bone defects with 
trabecular metal cones in revision total knee arthroplasty: short term clinical and 
radiographic outcomes. The Journal of Arthroplasty. 2014;29(1):122-126  
 
221. Kamath AF, Lewallen DG, et al. Porous tantalum metaphyseal cones for 
severe tibial bone loss in revision knee arthroplasty: a five to nine-year follow-
up. Journal of Bone and Joint Surgery American Volume. 2015;97(3):216-223 
 
222. Rao BM, Kamal TT, et al. Tantalum cones for major osteolysis in revision 




223. Shen C, Lichstein PM, et al. Revision knee arthroplasty for bone loss: 
choosing the right degree of constraint. The Journal of Arthroplasty. 
2014;29(1):127-131 
 
224. Harrison AK, Gioe TJ, et al. Do porous tantalum implants help preserve 
bone?: evaluation of tibial bone density surrounding tantalum tibial implants in 
TKA. Clinical Orthopaedics and Related Research. 2010;468(10):2739-2745 
 
225. Wang Q, Qiao Y, et al. Tantalum implanted entangled porous titanium 
promotes surface osseointegration and bone ingrowth. Scientific Reports. 
2016;6:26248 
 
226. Winther N, Jensen C, et al. Changes in bone mineral density of the 
proximal tibia after uncemented total knee arthroplasty. A prospective 
randomized study. International Orthopaedics. 2016;40(2):285-294 
 
227. Minoda Y, Kobayashi A, et al. Porous tantalum tibial component prevents 
periprosthetic loss of bone mineral density after total knee arthroplasty for five 
years-a matched cohort study. The Journal of Arthroplasty. 2013;28(10):1760-
1764 
 
228. Jensen Cl, Petersen MM et al. Bone mineral density changes of the 
proximal tibia after revision total knee arthroplasty. A randomised study with the 
use of porous tantalum metaphyseal cones. International Orthopaedics 
2012;36(9):1857-1863 
 
229. Faizan A, Bhowmik-Stoker M, et al. Development and verification of novel 
porous titanium metaphyseal cones for revision total knee arthroplasty. The 
Journal of Arthroplasty. 2017;32(6):1946-1953 
 
230. Cook SD, Thomas KA, et al. Hydroxyapatite-coated for orthopaedic 





231. Bøe BG, Støen RØ, et al. Coating of titanium with hydroxyapatite leads to 
decreased bone formation. Bone and Joint Research. 2012;1(6):125-130 
 
232. Beckmann NA, Mueller S, et al. Treatment of severe bone defects during 
revision total knee arthroplasty with structural allografts and porous metal 
cones-a systematic review. The Journal of Arthroplasty. 2015;30(2):249-253 
 
233. Freiberg Orthopaedics and Sports Medicine. Total knee replacement. 
Available from: http://www.freibergortho.com/knee-replacement.html 
Accessed June 20th 2020 
 
234. National Health Service. Overview knee replacement. Available from: 
http://www.nhs.uk/conditions/Knee-
replacement/Pages/Kneereplacementexplained.aspx Accessed June 20th 2020 
 
235. Greengard S. Step-by-step explanation of knee replacement surgery. 
2017. Available from: 
http://www.healthline.com/health-slideshow/total-knee-replacement-surgery-
step-by-step#9 Accessed June 20th 2020 
 
236. Arthritis Research UK. Knee replacement. Available from: 
https://www.arthritisresearchuk.org/arthritis-information/surgery/knee-
replacement/different-types/total-knee-replacement.aspx Accessed June 17th 
2018 
 
237. Ranawat S. Revision total knee replacement: frequently asked questions 
(FAQs).2010. Available from: 
https://www.hss.edu/conditions_revision-total-knee-replacement-faqs.asp 
Accessed June 20th 2020 
 
238. Kasahara Y, Majima T, et al. What are the causes of revision total knee 





239. Motififard M, Pesteh M, et al. Causes and rates of revision total knee 
arthroplasty: Local results from Isfahan, Iran. Advanced Biomedical Research. 
2015;4:111  
 
240. Patel AR, Barlow B, et al. Stem length in revision total knee arthroplasty. 
Current Reviews in Musculoskeletal Medicine. 2015;8(4):407-412 
 
241. Benazzo F, Rossie P, et al. Total knee replacement in acute and chronic 
traumatic events. Injury 2014;45(S6):S98-S104 
 
242. Lee SC, Nam CH, et al. Treatment of bone defect with modular metal 
augmentation using a downsized block in total knee arthroplasty: technical note 
and report of 17 cases. Open Journal of Orthopaedics. 2016;9(6) 
 
243. Conlisk N, Gray H, et al. The influence of stem length and fixation on initial 
femoral component stability in revision total knee replacement. Bone and Joint 
Research. 2012;1(11):281-288 
 
244. Patil N, Lee K, et al. Porous tantalum in hip and knee reconstructive 
surgery. Journal of Biomedical Materials Research Part B Applied Biomaterials. 
2009;89(1):242-251  
 
245. Stryker. Triathlon revision knee system surgical protocol. Available from: 
https://www.strykermeded.com/media/2195/triathlon-ts-including-cone-
augments-technique.pdf Accessed June 20th 2020 
 
246. Morrison W. What is knee replacement revision surgery? 2017. Available 
from: 
https://www.healthline.com/health/total-knee-replacement-surgery/revision#6 
Accessed June 20th 2020 
 
247.Gardner S. A guide to revision total knee replacement.  Patient information 
leaflet. 2012. Available from: https://www.wuth.nhs.uk/media/7234/guide-to-
revision-knee-replacement.pdf 




248. Theodorou DJ, Theodorou SJ, et al. Dual-energy X-ray absorptiometry in 
diagnosis of osteoporosis: Basic principles, indications, and scan interpretation. 
Comprehensive Therapy. 2002;28:190-200 
 
249. Blake GM, Fogelman I. The role of DXA bone density scans in the 
diagnosis and treatment of osteoporosis. Postgraduate Medical Journal. 
2007;83(982):509-517  
 
250. Bluemke DA, Liu S. Principles and practice of clinical research. 3rd edition. 
2012. p.597-617 
 
251. Densitometry techniques. In: bone densitometry for Technologists. 2006. 
Humana press. 
 
252. Wang Z, Heymsfield SB, et al. Estimation of percentage body fat by dual-
energy x-ray absorptiometry: evaluation by in vivo human elemental 
composition. Physics in Medicine and Biology. 2010;55(9):2619-2635 
 
253. Berger A. Bone mineral density scans. British Medical Journal. 
2002;325(7362):484 
 
254. Blake G M, Fogelman I. Clinical use of instruments that measure 
peripheral bone mass. Current Opinion in Endocrinology and Diabetes 
2002;9:502–511 
 
255. Trevisan C, Bigoni M, et al. Bone assessment after total knee arthroplasty 
by dual-energy X-ray absorptiometry: analysis protocol and reproducibility. 
Calcified Tissue International. 1998;62(4):359-361 
 
256. National Osteoporosis Foundation. Bone density exam/testing. Available 
from:https://www.nof.org/patients/diagnosis-information/bone-density-




257. Lekamwasam S, Lenora RS. Effect of leg rotation on hip bone mineral 
density measurements. Journal of Clinical Densitometry. 2003;6(4):331-336 
 
258. Shepherd JA, Lu Y. A generalized least significant change for individuals 
measured on different DXA systems. Journal of Clinical Densitometry. 
2007;10(3):249-258 
 
259. Baim S, Wilson CR, et al.  Precision assessment and radiation safety for 
dual energy x-ray absorptiometry (DXA). White Paper of the International 
Society for Clinical Densitometry Journal of Clinical Densitometry. 
2005;8(4):371-378 
 
260. Soininvaara T, Kröger H, et al. Measurement of bone density around total 
knee arthroplasty using fan-beam dual energy X-ray absorptiometry. Calcified 
Tissue International. 2000;67(3):267-272 
 
261. Therbo M, Petersen MM, et al. The precision and influence of rotation for 
measurements of bone mineral density of the distal femur following total knee 
arthroplasty: a methodological study using DEXA. Acta Orthopaedica 
Scandinavica. 2003;74(6):677-682 
 
262. Yoon JW, Choe BY, et al. Application of a mobile c-arm fluoroscopy 
system to bone densitometry by utilizing a dual energy x-ray spectrum. Journal 
of the Korean Physical Society. 2005;47(3):529-32. 
 
263. Hopkins SJ, Welshman JR, et al. Short-term precision error in dual energy 
x-ray absorptiometry, bone mineral density and trabecular bone score 
measurements; and effects of obesity on precision error. Journal of Biomedical 
Graphics and Computing, 2014;4(2):8-14 
 
264. Knapp KM, Welsman JR, et al. Obesity increases precision errors in dual-





265. Liu XS, Cohen A, et al. Bone density, geometry, microstructure, and 
stiffness: Relationships between peripheral and central skeletal sites assessed 
by DXA, HR-pQCT, and cQCT in premenopausal women. Journal of Bone 
Mineral Research. 2010;25(10):2229-2238 
 
266. Agarwal S, Das SK, et al. X-ray knee as a screening tool for osteoporosis. 
Journal of Clinical Densitometry. 2012;15(3):362-365 
 
267. Xu W, Robinson K. X-ray image review of the bone remodeling around an 
osseointegrated trans-femoral implant and a finite element simulation case 
study. Annals of Biomedical Engineering. 2008;36(3):435-443 
 
268.Serman N. Production of x-rays and interactions of x-rays with Matter. 
Available from:  
http://www.columbia.edu/itc/hs/dental/sophs/material/production_xrays.pdf 
Accessed September 20th 2019 
 
269. Kinds MB, Bartels LW, et al. Feasibility of bone density evaluation using 
plain digital radiography. Osteoarthritis Cartilage. 2011;19(11):1343-1348  
 
270. Andresen R, Haidekker MA, et al. CT determination of bone mineral 
density and structural investigations on the axial skeleton for estimating the 
osteoporosis-related fracture risk by means of a risk score. The British Journal 
of Radiology. 1999;72(858):569-578 
 
271. Jones A, Arns C, et al. Assessment of bone ingrowth into porous 
biomaterials using MICRO-CT. Biomaterials. 2007;28(15):2491-2504 
 
272. Shah FA, Snis A, et al. The use of x-ray micro-computed tomography for 
evaluation of bone growth in 3D printed metal implants - Correlation with 
histology. Frontiers in Bioengineering and Biotechnology. 2016 
 
273. Poggie R, Lefebvre LP, et al. Efficacy of a new porous titanium 
compression screw using an ovine osseointegration model. Frontiers in 




274. Wang Q, Qiao Y, et al. Tantalum implanted entangled porous titanium 
promotes surface osseointegration and bone ingrowth. Scientific Reports. 
2016;6:26248 
 
275. Takao K, Takahiro O, et al. Evaluation of the quantification of bone 
ingrowth and the influence of stress shieldings in cementless total knee 
arthroplasty: a prospective case-control study. Journal of Bone and Joint 
Surgery-british Volume. 2016;16(1) 
 
276. National Institute of Biomedical Imaging and Bioengineering. Computed 
Tomography (CT). Available from:https://www.nibib.nih.gov/science-
education/science-topics/computed-tomography-ct Accessed September 20th 
2019 
 
277. Palmquist A, Shah FA, et al. A technique for evaluating bone ingrowth into 
3D printed, porous Ti6Al4V implants accurately using X-ray micro-computed 
tomography and histomorphometry. Micron. 2017;94:1-8 
 
278. Kuchenbecker S, Faby S, et al. Dual energy CT: how well can pseudo-
monochromatic imaging reduce metal artifacts?. Medical Physics. 
2015;42(2):1023-1036 
 
279. Williams AL, Gornet MF, et al. CT evaluation of lumbar interbody fusion: 
current concepts. American Journal of Neuroradiology Sep 2005;26(8):2057-
2066 
 
280. Ginat D, Per-Lennart A, et al. Atlas of postsurgical neuroradiology: imaging 
of the brain, spine, head, and neck. Springer. 2012: Chapter 4 imaging the 
postoperative scalp and cranium; p. 144  
 
281. Blaty T, Krueger D, et al. DXA evaluation of femoral bone mineral density 





282. Rayan F, Konan S, et al. A review of periprosthetic fractures around total 
knee arthroplasties. Orthopaedics and Trauma. 2008;22(1):52-61 
 
283. Inglis AE, Walker PS. Revision of failed knee replacements using fixed-
axis hinges. Journal of Bone Joint Surgery. 1991;73-B:757–61 
 
284. Lizaur-Utrilla A, Miralles-Munoz FA, et al. Functional outcome of total knee 
arthroplasty after periprosthetic distal femoral fracture. The Journal of 
Arthroplasty. 2013; 28:1585-1588 
 
285. Reeves RA, Schairer WW, et al. Costs and risk factors for hospital 
readmission after periprosthetic knee fractures in the United States. The Journal 
of Arthroplasty 2018;33(324-330):e321 
 
286. Christ RM, Hagena FW. Bone mineral density after total knee arthroplasty 
in RA vs OA - the effect of preventive etidronate administration. Journal of Bone 
and Joint Surgery British. 2001;83-B:160 
 
287. Hagena, FW, Christ RM. Bone mineral density after total knee arthroplasty 
in RA vs OA - the effect of preventive etidronate administration. Journal of Bone 
and Joint Surgery British. 2001;286 
 
288. Wang CJ, Wang JW, et al. The effect of alendronate on bone mineral 
density in the distal part of the femur and proximal part of the tibia after total 
knee arthroplasty. Journal of Bone and Joint Surgery - American Volume 
2003;85(11):2121-2126 
 
289. Lin T, Yan SG, et al. Biophosphonates for periprosthetic bone loss after 
joint arthroplasty: a meta-analysis of 14 randomized controlled trials. 
Osteoporosis International. 2012;23(6):1823-1834 
 
290. Bhandari M, Bajammal S, et al. Effect of bisphosphonates on 
periprosthetic bone mineral density after total joint arthroplasty – A meta-





291. Windisch C, Windisch B, et al. Osteodensitometry measurements of 
periprosthetic bone using dual energy X-ray absorptiometry following total knee 
arthroplasty. Archives of Orthopaedic and Trauma Surgery. 2012;132(11):1595-
1601 
 
292. Jaroma A, Soininvaara TA, et al. Effect of one-year post-operative 
alendronate treatment on periprosthetic bone after total knee arthroplasty: A 
seven-year randomised controlled trial of 26 patients. Bone and Joint Journal. 
2015;97-B(3):337-345  
 
293. Saari T, Uvehammer J, et al. Posterior stabilized component increased 
femoral bone loss after total knee replacement. 5-year follow-up of 47 knees 
using dual energy X-ray absorptiometry. Knee. 2006;13(6):435-439 
 
294. Minoda Y, Kobayashi A, et al. Comparison of bone mineral density 
between porous tantalum and cemented tibial total knee arthroplasty 
components. Journal of Bone & Joint Surgery - American Volume. 
2010;92(3):700-706 
 
295. Abu-Rajab RB, Watson WS, et al. Peri-prosthetic bone mineral density 
after total knee arthroplasty - Cemented versus cementless fixation. Journal of 
Bone and Joint Surgery-British Volume. 2006;88B(5):606-61 
 
296. Albanese, C, Preite R, et al. Dual energy x-ray absorptiometry 
measurements of bone mineral density of the proximal tibia following total knee 
arthroplasty. Radiology. 1997;205:425-425 
 
297. Angers M, Belzile EL, et al. Randomised clinical evaluation of bone mineral 
density variation using cemented titanium versus non-cemented trabecular 
metal tibial base plates in primary total knee arthroplasty: 32. Journal of Bone & 




298. Giorgini M, Matassi F, et al. Analysis of bone remodeling in the revision of 
periprosthetic knee prosthesis with stems by diaphyseal densitometric 
evaluation. Journal of Orthopaedics and Traumatology. 2014;15:S88-S89 
 
299. Lautridou C, Hulet C, et al. DEXA study on mineralization redistribution 
under the tibial base plate in total knee arthroplasty: 38 knees with minimum 
five years follow-up. Journal of Bone and Joint Surgery British. 2005:144 
 
300. Saari T, Uvehammer J, et al. Joint area constraint had no influence on 
bone loss in proximal tibia 5 years total knee replacement. Journal of 
Orthopaedic Research 2007;25(6):798-803 
 
301. Soininvaara TA, Jurvelin JS, et al. Effect of alendronate on periprosthetic 
bone loss after total knee arthroplasty: A one-year, randomized, controlled trial 
of 19 patients. Calcified Tissue International. 2002;71(6):472-477 
 
302. Soininvaara TA, Miettinen HJA, et al. Periprosthetic femoral bone loss after 
total knee arthroplasty: 1-Year follow-up study of 69 patients. Knee. 
2004;11(4):297-302 
 
303. Soininvaara TA, Nikola T, et al. Bone mineral density and single photon 
emission computed tomography changes after total knee arthroplasty: A 2-year 
follow-up study. Clinical Physiology and Functional Imaging. 2008;28(2):101-
106 
 
304. Therbo M, Petersen MM, et al. Bone mineral density of the distal femur 
following uncemented total knee arthroplasty: A two-year follow-up of 11 knees 
using dual energy X-ray absorptiometry. Journal of Orthopaedics and 
Traumatology. 2004;5(2):81-85 
 
305. Tjørnild M, Søballe K, et al. Mobile-vs fixed-bearing total knee 
replacement: A randomized radiostereometric and bone mineral density study. 




306. Wang CJ, Wang JW, et al. Three-year changes in bone mineral density 
around the knee after a six-month course of oral alendronate following total 
knee arthroplasty: a prospective, randomized study. Journal of Bone & Joint 
Surgery - American Volume. 2006;88(2):267-272 
 
307. Bainbridge KE, Sowers MF, et al. Natural history of bone loss over 6 years 
among premenopausal and early postmenopausal women. American Journal of 
Epidemiology. 2002;156(5):410-417 
 
308. Stryker. Triathlon TS cones. Available at: 
https://strykermeded.com/medical-devices/hips-knees/knees/triathlon-ts-
cones/# Accessed 23rd March 2017 
 
309. Stanford CM, Keller JC. The concept of osseointegration and bone matrix 
expression. Critical Reviews in Oral Biology and Medicine 1991;2(1):83-101 
 
310. Apostu D, Lucaciu O, et al. Systemic drugs that influence titanium implant 
osseointegration. Drug Metabolism Reviews. 2017;49(1):92-104 
 
311. Barnett SL, Mayer RR, et al. Use of stepped porous titanium metaphyseal 
sleeves for tibial defects in revision total knee arthroplasty: short term results. 
Journal of Arthroplasty. 2014;29(6):1219-1224 
 
312. Le Guéhennec L, Soueidan A, et al. Surface treatments of titanium dental 
implants for rapid osseointegration. Dental Materials. 2007;23(7):844-854 
 
313. Millet PJ, Cohen B, et al. Bone mineral density changes during fracture 
healing: a densitometric study in rats. Bone Mineral Density Changes in 
Fracture Callus.2016:1-5 
 
314. Grizon F, Aguado E, et al. Enhanced bone integration of implants with 





315. Paganias CG, Tsakotos GA, et al. Osseous integration in porous tantalum 
implants. Indian Journal of Orthopaedics. 2012;46(5):505-513 
 
316. Meredith WJ, Massey JB. Fundamental Physics of Radiology. 3rd edition. 
John Wright and Sons. 1977 
 
317. Acton A. Issues in general physics research. 2012. Chapter 6 Physics 
Research. Asan Medical Centre, Seoul: Assessment of the effect of bone 
density and soft tissue thickness on phantom measurements 
 
318. Avioli LV, Krane SM. Metabolic bone disease and clinically related 
diseases. 3rd edition. 1998. Chapter 9 Noninvasive assessment bone p.282 
 
319. Bonnnick SL. Bone densitometry in clinical practice. Application and 
interpretation. 2nd edition. 2004. Springer. Chapter 4 quality control p.95 
 
320. Davies PSW, Cole TJ. Body composition techniques in health and disease. 
Cambridge University Press. 1995. Chapter 1 Application of dual-energy x-ray 
absorptiometry and related techniques to the assessment of bone and body 
composition p.1 
 
321. Mizner RL, Petterson SC, et al. Measuring functional improvement after 
total knee arthroplasty requires both performance-based and patient-report 
assessments: a longitudinal analysis of outcomes. The Journal of Arthroplasty. 
2011;26(5):728-737 
 
322. Loures FB, Góes RFA, et al. Anthropometric study of the knee and its 
correlation with the size of three implants available for arthroplasty. Revista 
Brasileira de Ortopedia. 2016;51(3):282-289 
 
323. Osterhoff G, Löffler S, et al. Comparative anatomical measurements of 
osseous structures in the ovine and human knee. Knee. 2011;18(2):98-103 
 
324. Sloan C, Holmes K, et al. Clark's pocket handbook for radiographers. 




325. Tanck E, Deenen JCW, et al. An anatomically shaped lower body model 
for CT scanning of cadaver femurs. Physics in Medicine and Biology. 
2010;55(2):N57-62  
 
326. Robertson DD, Mintzer CM, et al.  Distal loss of femoral bone following 
total knee arthroplasty. Measurement with visual and computer-processing of 
roentgenograms and dual-energy x-ray absorptiometry. The Journal of Bone 
and Joint Surgery American Volume. 1994;76(1):66-76 
 
327. Gorton S. Knee (AP view). Available at: 
https://radiopaedia.org/articles/knee-ap-view-1  Accessed 15th July 2020 
 
328. Debbierpa. Exposure-Knee. 2013. Available at: 
http://www.wikiradiography.net/page/Exposure+-+Knee Accessed 15th July 
2020 
 
329. Bellemans J. Osseointegration in porous coated knee arthroplasty. The 
influence of component coating type in sheep. Acta Orthopaedica Scandinavica 
Supplmentum. 1999;288:1–35 
 
330. Willie BM, Bloebaum RD, et al. Determining relevance of a weight-bearing 
ovine model for bone ingrowth assessment. Journal Biomedical Material 
Research. Part A. 2004;69(3):567-576 
 
331. Martini L, Fini M, et al. Sheep model in orthopaedic research: a literature 
review. Comparative Medicine. 2001;51(4):292-299 
 
332. Egermann M, Goldhahn J, et al. Animal models for fracture treatment in 
osteoporosis. Osteoporosis International. 2005;16(Suppl 2):S129–38 
 
333. Lu Y, Markel MD, et al. Comparison of single- versus double-tunnel 
tendon-to-bone healing in an ovine model: a biomechanical and histological 




334. Russlies M, Behrens P, et al. Periosteum stimulates subchondral bone 
densification in autologous chondrocyte transplantation in a sheep model. Cell 
and Tissue Research. 2005;319(1):133–42 
 
335. Schell H, Epari DR, et al. The course of bone healing is influenced by the 
initial shear fixation stability. Journal of Orthopaedic Research. 
2005;23(5):1022-1028 
 
336. Madry H, Ochi M, et al. Large animal models in experimental knee sports 
surgery: focus on clinical translation. Journal of Experimental Orthopaedics. 
2015;2(1):9 
 
337. Adams BJ, Crabtree PJ. Comparative skeletal anatomy a photographic 
atlas for medical examiners, coroners, forensic anthropologists, and 
archeologists.  Totowa, N.J: Humana Press. 2008: Cow vs Human; p.37 
 
338. Da Silva EMB, Albano MD, et al. Knee ligament injuries: biomechanics 
comparative study of two suture technique in tendon – analysis “in vitro” tendon 
of bovine. Revista Brasileira de Ortopedia. 2013;48(1):80-86 
 
339. Kazimoğlu C, Akdoğan Y, et al. Which is the best fixation method for 
lateral cortex disruption in the medial open wedge high tibial osteotomy? A 
biomechanical study. Knee. 2008;15(4):305-308 
 
340. McCoy AM. Animal models of osteoarthritis: comparisons and key 
considerations. Veterinary Pathology. 2015;52(5):803-818 
 
341. Hargrave-Thomas EJ, Thambyah A, et al. The bovine patella as a model of 
early osteoarthritis. Journal of Anatomy. 2013;223(6):651–664. 
 
342. Ding L, Guo D, et al. A single blunt impact on cartilage promotes 
fibronectin fragmentation and upregulates cartilage degrading stromelysin-





343. Homandberg GA, Ummadi V, et al. High molecular weight hyaluronan 
promotes repair of IL-1β-damaged cartilage explants from both young and old 
bovines. OsteoArthritis and Cartilage. 2003;11:177–186 
 
344. The University of Arizona. Cleaning and preserving animal skulls. Available 
at:https://extension.arizona.edu/sites/extension.arizona.edu/files/pubs/az1144.p
df Accessed 15th July 2020 
 
345. Habraken W, Habibovic P, et al. Calcium phosphates in biomedical 
applications: materials for the future? Materials Today. 2016;19(2):69-87 
 
346. Al-Sanabani JS, Madfa AA, et al. Application of calcium phosphate 
materials in dentistry. International Journal of Biomaterials. 2013;2013:876132 
 
347. Shipman M. Bioactive film improves how implants bond with bone in 
animal study. 2016. Available at: https://news.ncsu.edu/2016/06/film-improves-
implant-bone-bond-2016/ Accessed 15th July 2020 
 
348. Mahan KT, Carey MJ. Hydroxyapatite as a bone substitute. Journal of the 
American Podiatric Medical Association. 1999;89(8):392-397  
 
349. Reddy R, Swamy MKS. The use of hydroxyapatite as a bone graft 
substitute in orthopaedic conditions. Indian Journal of Orthopaedics. 
2005;39(1):52-54   
 
350. Zhang R. Hydroxyapatite Coatings for Biomedical Applications (Advances 
in Materials Science and Engineering. 2013. CRC Press.  
 
351. Ducheyne P, Hench LL, et al. Effect of hydroxyapatite impregnation on 
skeletal bonding of porous coated implants. Journal of Biomedical Materials 
Research. 1980;14(3):225-237 
 
352. Porter AE, Taak P, et al. Bone bonding to hydroxyapatite and titanium 
surfaces on femoral stems retrieved from human subjects at autopsy. 




353. Kobayashi T, Itoh S, et al. Enhanced bone bonding of hydroxyapatite-
coated titanium implants by electrical polarization. Journal of Biomedical 
Material Research Part A. 2007;82(1):145-151 
 
354. Tas, AC, Bhaduri, SB. Rapid coating of Ti6Al4V at room temperature with 
a calcium phosphate solution similar to 10× simulated body fluid. Journal of 
Materials Research. 2004;19(9): 2742–2749  
 
355. The American heritage dictionary of the English language. Room 
temperature. 2020. Available at: 
https://ahdictionary.com/word/search.html?q=room+temperature Accessed 15th 
July 2020 
 
356. Wang L, Luo J. Formation of hydroxyapatite coating on anodic titanium 
dioxide nanotubes via an efficient dipping treatment. Metallurgical and Materials 
Transactions A. 2011; 42:3255–3264 
 
357. Galgo Medical. Reveals cortical trabecular bone from DXA. Introducing 3D 
Shaper into your DXA clinical practice. 2017. Available at:  https://www.3d-
shaper.com/en/index.html Accessed 23rd March 2020 
 
358. El Hage R. Geometric indices of hip bone strength in obese, overweight, 
and normal-weight adolescent boys. Osteoporosis International. 
2012;23(5):1593-1600 
 
359. Nelson DA, Barondess DA, et al. Cross-sectional geometry, bone strength, 
and bone mass in the proximal femur in black and white postmenopausal 
women. Journal of Bone and Mineral Research. 2000;10(15):1992-1997 
 
360. Beck TJ. Hip structural analysis (HSA) program (BMD and structural 
geometry methodology) as used to create NHANES III dataset. 2002. Available 
at:  https://wwwn.cdc.gov/nchs/data/nhanes3/17a/hip_methods.pdf Accessed 




361. Choi YJ, Chung YS. Type 2 diabetes mellitus and bone fragility: Special 
focus on bone imaging. Osteoporosis and Sarcopenia. 2016;2(1):20-24  
 
362. Ramamurthi K, Ahmad O, et al. An in vivo comparison of hip structure 
analysis (HSA) with measurements obtained by QCT. Osteoporosis 
International. 2012;23(2):543-551 
 
363. Muschitz CH, Milassin L, et al. DXA and QCT geometric structural 
measurements of proximal femoral strength. Journal of Bone and Mineral 
Research. 2007;22(Suppl 1)  
 
364. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporosis 
International. 2003;14(Suppl 3):S13-S18 
 
365. Nordin M, Frankel VH. Basic biomechanics of the musculoskeletal system. 
4th edition. North American. Wolters Kluwer Lippincott Williams and Wilkins. 
2012 
 
366. Whitmarsh T, Humbert L, et al. Reconstructing the 3D shape and bone 
mineral density distribution of the proximal femur from dual-energy X-ray 
absorptiometry. IEEE Trans Med Imaging. 2011;30(12):2101-14 
 
367. Humbert L, Martelli Y, et al. 3D-DXA: Assessing the Femoral Shape, the 
Trabecular Macrostructure and the Cortex in 3D from DXA images. IEEE Trans 
Med Imaging. 2017;36(1):27-39 
 
368. Clotet J, Martelli Y, et al. Structural Parameters of the Proximal Femur by 
3-Dimensional Dual-Energy X-ray Absorptiometry Software: Comparison With 
Quantitative Computed Tomography. J Clin Densitom. 2018;21(4):550-562 
 
369. Winzenrieth R, Humbert L,et al. Effects of osteoporosis drug treatments on 
cortical and trabecular bone in the femur using DXA-based 3D modeling. 





370. García Hoyos M, Humbert L, et al. Analysis of volumetric BMD in people 
with Down syndrome using DXA-based 3D modeling. Arch Osteoporos. 
2019;14(1):98 
 
371. Freitas L, Amorim T, et al. Cortical and trabecular bone analysis of 
professional dancers using 3D-DXA: a case-control study. J Sports Sci. 
2019;37(1):82-89 
 
372. Gifre L, Humbert L, et al. Analysis of the evolution of cortical and 
trabecular bone compartments in the proximal femur after spinal cord injury by 
3D-DXA. Osteoporos Int. 2018;29(1):201-209 
 
373. Glago Medical. 3D-SHAPER in clinical practices. 2017. Available at:  
https://www.3d-shaper.com/en/index.html Accessed 23rd March 2020 
 
374. Humbert L, Marangalou J, et al. Technical note: Cortical thickness and 
density estimation from clinical CT using a prior thickness -density relationship. 
Medical Physics. 2016:43(4):1945-1954 
 
375. Humbert L, Martelli Y, et al. 3D -DXA: Assessing the femoral shape, the 
trabecular macrostructure and the cortex in 3D from DXA images. IEEE 
Transactions on Medical Imaging. 2017;36(1):27-39 
 
376. Li N, Li X, et al. Comparison of QCT and DXA: Osteoporosis detection 
rates in postmenopausal women. International Journal of Endocrinology 
2013(8):895474 
 
377. Orduna G, Humbert L, et al. Cortical and trabecular bone analysis of 
patients with high bone mass from the Barcelona osteoporosis cohort using 3-
dimensional dual-energy x-ray absorptiometry: a case-control study. Journal of 
Clinical Densitometry. 2018;21(4):480-484 
 
378. Kužma M, Vaňuga P, et al. Non-invasive DXA-derived bone structure 
assessment of acromegaly patients: a cross-sectional study. European Journal 




379. Humbert L, Bagué A, et al. DXA-based 3D analysis of the cortical and 
trabecular bone of hip fracture postmenopausal women: a case-control study. 
Journal of Clinical Densitometry. 2018;S1094-6950(18)30209-9 
 
380. García Hoyos M, Humbert L, et al. Analysis of volumetric BMD in people 
with Down syndrome using DXA-based 3D modeling. Archives Osteoporosis. 
2019;14:98 
 
381. Humbert L, Bagué A, et al. DXA-based 3D analysis of the cortical and 
trabecular bone of hip fracture postmenopausal women: a case-control study. 
Journal of Clinical Densitometry. 2018:S1094-6950(18)30209-9 
 
382. Rao A, Reddy S, et al. Is there a difference between right and left femoral 
bone density? Journal of Clinical Densitometry. 2000;3(1):57-61 
 
383. Humbert L, Winzenrieth R, et al. 3D Analysis of cortical and trabecular 
bone from hip DXA: Precision and trend assessment interval in postmenopausal 
women. Journal of Clinical Densitometry. 2019;22(2):214-218 
 
384. Gluer CC, Cummings SR, et al. Prediction of hip fractures from pelvic 
radiographs: the study of osteoporotic fractures. The study of osteoporotic 
fractures research group. Journal of Bone and Mineral Research. 
1994;9(5):671–677 
 
385. Epstein S. Is cortical bone hip? what determines cortical bone properties? 
Bone. 2007;41(1) Suppl 1:S3-S8 
 
386. Tarantino U, Rao C, et al. Hip fractures in the elderly: The role of cortical 
bone. Injury. 2016;47 Suppl 4:S107-S111 
 
387. Carter DR, Hayes WC. Compact bone fatigue damage: a microscopic 




388. Osterhoff G, Morgan EF, et al. Bone mechanical properties and changes 
with osteoporosis. Injury. 2016;47 (Suppl 2):S11-S20 
 
389. Cauley JA, Blackwell T, et al. Correlates of trabecular and cortical 
volumetric bone mineral density at the femoral neck and lumbar spine: the 
osteoporotic fractures in men study (MrOS). Journal of Bone Mineral Research. 
2010;25(9):1958-1971 
 
390. Anderson JB. Encyclopedia of food sciences and nutrition. 2nd edition. 
USA. Elsevier Science. 2003. Osteoporosis; p.4278-4781 
 
391. Preston S, Petrera M, et al. Towards an understanding of the painful total 
knee: what is the role of patient biology?. Current Reviews in Musculoskeletal 
Medicine. 2016;9(4):388-395 
 
392. Harrison AK, Gioe TJ, et al. Do porous tantalum implants help preserve 
bone?: evaluation of tibial bone density surrounding tantalum tibial implants in 
TKA. Clinical Orthopaedics and Related Research. 2010;468(10):2739-2745 
 
393. Benedetti MG, Furlini G, et al. The effectiveness of physical exercise on 
bone density in osteoporotic patients. BioMed Research International. 
2018;2018:4840531 
 
394. Sheu Y, Bunker CH, et al. Rates of and risk factors for trabecular and 
cortical BMD loss in middle-aged and elderly African-ancestry men. The Journal 
of Bone and Mineral Research. 2015;30(3):543-553 
 
395. Szulc P, Deboeuf F, et al. Structural determinants of hip fracture in elderly 
women: re-analysis of the data from the EPIDOS study. Osteoporosis 
International. 2006;17(2):231-236  
 
396. Ahlborg HG, Nguyen ND, et al. Contribution of hip strength indices to hip 





397. Özen A, Karacan I, et al. Hip strength analysis by dual energy x-ray 
absorptiometry in nephrolithiasis patients. Journal Clinical and Analytical 
Medicine. 2016;7(1):1-5 
 
398. Beck TJ, Ruff CB, et al.: Age-related changes in female femoral neck 
geometry: implications for bone strength. Calcified Tissue International. 
1993;53:S41–6 
 
399. Crabtree NJ, Kroger H, et al. Improving risk assessment: hip geometry, 
bone mineral distribution, and bone strength in hip fracture cases and controls. 
The EPOS study. Osteoporosis International 2002, 13:48–54. 
 
400. Alswat KA. Gender disparities in osteoporosis. Journal of Clinical Medicine 
Research. 2017;9(5):382-387 
 
401. Edidin AA, Ong KL, et al. Mortality risk for operated and nonoperated 
vertebral fracture patients in the Medicare population. Journal of Bone and 
Mineral Research. 2011;26(7):1617-1626 
 
402. Jacquot F, Letellier T, et al. Balloon reduction and cement fixation in 
calcaneal articular fractures: a five-year experience. International Orthopaedics. 
2013;37(5):905–910  
 
403. Osterhoff G, Baumgartner D, et al. Medial support by fibula bone graft in 
angular stable plate fixation of proximal humeral fractures: an in vitro study with 
synthetic bone. Journal of Shoulder and Elbow Surgery. 2011;20(5):740–746 
 
404. Paul O, Barker JU, et al. Functional and radiographic outcomes of 
intertrochanteric hip fractures treated with calcar reduction, compression, and 
trochanteric entry nailing. Journal of Orthopaedic Trauma. 2012;26(3):148-154 
 
405. Osterhoff G, Morgan EF, et al. Bone mechanical properties and changes 




406. National Osteoporosis Society. Dual-energy X-ray absorptiometry 
positioning. Available 
from:https://nos.org.uk/media/1728/documentunlocked.pdf Accessed 
September 20th 2017 
 
407. National Health and Nutritional Examination Survey (NHANES). Dual 
energy x-ray absorptiometry (DXA) procedures manual. 2007. Available from: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/manual_dexa.pdf 
Accessed September 20th 2019 
 
408. Hendrich E. Bone mineral density scan (bone densitometry or DXA scan). 
2017. Available from:https://www.insideradiology.com.au/bone-mineral-density-
scan/ Accessed July 10th 2020 
 
409. Gregson CL, Hardcastle SA, et al. Friend or foe: high bone mineral density 
on routine bone density scanning, a review of causes and management. 
Rheumatology (Oxford). 2013;52(6):968-985 
 
410. He QF, Sun H, et al. Radiographic predictors for bone mineral loss: 
Cortical thickness and index of the distal femur. Bone and Joint Research. 
2018;7(7):468-475 
 
411. Jack K, McLean SM, et al. Barriers to treatment adherence in 
physiotherapy outpatient clinics: a systematic review. Manual Therapy. 
2010;15(3):220-228 
 
412. Manios Y, Moschonis G, et al. Changes in biochemical indexes of bone 
metabolism and bone mineral density after a 12-month dietary intervention 
program: the Postmenopausal Health Study. The American Journal of Clinical 
Nutrition.  2007;86:781-789 
 
413. Reid IR, Ames R, et al. Randomized controlled trial of calcium 





414. Garg MK, Kharb S. Dual energy X-ray absorptiometry: Pitfalls in 
measurement and interpretation of bone mineral density. Indian Journal of 
Endocrinology Metabolism. 2013;17(2):203-210 
 
415. Loeser RF. Age-related changes in the musculoskeletal system and the 
development of osteoarthritis. Clinics in Geriatric Medicine. 2010;26(3):371-386 
 
416. TRA Medical Imaging. Available from: 
www.tramedicalimaging.com/file_viewer.php?id=941 Accessed September 20th 
2019 
 
417. Reeve J. Role of cortical bone in hip fracture. BoneKEy Reports. 
2017;6:867 
 
418. Rao AD, Reddy S, et al. Is there a difference between right and left femoral 
bone density?. Journal of Clinical Densitometry. 2000;3(1):57-61 
 
419. Tjørnild M, Søballe K, et al. Reproducibility of BMD Measurements in the 
Prosthetic Knee Comparing Knee-Specific Software to Traditional DXA 
Software: A Clinical Validation. Journal of Clinical Densitometry. 
2011;14(2):138-148  
 
420. Stilling M, Søballe K, et al. Knee flexion influences periprosthetic BMD 
measurement in the tibia. Suggestions for a reproducible clinical scan protocol. 
Acta Orthopaedica. 2010;81(4):463-470 
 
421. Frost HM. Wolff's Law and bone's structural adaptations to mechanical 
usage: an overview for clinicians. The Angle Orthodontist. 1994;64(3):175-188 
 
422. Van Lenthe GH, Willems MM, et al. Stemmed femoral knee prostheses: 





423. Prince JM, Bernatz JT, et al. Changes in femoral bone mineral density 
after total knee arthroplasty: a systematic review and meta-analysis. Achieves 
of Osteoporosis. 2019;14(1):23 
 
424. Da Silva RR, Santos AA, et al. Quality of life after total knee arthroplasty: 
systematic review. Revista brasileira de ortopedia. 2014;49(5):520-527 
 
425. Anijs T, Wolfson D, et al. Population-based effect of total knee arthroplasty 
alignment on simulated tibial bone remodelling. Journal of the Mechanical 
Behavior of Biomedical Materials. 2020. 104014 
 
426. Bono JV, Scott RD. Revision total knee arthroplasty. Second edition. 
Springer. 2018. Chapter 10 Metaphyseal sleeves and cones in revision in total 
knee arthroplasty. p; 139 
 
427. Jaroma A, Soininvaara T, et al. Changes in Bone Mineral Density of the 
Proximal Femur and Contralateral Knee after Total Knee Arthroplasty: A 4-Year 
Follow-Up of 38 Patients. Orthopaedic Research Online Journal. 2019;6(2):585-
590  
 
428. Challans A. Knee AP. Radiographic positioning. 2011. Available from:  
http://www.wikiradiography.net/page/Knee+-++AP Accessed July 10th 2020 
 
429. Subramanian SS, Sengodan MM. Role of full length weight bearing 
radiograph in assessing the alignment in total knee arthroplasty. IOSR Journal 
of Dental and Medical Sciences 2016;15(07):55-63 
 
430. Zampogna B, Vasta S, et al. Assessing lower limb alignment: comparison 
of standard knee x-ray vs long leg view. The Iowa Orthopaedic Journal. 
2015;35:49-54. 
 
431. Mangset WE, Izang N. Locally fabricated metal step wedge for quality 





432. Marijnissen AC, Vincken KL, et al. Knee Images Digital Analysis (KIDA): a 
novel method to quantify individual radiographic features of knee osteoarthritis 
in detail. Osteoarthritis Cartilage. 2008;16(2):234-243 
 
433. Morgan-Jones R, Oussedik SI, et al. Zonal fixation in revision total knee 
arthroplasty. The Bone and Joint Journal. 2015;97-B(2):147-149 
 
434. MicroDicom. MicroDicom - free DICOM viewer for Windows. Available at:  
https://www.microdicom.com/ Accessed 15th July 2020 
 
435. Waterson H, Hopkins SJ, et al. Effect of kinematic alignment on peri-
prosthetic bone mineral density, after total knee arthroplasty. BASK. 2013  
 
436. Kamath AF, Israelite C, et al. Editorial: What is varus or valgus knee 
alignment?: a call for a uniform radiographic classification. Clinical Orthopaedics 
and Related Research. 2010;468(6):1702-1704 
 
437. De Martino I, De Santis V, et al. Tantalum cones provide durable mid-term 
fixation in revision TKA. Clinical Orthopaedics and Related Research. 
2015;473(10):3176-3182 
 
438. Lachiewicz P. Metaphyseal cones for severe bone loss: when only metal 
will do. Orthopaedic Proceedings. 2018;100-B(Suppl10) 
 
439. Gebauer M, Gehrke T, et al. The use of tantalum cones for reconstruction 
of bone defects in revision total knee arthroplasty. Operative Orthopädie und 
Traumatologie. 2015;27:17-23 
 
441. Boureau F, Putman S, et al. Tantalum cones and bone defects in revision 
total knee arthroplasty. Orthopaedic and Traumatology, Surgery and Research. 
2015;101(2):251-255 
 
442. Mozella AP, Olivero RR, et al. Use of a trabecular metal cone made of 
tantalum, to treat bone defects during revision knee arthroplasty. Revista 
Brasileira de Ortopedia. 2014;49(3):245-251 
485 
 
443. Girerd D, Parratte S, et al. Total knee arthroplasty revision with trabecular 
tantalum cones: Preliminary retrospective study of 51 patients from two centres 
with a minimal 2-year follow-up. Orthopaedic and Traumatology, Surgery and 
Research. 2016;102(4):429-433 
 
444. Nackaerts O, Jacobs R, et al. Bone density measurements in intra-oral 
radiographs. Clinical Oral Investestigations. 2007;11:225-229 
 
445. Hunt MA, Fowler PJ, et al. Foot rotational effects on radiographic 
measures of lower limb alignment. Canadian Journal of Surgery. 
2006;49(6):401-406 
 
446. Perlick L, Bäthis H, et al. Revision total knee arthroplasty: a comparison of 
postoperative leg alignment after computer-assisted implantation versus the 
conventional technique. Knee Surgery, Sports Traumatology, Arthroscopy: 
Official Journal of the ESSKA. 2005 Apr;13(3):167-173 
 
447. Hadi M, Barlow T, et al. Does malalignment affect revision rate in total 
knee replacements: a systematic review of the literature. SpringerPlus. 
2015;4:835 
 
448. Mizu-Uchi H, Matsuda S, et al. Three-dimensional analysis of computed 
tomography-based navigation system for total knee arthroplasty: the accuracy 
of computed tomography-based navigation system. The Journal of Arthroplasty. 
2009;24:1103-1110 
 
449. Nakasone CK, Abdeen A, et al. Component alignment in revision total 
knee arthroplasty using diaphyseal engaging modular offset press-fit stems. 
The Journal of Arthroplasty. 2008;23(8):1178-1181 
 
450. Cheng T, Zhao S, et al. Does computer-assisted surgery improve 
postoperative leg alignment and implant positioning following total knee 
arthroplasty? A meta-analysis of randomized controlled trials? Knee Surgery, 




451. Ensini A, Catani F, et al. Alignments and clinical results in conventional 
and navigated total knee arthroplasty. Clinical Orthopaedics and Related 
Research, 2007;457:156–162 
 
452. Bonutti PM, Dethmers D, et al. Computer navigation-assisted versus 
minimally invasive TKA: benefits and drawbacks. Clinical Orthopaedics and 
Related Research. 2008;466(11):2756–2762 
 
453. Sikorski JM. Alignment in total knee replacement. The Journal of Bone and 
Joint Surgery - British Volume. 2008;90(9):1121–1127 
 
454. Tingart M, Lüring C, et al. Computer-assisted total knee arthroplasty 
versus the conventional technique: how precise is navigation in clinical routine? 
Knee Surgery, Sports Traumatology, Arthroscopy. 2008;16(1):44-50  
 
455. Cameron HU, Hunter GA. Failure in total knee arthroplasty: mechanisms, 
revisions, and results. Clinical Orthopaedics and Related Research. 
1982;170:141-146 
 
456. Dorr LD, Boiardo RA. Technical considerations in total knee arthroplasty. 
Clinical Orthopaedics and Related Research. 1986;205:5-11 
 
457. Kagen A. Mechanical causes of loosening in knee joint replacements. 
Journal of Biomechanics. 1977;10:387-391 
 
458. Lotke PA, Ecker ML. Influence of positioning of prosthesis in total knee 
replacement. The Journal of Bone and Joint Surgery American Volume. 
1977;59:77-79 
 
459. Tew M, Waugh W. Tibiofemoral alignment and the results of knee 





460. Moreland JR, Bassett LW, et al. Radiographic analysis of the axial 
alignment of the lower extremity. The Journal of Bone Joint Surgery American 
Volume. 1987;69:745-749 
 
461. Mayo Clinic. CT scan overview. Available from: 
http://www.mayoclinic.org/tests-procedures/ct-scan/basics/how-you-
prepare/prc-20014610 Accessed July 10th 2020 
 
462. Binkley JM, Stratford PW, et al. The Lower Extremity Functional Scale 
(LEFS): Scale development, measurement properties, and clinical application. 
Physical Therapy. 1999;79:371-383 
 
463. Snaith RP. The Hospital Anxiety And Depression Scale. Health and Quality 
of Life Outcomes. 2003;1;1:29 
 
464. Hansson M, Bodlund O, et al. Patient education and group counselling to 
improve the treatment of depression in primary care: a randomized controlled 
trial. Journal of Affective Disorders. 2008;105(1-3):235-240 
 
465. Bocéréan C, Dupret, E. A validation study of the Hospital Anxiety and 
Depression Scale (HADS) in a large sample of French employees. BMC 
Psychiatry 2014;14:354  
 
466. Montazeri A, Vahdaninia M, et al. The Hospital Anxiety and Depression 
Scale (HADS): translation and validation study of the Iranian version. Health 
and Quality of Life Outcomes. 2003;1:14 
 
461. Hansson M, Chotai J, et al. Comparison of two self-rating scales to detect 
depression: HADS and PHQ-9. British Journal of General Practice. 
2009;59(566):e283-e288 
 
462. Moonot P, Kamat Y, et al. The oxford knee scores for primary knee 





463. Jenny JY, Diesinger Y. The Oxford Knee Score: Compared performance 
before and after knee replacement. Orthopaedic and Traumatology, Surgery 
and Research. 2012;98(4):409-412 
 
464. Reito A, Järvistö A, et al. Translation and validation of the 12-item Oxford 
knee score for use in Finland. BMC Musculoskeletal Disorders. 2017;18(1):74 
 
465. Lodder MC, de Jong Z, et al. Bone mineral density in patients with 
rheumatoid arthritis: relation between disease severity and low bone mineral 
density. Annals of the Rheumatic Diseases 2004;63:1576-1580 
 
466. Shalaby AS, El-Sayed AS. Anxiety, depression, and quality of life in 
patients with knee osteoarthritis before and after knee joint replacement. 
Egyptian Journal of Psychiatry. 2017;38(1):8-12  
 
467. Meneghini RM, Lewallen DG, et al. Use of porous tantalum metaphyseal 
cones for severe tibial bone loss during revision total knee replacement. The 
Journal of the Bone and Joint Surgery American Volume. 2008;90:78-84 
 
468. Ones AR, Al-Naseer S, et al. Does pre-operative anxiety and/or 
depression affect patient outcome after primary knee replacement 
arthroplasty?. Knee. 2018;25(6):1238-1246 
 
469. Qi A, Lin C, et al. Negative emotions affect postoperative scores for 
evaluating functional knee recovery and quality of life after total knee 
replacement. Brazilian Journal of Medical and Biological Research. 
2016;49(1):e4616 
 
470. Mehta SP, Perrucccio AV, et al. Do women have poorer outcomes 
following total knee replacement? Osteoarthritis and Cartilage. 
2015;23(9):1476-1482 
 
471. O'Connor MI. Implant survival, knee function, and pain relief after TKA: are 





472. Brander V, Gondek S, et al. Pain and depression influence outcome 5 
years after knee replacement surgery. Clinical Orthopaedics and Related 
Research. 2007;464:21-26 
 
473. Phyomaung PP, Dubowitz J, et al. Are depression, anxiety and poor 
mental health risk factors for knee pain? A systematic review. BMC 
Musculoskeletal Disorders. 2014;15:10 
 
474. Craft LL, Perna FM. The Benefits of Exercise for the Clinically Depressed. 
Prim Care Companion to the Journal of Clinical Psychiatry. 2004;6(3):104-111 
 
475. Anderson E, Shivakumar G. Effects of exercise and physical activity on 
anxiety. Front Psychiatry. 2013;4:27 
 
476. Blalock D, Miller A. Joint instability and osteoarthritis. Clinical Medicine 
Insights Arthritis and Musculoskeletal Disorders. 2015;8:15-23 
 
477. Hauser RA, Woldin BA. Anatomy, posture, prevalence, pain, treatment and 
interventions of musculoskeletal disorders. Chapter 5 joint instability as the 
cause of chronic musculoskeletal pain and its successful treatment with 
prolotherapy. 2018 p. 65-85 
 
478. Moutzouri M, Gleeson N, et al. The effect of total knee arthroplasty on 
patients' balance and incidence of falls: a systematic review. Knee Surgery 
Sports Traumatology Arthroscopy. 2017;25(11):3439-3451 
 
479. Canovas F, Dagneaux L. Quality of life after total knee arthroplasty. 
Orthopaedics and Traumatology Surgery and Research. 2018;104(1S):S41-S46 
 
480. Martinez-Cano JP, Herrera-Escobar JP, et al. Prospective quality of life 
assessment after hip and knee arthroplasty: short- and mid-term follow-up 




481. Petersen CL, Kjærsgaard JB, et al. Thresholds for Oxford Knee Score after 
total knee replacement surgery: a novel approach to post-operative evaluation. 
Journal of Orthopaedic Surgery and Research. 2017;12(1):89 
 
482. Judge A, Arden NK, et al. Interpretation of patient-reported outcomes for 
hip and knee replacement surgery: identification of thresholds associated with 
satisfaction with surgery. Journal of Bone Joint Surgery British Volume. 
2012;94(3):412-418 
 
483. Beard DJ, Harris K, et al. Meaningful changes for the Oxford hip and knee 
scores after joint replacement surgery. Journal of Clinical Epidemiology. 
2015;68(1):73-79 
 
484. Weißenberger M, Petersen N, et al. Revision of unicompartmental knee 
arthroplasty using the in situ referencing technique. Operative Orthopädie und 
Traumatologie. 2020;32(4):273-283 
 
 
 
 
 
